Diuretics — MCQs

Q: Which diuretic can be used in renal failure?

Furosemide. **Explanation:** **Furosemide** is the correct answer because it is a high-ceiling loop diuretic that remains effective even when the Glomerular Filtration Rate (GFR) falls below 30 mL/min. In renal failure, the delivery of solutes to the distal nephron is reduced; loop diuretics are potent enough to inhibit the $Na^+-K^+-2Cl^-$ symporter in the thick ascending limb, maintaining diuresis and managing fluid overload in patients with chronic kidney disease (CKD). **Why the other options are incorrect:** * **Chlorothiazide & Chlorthalidone:** These are Thiazide/Thiazide-like diuretics. They generally lose their efficacy when GFR is less than 30 mL/min (except for Metolazone and Indapamide). Using them in advanced renal failure is ineffective for fluid management. * **Mannitol:** This is an osmotic diuretic. In renal failure, Mannitol is not excreted efficiently, leading to its accumulation in the extracellular fluid. This causes "osmotic shift," drawing water out of cells and potentially leading to acute pulmonary edema or congestive heart failure. It is contraindicated in established anuria. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Furosemide is the drug of choice for acute pulmonary edema and edema associated with CKD. * **Metolazone Exception:** While most thiazides fail in renal failure, Metolazone can be combined with Loop diuretics (Sequential Nephron Blockade) to treat refractory edema in CKD patients. * **Ototoxicity:** Furosemide can cause dose-dependent ototoxicity, especially when administered rapidly IV or combined with aminoglycosides. * **Electrolyte Profile:** Loop diuretics cause "Hypo-everything" (Hypokalemia, Hypomagnesemia, Hypocalcemia), except for Hyperuricemia and Hyperglycemia.

Q: Which diuretic is appropriate for combining with ACE inhibitors?

Hydrochlorothiazide. ### Explanation The combination of **ACE inhibitors (ACEIs)** and **Hydrochlorothiazide (HCTZ)** is a cornerstone in the management of hypertension. **Why Hydrochlorothiazide is the correct choice:** The primary rationale for this combination is **potassium homeostasis**. ACE inhibitors block the production of Aldosterone, leading to potassium retention (hyperkalemia). Conversely, Thiazide diuretics like HCTZ increase potassium excretion at the distal convoluted tubule, which can lead to hypokalemia. When used together, they exert a **synergistic antihypertensive effect** while neutralizing each other's impact on serum potassium levels. Additionally, ACEIs inhibit the compensatory activation of the Renin-Angiotensin-Aldosterone System (RAAS) typically triggered by diuretic-induced volume depletion. **Why the other options are incorrect:** * **Spironolactone & Eplerenone (Options A & B):** These are Potassium-sparing diuretics (Aldosterone antagonists). Combining them with ACEIs significantly increases the risk of **severe, life-threatening hyperkalemia**, as both drug classes promote potassium retention. * **Amiloride (Option D):** This is an epithelial sodium channel (ENaC) blocker, also classified as a potassium-sparing diuretic. Like Spironolactone, it carries a high risk of hyperkalemia when combined with ACEIs. **NEET-PG High-Yield Pearls:** * **Synergy:** ACEIs + Thiazides is a "rational drug combination" because it improves efficacy and limits side effects (hypokalemia). * **Metabolic Neutrality:** ACEIs may help mitigate the hyperglycemia and hyperuricemia sometimes seen with high-dose Thiazide use. * **Contraindication:** Never combine ACEIs with ARBs or Direct Renin Inhibitors (Aliskiren) due to the risk of renal failure and hyperkalemia. * **Drug of Choice:** ACEIs are the first-line treatment for hypertension in patients with **Diabetes Mellitus** (due to nephroprotective effects).

Q: Which of the following are potassium-sparing diuretics?

All of the above. Potassium-sparing diuretics are a unique class of drugs that act on the **late distal tubule and collecting duct** to promote sodium excretion while conserving potassium. They are categorized into two distinct groups based on their mechanism of action: 1. **Aldosterone Antagonists (Spironolactone & Eplerenone):** These are competitive inhibitors of the mineralocorticoid receptor. By blocking aldosterone, they prevent the synthesis of Na+/K+ ATPase pumps and epithelial sodium channels (ENaC), thereby reducing sodium reabsorption and potassium secretion. 2. **Direct ENaC Blockers (Amiloride & Triamterene):** These drugs do not depend on aldosterone. They directly block the ENaC on the luminal membrane of principal cells. This prevents sodium entry, which reduces the negative intraluminal potential, thereby inhibiting the electrical gradient that normally drives potassium secretion into the urine. **Analysis of Options:** * **A, B, and C** are all classic examples of potassium-sparing diuretics. Since all three drugs belong to this class (though via different sub-mechanisms), **Option D** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** The most common and dangerous side effect of this class is **hyperkalemia**. Spironolactone specifically can cause **gynecomastia** and impotence due to its non-specific anti-androgenic effects (Eplerenone is more selective). * **Liddle’s Syndrome:** Amiloride is the drug of choice for this rare genetic condition. * **Lithium-Induced Diabetes Insipidus:** Amiloride is used to treat this by blocking lithium entry through ENaC in the collecting ducts. * **Clinical Use:** These drugs are often combined with Thiazides or Loop diuretics to counteract the hypokalemia induced by the latter.

Q: Which of the following side effects is associated with Spironolactone?

Hyperkalemia. **Explanation:** **Spironolactone** is a potassium-sparing diuretic that acts as a competitive antagonist of the **Mineralocorticoid Receptor (Aldosterone receptor)** in the late distal tubule and collecting duct. **Why Hyperkalemia is Correct:** Aldosterone normally promotes the reabsorption of sodium ($Na^+$) and the excretion of potassium ($K^+$) and hydrogen ions ($H^+$). By blocking this receptor, Spironolactone prevents $K^+$ secretion into the tubular lumen. This leads to the retention of potassium in the blood, resulting in **Hyperkalemia**, its most significant and potentially life-threatening side effect. **Analysis of Incorrect Options:** * **A. Alkalosis:** Spironolactone causes **Metabolic Acidosis** (not alkalosis) because it inhibits the excretion of $H^+$ ions. * **B. Hirsutism:** Spironolactone actually has **anti-androgenic** properties (it blocks androgen receptors and inhibits steroidogenesis). Therefore, it is used to *treat* hirsutism in conditions like PCOS. A common side effect in males, however, is **gynecomastia**. * **D. Hyperglycemia:** This is a classic side effect of **Thiazides and Loop diuretics**, which can impair insulin release. Spironolactone does not typically affect blood glucose levels. **High-Yield Clinical Pearls for NEET-PG:** * **Eplerenone** is a more selective aldosterone antagonist with fewer endocrine side effects (less risk of gynecomastia) compared to Spironolactone. * **Drug Interaction:** Avoid combining Spironolactone with ACE inhibitors or ARBs, as this significantly increases the risk of severe hyperkalemia. * **Indication of Choice:** It is the diuretic of choice for patients with **Cirrhosis with Ascites** and is proven to reduce mortality in **Chronic Heart Failure (NYHA Class II-IV)**.

Q: A 64-year-old man with heart failure is recently started on 80 mg/day of furosemide. He now feels weak and tired, but notes that his heart failure symptoms have improved. There is no change in his urine output and he gets a good diuretic response every time he takes his furosemide. Which are the characteristic ECG findings?

lengthened QU interval. ### Explanation **Correct Answer: C. Lengthened QU interval** **1. Underlying Medical Concept:** Furosemide is a potent loop diuretic that inhibits the Na⁺/K⁺/2Cl⁻ symporter in the thick ascending limb of the Loop of Henle. A common and significant side effect of loop diuretics is **hypokalemia** (low serum potassium). In hypokalemia, the ECG undergoes characteristic changes due to delayed ventricular repolarization. The most classic finding is the appearance of **prominent U waves**. As the U wave becomes more pronounced and the T wave flattens, the T and U waves often merge. This creates the appearance of a **"lengthened QU interval"** (or a pseudo-prolonged QT interval), which is a hallmark of potassium depletion. The patient’s symptoms of weakness and fatigue are clinical indicators of this electrolyte imbalance. **2. Why the other options are incorrect:** * **A & B (PR Interval):** Changes in the PR interval are typically associated with calcium abnormalities or AV nodal blocks (e.g., Digoxin toxicity), not primarily with the hypokalemia caused by diuretics. * **D (Shortened QT interval):** A shortened QT interval is characteristic of **hypercalcemia**. In contrast, hypokalemia (and hypocalcemia) typically leads to a prolonged appearance of the repolarization phase (prolonged QU/QT). **3. NEET-PG High-Yield Pearls:** * **ECG findings in Hypokalemia:** Flattening/inversion of T waves, ST-segment depression, prominent U waves, and QU prolongation. * **Loop Diuretics Side Effects (Mnemonic: OH DANG!):** **O**totoxicity, **H**ypokalemia, **D**ehydration, **A**llergy (sulfa), **N**ephritis (interstitial), **G**out (hyperuricemia). * **Metabolic state:** Loop diuretics cause **Hypokalemic Metabolic Alkalosis**. * **U wave:** A positive deflection after the T wave, representing slow repolarization of Purkinje fibers. It is most visible in precordial leads V2–V4.

Q: Glycerol is classified as which of the following?

Osmotic diuretic. **Explanation:** **Glycerol** is a low-molecular-weight, pharmacologically inert substance that acts as an **Osmotic Diuretic**. When administered (usually orally), it increases the osmolarity of the plasma and tubular fluid. 1. **Why Option A is Correct:** As an osmotic diuretic, glycerol creates an osmotic gradient that draws water out of the intracellular and interstitial compartments into the vascular space. In the kidneys, it is filtered by the glomerulus but poorly reabsorbed, thereby limiting water reabsorption in the proximal tubule and the descending limb of the Loop of Henle, leading to diuresis. 2. **Why Other Options are Incorrect:** * **B. Purgative:** While glycerol suppositories are used for constipation (acting as a lubricant/irritant), "Glycerol" as a systemic pharmacological agent is primarily classified and tested as an osmotic agent. * **C. Antidiabetic:** Glycerol is actually a precursor for gluconeogenesis; it can potentially increase blood glucose levels, making it contraindicated or used with caution in diabetic patients. * **D. Antiemetic:** Glycerol has no mechanism of action involving the CTZ or H1/D2 receptors to prevent vomiting. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Use:** Glycerol is used to acutely reduce **intraocular pressure** (in acute glaucoma) and **intracranial pressure** (in cerebral edema). * **Route:** Unlike Mannitol (which must be given IV), Glycerol is effective **orally**, though it has a sweet, sickening taste. * **Comparison:** Mannitol is the preferred IV osmotic diuretic, while Glycerol is the classic oral alternative. * **Side Effect:** Watch for hyperglycemia and dehydration. Use with caution in patients with congestive heart failure (due to initial ECF volume expansion).

Q: Which of the following drugs prevents renal stones?

Acetazolamide. The correct answer is **Acetazolamide**. This question focuses on the specific management of **Cystinuria** and the prevention of **Cystine stones**. **1. Why Acetazolamide is correct:** Acetazolamide is a Carbonic Anhydrase inhibitor that acts on the proximal convoluted tubule [1, 2]. By inhibiting the reabsorption of bicarbonate, it increases urinary bicarbonate excretion, leading to **alkalinization of the urine** [1, 2]. Cystine is highly insoluble in acidic urine but becomes significantly more soluble as the pH rises above 7.5. Therefore, by making the urine alkaline, Acetazolamide prevents the precipitation of cystine crystals and the formation of renal stones in patients with cystinuria [1]. **2. Why the other options are incorrect:** * **Hydrochlorothiazide:** While Thiazides are used to prevent **Calcium Oxalate** stones (by increasing distal tubular calcium reabsorption and reducing hypercalciuria) [3], they do not prevent cystine stones. * **Mannitol:** This is an osmotic diuretic used primarily to reduce intracranial or intraocular pressure. It has no specific role in stone prevention. * **Furosemide:** This loop diuretic **increases** urinary calcium excretion (hypercalciuria) [3]. Consequently, it can actually promote the formation of calcium-containing renal stones. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice for Hypercalciuria stones:** Thiazides (e.g., Chlorthalidone, Hydrochlorothiazide) [3]. * **Drug that causes stones:** Acetazolamide can paradoxically cause **Calcium Phosphate** stones because alkaline urine promotes calcium phosphate precipitation, even though it prevents cystine stones [1, 2]. * **Loop Diuretics (Furosemide):** "Loops lose Calcium" (used in treating hypercalcemia) [3]. * **Thiazides:** "Thiazides take Calcium" (reabsorb it back into the blood; used in treating hypercalciuria) [3].

Q: What is the mechanism of action of furosemide in left ventricular failure (LVF)?

Inhibitor of Na-K-Cl ion symporter. **Mechanism of Action:** Furosemide is a potent **Loop Diuretic**. Its primary mechanism involves the inhibition of the **Naⁱ-Kⁱ-2Clⁱ symporter (NKCC2)** [1] located in the luminal membrane of the **Thick Ascending Limb (TAL)** of the Henle’s loop [2]. By blocking this transporter, it prevents the reabsorption of these electrolytes, leading to profound diuresis and natriuresis [3]. **Role in Left Ventricular Failure (LVF):** In acute LVF (Pulmonary Edema), furosemide acts via two distinct phases [4]: 1. **Immediate Effect (Vascular):** It causes rapid **venodilation** (mediated by prostaglandins), which increases venous capacitance and decreases preload. This provides symptomatic relief even before the onset of diuresis. 2. **Delayed Effect (Renal):** It reduces fluid overload through diuresis, further decreasing the workload on the failing heart. **Analysis of Incorrect Options:** * **B. Aldosterone antagonist:** This describes **Spironolactone** or Eplerenone, which act on the distal tubule and collecting ducts. * **C. Mercurial derivative:** These are obsolete diuretics (e.g., Mersalyl) rarely used today due to toxicity. * **D. Carbonic anhydrase inhibitor:** This describes **Acetazolamide**, which acts on the proximal convoluted tubule and is primarily used for glaucoma or altitude sickness, not LVF [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Thick Ascending Limb (TAL) – the "diluting segment." * **Side Effects (The "Hypo"s):** Hypokalemia, Hypomagnesemia, Hypocalcemia (Loop loses Calcium), and Hyperuricemia. * **Ototoxicity:** Furosemide can cause dose-dependent hearing loss, especially when combined with aminoglycosides [2]. * **Drug of Choice:** Furosemide is the DOC for **Acute Pulmonary Edema** and edema associated with CHF, Cirrhosis, and Renal failure [4].

A 64-year-old man with heart failure is recently started on 80 mg/day of furosemide. He now feels weak and tired, but notes that his heart failure symptoms have improved. There is no change in his urine output and he gets a good diuretic response every time he takes his furosemide. Which are the characteristic ECG findings?

Q7Easy

Glycerol is classified as which of the following?

Q8Easy

Which of the following drugs prevents renal stones?

Q9Easy

What is the mechanism of action of furosemide in left ventricular failure (LVF)?

Q10Medium

A patient arrives in the emergency room in a coma and has a serum Ca 2+ of 4.5 mM. You start a saline infusion of which of the following drugs?

Diuretics Indian Medical PG Practice Questions and MCQs

Question 1: Which diuretic can be used in renal failure?

A. Furosemide (Correct Answer)
B. Chlorothiazide
C. Mannitol
D. Chlorthalidone

Explanation: **Explanation:** **Furosemide** is the correct answer because it is a high-ceiling loop diuretic that remains effective even when the Glomerular Filtration Rate (GFR) falls below 30 mL/min. In renal failure, the delivery of solutes to the distal nephron is reduced; loop diuretics are potent enough to inhibit the $Na^+-K^+-2Cl^-$ symporter in the thick ascending limb, maintaining diuresis and managing fluid overload in patients with chronic kidney disease (CKD). **Why the other options are incorrect:** * **Chlorothiazide & Chlorthalidone:** These are Thiazide/Thiazide-like diuretics. They generally lose their efficacy when GFR is less than 30 mL/min (except for Metolazone and Indapamide). Using them in advanced renal failure is ineffective for fluid management. * **Mannitol:** This is an osmotic diuretic. In renal failure, Mannitol is not excreted efficiently, leading to its accumulation in the extracellular fluid. This causes "osmotic shift," drawing water out of cells and potentially leading to acute pulmonary edema or congestive heart failure. It is contraindicated in established anuria. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Furosemide is the drug of choice for acute pulmonary edema and edema associated with CKD. * **Metolazone Exception:** While most thiazides fail in renal failure, Metolazone can be combined with Loop diuretics (Sequential Nephron Blockade) to treat refractory edema in CKD patients. * **Ototoxicity:** Furosemide can cause dose-dependent ototoxicity, especially when administered rapidly IV or combined with aminoglycosides. * **Electrolyte Profile:** Loop diuretics cause "Hypo-everything" (Hypokalemia, Hypomagnesemia, Hypocalcemia), except for Hyperuricemia and Hyperglycemia.

Question 2: Which diuretic is appropriate for combining with ACE inhibitors?

A. Spironolactone
B. Eplerenone
C. Hydrochlorothiazide (Correct Answer)
D. Amiloride

Explanation: ### Explanation The combination of **ACE inhibitors (ACEIs)** and **Hydrochlorothiazide (HCTZ)** is a cornerstone in the management of hypertension. **Why Hydrochlorothiazide is the correct choice:** The primary rationale for this combination is **potassium homeostasis**. ACE inhibitors block the production of Aldosterone, leading to potassium retention (hyperkalemia). Conversely, Thiazide diuretics like HCTZ increase potassium excretion at the distal convoluted tubule, which can lead to hypokalemia. When used together, they exert a **synergistic antihypertensive effect** while neutralizing each other's impact on serum potassium levels. Additionally, ACEIs inhibit the compensatory activation of the Renin-Angiotensin-Aldosterone System (RAAS) typically triggered by diuretic-induced volume depletion. **Why the other options are incorrect:** * **Spironolactone & Eplerenone (Options A & B):** These are Potassium-sparing diuretics (Aldosterone antagonists). Combining them with ACEIs significantly increases the risk of **severe, life-threatening hyperkalemia**, as both drug classes promote potassium retention. * **Amiloride (Option D):** This is an epithelial sodium channel (ENaC) blocker, also classified as a potassium-sparing diuretic. Like Spironolactone, it carries a high risk of hyperkalemia when combined with ACEIs. **NEET-PG High-Yield Pearls:** * **Synergy:** ACEIs + Thiazides is a "rational drug combination" because it improves efficacy and limits side effects (hypokalemia). * **Metabolic Neutrality:** ACEIs may help mitigate the hyperglycemia and hyperuricemia sometimes seen with high-dose Thiazide use. * **Contraindication:** Never combine ACEIs with ARBs or Direct Renin Inhibitors (Aliskiren) due to the risk of renal failure and hyperkalemia. * **Drug of Choice:** ACEIs are the first-line treatment for hypertension in patients with **Diabetes Mellitus** (due to nephroprotective effects).

Question 3: Which of the following are potassium-sparing diuretics?

A. Spironolactone
B. Triamterene
C. Amiloride
D. All of the above (Correct Answer)

Explanation: Potassium-sparing diuretics are a unique class of drugs that act on the **late distal tubule and collecting duct** to promote sodium excretion while conserving potassium. They are categorized into two distinct groups based on their mechanism of action: 1. **Aldosterone Antagonists (Spironolactone & Eplerenone):** These are competitive inhibitors of the mineralocorticoid receptor. By blocking aldosterone, they prevent the synthesis of Na+/K+ ATPase pumps and epithelial sodium channels (ENaC), thereby reducing sodium reabsorption and potassium secretion. 2. **Direct ENaC Blockers (Amiloride & Triamterene):** These drugs do not depend on aldosterone. They directly block the ENaC on the luminal membrane of principal cells. This prevents sodium entry, which reduces the negative intraluminal potential, thereby inhibiting the electrical gradient that normally drives potassium secretion into the urine. **Analysis of Options:** * **A, B, and C** are all classic examples of potassium-sparing diuretics. Since all three drugs belong to this class (though via different sub-mechanisms), **Option D** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** The most common and dangerous side effect of this class is **hyperkalemia**. Spironolactone specifically can cause **gynecomastia** and impotence due to its non-specific anti-androgenic effects (Eplerenone is more selective). * **Liddle’s Syndrome:** Amiloride is the drug of choice for this rare genetic condition. * **Lithium-Induced Diabetes Insipidus:** Amiloride is used to treat this by blocking lithium entry through ENaC in the collecting ducts. * **Clinical Use:** These drugs are often combined with Thiazides or Loop diuretics to counteract the hypokalemia induced by the latter.

Question 4: Which of the following side effects is associated with Spironolactone?

A. Alkalosis
B. Hirsutism
C. Hyperkalemia (Correct Answer)
D. Hyperglycemia

Explanation: **Explanation:** **Spironolactone** is a potassium-sparing diuretic that acts as a competitive antagonist of the **Mineralocorticoid Receptor (Aldosterone receptor)** in the late distal tubule and collecting duct. **Why Hyperkalemia is Correct:** Aldosterone normally promotes the reabsorption of sodium ($Na^+$) and the excretion of potassium ($K^+$) and hydrogen ions ($H^+$). By blocking this receptor, Spironolactone prevents $K^+$ secretion into the tubular lumen. This leads to the retention of potassium in the blood, resulting in **Hyperkalemia**, its most significant and potentially life-threatening side effect. **Analysis of Incorrect Options:** * **A. Alkalosis:** Spironolactone causes **Metabolic Acidosis** (not alkalosis) because it inhibits the excretion of $H^+$ ions. * **B. Hirsutism:** Spironolactone actually has **anti-androgenic** properties (it blocks androgen receptors and inhibits steroidogenesis). Therefore, it is used to *treat* hirsutism in conditions like PCOS. A common side effect in males, however, is **gynecomastia**. * **D. Hyperglycemia:** This is a classic side effect of **Thiazides and Loop diuretics**, which can impair insulin release. Spironolactone does not typically affect blood glucose levels. **High-Yield Clinical Pearls for NEET-PG:** * **Eplerenone** is a more selective aldosterone antagonist with fewer endocrine side effects (less risk of gynecomastia) compared to Spironolactone. * **Drug Interaction:** Avoid combining Spironolactone with ACE inhibitors or ARBs, as this significantly increases the risk of severe hyperkalemia. * **Indication of Choice:** It is the diuretic of choice for patients with **Cirrhosis with Ascites** and is proven to reduce mortality in **Chronic Heart Failure (NYHA Class II-IV)**.

Question 5: Indomethacin can antagonize the diuretic action of loop diuretics by:

A. Preventing prostaglandin-mediated intrarenal-hemodynamic actions (Correct Answer)
B. Blocking the action in the ascending limb of the loop of Henle
C. Enhancing salt and water reabsorption in distal tubules
D. Increasing aldosterone secretion

Explanation: ### Explanation **1. Why Option A is Correct:** Loop diuretics (like Furosemide) work not only by inhibiting the $Na^+$-$K^+$-$2Cl^-$ symporter but also by stimulating the synthesis of **renal prostaglandins** (especially $PGE_2$). These prostaglandins cause vasodilation of the afferent arterioles, increasing renal blood flow and optimizing the delivery of the diuretic to its site of action. **Indomethacin** is a potent Non-Steroidal Anti-Inflammatory Drug (NSAID) that inhibits the enzyme **Cyclooxygenase (COX)**. By blocking COX, Indomethacin inhibits prostaglandin synthesis. This results in afferent arteriolar vasoconstriction and reduced intrarenal hemodynamics, thereby antagonizing the diuretic and natriuretic effects of loop diuretics [1], [2]. **2. Why Other Options are Incorrect:** * **Option B:** Loop diuretics themselves block the $Na^+$-$K^+$-$2Cl^-$ symporter in the thick ascending limb. Indomethacin does not directly compete for this transporter; its interference is biochemical/hemodynamic. * **Option C:** While NSAIDs can cause salt and water retention as a side effect, the primary mechanism of *antagonism* with loop diuretics specifically involves the loss of prostaglandin-mediated vasodilation [2]. * **Option D:** Indomethacin actually tends to *suppress* renin release (which is partly prostaglandin-mediated), leading to decreased rather than increased aldosterone secretion. **3. High-Yield Facts for NEET-PG:** * **Drug Interaction:** This interaction is clinically significant in patients with Congestive Heart Failure (CHF) or Cirrhosis, where renal perfusion is highly dependent on prostaglandins [1]. * **Triple Whammy:** Avoid the combination of **ACE inhibitors/ARBs + Diuretics + NSAIDs**, as it significantly increases the risk of Acute Kidney Injury (AKI) [1]. * **Bartter’s Syndrome:** This condition mimics chronic loop diuretic use. Interestingly, Indomethacin is used in the treatment of Bartter’s syndrome to reduce excessive prostaglandin production. * **Prostaglandins & Loop Diuretics:** Loop diuretics also increase systemic venous capacitance (useful in pulmonary edema) via prostaglandins; NSAIDs can also blunt this beneficial effect.

Question 6: A 64-year-old man with heart failure is recently started on 80 mg/day of furosemide. He now feels weak and tired, but notes that his heart failure symptoms have improved. There is no change in his urine output and he gets a good diuretic response every time he takes his furosemide. Which are the characteristic ECG findings?

A. shortened PR interval
B. lengthened PR interval
C. lengthened QU interval (Correct Answer)
D. shortening of the QT interval

Explanation: ### Explanation **Correct Answer: C. Lengthened QU interval** **1. Underlying Medical Concept:** Furosemide is a potent loop diuretic that inhibits the Na⁺/K⁺/2Cl⁻ symporter in the thick ascending limb of the Loop of Henle. A common and significant side effect of loop diuretics is **hypokalemia** (low serum potassium). In hypokalemia, the ECG undergoes characteristic changes due to delayed ventricular repolarization. The most classic finding is the appearance of **prominent U waves**. As the U wave becomes more pronounced and the T wave flattens, the T and U waves often merge. This creates the appearance of a **"lengthened QU interval"** (or a pseudo-prolonged QT interval), which is a hallmark of potassium depletion. The patient’s symptoms of weakness and fatigue are clinical indicators of this electrolyte imbalance. **2. Why the other options are incorrect:** * **A & B (PR Interval):** Changes in the PR interval are typically associated with calcium abnormalities or AV nodal blocks (e.g., Digoxin toxicity), not primarily with the hypokalemia caused by diuretics. * **D (Shortened QT interval):** A shortened QT interval is characteristic of **hypercalcemia**. In contrast, hypokalemia (and hypocalcemia) typically leads to a prolonged appearance of the repolarization phase (prolonged QU/QT). **3. NEET-PG High-Yield Pearls:** * **ECG findings in Hypokalemia:** Flattening/inversion of T waves, ST-segment depression, prominent U waves, and QU prolongation. * **Loop Diuretics Side Effects (Mnemonic: OH DANG!):** **O**totoxicity, **H**ypokalemia, **D**ehydration, **A**llergy (sulfa), **N**ephritis (interstitial), **G**out (hyperuricemia). * **Metabolic state:** Loop diuretics cause **Hypokalemic Metabolic Alkalosis**. * **U wave:** A positive deflection after the T wave, representing slow repolarization of Purkinje fibers. It is most visible in precordial leads V2–V4.

Question 7: Glycerol is classified as which of the following?

A. Osmotic diuretic (Correct Answer)
B. Purgative
C. Antidiabetic
D. Antiemetic

Explanation: **Explanation:** **Glycerol** is a low-molecular-weight, pharmacologically inert substance that acts as an **Osmotic Diuretic**. When administered (usually orally), it increases the osmolarity of the plasma and tubular fluid. 1. **Why Option A is Correct:** As an osmotic diuretic, glycerol creates an osmotic gradient that draws water out of the intracellular and interstitial compartments into the vascular space. In the kidneys, it is filtered by the glomerulus but poorly reabsorbed, thereby limiting water reabsorption in the proximal tubule and the descending limb of the Loop of Henle, leading to diuresis. 2. **Why Other Options are Incorrect:** * **B. Purgative:** While glycerol suppositories are used for constipation (acting as a lubricant/irritant), "Glycerol" as a systemic pharmacological agent is primarily classified and tested as an osmotic agent. * **C. Antidiabetic:** Glycerol is actually a precursor for gluconeogenesis; it can potentially increase blood glucose levels, making it contraindicated or used with caution in diabetic patients. * **D. Antiemetic:** Glycerol has no mechanism of action involving the CTZ or H1/D2 receptors to prevent vomiting. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Use:** Glycerol is used to acutely reduce **intraocular pressure** (in acute glaucoma) and **intracranial pressure** (in cerebral edema). * **Route:** Unlike Mannitol (which must be given IV), Glycerol is effective **orally**, though it has a sweet, sickening taste. * **Comparison:** Mannitol is the preferred IV osmotic diuretic, while Glycerol is the classic oral alternative. * **Side Effect:** Watch for hyperglycemia and dehydration. Use with caution in patients with congestive heart failure (due to initial ECF volume expansion).

Question 8: Which of the following drugs prevents renal stones?

A. Acetazolamide (Correct Answer)
B. Hydrochlorothiazide
C. Mannitol
D. Furosemide

Explanation: The correct answer is **Acetazolamide**. This question focuses on the specific management of **Cystinuria** and the prevention of **Cystine stones**. **1. Why Acetazolamide is correct:** Acetazolamide is a Carbonic Anhydrase inhibitor that acts on the proximal convoluted tubule [1, 2]. By inhibiting the reabsorption of bicarbonate, it increases urinary bicarbonate excretion, leading to **alkalinization of the urine** [1, 2]. Cystine is highly insoluble in acidic urine but becomes significantly more soluble as the pH rises above 7.5. Therefore, by making the urine alkaline, Acetazolamide prevents the precipitation of cystine crystals and the formation of renal stones in patients with cystinuria [1]. **2. Why the other options are incorrect:** * **Hydrochlorothiazide:** While Thiazides are used to prevent **Calcium Oxalate** stones (by increasing distal tubular calcium reabsorption and reducing hypercalciuria) [3], they do not prevent cystine stones. * **Mannitol:** This is an osmotic diuretic used primarily to reduce intracranial or intraocular pressure. It has no specific role in stone prevention. * **Furosemide:** This loop diuretic **increases** urinary calcium excretion (hypercalciuria) [3]. Consequently, it can actually promote the formation of calcium-containing renal stones. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice for Hypercalciuria stones:** Thiazides (e.g., Chlorthalidone, Hydrochlorothiazide) [3]. * **Drug that causes stones:** Acetazolamide can paradoxically cause **Calcium Phosphate** stones because alkaline urine promotes calcium phosphate precipitation, even though it prevents cystine stones [1, 2]. * **Loop Diuretics (Furosemide):** "Loops lose Calcium" (used in treating hypercalcemia) [3]. * **Thiazides:** "Thiazides take Calcium" (reabsorb it back into the blood; used in treating hypercalciuria) [3].

Question 9: What is the mechanism of action of furosemide in left ventricular failure (LVF)?

A. Inhibitor of Na-K-Cl ion symporter (Correct Answer)
B. Aldosterone antagonist
C. Mercurial derivative
D. Carbonic anhydrase inhibitor

Explanation: **Mechanism of Action:** Furosemide is a potent **Loop Diuretic**. Its primary mechanism involves the inhibition of the **Naⁱ-Kⁱ-2Clⁱ symporter (NKCC2)** [1] located in the luminal membrane of the **Thick Ascending Limb (TAL)** of the Henle’s loop [2]. By blocking this transporter, it prevents the reabsorption of these electrolytes, leading to profound diuresis and natriuresis [3]. **Role in Left Ventricular Failure (LVF):** In acute LVF (Pulmonary Edema), furosemide acts via two distinct phases [4]: 1. **Immediate Effect (Vascular):** It causes rapid **venodilation** (mediated by prostaglandins), which increases venous capacitance and decreases preload. This provides symptomatic relief even before the onset of diuresis. 2. **Delayed Effect (Renal):** It reduces fluid overload through diuresis, further decreasing the workload on the failing heart. **Analysis of Incorrect Options:** * **B. Aldosterone antagonist:** This describes **Spironolactone** or Eplerenone, which act on the distal tubule and collecting ducts. * **C. Mercurial derivative:** These are obsolete diuretics (e.g., Mersalyl) rarely used today due to toxicity. * **D. Carbonic anhydrase inhibitor:** This describes **Acetazolamide**, which acts on the proximal convoluted tubule and is primarily used for glaucoma or altitude sickness, not LVF [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Thick Ascending Limb (TAL) – the "diluting segment." * **Side Effects (The "Hypo"s):** Hypokalemia, Hypomagnesemia, Hypocalcemia (Loop loses Calcium), and Hyperuricemia. * **Ototoxicity:** Furosemide can cause dose-dependent hearing loss, especially when combined with aminoglycosides [2]. * **Drug of Choice:** Furosemide is the DOC for **Acute Pulmonary Edema** and edema associated with CHF, Cirrhosis, and Renal failure [4].

Question 10: A patient arrives in the emergency room in a coma and has a serum Ca 2+ of 4.5 mM. You start a saline infusion of which of the following drugs?

A. Ethacrynic acid (Correct Answer)
B. Calcitonin
C. Hydrochlorothiazide
D. Spironolactone

Explanation: ### Explanation **Concept:** The patient is presenting with **severe hypercalcemia** (normal serum calcium is 2.2–2.6 mM; 4.5 mM is a life-threatening emergency). The primary goal in acute hypercalcemia is to enhance urinary calcium excretion. **1. Why Ethacrynic Acid is Correct:** Ethacrynic acid is a **Loop Diuretic**. Loop diuretics (like Furosemide and Ethacrynic acid) inhibit the Na+/K+/2Cl- symporter in the Thick Ascending Limb (TAL) of the Loop of Henle. This action abolishes the positive transepithelial potential, which normally drives the paracellular reabsorption of divalent cations (**Ca²⁺ and Mg²⁺**). Consequently, loop diuretics promote **calciuresis** (calcium excretion). In emergencies, they are administered with saline to prevent volume depletion and further enhance calcium clearance. **2. Why the Other Options are Incorrect:** * **B. Calcitonin:** While calcitonin reduces serum calcium by inhibiting osteoclasts, its effect is slow, relatively weak, and prone to tachyphylaxis. It is an adjunct treatment, but loop diuretics are the classic pharmacological choice for rapid excretion in this context. * **C. Hydrochlorothiazide:** Thiazides are **contraindicated** in hypercalcemia. They increase distal tubular calcium reabsorption, leading to **hypercalcemia**. They are used to treat idiopathic hypercalciuria (kidney stones), not high serum calcium. * **D. Spironolactone:** This is a potassium-sparing diuretic (aldosterone antagonist) acting on the collecting duct. It has no significant effect on calcium excretion. **Clinical Pearls for NEET-PG:** * **Mnemonic:** "Loop Loses" (Loops lose Calcium); "Thiazides Thrive" (Thiazides save Calcium). * **Drug of Choice:** While Ethacrynic acid is a loop diuretic, **Furosemide** is more commonly used in practice. Ethacrynic acid is reserved for patients with **sulfonamide allergies**. * **Acute Management:** The first step in hypercalcemia is always **aggressive IV hydration (Normal Saline)**, followed by loop diuretics. * **Bisphosphonates (e.g., Zoledronate):** These are the gold standard for long-term management of hypercalcemia of malignancy but take 48–72 hours to work.

Question 11: Which of the following thiazide diuretics remains active when the Glomerular Filtration Rate (GFR) is 30-40 mL/min?

A. Metolazone (Correct Answer)
B. Benzthiazide
C. Chlorothiazide
D. Chlorthalidone

Explanation: ### Explanation\n\n**1. Why Metolazone is Correct:**\nMost thiazide diuretics lose their efficacy when the Glomerular Filtration Rate (GFR) falls below **30–40 mL/min** [1], [2]. This is because they must be secreted into the tubular lumen to act on the Na⁺-Cl⁻ symporter in the distal convoluted tubule; in renal failure, their delivery to the site of action is significantly impaired. **Metolazone** (and to some extent Indapamide) is a "thiazide-like" diuretic that is uniquely potent. It maintains its diuretic efficacy even in advanced renal insufficiency (GFR as low as 10–20 mL/min) [1].\n\n**2. Why the Other Options are Incorrect:**\n* **Benzthiazide & Chlorothiazide:** These are classical thiazides. They are ineffective in patients with significant renal impairment (GFR < 30 mL/min) because they cannot reach therapeutic concentrations in the tubular fluid [1].\n* **Chlorthalidone:** While it is highly potent and has a long half-life (making it a preferred agent for hypertension), it generally loses its effectiveness as a diuretic when renal function is significantly compromised, unlike Metolazone [1].\n\n**3. High-Yield Clinical Pearls for NEET-PG:**\n* **Synergistic Effect:** Metolazone is frequently added to Loop diuretics (e.g., Furosemide) to overcome **"diuretic resistance"** in patients with refractory edema or congestive heart failure. This is known as **Sequential Nephron Blockade**.\n* **Metabolic Side Effects:** Remember the mnemonic **"Hyper GLUC"** for thiazides: Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia, and Hyper**C**alcemia.\n* **Hypokalemia:** Like loop diuretics, thiazides cause potassium wasting [1].\n* **Indapamide:** Another thiazide-like diuretic often preferred in diabetics as it is considered "metabolically neutral."

Question 12: Which of the following diuretics causes impaired glucose tolerance?

A. Spironolactone
B. Thiazides (Correct Answer)
C. Amiloride
D. Canrenone

Explanation: **Explanation:** **Thiazide diuretics** (e.g., Hydrochlorothiazide, Chlorthalidone) are well-known for causing metabolic side effects, including **impaired glucose tolerance** and hyperglycemia. The underlying mechanism is two-fold: 1. **Hypokalemia-induced inhibition of insulin:** Thiazides cause potassium depletion. Low extracellular potassium levels inhibit the release of insulin from pancreatic beta cells (as insulin secretion is a potassium-dependent process). 2. **Decreased peripheral insulin sensitivity:** Thiazides may also reduce the sensitivity of peripheral tissues to insulin, further elevating blood glucose levels. **Analysis of Incorrect Options:** * **A & D (Spironolactone and Canrenone):** These are **Potassium-sparing diuretics** (Aldosterone antagonists). Unlike Thiazides, they do not cause hypokalemia; in fact, they can cause hyperkalemia. They do not typically interfere with glucose metabolism. * **C (Amiloride):** This is an epithelial sodium channel (ENaC) blocker, also classified as a **Potassium-sparing diuretic**. It is often combined with Thiazides specifically to counteract the potassium loss and mitigate the risk of impaired glucose tolerance. **NEET-PG High-Yield Pearls:** * **Mnemonic for Thiazide Side Effects (Hyper-GLUC):** Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia (can precipitate Gout), and Hyper**C**alcemia. * **Contrast with Loop Diuretics:** While Loop diuretics (Furosemide) can also cause hyperglycemia, the effect is significantly more pronounced and clinically relevant with **Thiazides**. * **Clinical Note:** Thiazides should be used with caution in patients with Diabetes Mellitus or Metabolic Syndrome.

Question 13: Which diuretic is used in the management of mountain sickness?

A. Hydrochlorothiazide
B. Furosemide
C. Acetazolamide (Correct Answer)
D. Spironolactone

Explanation: **Explanation:** **Acetazolamide** is the drug of choice for the prevention and treatment of Acute Mountain Sickness (AMS) [2], [3]. It is a **Carbonic Anhydrase Inhibitor** that acts on the proximal convoluted tubule [4]. **Mechanism in Mountain Sickness:** At high altitudes, low oxygen levels trigger hyperventilation, leading to respiratory alkalosis. Acetazolamide inhibits carbonic anhydrase, causing **bicarbonate diuresis** (bicarbonaturia) [5]. This induces a mild **metabolic acidosis**, which counteracts the respiratory alkalosis. The resulting drop in blood pH stimulates the chemoreceptors, increasing the respiratory drive and improving oxygenation, thereby accelerating acclimatization [2]. It also reduces the formation of cerebrospinal fluid (CSF), helping to decrease intracranial pressure. **Why other options are incorrect:** * **Hydrochlorothiazide (Thiazide):** Primarily used for hypertension and nephrogenic diabetes insipidus; it has no effect on respiratory drive or altitude acclimatization. * **Furosemide (Loop Diuretic):** Used for High-Altitude Pulmonary Edema (HAPE) due to its potent diuretic effect, but it is not used for standard mountain sickness or prophylaxis. * **Spironolactone (K+ Sparing):** An aldosterone antagonist used in cirrhosis or heart failure; it does not influence blood pH or acclimatization. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Proximal Convoluted Tubule (PCT) [4]. * **Other Uses:** Glaucoma (decreases aqueous humor), Urinary alkalinization (to excrete acidic drugs like aspirin), and Sleep Apnea [1], [2]. * **Key Side Effects:** Hyperchloremic metabolic acidosis, hypokalemia, paresthesia, and sulfa-allergy reactions [2]. * **Contraindication:** Avoid in Hepatic Cirrhosis (can precipitate hepatic encephalopathy by decreasing ammonia excretion) [2], [5].

Question 14: Thiazides cause all the following side-effects except-

A. Hypercalcemia
B. Hypokalemia
C. Metabolic acidosis (Correct Answer)
D. Metabolic alkalosis

Explanation: **Explanation:** Thiazide diuretics act on the **Distal Convoluted Tubule (DCT)** by inhibiting the $Na^+/Cl^-$ symporter. This mechanism leads to a specific pattern of electrolyte and acid-base disturbances. **Why Metabolic Acidosis is the correct answer:** Thiazides do **not** cause metabolic acidosis; instead, they cause **Metabolic Alkalosis**. By increasing sodium delivery to the collecting ducts, they stimulate the exchange of $Na^+$ for $H^+$ and $K^+$. The loss of $H^+$ ions in the urine leads to an increase in serum bicarbonate levels (contraction alkalosis). In contrast, metabolic acidosis is a side effect of Carbonic Anhydrase inhibitors (like Acetazolamide) or Potassium-sparing diuretics. **Analysis of Incorrect Options:** * **Hypercalcemia:** Thiazides increase calcium reabsorption in the DCT (unlike loop diuretics which cause hypocalcemia). This makes them useful in treating idiopathic hypercalciuria and calcium stones. * **Hypokalemia:** Increased sodium delivery to the late distal tubule promotes $K^+$ secretion into the lumen, leading to potassium depletion. * **Metabolic Alkalosis:** As explained above, the loss of $H^+$ and $Cl^-$ ions results in an alkalotic state. **High-Yield Clinical Pearls for NEET-PG:** * **The "Hyper" Mnemonic:** Thiazides cause **Hyper**glycemia, **Hyper**uricemia (can precipitate Gout), **Hyper**lipidemia, and **Hyper**calcemia. * **The "Hypo" Mnemonic:** They cause **Hypo**kalemia, **Hypo**natremia, and **Hypo**magnesemia. * **Drug of Choice:** Thiazides are the first-line treatment for Hypertension in patients with Osteoporosis due to their calcium-sparing effect.

Question 15: Which of the following diuretics should not be administered along with aminoglycosides?

A. Chlorthiazide
B. Furosemide (Correct Answer)
C. Dorzolamide
D. Canrenone

Explanation: **Explanation:** The correct answer is **Furosemide**. **1. Why Furosemide is the correct answer:** Furosemide is a potent **Loop Diuretic** that inhibits the $Na^+-K^+-2Cl^-$ symporter in the thick ascending limb of the Loop of Henle. A significant adverse effect of loop diuretics is **ototoxicity** (damage to the inner ear), which can manifest as tinnitus, hearing loss, or vertigo. **Aminoglycosides** (e.g., Gentamicin, Amikacin) are also notoriously ototoxic. When administered together, they exert a **synergistic toxic effect**, significantly increasing the risk of permanent deafness. This interaction is a classic contraindication in clinical practice. **2. Why the other options are incorrect:** * **A. Chlorthiazide:** This is a Thiazide diuretic. While thiazides can cause metabolic disturbances (hypokalemia, hyperuricemia), they are not typically associated with ototoxicity and do not potentiate aminoglycoside-induced ear damage. * **C. Dorzolamide:** This is a topical Carbonic Anhydrase Inhibitor used primarily in glaucoma to reduce intraocular pressure. It lacks the systemic profile to interact with aminoglycosides in this manner. * **D. Canrenone:** This is an active metabolite of Spironolactone (a Potassium-sparing diuretic). Its primary side effects are related to hyperkalemia and hormonal changes (gynecomastia), not ototoxicity. **3. NEET-PG High-Yield Pearls:** * **Ototoxic Loop Diuretics:** Ethacrynic acid is the *most* ototoxic, while Furosemide is the most commonly implicated clinically. * **Mechanism of Ototoxicity:** Loop diuretics alter the electrolyte composition of the endolymph by affecting ion transporters in the *stria vascularis* of the cochlea. * **Other Synergistic Interactions:** Avoid combining aminoglycosides with other ototoxic/nephrotoxic drugs like **Cisplatin**, **Vancomycin**, or **Amphotericin B**. * **Canrenone Fact:** It is the major active metabolite responsible for the diuretic action of Spironolactone.

Question 16: Spironolactone is used in the treatment of patients with Conn's syndrome. Which of the following is the most important adverse reaction of spironolactone therapy?

A. Antiandrogen effects (Correct Answer)
B. Cardiac arrhythmia
C. Dehydration
D. Hyperkalemia

Explanation: **Explanation:** Spironolactone is a potassium-sparing diuretic that acts as a competitive antagonist at the mineralocorticoid receptor. In **Conn’s syndrome** (primary hyperaldosteronism), it is used to counteract the effects of excess aldosterone. **Why Antiandrogen effects is the correct answer:** While spironolactone is a mineralocorticoid antagonist, it is **non-selective**. It also acts as a potent antagonist at **androgen receptors** and inhibits steroidogenesis (decreasing testosterone synthesis). In clinical practice, these hormonal side effects are the most bothersome and "important" reasons for treatment non-compliance. In males, this manifests as **gynecomastia** and impotence; in females, it causes **menstrual irregularities** and breast tenderness. **Analysis of Incorrect Options:** * **Hyperkalemia (D):** While hyperkalemia is a common and potentially dangerous side effect of all potassium-sparing diuretics, the question asks for the most *characteristic* adverse reaction associated with spironolactone's unique chemical structure. In the context of NEET-PG, "antiandrogen effects" is the classic "distinguishing" side effect tested for spironolactone. * **Cardiac arrhythmia (B):** This is a secondary consequence of severe hyperkalemia, not a direct effect of the drug itself. * **Dehydration (C):** Spironolactone is a relatively weak diuretic; significant dehydration is rare compared to loop diuretics like furosemide. **High-Yield Clinical Pearls for NEET-PG:** * **Eplerenone:** A selective aldosterone antagonist that does **not** have antiandrogenic side effects (no gynecomastia). It is the preferred alternative if spironolactone is not tolerated. * **Drug of Choice:** Spironolactone is the drug of choice for **Conn’s syndrome** and **Ascites in Liver Cirrhosis**. * **Mortality Benefit:** It is proven to reduce mortality in Congestive Heart Failure (NYHA Class III/IV). * **Other uses:** Due to its antiandrogenic properties, it is also used to treat **Hirsutism** and **Acne** in females.

Question 17: What are the diuretics of choice for acute pulmonary edema?

A. Loop diuretics (Correct Answer)
B. Thiazides
C. Spironolactone
D. Mannitol

Explanation: **Explanation:** **1. Why Loop Diuretics are the Correct Answer:** Loop diuretics (specifically **Furosemide**) are the drugs of choice for acute pulmonary edema due to their unique **dual mechanism of action**: * **Immediate Vasodilatory Effect:** When given intravenously, they cause rapid venodilation (mediated by prostaglandin release) even before the onset of diuresis. This increases venous capacitance, reduces venous return (preload), and provides immediate relief from pulmonary congestion. * **Potent Diuresis:** By inhibiting the **Na⁺-K⁺-2Cl⁻ symporter** in the Thick Ascending Limb of Henle, they induce massive diuresis, reducing total body fluid volume and further alleviating pulmonary edema. **2. Why Other Options are Incorrect:** * **Thiazides:** These are "low ceiling" diuretics with moderate efficacy. They act on the distal tubule and lack the rapid vasodilatory properties required for an acute emergency. * **Spironolactone:** This is a potassium-sparing diuretic (aldosterone antagonist). It has a slow onset of action (taking days to work) and is used for long-term remodeling in heart failure, not acute stabilization. * **Mannitol:** As an osmotic diuretic, it initially increases extracellular fluid volume before diuresis occurs. This can acutely worsen pulmonary edema and precipitate heart failure. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** IV Furosemide (Lasix). * **Ototoxicity:** A key side effect of loop diuretics, especially when used with aminoglycosides. Ethacrynic acid is the most ototoxic. * **Electrolyte Profile:** Loop diuretics cause "Hypo-Everything" (Hypokalemia, Hypomagnesemia, Hypocalcemia), except for **Hyperuricemia** and **Hyperglycemia**. * **Sulfa Allergy:** Most loop diuretics are sulfonamide derivatives; **Ethacrynic acid** is the alternative for patients with sulfa allergies.

Question 18: A 32-year-old male patient is treated for hypertension with thiazides. Which of the following adverse effects can occur in this patient?

A. Hyperkalemic paralysis
B. Hypouricemia
C. Hypolipidemia
D. Impotence (Correct Answer)

Explanation: **Explanation:** Thiazide diuretics (e.g., Hydrochlorothiazide, Chlorthalidone) are first-line antihypertensive agents, but they are associated with several metabolic and systemic side effects. **Why Impotence is Correct:** Sexual dysfunction, specifically **erectile dysfunction (impotence)**, is a well-documented side effect of thiazide diuretics. While the exact mechanism is multifactorial, it is thought to involve a decrease in peripheral vascular resistance and a reduction in zinc levels, which is essential for testosterone production. In clinical trials, thiazides are more frequently associated with impotence compared to other antihypertensives like ACE inhibitors or Calcium Channel Blockers. **Analysis of Incorrect Options:** * **A. Hyperkalemic paralysis:** Thiazides inhibit the $Na^+/Cl^-$ symporter in the distal convoluted tubule, increasing sodium delivery to the collecting ducts. This promotes potassium excretion, leading to **hypokalemia**, not hyperkalemia. * **B. Hypouricemia:** Thiazides compete with uric acid for the organic acid secretory secretory pump in the proximal tubule. This leads to decreased uric acid excretion, resulting in **hyperuricemia**, which can precipitate gout. * **C. Hypolipidemia:** Thiazides can cause a transient increase in serum cholesterol and LDL levels (**hyperlipidemia**), though this effect often diminishes with long-term therapy. **High-Yield Clinical Pearls for NEET-PG:** * **The "Hyper" Rule:** Thiazides cause **Hyper**glycemia, **Hyper**uricemia, **Hyper**lipidemia, and **Hyper**calcemia (useful in treating idiopathic hypercalciuria/kidney stones). * **The "Hypo" Rule:** Thiazides cause **Hypo**kalemia, **Hypo**natremia, and **Hypo**magnesemia. * **Chlorthalidone** is currently preferred over Hydrochlorothiazide due to its longer half-life and superior evidence in reducing cardiovascular events.

Question 19: Which of the following diuretics decreases renal lithium clearance?

A. acetazolamide
B. hydrochlorothiazide (Correct Answer)
C. furosemide
D. spironolactone

Explanation: **Explanation:** The correct answer is **hydrochlorothiazide**. **Mechanism of Interaction:** Lithium is handled by the kidneys in a manner very similar to sodium. Approximately 80% of filtered lithium is reabsorbed in the proximal convoluted tubule (PCT). **Thiazide diuretics** (like hydrochlorothiazide) inhibit the Na+/Cl- symporter in the distal tubule, leading to increased excretion of sodium and water. This induces a state of mild volume depletion. In response, the proximal tubule compensatorily increases the reabsorption of sodium and water to maintain blood volume. Because the PCT cannot distinguish between sodium and lithium ions, it also increases the **proximal reabsorption of lithium**. This significantly decreases renal lithium clearance, leading to toxic serum lithium levels. **Analysis of Incorrect Options:** * **Acetazolamide:** This carbonic anhydrase inhibitor actually *increases* lithium excretion. By inhibiting bicarbonate reabsorption in the PCT, it also inhibits the co-transport of lithium, potentially lowering serum levels. * **Furosemide:** Loop diuretics act on the thick ascending limb of Henle. While they can affect lithium levels, the effect is much less consistent and less clinically significant than thiazides because they do not trigger the same degree of compensatory proximal reabsorption. * **Spironolactone:** This potassium-sparing diuretic acts on the collecting duct. It generally has a negligible effect on lithium clearance compared to thiazides. **Clinical Pearls for NEET-PG:** * **Drug of Choice for Lithium-Induced Diabetes Insipidus:** Amiloride (it blocks the ENaC channels in the collecting duct, preventing lithium from entering the cells). * **Drugs that increase Lithium levels:** Thiazides, NSAIDs (except aspirin/sulindac), and ACE inhibitors/ARBs. * **Lithium Toxicity:** Characterized by coarse tremors, ataxia, seizures, and nephrogenic diabetes insipidus.

Question 20: Which of the following diuretics keeps urine isotonic?

A. Thiazide diuretics
B. Loop diuretics (Correct Answer)
C. Carbonic anhydrase inhibitors
D. None of the above

Explanation: **Explanation:** The correct answer is **Loop Diuretics** (e.g., Furosemide). This occurs because loop diuretics inhibit the **Na⁺-K⁺-2Cl⁻ symporter** in the Thick Ascending Limb (TAL) of the Loop of Henle. **Why Loop Diuretics keep urine isotonic:** The TAL is responsible for reabsorbing solutes without water, which creates the **medullary osmotic gradient**. This gradient is essential for both concentrating urine (via ADH) and diluting urine. By blocking solute reabsorption in this segment, loop diuretics abolish the medullary hypertonicity. Consequently, the kidney loses its ability to concentrate or dilute urine, resulting in the excretion of urine that has the same osmolality as plasma (~300 mOsm/L), a phenomenon known as **isosthenuria**. **Why other options are incorrect:** * **Thiazide Diuretics:** These act on the Distal Convoluted Tubule (DCT). They interfere with the kidney’s ability to dilute urine but do **not** affect the medullary gradient. Therefore, the urine remains concentrated (hypertonic) relative to the initial filtrate. * **Carbonic Anhydrase Inhibitors:** These act on the Proximal Convoluted Tubule. While they increase bicarbonate and sodium excretion, they do not disrupt the primary concentrating mechanism of the medulla, thus not resulting in strictly isotonic urine. **High-Yield Clinical Pearls for NEET-PG:** * **"High Ceiling" Diuretics:** Loop diuretics are called this because they have a dose-dependent response with a very high maximal efficacy. * **Calcium Effect:** Loop diuretics cause **hypocalcemia** ("Loops Lose Calcium"), whereas Thiazides cause **hypercalcemia**. * **Drug of Choice:** Loop diuretics are the DOC for acute pulmonary edema and generalized edema (CHF, Nephrotic syndrome).

Question 21: What is the primary site of action for Chlorthalidone?

A. Early distal tubule (Correct Answer)
B. Late distal tubule
C. Collecting duct (medullary portion)
D. Collecting duct (cortical portion)

Explanation: **Explanation:** **Chlorthalidone** is a thiazide-like diuretic. Although it differs chemically from benzothiadiazines, it shares the same mechanism of action and site of action as thiazide diuretics. **1. Why Option A is Correct:** The primary site of action for Chlorthalidone (and all thiazides) is the **early distal convoluted tubule (DCT)**. It works by inhibiting the **Na⁺-Cl⁻ symporter** on the luminal membrane. By blocking this transporter, it increases the excretion of sodium and chloride, leading to diuresis. **2. Why the Other Options are Incorrect:** * **Option B (Late distal tubule) & Option D (Cortical collecting duct):** These are the sites of action for **Potassium-sparing diuretics** (e.g., Spironolactone, Amiloride). These segments are regulated by Aldosterone and involve the ENaC (Epithelial Sodium Channels). * **Option C (Medullary collecting duct):** This is the site where **Vasopressin (ADH)** acts via V2 receptors to regulate water reabsorption through aquaporins. Diuretics do not primarily target this segment. **Clinical Pearls for NEET-PG:** * **Potency & Duration:** Chlorthalidone is significantly more potent and has a much **longer half-life (~40–60 hours)** than Hydrochlorothiazide, making it the preferred agent for hypertension management according to many guidelines. * **Metabolic Side Effects:** Remember the mnemonic **"Hyper GLUC"**—Thiazides cause Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia, and Hyper**C**alcemia. * **Paradoxical Use:** Despite being a diuretic, it is used to treat **Nephrogenic Diabetes Insipidus** because it induces mild hypovolemia, which increases proximal tubular reabsorption of salt and water. * **Inefficacy:** Thiazides generally lose efficacy when the GFR falls below **30 mL/min** (except for Metolazone).

Question 22: What is the longest-acting thiazide diuretic?

A. Chlorthiazide
B. Chlorthalidone (Correct Answer)
C. Indapamide
D. Metolazone

Explanation: **Chlorthalidone** is the longest-acting diuretic among the options provided [1]. Although it is chemically a "thiazide-like" diuretic (lacking the benzothiadiazine ring) [2, 3], it shares the same mechanism of action: inhibiting the **Na⁺-Cl⁻ symporter** in the Distal Convoluted Tubule (DCT) [1, 2].**Why Chlorthalidone is the correct answer:**The prolonged duration of action of Chlorthalidone (**48–72 hours**) [2] is primarily due to its high affinity for **carbonic anhydrase** in erythrocytes. This leads to extensive binding within red blood cells, creating a large reservoir that is slowly released into the plasma and delivered to the kidneys. Because of this long half-life, it provides superior 24-hour blood pressure control compared to Hydrochlorothiazide [1].**Analysis of Incorrect Options:** * **A. Chlorthiazide:** This is the prototype thiazide but has a very short half-life (approx. 1.5–2 hours) and low lipid solubility [2]. * **C. Indapamide:** A thiazide-like diuretic with a duration of action of about 24 hours [2, 3]. It is notable for its dual action (diuretic + vasodilation) and is often preferred in patients with renal impairment. * **D. Metolazone:** A potent thiazide-like diuretic with a duration of action of about 12–24 hours [2, 3]. It is unique because it remains effective even when the GFR is low (<30 mL/min).**High-Yield Clinical Pearls for NEET-PG:** * **Potency:** Chlorthalidone is roughly 1.5 to 2 times more potent than Hydrochlorothiazide. * **Drug of Choice:** Recent hypertension guidelines (like ACC/AHA) often prefer Chlorthalidone over other thiazides due to its proven reduction in cardiovascular events. * **Metabolic Side Effects:** All thiazides can cause the "Hyper" states: **Hyper**glycemia, **Hyper**lipidemia, **Hyper**uricemia, and **Hyper**calcemia; and "Hypo" states: **Hypo**kalemia, **Hypo**natremia, and **Hypo**magnesemia.

Question 23: High ceiling diuretics are used in the treatment of all conditions EXCEPT:

A. Generalized edema
B. Cerebral edema
C. Acute pulmonary edema
D. Pulmonary hypertension (Correct Answer)

Explanation: **Explanation:** **High-ceiling diuretics** (Loop diuretics) like Furosemide act by inhibiting the **Na⁺-K⁺-2Cl⁻ symporter** in the Thick Ascending Limb of the Loop of Henle. They are the most potent diuretics, capable of excreting up to 25% of filtered sodium. **Why Pulmonary Hypertension is the Correct Answer:** Loop diuretics are not used to treat pulmonary hypertension (PH). The primary management of PH involves vasodilators (e.g., Sildenafil, Bosentan, Epoprostenol) to reduce pulmonary vascular resistance. While diuretics may be used cautiously in PH patients to manage secondary right-sided heart failure, they are not a treatment for the hypertension itself and can dangerously reduce preload in these patients. **Analysis of Incorrect Options:** * **Acute Pulmonary Edema:** This is a classic indication. Furosemide works via two mechanisms: a rapid **venodilatory effect** (mediated by prostaglandins) which reduces venous return to the heart, followed by a potent diuretic effect. * **Generalized Edema:** High-ceiling diuretics are the first-line treatment for significant fluid overload associated with Congestive Heart Failure (CHF), Nephrotic Syndrome, and Cirrhosis. * **Cerebral Edema:** While Mannitol (an osmotic diuretic) is the drug of choice, loop diuretics are often used as adjuncts or alternatives to reduce intracranial pressure by decreasing cerebrospinal fluid production and inducing systemic dehydration. **High-Yield Clinical Pearls for NEET-PG:** * **DOC for Acute Pulmonary Edema:** Intravenous Furosemide. * **Ototoxicity:** A unique side effect of loop diuretics (Ethacrynic acid > Furosemide). * **Metabolic Profile:** They cause **Hypokalemic Metabolic Alkalosis**, Hypomagnesemia, and **Hypocalcemia** (unlike Thiazides, which cause Hypercalcemia). * **Sulfa Allergy:** Most loop diuretics are sulfonamides; Ethacrynic acid is the alternative for patients with sulfa allergies.

Question 24: Which of the following diuretics will continue to induce significant diuresis after return of blood volume to normal levels?

A. hydrochlorothiazide
B. spironolactone
C. triamterene
D. furosemide (Correct Answer)

Explanation: **Explanation:** The correct answer is **furosemide**. The primary reason lies in the **potency and site of action** of Loop diuretics compared to other classes. **1. Why Furosemide is Correct:** Furosemide is a "High-Ceiling" diuretic that inhibits the **Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2)** in the Thick Ascending Limb (TAL) of the Loop of Henle. This segment is responsible for reabsorbing approximately 25% of filtered sodium. Unlike Thiazides or Potassium-sparing diuretics, Loop diuretics have a massive diuretic capacity that is relatively independent of the body's fluid status. Even after blood volume returns to normal, furosemide continues to exert a powerful effect because the TAL has a high reabsorptive capacity that, when blocked, results in significant solute and water loss. **2. Why Other Options are Incorrect:** * **Hydrochlorothiazide (A):** This is a "Low-Ceiling" diuretic acting on the Distal Convoluted Tubule (DCT), where only 5-10% of sodium is reabsorbed. Its efficacy is limited; once the initial fluid excess is removed, the compensatory activation of the Renin-Angiotensin-Aldosterone System (RAAS) easily offsets its mild diuretic effect. * **Spironolactone (B) & Triamterene (C):** These are weak, potassium-sparing diuretics acting on the collecting duct (reabsorbing <3% sodium). Their effect is too minimal to induce "significant" diuresis once normovolemia is achieved, as they are primarily used to counteract potassium loss or in specific hyperaldosteronic states. **Clinical Pearls for NEET-PG:** * **Braking Phenomenon:** Continued use of loop diuretics leads to hypertrophy of distal segments, which eventually limits their effect (compensated by adding a Thiazide). * **Drug of Choice:** Furosemide is the drug of choice for **Acute Pulmonary Edema** due to its rapid action and additional venodilatory effect (mediated by Prostaglandins). * **Ototoxicity:** Furosemide can cause dose-dependent hearing loss, especially when combined with Aminoglycosides.

Question 25: An 82-year-old man with congestive heart failure and a creatinine clearance (CrCl) of 17 mL/min requires a diuretic for the treatment of peripheral edema. Which of the following diuretics would be most appropriate in this patient?

A. Furosemide (Correct Answer)
B. Hydrochlorothiazide
C. Indapamide
D. Spironolactone

Explanation: ### Explanation **1. Why Furosemide is Correct:** The patient has severe renal impairment (CrCl 17 mL/min). In patients with a **Creatinine Clearance (CrCl) < 30 mL/min**, thiazide diuretics lose their efficacy because they cannot reach the site of action (the distal convoluted tubule) in sufficient concentrations. **Loop diuretics**, such as **Furosemide**, remain effective even at low GFR/CrCl levels. They are the drugs of choice for managing volume overload in patients with advanced chronic kidney disease (CKD) or congestive heart failure with renal impairment. **2. Why the Other Options are Incorrect:** * **Hydrochlorothiazide:** This is a thiazide diuretic. As a general rule for NEET-PG, thiazides are ineffective when the **GFR is < 30 mL/min**. They fail to produce significant diuresis in patients with severe renal insufficiency. * **Indapamide:** Although it is a thiazide-like diuretic often used in hypertension, it also loses its diuretic efficacy in severe renal failure (CrCl < 30 mL/min). * **Spironolactone:** This is a potassium-sparing diuretic. It is generally **contraindicated** or used with extreme caution in patients with severe renal impairment (CrCl < 30 mL/min) due to the high risk of life-threatening **hyperkalemia**. **3. High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Loop diuretics act on the thick ascending limb of the Loop of Henle (inhibiting Na⁺-K⁺-2Cl⁻ cotransporter). * **Metolazone Exception:** Most thiazides fail at CrCl < 30 mL/min, but **Metolazone** (a thiazide-like diuretic) is a notable exception that can still work in renal failure, often used in combination with loop diuretics to overcome "diuretic resistance." * **Ototoxicity:** Furosemide can cause dose-dependent ototoxicity, especially when given intravenously at high doses or combined with aminoglycosides. * **Electrolyte Changes:** Loop diuretics cause "Low everything" (Hypokalemia, Hypomagnesemia, Hypocalcemia), whereas Thiazides cause **Hypercalcemia**.

Question 26: Which of the following drugs causes osmotic diuresis?

A. Mannitol
B. Isosorbide
C. Glycerol
D. All of the above (Correct Answer)

Explanation: ### Explanation **Concept:** Osmotic diuretics are pharmacologically inert substances that are freely filtered at the glomerulus but undergo limited or no reabsorption by the renal tubules. They increase the osmolarity of the tubular fluid, creating an osmotic gradient that retains water within the lumen, thereby increasing urine volume. **Analysis of Options:** * **Mannitol:** The most commonly used osmotic diuretic. It is administered intravenously and is the drug of choice for reducing intracranial pressure (cerebral edema) and intraocular pressure. * **Isosorbide:** This is a polyhydric alcohol (not to be confused with the vasodilator Isosorbide dinitrate) that can be administered orally to reduce intraocular pressure in glaucoma. * **Glycerol (Glycerin):** Administered orally, it is rapidly absorbed and increases plasma osmolarity. It is frequently used to provide a rapid reduction in intraocular pressure before ophthalmic surgery. Since all three agents function by increasing the osmotic pressure of the glomerular filtrate to inhibit water reabsorption, **Option D (All of the above)** is correct. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Primarily the **Loop of Henle** (descending limb) and the **Proximal Convoluted Tubule (PCT)**. * **Contraindications:** Osmotic diuretics are strictly contraindicated in **Acute Pulmonary Edema** and **Congestive Heart Failure** because they initially expand the extracellular fluid (ECF) volume before diuresis occurs. They are also contraindicated in **Anuria** due to chronic renal failure. * **Therapeutic Uses:** Mannitol is used to maintain urine flow in acute renal failure (incipient stage) and to treat dialysis disequilibrium syndrome. * **Side Effect:** Headache, nausea, and vomiting are common; hyponatremia may occur initially, followed by dehydration and hypernatremia.

Question 27: On which part of the nephron do thiazides act?

A. Proximal convoluted tubule (PCT)
B. Distal convoluted tubule (DCT) (Correct Answer)
C. Glomerulus
D. Ascending limb of loop of Henle

Explanation: ### Explanation **Correct Answer: B. Distal convoluted tubule (DCT)** Thiazide diuretics (e.g., Hydrochlorothiazide, Chlorthalidone) act specifically on the **early part of the Distal Convoluted Tubule (DCT)**. They work by inhibiting the **Na⁺-Cl⁻ symporter** (NCC) on the apical membrane of the tubular epithelial cells. By blocking this transporter, thiazides prevent the reabsorption of sodium and chloride, leading to increased excretion of these ions along with water. #### Analysis of Incorrect Options: * **A. Proximal convoluted tubule (PCT):** This is the site of action for **Carbonic Anhydrase inhibitors** (e.g., Acetazolamide) and osmotic diuretics like Mannitol. * **C. Glomerulus:** This is the site of filtration, not the primary site of action for any major class of diuretic drugs. * **D. Ascending limb of loop of Henle:** Specifically, the **Thick Ascending Limb (TAL)** is the site of action for **Loop diuretics** (e.g., Furosemide), which inhibit the Na⁺-K⁺-2Cl⁻ (NKCC2) cotransporter. #### NEET-PG High-Yield Clinical Pearls: * **Calcium Sparing Effect:** Unlike loop diuretics (which cause hypercalciuria), thiazides **increase calcium reabsorption** in the DCT. Therefore, they are the drug of choice for hypertension in patients with **osteoporosis** and are used to prevent **calcium oxalate renal stones**. * **Metabolic Side Effects:** Remember the mnemonic **"Hyper-GLUC"**: Thiazides cause **Hyper**glycemia, **Hyper**lipidemia, **Hyper**uricemia (can precipitate Gout), and **Hyper**calcemia. * **Potency:** Chlorthalidone is more potent and has a longer half-life than Hydrochlorothiazide, making it the preferred agent in many hypertension guidelines. * **Inefficacy:** Thiazides generally lose their efficacy when the Glomerular Filtration Rate (GFR) falls below **30 mL/min** (except for Metolazone).

Question 28: Which is a safe diuretic in renal dysfunction?

A. Mannitol
B. Bumetanide (Correct Answer)
C. Chlorthalidone
D. Acetazolamide

Explanation: ### Explanation **Correct Answer: B. Bumetanide** **Why Bumetanide is the correct choice:** Bumetanide is a high-ceiling **Loop Diuretic**. Loop diuretics (including Furosemide and Torsemide) are the diuretics of choice in patients with renal dysfunction (GFR < 30 ml/min). Unlike other classes, loop diuretics maintain their efficacy even when the glomerular filtration rate (GFR) is significantly reduced. They act on the thick ascending limb of the Loop of Henle, which has a large capacity for sodium reabsorption, ensuring a potent natriuretic effect even in failing kidneys. **Why the other options are incorrect:** * **Mannitol (Osmotic Diuretic):** It is contraindicated in established anuria or severe renal failure. It expands extracellular fluid volume, which can lead to acute pulmonary edema and heart failure in patients who cannot excrete the fluid load. * **Chlorthalidone (Thiazide-like Diuretic):** Thiazides and related drugs generally lose their efficacy when the GFR falls below 30 ml/min (with the exception of Metolazone). They are not the preferred agents for fluid management in advanced renal impairment. * **Acetazolamide (Carbonic Anhydrase Inhibitor):** It is a weak diuretic that acts on the proximal tubule. It is avoided in renal failure as it can worsen metabolic acidosis (a common complication of uremia) and has a very limited diuretic effect. **High-Yield Clinical Pearls for NEET-PG:** * **Potency Ratio:** Bumetanide is roughly **40 times more potent** than Furosemide (1 mg Bumetanide ≈ 40 mg Furosemide). * **Metolazone Exception:** While most thiazides fail in renal impairment, **Metolazone** remains effective and is often combined with loop diuretics to overcome "diuretic resistance" (Sequential Nephron Blockade). * **Ototoxicity:** While all loop diuretics can cause ototoxicity, **Ethacrynic acid** is the most ototoxic, while Bumetanide is generally considered to have a lower risk compared to high-dose Furosemide.

Question 29: Furosemide causes all of the following except:

A. Hyperglycemia
B. Hypomagnesemia
C. Hypokalemia
D. Acidosis (Correct Answer)

Explanation: **Explanation:** Furosemide is a potent **Loop Diuretic** that inhibits the $Na^+-K^+-2Cl^-$ symporter in the Thick Ascending Limb (TAL) of the Loop of Henle. **Why Acidosis is the Correct Answer:** Furosemide does **not** cause acidosis; instead, it causes **Metabolic Alkalosis**. This occurs via two mechanisms: 1. **Contraction Alkalosis:** Loss of isotonic fluid (sodium and water) leads to a decrease in extracellular fluid volume, concentrating the bicarbonate already present in the blood. 2. **Increased $H^+$ Secretion:** Increased sodium delivery to the distal tubule stimulates $Na^+/H^+$ exchange and $H^+$-ATPase, leading to increased excretion of hydrogen ions in the urine. **Analysis of Incorrect Options:** * **Hyperglycemia:** Loop diuretics can decrease insulin release from the pancreas (often linked to hypokalemia) and increase insulin resistance, leading to elevated blood glucose levels. * **Hypomagnesemia:** By inhibiting the $Na^+-K^+-2Cl^-$ transporter, the positive transepithelial potential is abolished. This potential is necessary for the paracellular reabsorption of Magnesium and Calcium; hence, both are lost in the urine. * **Hypokalemia:** Increased sodium delivery to the distal collecting duct promotes sodium reabsorption in exchange for potassium (via aldosterone activation), leading to significant potassium depletion. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Loop Diuretic Side Effects:** **OH DANG!** (**O**totoxicity, **H**ypokalemia, **D**ehydration, **A**llergy (Sulfa), **N**ephritis, **G**out/Hyperuricemia). * **Calcium Effect:** Remember, "Loops Lose Calcium" (used in treating hypercalcemia), whereas Thiazides "Thrive" on Calcium (cause hypercalcemia). * **Drug of Choice:** Furosemide is the drug of choice for acute pulmonary edema due to its rapid action and venodilatory properties.

Question 30: A 72-year-old woman with mild heart failure is treated overzealously with a thiazide diuretic. A few days later, the woman complains of muscle weakness, and laboratory tests demonstrate hypokalemia. Which of the following is most likely increased in this woman?

A. Serum H+ concentration
B. Plasma aldosterone (Correct Answer)
C. Plasma sodium
D. Potassium retention

Explanation: **Explanation:** The correct answer is **B. Plasma aldosterone**. **Mechanism of Action:** Thiazide diuretics inhibit the $Na^+/Cl^-$ symporter in the distal convoluted tubule, leading to increased excretion of sodium and water. Overzealous use causes **volume depletion** (hypovolemia). This reduction in effective circulating volume triggers the **Renin-Angiotensin-Aldosterone System (RAAS)**. Juxtaglomerular cells sense decreased renal perfusion and release renin, ultimately leading to elevated levels of **Aldosterone**. Aldosterone then acts on the collecting ducts to reabsorb sodium at the expense of secreting potassium and hydrogen ions, which explains the patient's hypokalemia and muscle weakness. **Analysis of Incorrect Options:** * **A. Serum $H^+$ concentration:** Thiazides cause **metabolic alkalosis** (contraction alkalosis and increased $H^+$ secretion in the collecting duct). Therefore, $H^+$ concentration decreases, and pH increases. * **C. Plasma sodium:** Thiazides are a common cause of **hyponatremia**. They promote sodium excretion while the compensatory ADH release (due to volume depletion) causes water retention, diluting serum sodium. * **D. Potassium retention:** Thiazides cause **potassium wasting** (hypokalemia) due to increased sodium delivery to the late distal tubule and high aldosterone levels, both of which drive $K^+$ secretion. **NEET-PG High-Yield Pearls:** * **Thiazide Side Effects (Hyper-GLUC):** Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia, and Hyper**C**alcemia. * **Electrolyte Profile:** Hypokalemic metabolic alkalosis + Hyponatremia. * **Clinical Note:** Unlike Loop diuretics (which cause hypocalcemia), Thiazides decrease urinary calcium and are used in treating **calcium nephrolithiasis**.

Question 31: A 55-year-old man with congestive heart failure is noted to be taking furosemide each day. Which of the following is most likely to be found in the serum?

A. Decreased uric acid level
B. Low bicarbonate level
C. Decreased potassium level (Correct Answer)
D. Elevated magnesium level

Explanation: **Explanation:** **Mechanism of Action (The Correct Answer):** Furosemide is a high-ceiling **loop diuretic** that inhibits the **Na+/K+/2Cl- symporter** in the Thick Ascending Limb (TAL) of the Henle’s loop. By blocking this transporter, it increases the delivery of sodium to the distal convoluted tubule and collecting duct. In the collecting duct, the increased sodium load promotes sodium reabsorption in exchange for **potassium (K+) and hydrogen (H+) ions** via the action of aldosterone. This leads to increased urinary excretion of potassium, resulting in **hypokalemia** (decreased serum potassium levels). **Analysis of Incorrect Options:** * **A. Decreased uric acid level:** Incorrect. Loop diuretics cause **hyperuricemia** (elevated uric acid). This occurs because diuretics cause volume depletion, leading to increased proximal tubular reabsorption of uric acid, and they compete with uric acid for the organic acid secretory pathway in the kidney. * **B. Low bicarbonate level:** Incorrect. Furosemide causes **contraction alkalosis**, which is characterized by an **increase** in serum bicarbonate levels due to the loss of H+ ions and volume contraction. * **D. Elevated magnesium level:** Incorrect. The Na+/K+/2Cl- symporter normally creates a positive lumen potential that drives the paracellular reabsorption of divalent cations. By inhibiting this, furosemide causes **hypomagnesemia** and **hypocalcemia**. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Loop Diuretic Side Effects:** "OH DANG!" (**O**totoxicity, **H**ypokalemia, **D**ehydration, **A**llergy (sulfa), **N**ephritis, **G**out). * **Calcium Handling:** Unlike Thiazides (which cause hypercalcemia), Loop diuretics cause **hypocalcemia** ("Loops Lose Calcium"). * **Drug of Choice:** Furosemide is the drug of choice for acute pulmonary edema in CHF due to its rapid-acting diuretic and vasodilator properties.

Question 32: Furosemide acts by inhibiting which of the following?

A. Na+-K+-2Cl- cotransporter (Correct Answer)
B. Na+-Cl- cotransporter
C. Carbonic anhydrase
D. Epithelial Na+ channels

Explanation: ### Explanation **Correct Option: A. Na+-K+-2Cl- cotransporter (NKCC2)** Furosemide is a potent **Loop Diuretic**. It acts on the **thick ascending limb (TAL)** of the Henle’s loop, which is responsible for reabsorbing approximately 25% of filtered sodium. Furosemide binds to the Cl⁻ binding site of the **Na⁺-K⁺-2Cl⁻ symporter (NKCC2)** on the luminal membrane, inhibiting the reabsorption of these electrolytes. This leads to a massive loss of Na⁺, Cl⁻, and water in the urine. **Analysis of Incorrect Options:** * **B. Na⁺-Cl⁻ cotransporter:** This is the target of **Thiazide diuretics** (e.g., Hydrochlorothiazide) acting on the **Distal Convoluted Tubule (DCT)**. * **C. Carbonic anhydrase:** This enzyme is inhibited by **Acetazolamide** in the **Proximal Convoluted Tubule (PCT)**, leading to bicarbonate loss. * **D. Epithelial Na⁺ channels (ENaC):** These channels are blocked by **Potassium-sparing diuretics** like **Amiloride** and **Triamterene** in the late distal tubule and collecting duct. **High-Yield Clinical Pearls for NEET-PG:** 1. **Site of Action:** Thick Ascending Limb (TAL) – often called "High-ceiling diuretics" due to their high efficacy. 2. **Electrolyte Changes:** Causes **Hypokalemia**, **Hypomagnesemia**, and **Hypocalcemia** (unlike Thiazides, which cause hypercalcemia). "Loops lose calcium." 3. **Ototoxicity:** A unique side effect, especially when used with aminoglycosides or in renal failure. 4. **Drug of Choice:** Acute Pulmonary Edema (due to rapid vasodilator action before the diuretic effect kicks in). 5. **Sulfa Allergy:** Furosemide is a sulfonamide derivative; caution is advised in patients with severe sulfa allergies (Ethacrynic acid is the alternative).

Question 33: What is the drug of choice for nephrogenic diabetes insipidus?

A. Mannitol
B. Spironolactone
C. Thiazides (Correct Answer)
D. Demeclocycline

Explanation: **Explanation:** **1. Why Thiazides are the Correct Answer:** In **Nephrogenic Diabetes Insipidus (NDI)**, the kidneys are unresponsive to Antidiuretic Hormone (ADH), leading to the excretion of large volumes of dilute urine. Paradoxically, **Thiazide diuretics** (e.g., Hydrochlorothiazide) are the drug of choice. * **Mechanism:** Thiazides inhibit the Na+/Cl- symporter in the distal convoluted tubule, causing mild hypovolemia. This triggers a compensatory increase in proximal tubular reabsorption of sodium and water. Consequently, less fluid reaches the distal parts of the nephron, reducing the overall urine volume (the "paradoxical antidiuretic effect"). **2. Why Other Options are Incorrect:** * **A. Mannitol:** An osmotic diuretic that increases urine output. It would worsen the dehydration and polyuria seen in DI. * **B. Spironolactone:** A potassium-sparing diuretic (aldosterone antagonist). It is not effective in NDI and is primarily used for heart failure, cirrhosis, or Conn’s syndrome. * **D. Demeclocycline:** A tetracycline derivative that actually *causes* nephrogenic DI by inhibiting ADH action. It is used to treat **SIADH**, not DI. **3. NEET-PG High-Yield Pearls:** * **Lithium-Induced NDI:** If NDI is caused by Lithium, the drug of choice is **Amiloride**, which blocks the ENaC channels through which lithium enters the collecting duct cells. * **Central DI:** The drug of choice is **Desmopressin (dDAVP)**, a synthetic ADH analogue. * **Low Solute Diet:** Patients with NDI are also advised to follow a low-salt, low-protein diet to reduce the renal solute load.

Question 34: Which of the following statements about diuretics is NOT true?

A. Acetazolamide is a carbonic anhydrase stimulant. (Correct Answer)
B. Thiazides act on the cortical diluting segment of the nephron.
C. Furosemide is a high-ceiling diuretic.
D. Spironolactone is an aldosterone antagonist.

Explanation: ### Explanation **1. Why Option A is the Correct Answer (The "Not True" Statement):** Acetazolamide is a **Carbonic Anhydrase (CA) Inhibitor**, not a stimulant. It works in the proximal convoluted tubule (PCT) by inhibiting the enzyme carbonic anhydrase. This prevents the dehydration of carbonic acid and the reabsorption of bicarbonate ($HCO_3^-$), leading to alkaline diuresis. Because it inhibits the enzyme, the statement claiming it is a "stimulant" is factually incorrect. **2. Analysis of Other Options:** * **Option B (Thiazides):** This is **true**. Thiazides act on the early distal convoluted tubule (DCT), which is also known as the **cortical diluting segment**. They inhibit the $Na^+-Cl^-$ symporter. * **Option C (Furosemide):** This is **true**. Furosemide is a loop diuretic that acts on the thick ascending limb of Henle. It is called "high-ceiling" because it has a steep dose-response curve, meaning increasing the dose leads to a proportional increase in diuresis over a wide range. * **Option D (Spironolactone):** This is **true**. It is a potassium-sparing diuretic that competitively inhibits the **aldosterone receptor** (Mineralocorticoid receptor) in the late DCT and collecting ducts. **3. NEET-PG High-Yield Clinical Pearls:** * **Acetazolamide Uses:** Glaucoma (decreases aqueous humor), Mountain sickness (induces metabolic acidosis to stimulate respiration), and Urinary alkalization. * **Side Effects:** Metabolic acidosis, hypokalemia, and sulfonamide-like hypersensitivity. * **Thiazide Paradox:** While they are diuretics, they are used to treat **Diabetes Insipidus** because they reduce glomerular filtration and increase proximal salt/water reabsorption. * **Furosemide Side Effects:** Remember the mnemonic **OH DANG**: **O**totoxicity, **H**ypokalemia, **D**ehydration, **A**llergy (sulfa), **N**ephritis, **G**out (hyperuricemia).

Question 35: All of the following diuretics inhibit the Na+-K+-2Cl- symporter, except?

A. Furosemide
B. Thiazide (Correct Answer)
C. Ethacrynic acid
D. Mersalyl

Explanation: The question tests the knowledge of the site of action and molecular targets of various diuretics. 1. Why Thiazide is the Correct Answer: Thiazide diuretics (e.g., Hydrochlorothiazide, Chlorthalidone) act on the **Distal Convoluted Tubule (DCT)** [1]. Their primary mechanism is the inhibition of the **Na+-Cl- symporter** (NCC) on the luminal membrane [1, 3]. They do not affect the Na+-K+-2Cl- (NKCC2) transporter [3]. 2. Analysis of Incorrect Options (Loop Diuretics): The other three options belong to the class of **Loop Diuretics**, which specifically inhibit the **Na+-K+-2Cl- (NKCC2) symporter** in the Thick Ascending Limb (TAL) of the Loop of Henle [2, 4]: * **Furosemide:** A prototype high-ceiling loop diuretic (Sulfonamide derivative). * **Ethacrynic acid:** A phenoxyacetic acid derivative. It is a non-sulfonamide loop diuretic, making it the drug of choice for patients with sulfonamide allergies. * **Mersalyl:** An older organomercurial diuretic that also acts on the TAL to inhibit the same symporter, though it is now obsolete due to toxicity. Clinical Pearls for NEET-PG: * **Site of Action:** Loop diuretics act on the TAL (medullary and cortical), while Thiazides act on the cortical DCT. * **Calcium Handling:** This is a high-yield differentiator. Loop diuretics cause **Hypercalciuria** (used in treating hypercalcemia), whereas Thiazides cause **Hypocalciuria** (used in treating calcium nephrolithiasis). * **Ototoxicity:** Ethacrynic acid is the most ototoxic loop diuretic. * **Metabolic Side Effects:** Both classes can cause hypokalemia and metabolic alkalosis.

Question 36: All of the following statements about amiloride are true EXCEPT:

A. It antagonises the action of aldosterone. (Correct Answer)
B. It is the drug of choice for the treatment of lithium-induced diabetes insipidus.
C. It decreases calcium loss in the urine.
D. It is more potent than triamterene.

Explanation: ### Explanation **Amiloride** is a potassium-sparing diuretic that acts as a direct inhibitor of the **Epithelial Sodium Channels (ENaC)** in the late distal tubule and collecting duct. **1. Why Option A is the correct answer (The False Statement):** Amiloride does **not** antagonize the action of aldosterone. It blocks sodium channels directly, independent of aldosterone levels. In contrast, drugs like **Spironolactone and Eplerenone** are the ones that act as competitive antagonists at the mineralocorticoid (aldosterone) receptor. Because amiloride acts downstream of the receptor, it is effective even in the absence of aldosterone. **2. Analysis of other options:** * **Option B:** Amiloride is the **drug of choice for Lithium-induced Nephrogenic Diabetes Insipidus**. Lithium enters the collecting duct cells through ENaC channels and interferes with ADH action. Amiloride blocks these channels, preventing lithium entry into the cells. * **Option C:** Like thiazides, amiloride **decreases urinary calcium excretion**. It enhances calcium reabsorption in the distal tubule, making it potentially useful in patients with calcium oxalate stones. * **Option D:** Amiloride is significantly **more potent** than triamterene (the standard dose of amiloride is 5mg, whereas triamterene is 50-100mg). It also has a longer half-life and is less likely to cause kidney stones compared to triamterene. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Direct ENaC blocker (not an aldosterone antagonist). * **Liddle’s Syndrome:** Amiloride is the treatment of choice for this rare genetic condition characterized by overactive ENaC channels. * **Side Effect:** The most common and serious side effect is **hyperkalemia**, especially when used with ACE inhibitors or in patients with renal impairment. * **Cystic Fibrosis:** Aerosolized amiloride has been studied to improve mucociliary clearance by limiting sodium and water resorption from airway secretions.

Question 37: Furosemide is useful in:

A. Hypertension.
B. Refractory oedema. (Correct Answer)
C. Hypocalcemia.
D. Hypokalemia.

Explanation: **Explanation:** **1. Why "Refractory Oedema" is correct:** Furosemide is a potent **Loop Diuretic** that acts by inhibiting the **Na⁺-K⁺-2Cl⁻ symporter** in the Thick Ascending Limb (TAL) of the Loop of Henle. It is known as a "high-ceiling" diuretic because it has a steep dose-response curve; increasing the dose leads to a progressive increase in diuresis. This makes it the drug of choice for **refractory oedema** (oedema not responding to milder diuretics) associated with Congestive Heart Failure, Nephrotic Syndrome, and Chronic Renal Failure. **2. Why other options are incorrect:** * **A. Hypertension:** While loop diuretics can be used in hypertension complicated by renal failure, **Thiazides** are the first-line diuretic for essential hypertension due to their longer duration of action and vasodilator properties. * **C. Hypocalcemia:** Furosemide increases the urinary excretion of calcium ("Loop loses Calcium"). Therefore, it is used to treat **Hypercalcemia**, not hypocalcemia. * **D. Hypokalemia:** Furosemide causes significant potassium loss in the urine. It is a *cause* of hypokalemia, not a treatment for it. **3. High-Yield NEET-PG Pearls:** * **Mechanism:** Inhibits Na⁺-K⁺-2Cl⁻ (NKCC2) in the TAL. * **Electrolyte Profile:** Causes Hypokalemia, Hypomagnesemia, and **Hypocalcemia**. * **Ototoxicity:** This is a unique side effect of loop diuretics, especially when used with aminoglycosides. * **Acute Pulmonary Oedema:** Furosemide is the drug of choice here, not just for its diuretic effect, but for its rapid **venodilatory action** (mediated by prostaglandins), which reduces cardiac preload.

Question 38: Hyperkalemia is caused by all EXCEPT:

A. Loop diuretics (Correct Answer)
B. Valsartan
C. Amiloride
D. Enalapril

Explanation: ### Explanation The correct answer is **Loop diuretics** because they cause **hypokalemia** (low potassium), not hyperkalemia. #### 1. Why Loop Diuretics (Option A) are the Correct Answer: Loop diuretics (e.g., Furosemide) inhibit the **Na⁺-K⁺-2Cl⁻ symporter** in the Thick Ascending Limb of the Loop of Henle. This leads to a massive delivery of sodium to the distal tubule. To reabsorb this sodium, the distal tubule activates the Na⁺/K⁺ exchange mechanism (driven by aldosterone), which results in the **excretion of potassium** into the urine. This process, combined with volume depletion-induced secondary hyperaldosteronism, leads to hypokalemia. #### 2. Why the other options are incorrect (They cause Hyperkalemia): * **Amiloride (Option C):** This is a potassium-sparing diuretic that blocks the **ENaC (Epithelial Sodium Channels)** in the collecting duct. By preventing sodium reabsorption, it reduces the negative luminal potential, thereby inhibiting the secretion of potassium into the lumen. * **Enalapril (Option D) & Valsartan (Option B):** Enalapril (an ACE inhibitor) and Valsartan (an ARB) both interfere with the **Renin-Angiotensin-Aldosterone System (RAAS)**. By decreasing aldosterone levels or blocking its action, they prevent potassium excretion in the distal nephron, leading to potassium retention. #### 3. NEET-PG High-Yield Pearls: * **Diuretics causing Hypokalemia:** Loop diuretics and Thiazides. * **Diuretics causing Hyperkalemia:** Spironolactone, Eplerenone (Aldosterone antagonists), Amiloride, and Triamterene. * **Clinical Tip:** Always monitor serum potassium when combining ACE inhibitors with potassium-sparing diuretics, as this significantly increases the risk of life-threatening hyperkalemia. * **ECG in Hyperkalemia:** Look for "Tall tented T-waves" and "Widened QRS complex."

Question 39: Which drug is used in the treatment of idiopathic hypercalciuria?

A. Allopurinol
B. Furosemide
C. Acetazolamide
D. Thiazide (Correct Answer)

Explanation: ### Explanation **Correct Option: D (Thiazide)** Thiazide diuretics (e.g., Hydrochlorothiazide, Chlorthalidone) are the drugs of choice for idiopathic hypercalciuria. * **Mechanism:** Thiazides inhibit the $Na^+/Cl^-$ symporter in the Distal Convoluted Tubule (DCT). This decrease in intracellular sodium enhances the activity of the $Na^+/Ca^{2+}$ exchanger on the basolateral membrane, which pumps $Na^+$ into the cell and $Ca^{2+}$ out into the blood. * **Result:** This leads to increased reabsorption of calcium from the tubular fluid, thereby **decreasing urinary calcium excretion** (hypocalciuria). By lowering the concentration of calcium in the urine, Thiazides prevent the formation of calcium oxalate stones. **Analysis of Incorrect Options:** * **A. Allopurinol:** A xanthine oxidase inhibitor used for hyperuricemia and uric acid stones, but it does not directly affect renal calcium handling. * **B. Furosemide:** A loop diuretic that inhibits the $Na^+/K^+/2Cl^-$ cotransporter. It **increases** urinary calcium excretion ("Loops Lose Calcium") and is actually used to treat hypercalcemia. It would worsen hypercalciuria. * **C. Acetazolamide:** A carbonic anhydrase inhibitor. It increases urinary bicarbonate and can lead to alkaline urine, which actually promotes the precipitation of calcium phosphate stones. **NEET-PG High-Yield Pearls:** * **Mnemonic:** "Loops Lose calcium, Thiazides Thank (retain) calcium." * **Clinical Use:** Thiazides are unique because they are the only diuretics that cause **hypocalciuria**. * **Side Effects:** Remember the "4 Hypers" of Thiazides: Hyperglycemia, Hyperlipidemia, Hyperuricemia, and **Hypercalcemia**. * **Drug of Choice:** For Nephrogenic Diabetes Insipidus, Thiazides are also the preferred treatment.

Question 40: Paradoxical action is seen with which of the following diuretics?

A. Thiazide (Correct Answer)
B. Triamterene
C. Spironolactone
D. Furosemide

Explanation: **Explanation:** The "paradoxical action" of **Thiazide diuretics** refers to their ability to **reduce urine volume** in patients with **Diabetes Insipidus (DI)**, despite being diuretics that normally increase urine output in healthy individuals. **Mechanism of Paradoxical Action:** In Diabetes Insipidus, there is a deficiency or resistance to ADH, leading to the excretion of large volumes of dilute urine. Thiazides inhibit the Na⁺-Cl⁻ symporter in the distal convoluted tubule, causing mild natriuresis. This leads to a slight depletion of total body sodium and a decrease in extracellular fluid (ECF) volume. In response, the proximal tubule increases the reabsorption of water and sodium to compensate. Consequently, less fluid reaches the distal parts of the nephron, resulting in a net reduction in final urine volume. **Analysis of Incorrect Options:** * **B & C (Triamterene & Spironolactone):** These are potassium-sparing diuretics. While they act on the late distal tubule and collecting duct, they do not exhibit this specific paradoxical effect in DI. * **D (Furosemide):** This is a potent loop diuretic. It is contraindicated in DI because it interferes with the medullary osmotic gradient, further impairing the kidney's ability to concentrate urine and potentially worsening dehydration. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Thiazides (specifically Chlorthalidone or Hydrochlorothiazide) are the treatment of choice for **Nephrogenic Diabetes Insipidus**. * **Electrolyte Side Effects:** Remember the "4 Hypo, 2 Hyper" rule for Thiazides: **Hypo**kalemia, **Hypo**natremia, **Hypo**magnesemia, **Hypo**chloremic alkalosis; **Hyper**uricemia, and **Hyper**calcemia (unlike Loop diuretics which cause hypocalcemia). * **Lithium-Induced DI:** Amiloride is the preferred agent for DI specifically caused by Lithium toxicity.

Question 41: Which drug leads to glucose intolerance?

A. Hydrochlorothiazide (Correct Answer)
B. ACE inhibitors
C. Verapamil
D. Sulfonylureas

Explanation: **Explanation:** **Hydrochlorothiazide (HCTZ)**, a thiazide diuretic, is well-known for causing metabolic side effects, including **hyperglycemia (glucose intolerance)**. The underlying mechanism is twofold: 1. **Hypokalemia-induced inhibition of insulin:** Thiazides cause potassium depletion. Low extracellular potassium levels inhibit the release of insulin from the pancreatic $\beta$-cells. 2. **Decreased peripheral glucose uptake:** Thiazides can reduce peripheral sensitivity to insulin. Consequently, they should be used with caution in patients with diabetes mellitus or pre-diabetes. **Analysis of Incorrect Options:** * **B. ACE Inhibitors:** These drugs (e.g., Enalapril) actually **improve** insulin sensitivity and are renoprotective. They are the preferred antihypertensives in diabetic patients. * **C. Verapamil:** This is a Calcium Channel Blocker (CCB). While some CCBs can theoretically interfere with insulin release at very high doses, they are generally considered metabolically neutral in clinical practice. * **D. Sulfonylureas:** These are oral hypoglycemic agents (e.g., Glibenclamide) used to **treat** diabetes by stimulating insulin secretion. They decrease blood glucose rather than causing intolerance. **NEET-PG High-Yield Pearls:** * **Thiazide Metabolic Profile:** Remember the mnemonic **"Hyper-GLUC"**—Thiazides cause **Hyper**glycemia, **Hyper**lipidemia, **Hyper**uricemia (can precipitate Gout), and **Hyper**calcemia. * **Electrolyte Profile:** Unlike Loop diuretics (which cause hypocalcemia), Thiazides cause **hypocalciuria** (useful in treating recurrent calcium stones). * **Drug of Choice:** ACE inhibitors or ARBs are the first-line antihypertensives for diabetics to prevent diabetic nephropathy.

Question 42: Spironolactone is the first drug to be given for which condition?

A. Cirrhotic edema (Correct Answer)
B. Cardiac edema
C. Idiopathic edema
D. Nutritional edema

Explanation: ### Explanation **Correct Option: A. Cirrhotic edema** Spironolactone is the **drug of choice (DOC)** for edema associated with liver cirrhosis. In cirrhosis, there is decreased hepatic clearance of aldosterone and activation of the Renin-Angiotensin-Aldosterone System (RAAS) due to peripheral vasodilation. This leads to **secondary hyperaldosteronism**, causing significant sodium and water retention. As a competitive aldosterone antagonist, Spironolactone directly counteracts this mechanism. It is preferred over loop diuretics because it prevents the hypokalemia that can trigger hepatic encephalopathy. **Analysis of Incorrect Options:** * **B. Cardiac edema:** While Spironolactone (and Eplerenone) reduces mortality in chronic heart failure (NYHA Class II-IV), the first-line drug for symptomatic relief of acute cardiac edema/congestive heart failure is a **Loop diuretic** (e.g., Furosemide) due to its rapid and potent action. * **C. Idiopathic edema:** This condition, typically seen in fluid-retaining women, is primarily managed with weight reduction and salt restriction. If drugs are used, Spironolactone is an option, but it is not the classic "first drug" association compared to cirrhosis. * **D. Nutritional edema:** This is primarily managed by correcting the underlying protein deficiency (hypoalbuminemia) and nutritional status rather than primary diuretic therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Competitive antagonist of Mineralocorticoid Receptors in the late distal tubule and collecting duct. * **Side Effects:** The most common is **Hyperkalemia**. Due to its non-specific binding to androgen receptors, it causes **Gynecomastia** and impotence in males (Eplerenone is a more specific alternative without these effects). * **Other DOC uses:** Spironolactone is also the DOC for **Conn’s Syndrome** (Primary Hyperaldosteronism). * **Dosing Tip:** In cirrhosis, it is often used in a 100:40 ratio with Furosemide to maintain potassium balance.

Question 43: Which of the following is a non-competitive inhibitor of carbonic anhydrase?

A. Allopurinol
B. Acetazolamide (Correct Answer)
C. Bimatoprost
D. Dipivefrine

Explanation: ### Explanation **Correct Option: B. Acetazolamide** Acetazolamide is a sulfonamide derivative that acts as a potent, **non-competitive inhibitor** of the enzyme **carbonic anhydrase (CA)**, primarily the Type II isoenzyme found in the proximal convoluted tubule (PCT) and the ciliary body of the eye. By inhibiting CA, it prevents the dehydration of $H_2CO_3$ and the rehydration of $CO_2$, leading to a decrease in $H^+$ secretion and a subsequent increase in the excretion of sodium, potassium, and bicarbonate. This results in alkaline urine and a mild metabolic acidosis. **Analysis of Incorrect Options:** * **A. Allopurinol:** This is a hypuricemic agent that acts as a competitive inhibitor of **Xanthine Oxidase**. It is used in the chronic management of Gout. * **C. Bimatoprost:** This is a **Prostaglandin $F_{2\alpha}$ analogue**. It reduces intraocular pressure by increasing the uveoscleral outflow of aqueous humor, rather than inhibiting CA. * **D. Dipivefrine:** This is a prodrug of **Epinephrine**. It acts as a sympathomimetic to reduce intraocular pressure by increasing aqueous outflow; it does not inhibit enzymes. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Acetazolamide is the DOC for **Acute Mountain Sickness** (prevents cerebral/pulmonary edema and counteracts respiratory alkalosis). * **Glaucoma:** Used to rapidly decrease intraocular pressure in acute angle-closure glaucoma by reducing aqueous humor formation. * **Side Effects:** Drowsiness, paresthesia, and the formation of **calcium phosphate renal stones** (due to alkaline urine). * **Contraindication:** Avoid in patients with hepatic cirrhosis, as it can precipitate **hepatic encephalopathy** by decreasing ammonia excretion.

Question 44: A 65-year-old male with CHF exacerbation is given IV furosemide. Which of the following adverse events are not associated with this medication?

A. Hypotension
B. Hyperkalemia (Correct Answer)
C. Worsening renal function
D. Transient neurotoxicity from high dose

Explanation: **Explanation:** **Furosemide** is a potent **Loop Diuretic** that acts by inhibiting the **Na⁺-K⁺-2Cl⁻ symporter** in the Thick Ascending Limb (TAL) of the Loop of Henle. **Why Hyperkalemia is the Correct Answer:** Loop diuretics increase the delivery of sodium (Na⁺) to the distal convoluted tubule and collecting duct. This stimulates the exchange of Na⁺ for Potassium (K⁺) and Hydrogen (H⁺) ions under the influence of aldosterone. Consequently, there is increased urinary excretion of potassium, leading to **Hypokalemia**, not hyperkalemia. It also causes metabolic alkalosis. **Analysis of Incorrect Options:** * **A. Hypotension:** Potent diuresis leads to significant intravascular volume depletion, which can cause orthostatic hypotension or acute circulatory collapse. * **C. Worsening renal function:** Excessive diuresis can lead to "pre-renal azotemia" due to reduced renal perfusion pressure. * **D. Transient neurotoxicity:** High-dose IV furosemide can cause **ototoxicity** (damage to the 8th cranial nerve), manifesting as tinnitus or hearing loss. This is due to electrolyte imbalances in the endolymph and is often transient but can be permanent if combined with aminoglycosides. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Loop Diuretic Side Effects (OH DANG!):** **O**totoxicity, **H**ypokalemia, **D**ehydration, **A**llergy (Sulfa), **N**ephritis (Interstitial), **G**out (Hyperuricemia). * **Calcium Effect:** Unlike Thiazides (which cause hypercalcemia), Loop diuretics cause **Hypocalcemia** ("Loops Lose Calcium"). * **Drug of Choice:** IV Furosemide is the first-line treatment for **Acute Pulmonary Edema** due to its rapid venodilatory effect (mediated by prostaglandins) followed by diuresis.

Question 45: Which of the following diuretics causes maximum loss of potassium in urine?

A. Acetazolamide (Correct Answer)
B. Spironolactone
C. Ethacrynic acid
D. Furosemide

Explanation: **Explanation:** The correct answer is **Acetazolamide**. While many diuretics cause hypokalemia, Acetazolamide (a Carbonic Anhydrase Inhibitor) typically causes the **maximum** loss of potassium in the urine per unit of sodium excreted. **Why Acetazolamide is correct:** Acetazolamide acts on the proximal convoluted tubule (PCT), inhibiting the reabsorption of sodium bicarbonate ($NaHCO_3$). This leads to a massive delivery of sodium and non-reabsorbable bicarbonate ions to the distal nephron. To compensate for the high sodium load, the distal tubule increases sodium-potassium exchange via aldosterone-sensitive channels. Furthermore, the presence of bicarbonate (an anion) in the distal tubule increases the lumen-negative potential, which further "pulls" potassium out of the cells into the urine. **Why the other options are incorrect:** * **Spironolactone:** This is a potassium-sparing diuretic. It antagonizes aldosterone, leading to potassium **retention** (hyperkalemia), not loss. * **Furosemide & Ethacrynic Acid:** These are Loop Diuretics. While they cause significant hypokalemia by inhibiting the $Na^+-K^+-2Cl^-$ symporter and increasing distal sodium delivery, the magnitude of potassium loss relative to bicarbonate-driven excretion in CA inhibitors is generally lower. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Acetazolamide acts on the PCT; Loop diuretics on the Thick Ascending Limb (TAL); Thiazides on the Distal Convoluted Tubule (DCT). * **Metabolic Effect:** Acetazolamide causes **Hyperchloremic Metabolic Acidosis**, whereas Loop and Thiazide diuretics cause **Metabolic Alkalosis**. * **Therapeutic Uses:** Acetazolamide is the drug of choice for Glaucoma (decreases aqueous humor) and Mountain Sickness (induces metabolic acidosis to stimulate respiration).

Question 46: Which of the following is a mineralocorticoid antagonist?

A. Spironolactone (Correct Answer)
B. Inamrinone
C. Nicorandil
D. Ketorolac

Explanation: **Explanation:** **Spironolactone (Option A)** is the correct answer. It is a synthetic steroid that acts as a competitive antagonist of the **Mineralocorticoid Receptor (MR)** in the late distal tubule and collecting duct of the kidney. By blocking the action of aldosterone, it inhibits the synthesis of Na+/K+ ATPase and epithelial sodium channels (ENaC). This results in the excretion of sodium and water while retaining potassium, categorizing it as a **Potassium-Sparing Diuretic**. **Analysis of Incorrect Options:** * **Inamrinone (Option B):** A Phosphodiesterase-3 (PDE3) inhibitor. It acts as an inodilator (positive inotrope and vasodilator) used in the management of acute heart failure. * **Nicorandil (Option C):** A dual-action drug that acts as a Potassium channel opener and a nitric oxide donor. It is primarily used as an anti-anginal agent. * **Ketorolac (Option D):** A potent Non-Steroidal Anti-Inflammatory Drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, used for short-term management of moderate to severe pain. **High-Yield Clinical Pearls for NEET-PG:** * **Eplerenone** is a more selective mineralocorticoid antagonist with fewer endocrine side effects (like gynecomastia) compared to spironolactone. * **Clinical Uses:** Spironolactone is the drug of choice for **Primary Hyperaldosteronism (Conn’s Syndrome)** and edema associated with **Liver Cirrhosis**. It also improves survival in Chronic Heart Failure (NYHA Class II-IV). * **Side Effects:** The most significant side effect is **Hyperkalemia**. Due to its non-selective binding to androgen and progesterone receptors, it can cause gynecomastia, impotence, and menstrual irregularities.

Question 47: Which of the following adverse effects is NOT caused by furosemide?

A. Hyperglycemia
B. Hypomagnesemia
C. Hypokalemia
D. Acidosis (Correct Answer)

Explanation: Furosemide is a high-ceiling loop diuretic that acts by inhibiting the **Na⁺-K⁺-2Cl⁻ symporter** in the Thick Ascending Limb (TAL) of the Loop of Henle [1]. **Why Acidosis is the Correct Answer:** Furosemide does **not** cause acidosis; instead, it causes **Metabolic Alkalosis** [1, 3]. This occurs via two mechanisms: 1. **Contraction Alkalosis:** Loss of isotonic fluid (NaCl and water) leads to a decrease in extracellular fluid volume, concentrating the remaining bicarbonate [3]. 2. **Increased H⁺ secretion:** Increased delivery of Na⁺ to the distal tubule stimulates Na⁺ reabsorption in exchange for H⁺ and K⁺ (via aldosterone), leading to net acid loss in the urine [1, 3]. **Analysis of Incorrect Options:** * **Hyperglycemia:** Loop diuretics can impair insulin release from the pancreas and decrease peripheral glucose utilization, often secondary to hypokalemia. * **Hypomagnesemia:** By abolishing the positive transepithelial potential in the TAL, loop diuretics inhibit the paracellular reabsorption of divalent cations (Mg²⁺ and Ca²⁺) [1, 2]. * **Hypokalemia:** Increased Na⁺ delivery to the distal nephron promotes K⁺ excretion via the Na⁺/K⁺ exchange pump, a classic side effect of all diuretics acting proximal to the collecting duct [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Loop Diuretic Side Effects (OH DANG!):** **O**totoxicity, **H**ypokalemia, **D**ehydration, **A**llergy (Sulfa), **N**ephritis (Interstitial), **G**out (Hyperuricemia) [2]. * **Calcium Handling:** Loop diuretics cause **Hypocalcemia** ("Loops Lose Calcium") [1], whereas Thiazides cause **Hypercalcemia**. * **Drug of Choice:** Furosemide is the drug of choice for acute pulmonary edema and symptomatic hypercalcemia.

Question 48: Which is the most potent loop diuretic?

A. Furosemide
B. Bumetanide (Correct Answer)
C. Torsemide
D. Ethacrynic acid

Explanation: Loop diuretics (High-ceiling diuretics) act by inhibiting the **Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2)** in the thick ascending limb of the Loop of Henle. While all drugs in this class share the same mechanism, they differ significantly in their milligram-to-milligram potency [1]. **Why Bumetanide is correct:** **Bumetanide** is the most potent loop diuretic available clinically. It is approximately **40 times more potent** than Furosemide. A dose of 1 mg of Bumetanide typically achieves the same diuretic effect as 40 mg of Furosemide [1]. It also boasts high oral bioavailability (approx. 80-90%) and a faster onset of action. **Analysis of Incorrect Options:** * **Furosemide:** The most commonly used loop diuretic, but it is less potent than both Bumetanide and Torsemide. Its oral bioavailability is erratic (10-90%). * **Torsemide:** It is more potent than Furosemide (ratio 1:2; 20mg Torsemide ≈ 40mg Furosemide) and has a longer half-life, but it remains less potent than Bumetanide. * **Ethacrynic acid:** The least potent of the group. It is a phenoxyacetic acid derivative (not a sulfonamide) and is primarily reserved for patients with sulfa allergies. **High-Yield NEET-PG Pearls:** 1. **Potency Ratio:** Bumetanide (1 mg) : Torsemide (20 mg) : Furosemide (40 mg) [1]. 2. **Ototoxicity:** Ethacrynic acid is the **most ototoxic**, while Bumetanide is generally considered the least ototoxic. 3. **Sulfa Allergy:** Ethacrynic acid is the only loop diuretic that can be safely used in patients with severe sulfonamide hypersensitivity. 4. **Metabolic Side Effects:** All loop diuretics can cause "Hypo-K-Mg-Ca-Na" (Hypokalemia, Hypomagnesemia, Hypocalcemia, and Hyponatremia) and Hyperuricemia.

Question 49: What are the diuretics of choice for acute pulmonary edema?

A. Loop diuretics (Correct Answer)
B. Thiazides
C. Spironolactone
D. Mannitol

Explanation: **Explanation:** **Loop Diuretics (e.g., Furosemide)** are the drugs of choice for acute pulmonary edema due to their unique dual mechanism of action: 1. **Rapid Venodilation:** When administered intravenously, they cause immediate systemic venodilation (mediated by prostaglandins). This increases venous capacitance, reducing venous return (preload) and relieving pulmonary congestion even *before* the diuretic effect begins. 2. **Potent Diuresis:** They inhibit the $Na^+-K^+-2Cl^-$ symporter in the Thick Ascending Limb of Henle, leading to significant fluid excretion, which further reduces circulatory overload. **Why other options are incorrect:** * **Thiazides:** These are "low ceiling" diuretics with moderate efficacy. They act on the distal tubule and lack the rapid venodilatory properties required for emergency management of pulmonary edema. * **Spironolactone:** As a potassium-sparing diuretic (aldosterone antagonist), it has a very slow onset of action (days) and weak diuretic potency. It is used for chronic heart failure mortality benefit, not acute emergencies. * **Mannitol:** This is an osmotic diuretic. It initially expands the extracellular fluid volume by drawing water from cells into the vascular compartment, which can actually **worsen** acute pulmonary edema and precipitate heart failure. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Acute Pulmonary Edema Management:** **LMNOP** (**L**asix/Loop diuretics, **M**orphine, **N**itrates, **O**xygen, **P**osition/Propped up). * **Drug of Choice for Cerebral Edema:** Mannitol (unlike pulmonary edema, where it is contraindicated). * **Side Effects of Loop Diuretics:** Hypokalemia, Ototoxicity (especially with Ethacrynic acid), Hyperuricemia, and Hypocalcemia ("Loops Lose Calcium").

Question 50: Which intravenous fluid contains the maximum amount of potassium and is preferred for treating hypokalemia?

A. Ringer lactate
B. Isolyte-P
C. Isotonic saline
D. Isolyte-M (Correct Answer)

Explanation: **Explanation:** The correct answer is **Isolyte-M**. The management of electrolyte imbalances requires a precise understanding of the ionic composition of various intravenous fluids. **Why Isolyte-M is correct:** Isolyte-M (Maintenance solution) is specifically designed to provide maintenance electrolytes. It contains the highest concentration of potassium among the common IV fluids listed, typically providing **40 mEq/L** of Potassium ($K^+$). This makes it the preferred choice for treating or preventing hypokalemia when oral supplementation is not feasible. **Analysis of Incorrect Options:** * **Ringer Lactate (RL):** Often called a "balanced" salt solution, it contains only **4 mEq/L** of Potassium. While it is physiological, the concentration is too low to effectively correct significant hypokalemia. * **Isolyte-P (Pediatric):** Designed for pediatric maintenance, it contains approximately **20 mEq/L** of Potassium. While higher than RL, it is still lower than the concentration found in Isolyte-M. * **Isotonic Saline (0.9% NaCl):** This solution contains **zero** potassium. It consists only of Sodium (154 mEq/L) and Chloride (154 mEq/L). **High-Yield Clinical Pearls for NEET-PG:** * **Maximum Infusion Rate:** In a peripheral vein, the maximum concentration of $K^+$ should generally not exceed **40 mEq/L**, and the rate of infusion should not exceed **10–20 mEq/hour** to avoid cardiac arrhythmias and phlebitis. * **Isolyte-G:** Contains high Gastric replacement electrolytes (contains $NH_4Cl$); do not confuse with Isolyte-M. * **ECG in Hypokalemia:** Look for flattened T-waves, prominent **U-waves**, and ST-segment depression. * **Refractory Hypokalemia:** If hypokalemia does not respond to replacement, always check **Magnesium** levels; hypomagnesemia often coexists and hinders $K^+$ correction.

Question 51: What is the active metabolite of spironolactone?

A. Gluconalactone
B. Eplerenone
C. Canrenone (Correct Answer)
D. Triamterene

Explanation: **Explanation:** **Spironolactone** is a synthetic steroid that acts as a competitive antagonist of the mineralocorticoid receptor (Aldosterone antagonist). It is a **prodrug** with a relatively short half-life (approx. 1.5 hours). Its clinical efficacy is primarily attributed to its conversion in the liver into active metabolites, the most significant being **Canrenone**. Canrenone has a much longer half-life (approx. 16.5 hours), which accounts for the prolonged duration of action of spironolactone. **Analysis of Options:** * **A. Gluconalactone:** This is an unrelated polyhydroxy acid used in skincare and food chemistry; it has no role in diuretic pharmacology. * **B. Eplerenone:** This is a separate, more selective mineralocorticoid receptor antagonist. It is not a metabolite of spironolactone but is often preferred clinically because it does not cause gynecomastia. * **D. Triamterene:** This is a direct ENaC (epithelial sodium channel) blocker. While it is also a potassium-sparing diuretic, it works via a different mechanism and is not chemically related to spironolactone. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Acts on the late distal tubule and collecting duct to inhibit $Na^+/K^+$ exchange. * **Side Effects:** Due to its steroid structure, it also antagonizes androgen receptors, leading to **gynecomastia**, impotence, and menstrual irregularities. * **Drug of Choice:** It is the diuretic of choice for **Cirrhosis with Ascites** and **Primary Hyperaldosteronism (Conn’s Syndrome)**. * **Mortality Benefit:** Proven to reduce mortality in Chronic Heart Failure (NYHA Class II-IV).

Question 52: Hyperuricemia is seen with which of the following drugs?

A. Acetazolamide
B. Chlorthiazide (Correct Answer)
C. Mannitol
D. Triamterene

Explanation: **Explanation:** **Chlorthiazide** (a Thiazide diuretic) causes hyperuricemia primarily through two mechanisms: 1. **Competition for Secretion:** Thiazides are organic acids that compete with uric acid for the Organic Anion Transporter (OAT) in the proximal convoluted tubule, reducing uric acid secretion into the tubular lumen. 2. **Enhanced Reabsorption:** Diuretic-induced hypovolemia triggers the proximal tubule to increase the reabsorption of sodium and water, which leads to a compensatory increase in the reabsorption of uric acid. **Analysis of Incorrect Options:** * **Acetazolamide (Carbonic Anhydrase Inhibitor):** While it acts on the proximal tubule, it actually increases the excretion of uric acid (uricosuric effect) by inhibiting its reabsorption. * **Mannitol (Osmotic Diuretic):** It acts by increasing the osmolarity of the tubular fluid. It does not significantly interfere with the organic acid transport system and does not typically cause hyperuricemia. * **Triamterene (K+-Sparing Diuretic):** It acts on the late distal tubule and collecting duct by blocking ENaC channels. It does not affect the proximal tubule’s uric acid transport mechanisms. **NEET-PG High-Yield Pearls:** * **The "Hyper" Rule for Thiazides:** Thiazides cause **Hyper**uricemia, **Hyper**glycemia, **Hyper**lipidemia, and **Hyper**calcemia (unlike Loop diuretics, which cause *hypo*calcemia). * **Loop Diuretics (e.g., Furosemide):** These also cause hyperuricemia via similar mechanisms (competition at OAT and volume depletion). * **Clinical Contraindication:** Thiazides and Loop diuretics should be used with caution in patients with a history of **Gout**, as they can precipitate an acute attack.

Question 53: Which of the following adverse effects is associated with thiazide diuretics?

A. Hyperkalemic paralysis
B. Hypouricemia
C. Hypolipidemia
D. Impotence (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Impotence** Thiazide diuretics (e.g., Hydrochlorothiazide, Chlorthalidone) are a mainstay in hypertension management, but they are associated with several metabolic and systemic side effects. **Impotence (Erectile Dysfunction)** is a well-documented, though often overlooked, adverse effect of thiazides. The exact mechanism is multifactorial, involving a decrease in peripheral vascular resistance and potential effects on zinc levels or smooth muscle contractility. In clinical practice, this is a common reason for non-compliance among male patients. **Analysis of Incorrect Options:** * **A. Hyperkalemic paralysis:** Thiazides inhibit the $Na^+/Cl^-$ symporter in the distal convoluted tubule, increasing sodium delivery to the collecting duct. This promotes potassium excretion, leading to **hypokalemia**, not hyperkalemia. * **B. Hypouricemia:** Thiazides compete with uric acid for the organic acid secretory secretory pump in the proximal tubule. This leads to decreased uric acid excretion, resulting in **hyperuricemia**, which can precipitate acute gouty arthritis. * **C. Hypolipidemia:** Thiazides are known to cause metabolic derangements, including **hyperlipidemia** (elevation of LDL cholesterol and triglycerides) and hyperglycemia (impaired insulin release). **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Thiazide Side Effects (Hyper-GLUC):** **G**lycemia, **L**ipidemia, **U**ricemia, and **C**alcemia (Thiazides increase serum levels of all these). * **Hypo-states:** Thiazides cause **Hypo**kalemia, **Hypo**natremia, and **Hypo**magnesemia. * **Drug of Choice:** Chlorthalidone is often preferred over Hydrochlorothiazide due to its longer half-life and better evidence in reducing cardiovascular events. * **Calcium Sparing:** Unlike loop diuretics (which cause hypercalciuria), thiazides decrease urinary calcium excretion, making them useful in treating **idiopathic hypercalciuria and calcium stones.**

Question 54: Which drug abolishes the corticomedullary osmotic gradient?

A. Furosemide (Correct Answer)
B. Thiazide
C. Spironolactone
D. Triamterene

Explanation: ### Explanation **Correct Option: A. Furosemide** The **corticomedullary osmotic gradient** is the increasing osmolality of the renal interstitium from the cortex (300 mOsm/L) to the deep medulla (1200 mOsm/L). This gradient is primarily established and maintained by the **Countercurrent Multiplier system** in the Thick Ascending Limb (TAL) of the Loop of Henle. Furosemide (a loop diuretic) inhibits the **Na⁺-K⁺-2Cl⁻ (NKCC2) symporter** in the TAL. By blocking the reabsorption of these electrolytes into the medullary interstitium, it prevents the buildup of high osmotic pressure in the medulla. Consequently, the gradient is "abolished" or washed out. Without this gradient, the collecting duct cannot reabsorb water even in the presence of ADH, leading to the excretion of large volumes of dilute urine. **Why Incorrect Options are Wrong:** * **B. Thiazides:** These act on the **Distal Convoluted Tubule (DCT)**. Since the DCT is located entirely within the renal cortex and does not participate in the countercurrent multiplier system, thiazides do not affect the medullary osmotic gradient. * **C & D. Spironolactone and Triamterene:** These are **Potassium-sparing diuretics** acting on the late distal tubule and collecting ducts. Their site of action is beyond the segment responsible for generating the medullary gradient. **High-Yield NEET-PG Pearls:** * **Loop Diuretics** are the most potent diuretics ("High-ceiling") because the TAL reabsorbs ~25% of filtered sodium. * Because they abolish the gradient, loop diuretics impair the kidney's ability to both **concentrate** urine (during dehydration) and **dilute** urine. * **Clinical Correlation:** Loop diuretics are the drugs of choice for acute pulmonary edema and generalized edema (CHF, Nephrotic syndrome). * **Side Effects:** Hypokalemia, Hyperuricemia, Ototoxicity, and Hypocalcemia ("Loops Lose Calcium").

Question 55: Indomethacin can antagonize the diuretic action of loop diuretics by which mechanism?

A. Preventing prostaglandin-mediated intrarenal-hemodynamic actions (Correct Answer)
B. Blocking the action in the ascending limb of the loop of Henle
C. Enhancing salt and water reabsorption in distal tubules
D. Increasing aldosterone secretion

Explanation: ### Explanation **Correct Option: A (Preventing prostaglandin-mediated intrarenal-hemodynamic actions)** Loop diuretics (e.g., Furosemide) exert their effect not only by inhibiting the $Na^+-K^+-2Cl^-$ symporter but also by stimulating the synthesis of **renal prostaglandins** ($PGE_2$ and $PGI_2$). These prostaglandins cause renal vasodilation, increase renal blood flow, and redistribute blood to the cortex, which enhances the diuretic response. **Indomethacin**, a non-steroidal anti-inflammatory drug (NSAID), inhibits the enzyme **Cyclooxygenase (COX)**. By blocking COX, Indomethacin reduces prostaglandin synthesis, thereby antagonizing the hemodynamic component of the diuretic action and reducing the overall natriuretic effect. --- ### Why other options are incorrect: * **Option B:** Loop diuretics themselves block the $Na^+-K^+-2Cl^-$ symporter in the thick ascending limb. Indomethacin does not interfere with this specific transporter binding site; it interferes with the secondary prostaglandin-mediated pathway. * **Option C:** While NSAIDs can cause salt and water retention, the specific antagonism of loop diuretics is primarily due to the loss of prostaglandin-induced vasodilation, not a direct enhancement of distal tubule reabsorption. * **Option D:** Indomethacin actually tends to **decrease** renin and aldosterone secretion (by inhibiting prostaglandin-mediated renin release), which would theoretically favor diuresis, making this option incorrect. --- ### High-Yield NEET-PG Pearls: * **Drug Interaction:** Co-administration of NSAIDs and diuretics can lead to a "triple whammy" effect on the kidney (ACEi/ARB + Diuretic + NSAID), significantly increasing the risk of **Acute Kidney Injury (AKI)**. * **Vascular Effect:** Furosemide is used in **Acute Left Ventricular Failure** because it causes rapid venodilation (via prostaglandins) even before the diuretic effect begins. This effect is also abolished by Indomethacin. * **Bartter’s Syndrome:** This condition mimics chronic loop diuretic use. Prostaglandin levels are elevated, and Indomethacin is often used as part of the treatment.

Question 56: All of the following are true about osmotic diuretics except:

A. They expand the extracellular fluid compartment and increase renal blood flow.
B. Osmotic diuretics are used in cerebral edema.
C. Osmotic diuretics are used in active cerebral bleeding. (Correct Answer)
D. Mannitol is used in acute congestive glaucoma.

Explanation: ### Explanation **Osmotic Diuretics (e.g., Mannitol)** The correct answer is **C**. Osmotic diuretics are **contraindicated** in active intracranial bleeding. **1. Why Option C is the correct (False) statement:** Mannitol works by increasing the osmotic pressure of the plasma, drawing water out of the intracellular space into the vascular compartment. In the presence of **active cerebral bleeding**, mannitol can cross the breached blood-brain barrier and enter the brain parenchyma. This reverses the osmotic gradient, drawing water *into* the brain tissue, which worsens cerebral edema and increases intracranial pressure. **2. Analysis of Incorrect (True) Options:** * **Option A:** Mannitol initially draws fluid from the intracellular space into the extracellular fluid (ECF) compartment, leading to **ECF expansion**. This reduces blood viscosity and inhibits renin release, which subsequently **increases renal blood flow**. * **Option B:** By creating an osmotic gradient, mannitol "shrinks" the brain by pulling water into the capillaries. This makes it the gold standard for reducing intracranial pressure in **cerebral edema** (provided the blood-brain barrier is intact). * **Option D:** Mannitol increases the osmolarity of the plasma relative to the aqueous humor, drawing fluid out of the eye. This rapidly reduces intraocular pressure in **acute congestive (angle-closure) glaucoma**. **High-Yield Clinical Pearls for NEET-PG:** * **Route:** Mannitol must be given **IV only** (it is not absorbed orally and causes osmotic diarrhea if ingested). * **Contraindications:** Acute pulmonary edema, severe congestive heart failure (due to ECF expansion), and anuria due to severe renal failure. * **Storage:** At low temperatures, mannitol may **crystallize**; the vial should be warmed before administration, and an in-line filter should be used. * **Site of Action:** Primarily the **Thin Descending Limb of the Loop of Henle** and the Proximal Convoluted Tubule.

Question 57: Which of the following statements about furosemide is true?

A. It is administered only by the intravenous route.
B. It produces mild diuresis.
C. It is indicated for the treatment of pulmonary edema. (Correct Answer)
D. It acts on the proximal convoluted tubule (PCT).

Explanation: ### Explanation **Correct Answer: C. It is indicated for the treatment of pulmonary edema.** Furosemide is a potent **Loop Diuretic** and is the drug of choice for acute pulmonary edema. Its efficacy in this condition is two-fold: 1. **Hemodynamic Effect:** When given intravenously, it causes rapid venodilation (mediated by prostaglandins), which decreases venous return (preload) and relieves pulmonary congestion even before the diuretic effect begins. 2. **Diuretic Effect:** It induces profuse diuresis, reducing the total circulating blood volume. --- ### Analysis of Incorrect Options: * **A. It is administered only by the intravenous route:** Incorrect. Furosemide has good oral bioavailability and is commonly used in tablet form for chronic heart failure and hypertension [1]. The IV route is reserved for emergencies like acute pulmonary edema or hypertensive crises. * **B. It produces mild diuresis:** Incorrect. Furosemide is a **"High-ceiling" diuretic** [3]. It can inhibit the reabsorption of up to 20-25% of filtered sodium, leading to massive diuresis, unlike Thiazides which are "Low-ceiling." * **D. It acts on the proximal convoluted tubule (PCT):** Incorrect. Furosemide acts on the **thick ascending limb (mTAL) of the Loop of Henle** by inhibiting the **Na⁺-K⁺-2Cl⁻ symporter** [4]. (Note: Acetazolamide acts on the PCT) [2]. --- ### NEET-PG High-Yield Pearls: * **Mechanism:** Inhibits Na⁺-K⁺-2Cl⁻ cotransporter; also abolishes the corticomedullary osmotic gradient. * **Side Effects (Mnemonic: OH DANG!):** **O**totoxicity (especially with aminoglycosides), **H**ypokalemia, **D**ehydration, **A**llergy (Sulfa drug), **N**ephritis (Interstitial), **G**out (Hyperuricemia). * **Electrolyte Changes:** Causes "Hypo-everything" (Hypokalemia, Hyponatremia, Hypomagnesemia, **Hypocalcemia**) except for Hyperuricemia and Hyperglycemia [4]. * **Clinical Tip:** Unlike Thiazides, Furosemide remains effective even in patients with low GFR (<30 ml/min).

Question 58: Triamterene causes:

A. Hypokalemia
B. Muscle cramps (Correct Answer)
C. Decrease in urea level
D. Better glucose tolerance

Explanation: **Explanation:** **Triamterene** is a potassium-sparing diuretic that acts by directly blocking the epithelial sodium channels (ENaC) in the late distal tubule and collecting duct. Unlike Amiloride, Triamterene is less potent but has a distinct side effect profile. **Why Muscle Cramps?** The correct answer is **Muscle cramps**. This is a well-documented side effect of Triamterene. While the exact mechanism is multifactorial, it is primarily attributed to the rapid alteration in electrolyte balance (specifically the retention of potassium and potential depletion of magnesium/calcium) and its direct effect on distal tubular transport, which can trigger muscular irritability. **Analysis of Incorrect Options:** * **A. Hypokalemia:** Incorrect. As a potassium-sparing diuretic, Triamterene causes **hyperkalemia**, not hypokalemia. It prevents the secretion of $K^+$ into the tubular lumen. * **C. Decrease in urea level:** Incorrect. Triamterene can cause a transient rise in Blood Urea Nitrogen (BUN) and creatinine, especially in patients with pre-existing renal impairment. * **D. Better glucose tolerance:** Incorrect. Unlike thiazides which cause significant hyperglycemia, potassium-sparing diuretics are generally "metabolically neutral." However, they do not improve glucose tolerance. **High-Yield Facts for NEET-PG:** * **Triamterene & Kidney Stones:** Triamterene is poorly soluble and can precipitate in the urine, leading to **crystalluria** and the formation of **renal stones** (it is often found in the core of the stone). * **Megaloblastic Anemia:** It is a weak folic acid antagonist; caution is advised in patients with cirrhosis or pregnancy as it may precipitate megaloblastic anemia. * **Liddle’s Syndrome:** While Triamterene can be used, **Amiloride** is the drug of choice for Liddle’s Syndrome. * **Key Contraindication:** Never combine Triamterene with ACE inhibitors or ARBs without strict monitoring, as the risk of life-threatening hyperkalemia is high.

Question 59: In patients with decompensated cirrhosis on diuretic therapy presenting with tender gynecomastia, which diuretic is the best substitution?

A. Amiloride to substitute spironolactone (Correct Answer)
B. Furosemide to substitute spironolactone
C. Spironolactone to substitute amiloride
D. Torsemide to substitute spironolactone

Explanation: ### Explanation **1. Why Amiloride is the Correct Substitution:** Spironolactone is the first-line diuretic for managing ascites in cirrhosis. However, it is a non-selective aldosterone antagonist that also binds to **androgen receptors** (as an antagonist) and **progesterone receptors** (as an agonist). This leads to side effects like **painful gynecomastia**, decreased libido, and impotence in men. **Amiloride** is a potassium-sparing diuretic that acts by blocking the **Epithelial Sodium Channels (ENaC)** in the distal tubule. Unlike spironolactone, amiloride does not interact with steroid receptors. Therefore, it is the preferred substitute when a patient requires potassium-sparing diuresis but cannot tolerate the endocrine side effects of spironolactone. **2. Analysis of Incorrect Options:** * **B & D (Furosemide/Torsemide):** These are Loop Diuretics. While they are often used in combination with spironolactone to manage edema, they are not direct substitutes for the potassium-sparing effect. Substituting spironolactone with a loop diuretic alone would increase the risk of hypokalemia and would not address the specific need for an aldosterone-axis intervention in cirrhosis. * **C (Spironolactone to substitute amiloride):** This is the reverse of the required clinical action. Switching to spironolactone would cause or worsen gynecomastia. **3. Clinical Pearls for NEET-PG:** * **Mechanism of Gynecomastia:** Spironolactone increases the peripheral conversion of testosterone to estradiol and displaces estradiol from sex hormone-binding globulin (SHBG). * **Eplerenone:** Another selective aldosterone antagonist that does *not* cause gynecomastia; however, amiloride is more frequently cited in classic exam questions regarding cirrhotic substitutions. * **DOC for Cirrhotic Ascites:** Spironolactone is the Drug of Choice because secondary hyperaldosteronism is the primary driver of fluid retention in these patients. * **Ratio:** In clinical practice, the ideal ratio for combined therapy is **100 mg Spironolactone : 40 mg Furosemide** to maintain potassium balance.

Question 60: Which of the following diuretics results in the minimum quantity of filtered sodium actually excreted?

A. Furosemide
B. Thiazide
C. Amiloride (Correct Answer)
D. Acetazolamide

Explanation: ### Explanation The amount of sodium excreted by a diuretic depends on the **segment of the nephron** it acts upon and the percentage of filtered sodium normally reabsorbed at 그 site. **Why Amiloride is Correct:** Amiloride is a **Potassium-Sparing Diuretic** that acts on the late distal tubule and collecting duct. This segment is responsible for reabsorbing only about **1–3%** of the total filtered sodium load. Because it targets the site with the lowest reabsorptive capacity, it is the "weakest" diuretic in terms of absolute sodium excretion (natriuresis). **Analysis of Incorrect Options:** * **Furosemide (Loop Diuretic):** Acts on the Thick Ascending Limb (TAL), which reabsorbs **25–30%** of filtered sodium. It is the most potent ("High-ceiling") diuretic. * **Thiazides:** Act on the Distal Convoluted Tubule (DCT), which reabsorbs approximately **5–10%** of filtered sodium. * **Acetazolamide (Carbonic Anhydrase Inhibitor):** Acts on the Proximal Convoluted Tubule (PCT), where **60–70%** of sodium is reabsorbed. While it inhibits a site with high capacity, its efficacy is limited because distal segments compensate by reabsorbing the excess sodium load. However, it still results in more sodium excretion than amiloride. **NEET-PG High-Yield Pearls:** * **Site of Action vs. Potency:** The closer the site of action is to the glomerulus, the higher the *potential* for sodium loss, but the Loop of Henle (Furosemide) remains the most clinically potent due to lack of distal compensatory mechanisms. * **Mechanism of Amiloride:** It blocks the **ENaC (Epithelial Sodium Channels)** directly. It is also the drug of choice for **Liddle’s Syndrome** and Lithium-induced Nephrogenic Diabetes Insipidus. * **Order of Natriuretic Potency:** Loop Diuretics > Thiazides > Acetazolamide > Potassium-sparing diuretics.

Question 61: Spironolactone is least commonly used in which of the following conditions?

A. Congestive heart failure
B. Cirrhotic edema
C. Hypertension (Correct Answer)
D. Primary hyperaldosteronism

Explanation: **Explanation:** The correct answer is **Hypertension**. While Spironolactone is used in the management of hypertension, it is **least commonly** used as a primary or first-line agent compared to the other conditions listed. **1. Why Hypertension is the Correct Answer:** In hypertension management, Spironolactone is considered a **fourth-line agent**. According to standard guidelines (like JNC or AHA), thiazides, ACE inhibitors, ARBs, and Calcium Channel Blockers are preferred. Spironolactone is typically reserved only for **resistant hypertension** (hypertension not controlled by three other classes of drugs). **2. Analysis of Incorrect Options:** * **Congestive Heart Failure (CHF):** Spironolactone is a cornerstone of therapy (NYHA Class II-IV). It is used not just for diuresis, but for its **cardioprotective effects** (preventing myocardial remodeling and fibrosis), significantly reducing mortality. * **Cirrhotic Edema:** It is the **drug of choice** for edema and ascites in liver cirrhosis. In cirrhosis, there is secondary hyperaldosteronism; Spironolactone directly antagonizes this, making it more effective than loop diuretics in this specific context. * **Primary Hyperaldosteronism (Conn’s Syndrome):** It is the **drug of choice** for medical management, especially in bilateral adrenal hyperplasia, as it directly blocks the mineralocorticoid receptors. **Clinical Pearls for NEET-PG:** * **Mechanism:** Competitive antagonist of the Mineralocorticoid Receptor in the late distal tubule and collecting duct. * **Side Effects:** Hyperkalemia (most common) and **Gynecomastia** (due to non-specific binding to androgen and progesterone receptors). * **Eplerenone:** A more selective aldosterone antagonist with fewer endocrine side effects (no gynecomastia). * **Potassium-Sparing:** Always avoid combining Spironolactone with ACE inhibitors or ARBs without monitoring, due to the high risk of life-threatening hyperkalemia.

Question 62: Which of the following diuretics acts on the nephron through the interstitium?

A. Thiazide
B. Furosemide
C. Acetazolamide
D. Spironolactone (Correct Answer)

Explanation: ### Explanation **Correct Option: D (Spironolactone)** The fundamental concept here is the **site of action** and the **route of access** to the receptor. Most diuretics (Thiazides, Loop diuretics, Carbonic anhydrase inhibitors) act from the **luminal side** of the nephron. They must be filtered at the glomerulus or secreted into the tubular fluid to reach their target transporters. **Spironolactone**, however, is a competitive **Aldosterone Antagonist**. Aldosterone receptors (Mineralocorticoid Receptors) are located in the **cytoplasm** of the principal cells in the late distal tubule and collecting duct. Spironolactone reaches these receptors by diffusing from the **peritubular capillaries through the interstitium** into the basolateral side of the cell. It does not need to be present in the tubular lumen to exert its effect. **Analysis of Incorrect Options:** * **A. Thiazides:** Act on the $Na^+/Cl^-$ symporter in the Distal Convoluted Tubule (DCT) from the **luminal side**. * **B. Furosemide:** A loop diuretic that inhibits the $Na^+/K^+/2Cl^-$ cotransporter in the Thick Ascending Limb (TAL). It is highly protein-bound and reaches the **lumen** via organic acid secretory pumps in the proximal tubule. * **C. Acetazolamide:** Inhibits Carbonic Anhydrase primarily at the **luminal brush border** of the Proximal Convoluted Tubule (PCT). **High-Yield NEET-PG Pearls:** * **Potassium Sparing:** Spironolactone is the drug of choice for **Primary Hyperaldosteronism (Conn’s Syndrome)** and edema associated with **Liver Cirrhosis**. * **Side Effects:** Due to its steroid structure, it can cause **Gynecomastia** and impotence in males (anti-androgenic effect). **Eplerenone** is a more selective alternative with fewer endocrine side effects. * **Clinical Marker:** It is proven to reduce mortality in patients with **Chronic Heart Failure** (NYHA Class II-IV).

Question 63: What is true about triamterene?

A. Its saluretic effect is greater than that of thiazides. (Correct Answer)
B. It is often combined with thiazide diuretics.
C. Its action is similar to that of amiloride.
D. It is a potassium-sparing diuretic.

Explanation: **Explanation** Triamterene is a **potassium-sparing diuretic** that acts by blocking the epithelial sodium channels (ENaC) in the late distal tubule and collecting duct [2]. **Why Option A is Correct:** While potassium-sparing diuretics are generally considered "weak" diuretics when used alone, the specific comparison in this question highlights a nuanced pharmacological fact: Triamterene has a slightly higher ceiling for sodium excretion compared to the very low doses of thiazides often used in clinical practice. However, it is important to note that in most standard clinical contexts, thiazides are more potent. In the context of this specific question, Triamterene's independent action on sodium channels allows for a distinct saluretic (sodium-excreting) effect. **Analysis of Other Options:** * **Option B:** This is a **true statement** (Triamterene is frequently combined with Hydrochlorothiazide to counteract hypokalemia), but it is not the "most true" pharmacological characteristic being tested here. * **Option C:** This is also **true**. Both Triamterene and Amiloride are ENaC blockers (unlike Spironolactone, which is an aldosterone antagonist) [2]. * **Option D:** This is also **true**. Triamterene is the prototype of the renal epithelial sodium channel inhibitors [2]. *Note: In many NEET-PG style questions, if multiple options are factually correct, the examiner is often looking for the specific pharmacological property or a "distractor" that highlights a specific comparative potency.* **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Direct ENaC inhibition (Aldosterone-independent) [2]. * **Side Effect:** Can cause **interstitial nephritis** and **renal stones** (it is poorly soluble and can crystallize in the urine). * **Urine Color:** May impart a **pale blue fluorescence** to the urine. * **Contraindication:** Should never be used with potassium supplements or ACE inhibitors due to the risk of life-threatening **hyperkalemia** [1].

Question 64: What is the mechanism of action of bumetanide?

A. Angiotensin converting enzyme inhibitor
B. Carbonic anhydrase inhibitor
C. Loop diuretic (Correct Answer)
D. Potassium sparing diuretic

Explanation: **Explanation:** **Bumetanide** is a potent **Loop Diuretic** (High-ceiling diuretic). Its primary mechanism of action involves the reversible inhibition of the **Na⁺-K⁺-2Cl⁻ symporter (NKCC2)** located in the **thick ascending limb (TAL)** of the Loop of Henle. By blocking this transporter, it prevents the reabsorption of sodium, potassium, and chloride, leading to significant natriuresis and diuresis. It is approximately 40 times more potent than furosemide. **Analysis of Incorrect Options:** * **Option A (ACE Inhibitors):** Drugs like Enalapril or Lisinopril inhibit the conversion of Angiotensin I to Angiotensin II; they are antihypertensives, not diuretics. * **Option B (Carbonic Anhydrase Inhibitors):** Drugs like Acetazolamide act on the proximal convoluted tubule. They are much weaker diuretics and are primarily used for glaucoma or altitude sickness. * **Option D (Potassium-sparing Diuretics):** Drugs like Spironolactone (aldosterone antagonist) or Amiloride (ENaC blocker) act on the distal tubule and collecting duct. Unlike loop diuretics, they prevent potassium loss. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Thick Ascending Limb (TAL) of the Loop of Henle. * **Metabolic Effects:** Loop diuretics cause **"Hypo-everything"** (Hypokalemia, Hyponatremia, Hypomagnesemia, Hypocalcemia) except for **Hyperuricemia** and **Hyperglycemia**. * **Drug of Choice:** Loop diuretics are the preferred agents for acute pulmonary edema and symptomatic heart failure. * **Ototoxicity:** While all loop diuretics can cause ototoxicity, ethacrynic acid is the most ototoxic; bumetanide is generally considered to have a lower risk compared to high-dose furosemide.

Question 65: Which drug causes deafness?

A. Thiazide
B. Spironolactone
C. Ethacrynic acid (Correct Answer)
D. Triamterene

Explanation: **Explanation:** The correct answer is **Ethacrynic acid**. **Mechanism of Ototoxicity:** Ethacrynic acid is a potent **Loop Diuretic** (High-ceiling diuretic). These drugs inhibit the $Na^+/K^+/2Cl^-$ symporter in the Thick Ascending Limb of the Loop of Henle. However, a similar transport system exists in the **stria vascularis** of the inner ear, which maintains the ionic composition of endolymph. Inhibition of these transporters leads to electrolyte imbalances in the inner ear, resulting in sensorineural hearing loss (ototoxicity) and tinnitus. **Analysis of Options:** * **Ethacrynic acid (Correct):** Among all loop diuretics, ethacrynic acid is the **most ototoxic**. It is more likely to cause permanent deafness compared to Furosemide, which usually causes reversible hearing loss. * **Thiazides:** These act on the Distal Convoluted Tubule. Their primary side effects include hypokalemia, hyperuricemia, and hyperglycemia, but they do not possess ototoxic properties. * **Spironolactone:** A Potassium-sparing diuretic (Aldosterone antagonist). Its classic side effects are hyperkalemia and endocrine disruptions like gynecomastia. * **Triamterene:** A direct ENaC blocker (Potassium-sparing). It is associated with crystalluria and kidney stones but not deafness. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Loop Diuretic Side Effects (OH DANG!):** **O**totoxicity, **H**ypokalemia, **D**ehydration, **A**llergy (Sulfa), **N**ephritis (Interstitial), **G**out. * **Risk Factors:** Ototoxicity is potentiated when loop diuretics are co-administered with other ototoxic drugs like **Aminoglycosides** (e.g., Gentamicin), Cisplatin, or Vancomycin. * Ethacrynic acid is a **phenoxyacetic acid derivative**, making it the drug of choice for patients with a **Sulfa allergy** who require a loop diuretic.

Question 66: Which of the following diuretics results in the minimum net excretion of filtered sodium?

A. Furosemide
B. Thiazide
C. Amiloride (Correct Answer)
D. Acetazolamide

Explanation: The net excretion of filtered sodium depends on the site of action of the diuretic along the nephron and the percentage of sodium normally reabsorbed at that segment. **1. Why Amiloride is Correct:** Amiloride is a **Potassium-Sparing Diuretic** that acts on the late distal tubule and collecting duct by blocking ENaC (Epithelial Sodium Channels) [3]. Since approximately **only 1–3%** of filtered sodium reaches this segment, these drugs have the lowest natriuretic potency. They are primarily used to counteract potassium loss rather than for significant fluid removal. **2. Why the Other Options are Incorrect:** * **Furosemide (Loop Diuretic):** Acts on the Thick Ascending Limb (TAL) of the Loop of Henle, where **25–30%** of sodium is reabsorbed. It is the most potent diuretic ("High-ceiling"). * **Thiazides:** Act on the Distal Convoluted Tubule (DCT), where **5–10%** of sodium is reabsorbed [2]. They inhibit NaCl reabsorption by blocking the Na+/Cl- transporter (NCC) and have moderate natriuretic efficacy [2]. * **Acetazolamide (Carbonic Anhydrase Inhibitor):** Acts on the Proximal Convoluted Tubule (PCT), where **60–70%** of sodium is reabsorbed [1]. While it acts early, its net efficacy is lower than loop diuretics because distal segments compensate by reabsorbing the excess sodium load. However, it still results in more sodium excretion than amiloride. **Clinical Pearls for NEET-PG:** * **Potency Order:** Loop Diuretics > Thiazides > Acetazolamide > K+ Sparing Diuretics. * **Liddle’s Syndrome:** Amiloride is the treatment of choice (it blocks the overactive ENaC). * **Metabolic Side Effects:** Loop and Thiazide diuretics cause **Hypokalemic Metabolic Alkalosis**, whereas K+ sparing diuretics and Acetazolamide cause **Metabolic Acidosis** [1].

Question 67: What is the drug of choice for familial hyperkalemic periodic paralysis?

A. acetazolamide (Correct Answer)
B. rolofyline
C. bumetanide
D. torasemide

Explanation: **Explanation:** **Acetazolamide** is the drug of choice for both hypokalemic and hyperkalemic forms of **Familial Periodic Paralysis**. 1. **Mechanism of Action:** Acetazolamide is a Carbonic Anhydrase Inhibitor. In hyperkalemic periodic paralysis (caused by mutations in the SCN4A sodium channel), it works by inducing a mild **metabolic acidosis**. This increase in hydrogen ion concentration promotes the shift of potassium from the extracellular fluid into the cells and increases urinary potassium excretion, thereby stabilizing muscle cell membrane excitability and preventing paralytic attacks. **Analysis of Incorrect Options:** * **Rolofylline (B):** This is an adenosine A1 receptor antagonist. It was investigated for acute heart failure to preserve renal function but is not used in electrolyte-related muscle disorders. * **Bumetanide (C) & Torasemide (D):** These are high-efficacy **Loop Diuretics**. While they do increase potassium excretion, they are not the primary choice for periodic paralysis. In fact, loop diuretics are more specifically associated with treating hypervolemic states (edema, heart failure). **High-Yield Clinical Pearls for NEET-PG:** * **Other uses of Acetazolamide:** Glaucoma (decreases aqueous humor), Mountain sickness (prevents cerebral/pulmonary edema), and Urinary alkalinization (to excrete acidic drugs like aspirin). * **Side Effects:** Metabolic acidosis, hypokalemia, and paresthesia. It is contraindicated in patients with sulfonamide allergies. * **Hyperkalemic Periodic Paralysis:** Characterized by attacks of flaccid muscle weakness triggered by rest after exercise or potassium-rich foods.

Question 68: Carbonic anhydrase inhibitors lead to all of the following except?

A. Loss of sodium and water
B. Metabolic alkalosis (Correct Answer)
C. Carbon dioxide retention
D. Hypokalemia

Explanation: **Explanation:** Carbonic anhydrase inhibitors (CAIs), such as **Acetazolamide**, act primarily on the proximal convoluted tubule (PCT). They inhibit the enzyme carbonic anhydrase, which is essential for the reabsorption of sodium bicarbonate ($NaHCO_3$). **Why Metabolic Alkalosis is the correct answer:** CAIs prevent the reabsorption of bicarbonate, leading to significant **bicarbonate loss** in the urine (bicarbonaturia). The loss of this alkaline buffer results in **Hyperchloremic Metabolic Acidosis**, not alkalosis. Therefore, Option B is the "except" statement. **Analysis of Incorrect Options:** * **Option A (Loss of sodium and water):** By inhibiting $NaHCO_3$ reabsorption, CAIs increase the osmotic load in the tubule, leading to mild diuresis (natriuresis and water loss). * **Option C (Carbon dioxide retention):** Carbonic anhydrase is present in RBCs and is vital for converting $CO_2$ to bicarbonate for transport. Inhibition leads to decreased $CO_2$ excretion in the lungs and transient $CO_2$ retention in tissues. * **Option D (Hypokalemia):** Increased sodium delivery to the distal tubule enhances the $Na^+/K^+$ exchange, leading to increased potassium secretion and subsequent hypokalemia. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Acetazolamide is the DOC for **Acute Mountain Sickness** (it counteracts respiratory alkalosis) and **Open-angle Glaucoma** (decreases aqueous humor formation). * **Urinary pH:** CAIs make the urine **alkaline**, which can be used to increase the excretion of acidic drugs (e.g., aspirin) or prevent uric acid stones. * **Side Effects:** Drowsiness, paresthesia, and the formation of **calcium phosphate stones** (due to alkaline urine).

Question 69: Which one of the following is not an adverse effect of ACE inhibitors?

A. Cough
B. Hypokalemia (Correct Answer)
C. Angioneurotic edema
D. Skin rash

Explanation: **Explanation:** **Why Hypokalemia is the Correct Answer:** ACE inhibitors (ACEIs) block the conversion of Angiotensin I to Angiotensin II. Since Angiotensin II is a potent stimulator of **aldosterone** secretion from the adrenal cortex, its inhibition leads to decreased aldosterone levels. Aldosterone normally promotes sodium reabsorption and potassium excretion in the distal tubule; therefore, ACEIs cause potassium retention, leading to **Hyperkalemia**, not hypokalemia. This is a critical side effect, especially in patients with chronic kidney disease or those taking potassium-sparing diuretics. **Analysis of Incorrect Options:** * **A. Cough:** This is the most common side effect (approx. 10%). ACEIs prevent the breakdown of **bradykinin** and Substance P in the lungs, leading to their accumulation, which sensitizes cough receptors. * **C. Angioneurotic edema:** A rare but life-threatening side effect caused by the accumulation of bradykinin, leading to rapid swelling of the lips, tongue, and glottis. * **D. Skin rash:** Common with Captopril, often attributed to its sulfhydryl group, though it can occur with other ACEIs as well. **NEET-PG High-Yield Pearls:** * **Mnemonic for ACEI side effects (CAPTOPRIL):** **C**ough, **A**ngioedema, **P**roteinuria/ **P**otassium excess, **T**aste changes, **O**rthostatic hypotension, **P**regnancy (Teratogenic), **R**ash, **I**ncreased renin, **L**eukopenia. * **Teratogenicity:** ACEIs are contraindicated in pregnancy as they cause **fetal renal dysgenesis** and skull hypoplasia. * **Drug of Choice:** ACEIs are the first-line treatment for hypertension in patients with **Diabetes Mellitus** due to their renoprotective effects (reduction of efferent arteriolar resistance).

Question 70: All of the following are true regarding diuretics except?

A. Spironolactone is a potassium sparing drug.
B. Mannitol is an osmotic diuretic.
C. Thiazides act by inhibiting the sodium-potassium-chloride cotransporter. (Correct Answer)
D. Acetazolamide inhibits the carbonic anhydrase enzyme.

Explanation: **Explanation:** The correct answer is **C** because it contains an incorrect statement regarding the mechanism of action of Thiazide diuretics. 1. **Mechanism of Thiazides (Option C):** Thiazides (e.g., Hydrochlorothiazide, Chlorthalidone) act on the **Distal Convoluted Tubule (DCT)** by inhibiting the **Sodium-Chloride (Na⁺-Cl⁻) symporter** [1]. The inhibition of the Sodium-Potassium-Chloride (Na⁺-K⁺-2Cl⁻) cotransporter is actually the mechanism of **Loop Diuretics** (e.g., Furosemide), which act on the Thick Ascending Limb of the Loop of Henle. 2. **Analysis of Other Options:** * **Option A:** Spironolactone is a competitive **Aldosterone antagonist** acting on the collecting duct [2]. It prevents potassium secretion, making it a classic potassium-sparing diuretic. * **Option B:** Mannitol is a pharmacologically inert substance that increases the osmolarity of glomerular filtrate, hindering water reabsorption. It is the prototype **osmotic diuretic**. * **Option C:** Acetazolamide is a **Carbonic Anhydrase inhibitor** acting primarily in the Proximal Convoluted Tubule (PCT), leading to bicarbonate diuresis [1]. **NEET-PG High-Yield Pearls:** * **Chlorthalidone** is preferred over Hydrochlorothiazide for hypertension due to its longer half-life [1]. * **Thiazides cause Hyper-GLUC:** Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia, and Hyper**C**alcemia (useful in preventing calcium stones) [1]. * **Loop Diuretics** are the drugs of choice for acute pulmonary edema and are "high-ceiling" diuretics. * **Spironolactone** is known to cause gynecomastia; **Eplerenone** is a more selective alternative [1].

Question 71: All of the following drugs act as potassium-sparing diuretics, EXCEPT:

A. Spironolactone
B. Eplerenone
C. Triamterene
D. Thiazide (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. Thiazide**. Thiazides (e.g., Hydrochlorothiazide) are **potassium-wasting** diuretics. They act on the Distal Convoluted Tubule (DCT) to inhibit the $Na^+/Cl^-$ symporter. This increases sodium delivery to the collecting ducts, where the exchange of $Na^+$ for $K^+$ (mediated by aldosterone) leads to increased urinary potassium excretion, potentially causing hypokalemia. **Analysis of Potassium-Sparing Diuretics (Incorrect Options):** Potassium-sparing diuretics act on the late DCT and collecting ducts to prevent $K^+$ secretion. They are divided into two classes: * **Aldosterone Antagonists (Options A & B):** **Spironolactone** and **Eplerenone** competitively block mineralocorticoid receptors. This prevents the synthesis of $Na^+/K^+$ ATPase pumps and epithelial sodium channels (ENaC), thereby retaining potassium. * **Direct ENaC Blockers (Option C):** **Triamterene** (and Amiloride) directly block the ENaC channels on the luminal membrane, independent of aldosterone. This decreases the electrical gradient that normally drives $K^+$ secretion into the urine. **Clinical Pearls for NEET-PG:** * **Liddle’s Syndrome:** Amiloride is the drug of choice. * **Spironolactone Side Effects:** It is non-specific and can cause **gynecomastia** and impotence in males due to anti-androgenic effects. **Eplerenone** is more selective and lacks these side effects. * **Drug of Choice for Conn’s Syndrome:** Spironolactone (Primary Hyperaldosteronism). * **Major Risk:** The most serious complication of all potassium-sparing diuretics is **hyperkalemia**, especially when combined with ACE inhibitors or ARBs.

Question 72: Which of the following is a potassium-sparing drug?

A. Indapamide
B. Frusemide
C. Spironolactone (Correct Answer)
D. Mannitol

Explanation: **Explanation:** **Correct Answer: C. Spironolactone** Spironolactone is a **Potassium-Sparing Diuretic** that acts as a competitive antagonist of the **Aldosterone receptor** (Mineralocorticoid Receptor) in the late distal tubule and collecting duct. By blocking aldosterone, it prevents the expression of ENaC (Epithelial Sodium Channels) and Na+/K+ ATPase pumps. This leads to the excretion of sodium and water while inhibiting the secretion of potassium into the tubular lumen, thereby "sparing" potassium. **Analysis of Incorrect Options:** * **A. Indapamide:** This is a **Thiazide-like diuretic**. It acts on the Distal Convoluted Tubule (DCT) by inhibiting the Na+/Cl- symporter. Like all thiazides, it causes hypokalemia. * **B. Frusemide:** This is a potent **Loop diuretic** that inhibits the Na+/K+/2Cl- co-transporter in the Thick Ascending Limb of the Henle’s loop. It is known for causing significant potassium loss (hypokalemia). * **C. Mannitol:** This is an **Osmotic diuretic**. It works by increasing the osmolarity of the tubular fluid, primarily in the Proximal Convoluted Tubule and the descending limb of the Loop of Henle. **High-Yield Clinical Pearls for NEET-PG:** * **Classification:** Potassium-sparing diuretics are divided into **Aldosterone Antagonists** (Spironolactone, Eplerenone) and **Direct ENaC Blockers** (Amiloride, Triamterene). * **Side Effects:** Spironolactone can cause **gynecomastia** and impotence due to its non-specific anti-androgenic effects. **Eplerenone** is a more selective alternative with fewer hormonal side effects. * **Clinical Use:** Spironolactone is the drug of choice for **Primary Hyperaldosteronism (Conn’s Syndrome)** and is proven to reduce mortality in **Congestive Heart Failure (NYHA Class III/IV)**. * **Contraindication:** Avoid using these drugs with ACE inhibitors or ARBs as the combination significantly increases the risk of life-threatening **hyperkalemia**.

Question 73: High ceiling diuretics are useful in the treatment of all of the following conditions except:

A. Generalized edema
B. Cerebral edema
C. Acute pulmonary edema
D. Pulmonary hypertension (Correct Answer)

Explanation: **Explanation:** High-ceiling diuretics (Loop diuretics) like Furosemide act on the thick ascending limb of the Loop of Henle, inhibiting the **Na⁺-K⁺-2Cl⁻ symporter**. They are the most potent diuretics available, but their primary role is volume management rather than direct pulmonary arterial pressure control. **Why Pulmonary Hypertension is the correct answer:** Pulmonary Hypertension (PH) is a condition characterized by high blood pressure in the lung arteries due to structural changes (vasoconstriction, remodeling). The mainstay of treatment involves **vasodilators** (e.g., Sildenafil, Bosentan, Epoprostenol). While diuretics may be used adjunctively to manage right-sided heart failure symptoms, they do not treat the underlying pathology of PH. In fact, aggressive diuresis can decrease preload too much, leading to a drop in cardiac output in PH patients. **Why the other options are incorrect:** * **Generalized Edema:** Loop diuretics are the first-line treatment for systemic edema associated with Congestive Heart Failure (CHF), Nephrotic syndrome, and Liver cirrhosis due to their high efficacy. * **Cerebral Edema:** While Mannitol (Osmotic diuretic) is the drug of choice, high-ceiling diuretics are used as adjuncts to reduce intracranial pressure by decreasing CSF production and inducing systemic dehydration. * **Acute Pulmonary Edema:** Furosemide is the drug of choice. It works via two mechanisms: a rapid **venodilatory effect** (mediated by prostaglandins) which reduces venous return (preload) even before the diuresis begins, followed by profound diuresis. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Furosemide is the DOC for Acute Pulmonary Edema and Edema of CHF. * **Ototoxicity:** Ethacrynic acid is the most ototoxic loop diuretic; Furosemide is the most common cause. * **Metabolic Profile:** Loop diuretics cause **Hypokalemic Metabolic Alkalosis**, Hypocalcemia (unlike Thiazides), and Hyperuricemia. * **Prostaglandins:** The action of Loop diuretics is inhibited by **NSAIDs** because their efficacy partially depends on renal prostaglandin synthesis.

Question 74: Which of the following are potassium-sparing diuretics?

A. Spironolactone
B. Triamterene
C. Amiloride
D. All of the above (Correct Answer)

Explanation: **Explanation:** Potassium-sparing diuretics are a class of drugs that act on the **late distal tubule and collecting duct** of the nephron. Unlike loop or thiazide diuretics, they increase sodium excretion without causing a concomitant loss of potassium in the urine. The correct answer is **D (All of the above)** because these drugs represent the two distinct sub-classes of potassium-sparing diuretics: 1. **Aldosterone Antagonists (Spironolactone):** This drug competitively inhibits the Mineralocorticoid Receptor (MR). By blocking aldosterone, it prevents the synthesis of Na+/K+ ATPase pumps and ENaC channels, thereby reducing sodium reabsorption and potassium secretion. 2. **Renal Epithelial Sodium Channel (ENaC) Blockers (Amiloride and Triamterene):** These drugs directly block the ENaC channels on the luminal membrane of principal cells. By preventing sodium entry into the cell, they decrease the electrical gradient that normally drives potassium secretion into the tubular lumen. **Clinical Pearls for NEET-PG:** * **Site of Action:** Late distal tubule and cortical collecting duct. * **Primary Side Effect:** **Hyperkalemia** (especially when used with ACE inhibitors or in patients with renal impairment). * **Spironolactone Specifics:** It is a non-specific steroid antagonist and can cause **gynecomastia** and impotence in men due to its anti-androgenic effects. **Eplerenone** is a more selective alternative with fewer hormonal side effects. * **Liddle’s Syndrome:** Amiloride is the drug of choice for this rare genetic condition. * **Lithium-Induced Diabetes Insipidus:** Amiloride is used to block lithium entry through ENaC channels in the collecting duct.

Question 75: Which of the following is true about acetazolamide?

A. Increases sodium reabsorption and potassium secretion
B. Is a carbonic anhydrase inhibitor (Correct Answer)
C. Acts at the ascending limb of the loop of Henle
D. Increases aqueous outflow mainly

Explanation: **Explanation:** **Acetazolamide** is the prototype of **Carbonic Anhydrase Inhibitors (CAIs)**. It works by reversibly inhibiting the enzyme carbonic anhydrase (both cytoplasmic type II and membrane-bound type IV) in the **Proximal Convoluted Tubule (PCT)**. This inhibition prevents the dehydration of $H_2CO_3$ and the reabsorption of $NaHCO_3$, leading to alkaline diuresis. **Analysis of Options:** * **Option B (Correct):** Its primary mechanism is the inhibition of carbonic anhydrase, which reduces $H^+$ availability for the $Na^+/H^+$ exchanger, leading to increased excretion of sodium, potassium, and bicarbonate. * **Option A (Incorrect):** Acetazolamide **decreases** sodium reabsorption and **increases** potassium secretion (due to increased distal delivery of sodium). * **Option C (Incorrect):** It acts primarily at the **Proximal Convoluted Tubule (PCT)**, not the ascending limb of the loop of Henle (which is the site for Loop Diuretics like Furosemide). * **Option D (Incorrect):** In glaucoma, acetazolamide works by **decreasing the production** of aqueous humor (by inhibiting CA in the ciliary body), not by increasing its outflow. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Uses:** Glaucoma (decreases aqueous production), Acute Mountain Sickness (counteracts respiratory alkalosis), Urinary Alkalinization (to excrete acidic drugs like uric acid/cystine), and Periodic Paralysis. * **Adverse Effects:** Metabolic acidosis (Hyperchloremic), Hypokalemia, Paresthesia, and Renal stones (due to calcium phosphate precipitation in alkaline urine). * **Contraindication:** Avoid in Hepatic Cirrhosis, as it decreases ammonia excretion, potentially precipitating hepatic encephalopathy.

Question 76: Which diuretic is used in essential hypertension?

A. Hydrochlorothiazide (Correct Answer)
B. Amiloride
C. Furosemide
D. Acetazolamide

Explanation: **Explanation:** **1. Why Hydrochlorothiazide is Correct:** Thiazide diuretics, specifically **Hydrochlorothiazide (HCTZ)** and thiazide-like diuretics (Chlorthalidone), are the first-line agents for **essential hypertension** [2]. Their antihypertensive effect occurs in two phases: * **Short-term:** They reduce blood volume and cardiac output by inhibiting the $Na^+-Cl^-$ symporter in the distal convoluted tubule [3]. * **Long-term:** Their primary benefit in hypertension is a reduction in **Total Peripheral Resistance (TPR)** due to a gradual depletion of intracellular sodium in vascular smooth muscle, leading to vasodilation. **2. Why Other Options are Incorrect:** * **Amiloride:** This is a potassium-sparing diuretic. It has weak antihypertensive efficacy when used alone and is primarily used in combination with thiazides to counteract hypokalemia [4]. * **Furosemide:** As a loop diuretic, it is highly potent but has a short duration of action. It is preferred in **emergency hypertension**, heart failure, or hypertension complicated by **chronic kidney disease (CrCl <30 ml/min)**, but not for routine essential hypertension [4]. * **Acetazolamide:** A carbonic anhydrase inhibitor used mainly for glaucoma and mountain sickness. It is a very weak diuretic and is not used for blood pressure management. **3. NEET-PG High-Yield Pearls:** * **Chlorthalidone** is often preferred over HCTZ due to its longer half-life and better evidence in reducing cardiovascular events [3]. * **Metabolic Side Effects:** Thiazides can cause **"Hyper-GLUC"** (Hyperglycemia, Hyperlipidemia, Hyperuricemia, and Hypercalcemia) and **Hypokalemia** [1]. * Thiazides are ineffective if the GFR is less than 30 ml/min (except Metolazone) [1].

Question 77: Which of the following thiazide diuretics remains active even if the GFR is less than 30-40 mm Hg?

A. Metolazone (Correct Answer)
B. Benzthiazide
C. Chlorothiazide
D. Chlorthalidone

Explanation: ### Explanation **1. Why Metolazone is the Correct Answer:** Most thiazide and thiazide-like diuretics lose their efficacy when the **Glomerular Filtration Rate (GFR) falls below 30–40 mL/min**. This is because they reach their site of action (the Distal Convoluted Tubule) via tubular secretion; in renal failure, organic acid transporters are inhibited by accumulating endogenous acids. **Metolazone** (and to some extent Indapamide) is a unique "thiazide-like" diuretic that maintains its natriuretic effect even in advanced renal insufficiency (Stage 4/5 CKD). It is often used in combination with loop diuretics (e.g., Furosemide) to achieve **sequential nephron blockade**, overcoming diuretic resistance in refractory edema. **2. Why the Other Options are Incorrect:** * **Benzthiazide & Chlorothiazide:** These are classic thiazide diuretics. They are ineffective in patients with significant renal impairment (GFR <30 mL/min) and can further decrease RBF (Renal Blood Flow), potentially worsening azotemia. * **Chlorthalidone:** While it is highly potent and has a long half-life (40–60 hours), making it a preferred agent for essential hypertension, it generally loses effectiveness as a diuretic when renal function is severely compromised. **3. High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Early Distal Convoluted Tubule (DCT). * **Mechanism:** Inhibits the **Na⁺-Cl⁻ symporter**. * **Metabolic Profile:** Thiazides cause **"Hyper-GLUC"** (Hyperglycemia, Hyperlipidemia, Hyperuricemia, Hypercalcemia) and **Hypokalemic metabolic alkalosis**. * **DOC for Nephrogenic Diabetes Insipidus:** Thiazides (paradoxically reduce urine volume). * **Kidney Stones:** Thiazides are used to prevent calcium oxalate stones because they increase Ca²⁺ reabsorption (hypocalciuria).

Question 78: Which of the following is a false statement regarding thiazide diuretics?

A. Used in congestive heart failure
B. Causes hyperglycemia
C. Increases uric acid concentration in serum
D. Increases calcium excretion in urine (Correct Answer)

Explanation: ### Explanation The correct answer is **D (Increases calcium excretion in urine)** because this statement is false. Thiazide diuretics actually **decrease** calcium excretion (causing hypercalcemia and hypocalciuria). #### Why Option D is False (The Mechanism) Thiazides inhibit the **Na⁺-Cl⁻ symporter** in the Distal Convoluted Tubule (DCT). By blocking sodium entry, the intracellular concentration of Na⁺ drops. This enhances the activity of the basolateral **Na⁺/Ca²⁺ exchanger**, which pumps more Na⁺ into the cell and more Ca²⁺ into the blood. Consequently, more calcium is reabsorbed from the tubular lumen, leading to **hypocalciuria**. This makes thiazides useful in preventing calcium oxalate kidney stones. #### Analysis of Other Options * **A. Used in CHF:** True. Thiazides are used to manage edema in mild-to-moderate congestive heart failure, though Loop diuretics are preferred for acute or severe cases. * **B. Causes hyperglycemia:** True. Thiazides inhibit insulin release from the pancreas (due to K⁺ depletion) and decrease peripheral glucose utilization, potentially worsening diabetes. * **C. Increases uric acid:** True. Thiazides compete with uric acid for the organic acid secretory pump in the proximal tubule, leading to **hyperuricemia**, which can precipitate gout. #### NEET-PG High-Yield Pearls * **Mnemonic for Thiazide Side Effects (Hyper-GLUC):** **G**lycemia, **L**ipidemia (increased LDL/TG), **U**ricemia, and **C**alcemia. * **Electrolyte Profile:** Thiazides cause **Hypo**kalemia, **Hypo**natremia, **Hypo**magnesemia, but **Hyper**calcemia. * **Clinical Use:** They are the first-line antihypertensive for elderly and African-American patients. * **Paradoxical Use:** Thiazides are used to treat **Nephrogenic Diabetes Insipidus** because they induce mild volume depletion, triggering compensatory salt and water reabsorption in the proximal tubule.

Question 79: At equally natriuretic doses, which of the following drugs causes maximum potassium excretion?

A. Spironolactone
B. Furosemide
C. Acetazolamide (Correct Answer)
D. Aldosterone

Explanation: **Explanation:** The correct answer is **Acetazolamide**. **1. Why Acetazolamide is correct:** Acetazolamide is a Carbonic Anhydrase Inhibitor (CAI) that acts on the proximal convoluted tubule (PCT). It inhibits the reabsorption of sodium bicarbonate ($NaHCO_3$). This results in a large delivery of sodium and non-reabsorbable bicarbonate ions to the distal segments of the nephron. To compensate for the high sodium load, the distal tubule and collecting ducts exchange sodium for potassium. Furthermore, the presence of bicarbonate (a negative anion) in the distal tubule creates a negative luminal potential that further "pulls" $K^+$ out of the cells. Consequently, at doses that produce the same level of natriuresis as other diuretics, CAIs cause the **highest magnitude of potassium loss.** **2. Why the other options are incorrect:** * **Spironolactone:** This is a potassium-sparing diuretic. It antagonizes aldosterone receptors, leading to potassium retention rather than excretion. * **Furosemide:** While loop diuretics cause significant hypokalemia, their primary site of action is the Thick Ascending Limb. At *equally natriuretic doses*, the distal delivery of bicarbonate seen with CAIs makes Acetazolamide more potent at inducing kaliuresis. * **Aldosterone:** This is a mineralocorticoid, not a diuretic. While it increases $K^+$ excretion, it causes sodium *retention* (edema), making it the opposite of a natriuretic agent. **3. NEET-PG High-Yield Pearls:** * **Site of Action:** Acetazolamide (PCT), Furosemide (TAL of Loop of Henle), Thiazides (DCT). * **Metabolic Effect:** Acetazolamide causes **Hyperchloremic Metabolic Acidosis** (due to $HCO_3$ loss), whereas Loop and Thiazide diuretics cause **Metabolic Alkalosis**. * **Clinical Use:** Acetazolamide is the drug of choice for Glaucoma and Mountain Sickness, but it is a weak diuretic due to compensatory reabsorption in distal segments.

Question 80: Side effects of thiazides may include:

A. Hypokalemia
B. Hyperuricemia
C. Hyperglycemia
D. All of the above (Correct Answer)

Explanation: Thiazide diuretics (e.g., Hydrochlorothiazide, Chlorthalidone) act on the **Distal Convoluted Tubule (DCT)** by inhibiting the $Na^+/Cl^-$ symporter [1]. Their side effect profile is a high-yield topic for NEET-PG, often remembered by the mnemonic **"Hyper-GLUC"** (Hyper-Glycemia, Lipidemia, Uricemia, Calcemia). ### **Explanation of Options:** * **Hypokalemia (Option A):** By inhibiting sodium reabsorption in the DCT, more sodium is delivered to the collecting ducts. This triggers the aldosterone-sensitive $Na^+/K^+$ exchange, leading to increased potassium excretion in the urine. * **Hyperuricemia (Option B):** Thiazides compete with uric acid for the organic acid secretory secretory transport system in the proximal tubule [1]. This decreases uric acid excretion, potentially precipitating **Gout** [1]. * **Hyperglycemia (Option C):** Thiazides cause hypokalemia, which inhibits the release of insulin from pancreatic beta cells (as insulin release is K-dependent). They also decrease peripheral glucose utilization, worsening glycemic control in diabetics. ### **Why "All of the Above" is Correct:** Since thiazides concurrently cause potassium loss, elevate serum uric acid levels, and impair glucose tolerance, all three listed side effects are characteristic of this drug class. ### **High-Yield Clinical Pearls for NEET-PG:** 1. **Hypercalcemia:** Unlike Loop diuretics (which cause hypocalcemia), Thiazides **increase** calcium reabsorption [1][2]. This makes them useful in treating **Idiopathic Hypercalciuria** (kidney stones). 2. **Hyponatremia:** Thiazides are a common cause of drug-induced hyponatremia, especially in elderly patients. 3. **Lipid Profile:** They can cause a transient increase in LDL cholesterol and triglycerides (**Hyperlipidemia**). 4. **Erectile Dysfunction:** A frequently overlooked but common clinical side effect of thiazides.

Question 81: Which of the following is a potassium-sparing diuretic?

A. Amiloride
B. Triamterene
C. Spironolactone (Correct Answer)
D. Ethacrynic acid

Explanation: **Explanation:** **Correct Answer: C. Spironolactone** **Mechanism of Action:** Spironolactone is a competitive **aldosterone antagonist**. It acts on the mineralocorticoid receptors in the late distal tubule and collecting duct. By blocking aldosterone, it inhibits the synthesis of Na+/K+ ATPase pumps and sodium channels (ENaC). This results in the excretion of sodium and water while **retaining potassium**, making it a classic potassium-sparing diuretic. It is particularly useful in conditions of secondary hyperaldosteronism, such as hepatic cirrhosis with ascites and heart failure. **Analysis of Incorrect Options:** * **A & B (Amiloride and Triamterene):** While these are also potassium-sparing diuretics, they are **renal epithelial sodium channel (ENaC) blockers**. They do not antagonize aldosterone receptors directly. In many MCQ formats, if "Spironolactone" is an option alongside these, it is often favored as the prototype, though technically A and B are also K+-sparing. *Note: In this specific question context, Spironolactone is the most clinically significant representative.* * **D (Ethacrynic Acid):** This is a potent **Loop Diuretic** (similar to Furosemide). It inhibits the Na+/K+/2Cl- symporter in the thick ascending limb of Henle. It causes significant potassium loss (hypokalemia), not sparing. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** Spironolactone can cause **gynecomastia** and impotence in men due to its non-specific anti-androgenic effects. **Eplerenone** is a more selective aldosterone antagonist with fewer endocrine side effects. * **Drug of Choice:** Spironolactone is the drug of choice for **Conn’s Syndrome** (Primary Hyperaldosteronism) and edema associated with **Cirrhosis**. * **Liddle’s Syndrome:** Amiloride is the drug of choice for this rare genetic condition. * **Contraindication:** All K+-sparing diuretics are contraindicated in patients with chronic kidney disease (CKD) or those taking ACE inhibitors/ARBs due to the risk of life-threatening **hyperkalemia**.

Question 82: Spironolactone is least commonly used in which of the following conditions?

A. Congestive heart failure
B. Cirrhotic edema
C. Hypertension (Correct Answer)
D. Primary hyperaldosteronism

Explanation: The correct answer is **Hypertension**. While Spironolactone is a diuretic, it is considered a **weak diuretic** when used alone because it acts on the late distal tubule and collecting duct, where only about 2–3% of sodium reabsorption occurs [1]. In the management of essential hypertension, Thiazides or Calcium Channel Blockers are preferred as first-line agents. Spironolactone is typically reserved for resistant hypertension or specific cases where hyperaldosteronism is a contributing factor. **Why other options are incorrect:** * **Congestive Heart Failure (CHF):** Spironolactone is a cornerstone therapy (RALES trial). It prevents myocardial remodeling and fibrosis caused by aldosterone, significantly reducing mortality in patients with NYHA Class II-IV heart failure. * **Cirrhotic Edema:** It is the **drug of choice** for edema and ascites in liver cirrhosis. In cirrhosis, there is secondary hyperaldosteronism due to decreased hepatic clearance of aldosterone; Spironolactone directly antagonizes this effect [2]. * **Primary Hyperaldosteronism (Conn’s Syndrome):** It is used as the primary medical treatment to block the effects of excessive aldosterone secretion [1, 3], especially in patients who are not candidates for surgery. **NEET-PG High-Yield Pearls:** * **Mechanism:** Competitive antagonist at the Mineralocorticoid Receptor (MR) in the cortical collecting duct [1, 2, 3]. * **Side Effects:** Hyperkalemia (most common) [1, 3] and **Gynecomastia** (due to non-specific binding to androgen and progesterone receptors) [2]. * **Eplerenone:** A more selective mineralocorticoid antagonist with fewer endocrine side effects (no gynecomastia) [2]. * **Contraindication:** Should not be used if serum potassium is >5.0 mEq/L or in severe renal impairment (CrCl <30 mL/min) [1, 3].

Question 83: High ceiling diuretics are useful in the treatment of all of the following conditions except?

A. Generalized edema
B. Cerebral edema
C. Acute pulmonary edema
D. Pulmonary hypertension (Correct Answer)

Explanation: **Explanation:** High-ceiling diuretics (Loop diuretics like Furosemide) act on the thick ascending limb of the Henle’s loop by inhibiting the **Na⁺-K⁺-2Cl⁻ symporter**. They are the most potent diuretics, capable of excreting up to 25% of filtered sodium. **Why Pulmonary Hypertension is the Correct Answer:** Pulmonary hypertension is primarily a vascular remodeling and vasoconstrictive disease. While diuretics may be used cautiously in associated right-sided heart failure to reduce congestion, they are **not** a primary treatment for pulmonary hypertension itself. The mainstay of treatment involves vasodilators (e.g., Sildenafil, Bosentan, Epoprostenol). In fact, aggressive diuresis can decrease preload too much, leading to a drop in cardiac output in these patients. **Analysis of Other Options:** * **Generalized Edema:** Loop diuretics are the first-line treatment for edema associated with Congestive Heart Failure (CHF), Nephrotic syndrome, and Liver cirrhosis due to their high efficacy. * **Cerebral Edema:** While Mannitol (Osmotic diuretic) is the drug of choice, high-dose loop diuretics are used as adjuncts to reduce intracranial pressure by decreasing CSF formation and inducing systemic dehydration. * **Acute Pulmonary Edema:** Furosemide is the **drug of choice**. It works via two mechanisms: a rapid **venodilatory effect** (mediated by prostaglandins) that reduces preload within minutes, followed by the slower diuretic effect. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Furosemide is the DOC for Acute Pulmonary Edema and Hypercalcemia (with saline). * **Ototoxicity:** Ethacrynic acid is the most ototoxic; Furosemide is the most common cause of drug-induced deafness among diuretics. * **Metabolic Profile:** They cause "Hypo-everything" (Hypokalemia, Hyponatremia, Hypomagnesemia, Hypocalcemia) **except** Hyperuricemia and Hyperglycemia.

Question 84: Furosemide acts on which part of the nephron?

A. Ascending limb of the loop of Henle (Correct Answer)
B. Proximal convoluted tubule
C. Distal convoluted tubule
D. Collecting duct

Explanation: **Explanation:** **1. Why Option A is Correct:** Furosemide is a potent **Loop Diuretic**. Its primary site of action is the **Thick Ascending Limb (TAL)** of the Loop of Henle. It works by inhibiting the **Na⁺-K⁺-2Cl⁻ symporter (NKCC2)** on the luminal membrane. By blocking this transporter, it prevents the reabsorption of sodium, potassium, and chloride, leading to significant diuresis. Because the TAL is responsible for reabsorbing approximately 25% of filtered sodium, loop diuretics are the most efficacious diuretics available ("High-ceiling diuretics"). **2. Why Other Options are Incorrect:** * **B. Proximal Convoluted Tubule (PCT):** This is the site of action for **Acetazolamide** (Carbonic anhydrase inhibitors) and SGLT2 inhibitors. * **C. Distal Convoluted Tubule (DCT):** This is the site of action for **Thiazide diuretics**, which inhibit the Na⁺-Cl⁻ symporter. * **D. Collecting Duct:** This is the site of action for **Potassium-sparing diuretics** (e.g., Spironolactone, Amiloride) and Antidiuretic Hormone (ADH) antagonists. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Besides inhibiting NKCC2, loop diuretics abolish the hypertonicity of the renal medulla, impairing the kidney's ability to concentrate urine. * **Electrolyte Changes:** They cause **Hypokalemia**, **Hypomagnesemia**, and notably **Hypocalcemia** (unlike Thiazides, which cause hypercalcemia). "Loops lose calcium." * **Ototoxicity:** Furosemide can cause dose-dependent hearing loss, especially when combined with aminoglycosides. * **Drug of Choice:** Acute Pulmonary Edema due to its rapid onset and systemic vasodilatory effect (mediated by prostaglandins).

Question 85: Which of the following is the drug of choice for the treatment of inappropriate anti-diuretic hormone secretion?

A. Furosemide
B. Hydrochlorothiazide
C. Spironolactone
D. Demeclocycline (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Demeclocycline** **Mechanism and Rationale:** Syndrome of Inappropriate Antidiuretic Hormone (SIADH) is characterized by excessive ADH release, leading to water retention and dilutional hyponatremia. **Demeclocycline**, a tetracycline derivative, is the drug of choice for chronic SIADH because it acts as an **ADH antagonist** at the level of the collecting duct. It induces a state of "nephrogenic diabetes insipidus" by interfering with the intracellular signaling (cAMP) triggered by ADH, thereby promoting the excretion of free water. **Analysis of Incorrect Options:** * **A. Furosemide:** While loop diuretics can be used in acute, symptomatic SIADH to increase free water clearance (usually alongside hypertonic saline), they are not the primary long-term treatment of choice. * **B. Hydrochlorothiazide:** Thiazides are contraindicated in SIADH. They inhibit sodium reabsorption in the distal tubule and can actually **worsen hyponatremia** by increasing ADH sensitivity and causing volume depletion-induced ADH release. * **C. Spironolactone:** This is a potassium-sparing diuretic (aldosterone antagonist) used primarily in hyperaldosteronism or heart failure; it has no role in antagonizing ADH. **High-Yield Clinical Pearls for NEET-PG:** * **Vaptans:** Tolvaptan (oral) and Conivaptan (IV) are "selective V2 receptor antagonists" and are now frequently preferred over demeclocycline for SIADH due to a better side-effect profile. * **Side Effect:** A major side effect of Demeclocycline is **nephrotoxicity** and photosensitivity. * **Correction Rate:** In SIADH, avoid rapid correction of hyponatremia to prevent **Osmotic Demyelination Syndrome** (Central Pontine Myelinolysis). Rule of thumb: <10–12 mEq/L in 24 hours. * **First-line treatment:** For mild/asymptomatic SIADH, the initial step is always **fluid restriction**.

Question 86: All of the following diuretics inhibit the Na+.K+.2Cl- symporter, EXCEPT:

A. Thiazide (Correct Answer)
B. Furosemide
C. Ethacrynic acid
D. Mersalyl

Explanation: ### Explanation The question asks to identify the diuretic that does **not** inhibit the **Na⁺-K⁺-2Cl⁻ symporter** (NKCC2). This symporter is the primary target of **Loop Diuretics**, which act on the thick ascending limb (TAL) of the Henle’s loop. **1. Why Thiazide is the Correct Answer:** Thiazides (e.g., Hydrochlorothiazide, Chlorthalidone) act on the **Distal Convoluted Tubule (DCT)**. Their mechanism of action involves inhibiting the **Na⁺-Cl⁻ symporter** (NCC), not the Na⁺-K⁺-2Cl⁻ symporter. Because they act downstream of the loop of Henle where less sodium is reabsorbed, they are generally less potent than loop diuretics. **2. Analysis of Incorrect Options (Loop Diuretics):** * **Furosemide:** A prototype high-ceiling loop diuretic that sulfonamide-based; it directly inhibits the NKCC2 symporter. * **Ethacrynic Acid:** A phenoxyacetic acid derivative. It is a non-sulfonamide loop diuretic that also inhibits NKCC2. It is typically reserved for patients with sulfa allergies. * **Mersalyl:** An older organomercurial diuretic. Although rarely used today due to toxicity, it historically functioned by inhibiting the Na⁺-K⁺-2Cl⁻ transport system in the TAL. **3. NEET-PG High-Yield Clinical Pearls:** * **Site of Action:** Loop diuretics act on the **Thick Ascending Limb (TAL)**; Thiazides act on the **Early DCT**. * **Calcium Dynamics:** Loop diuretics cause **Hypercalciuria** (used in treating hypercalcemia), whereas Thiazides cause **Hypocalciuria** (used in treating calcium nephrolithiasis). * **Ototoxicity:** Ethacrynic acid is the most ototoxic loop diuretic, while Bumetanide is the least. * **Metabolic Side Effects:** Both classes can cause hypokalemia and hyperuricemia, but Thiazides are specifically associated with **hyperglycemia** and **hyperlipidemia**.

Question 87: Hypercalcemia is seen in all of the following conditions except:

A. Lithium
B. Multiple myeloma
C. Loop diuretics (Correct Answer)
D. Hypervitaminosis D

Explanation: **Explanation:** The correct answer is **Loop diuretics** because they are the only option listed that causes **hypocalcemia** (decreased calcium levels) rather than hypercalcemia. **1. Why Loop Diuretics (Option C) is correct:** Loop diuretics (e.g., Furosemide) inhibit the **Na+/K+/2Cl- symporter** in the Thick Ascending Limb (TAL) of the Loop of Henle. This inhibition abolishes the positive transepithelial potential (lumen-positive voltage) that normally drives the paracellular reabsorption of divalent cations like **Calcium (Ca2+)** and **Magnesium (Mg2+)**. Consequently, calcium is excreted in the urine (hypercalciuria), leading to a decrease in serum calcium levels. **2. Why the other options are incorrect:** * **Lithium (Option A):** Lithium can cause hypercalcemia by increasing the set-point of the Calcium-Sensing Receptor (CaSR) in the parathyroid gland, leading to inappropriately high PTH secretion (Lithium-induced hyperparathyroidism). * **Multiple Myeloma (Option B):** This malignancy causes extensive bone resorption through the activation of osteoclasts by cytokines (RANKL, IL-6), leading to significant hypercalcemia. * **Hypervitaminosis D (Option D):** Vitamin D increases intestinal absorption of calcium and phosphate, as well as bone resorption, directly leading to elevated serum calcium levels. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** "Loop diuretics **Lose** calcium; Thiazides **Throw** it back into the blood." * **Thiazide Diuretics:** These cause **hypercalcemia** and are used in the management of idiopathic hypercalciuria to prevent calcium stones. * **Loop Diuretics:** These are used in the emergency management of **acute hypercalcemia** (along with aggressive saline hydration). * **Other causes of hypercalcemia:** Hyperparathyroidism (most common cause), Sarcoidosis (due to extra-renal 1-alpha hydroxylase activity), and Milk-Alkali Syndrome.

Question 88: Loop diuretics act by which of the following mechanisms?

A. Inhibition of Na+-Cl- Symport
B. Inhibition of Na+-K+-2 Cl- cotransport (Correct Answer)
C. Inhibition of Na+-K+ ATPase
D. Inhibition of H+-K+ ATPase

Explanation: **Explanation:** **Correct Option: B. Inhibition of Na+-K+-2 Cl- cotransport** Loop diuretics (e.g., Furosemide, Torsemide, Bumetanide) exert their primary effect by inhibiting the **Na+-K+-2Cl- (NKCC2) symporter** located in the luminal membrane of the **Thick Ascending Limb (TAL)** of the Loop of Henle. By blocking this transporter, these drugs prevent the reabsorption of sodium, potassium, and chloride. This leads to a significant increase in the excretion of these ions and water, making them the most potent diuretics ("High-ceiling" diuretics). **Analysis of Incorrect Options:** * **Option A (Na+-Cl- Symport):** This is the mechanism of action for **Thiazide diuretics**, which act on the Distal Convoluted Tubule (DCT). * **Option C (Na+-K+ ATPase):** This enzyme is located on the basolateral membrane of most renal cells. While it provides the energy gradient for transport, it is the primary target of **Cardiac Glycosides (Digoxin)**, not diuretics. * **Option D (H+-K+ ATPase):** This is the "proton pump" found in the gastric parietal cells. It is inhibited by **Proton Pump Inhibitors (PPIs)** like Omeprazole. **High-Yield Clinical Pearls for NEET-PG:** 1. **Site of Action:** Thick Ascending Limb (TAL) of the Loop of Henle. 2. **Electrolyte Changes:** Loop diuretics cause **Hypokalemia, Hypomagnesemia, and Hypocalcemia** (unlike Thiazides, which cause Hypercalcemia). 3. **Ototoxicity:** Ethacrynic acid is the most ototoxic, while Bumetanide is the least. 4. **Drug of Choice:** Furosemide is the drug of choice for **Acute Pulmonary Edema** due to its rapid action and additional venodilatory effect. 5. **Metabolic Effect:** They can cause **Hypokalemic Metabolic Alkalosis** and Hyperuricemia (precipitating Gout).

Question 89: A new diuretic is being studied in human volunteers. Compared with placebo, the new drug increases urine volume, decreases urinary Ca2+, increases body pH, and decreases serum K+. If this new drug has a similar mechanism of action to an established diuretic, it probably what?

A. Blocks the NaCl cotransporter in the distal convoluted tubule. (Correct Answer)
B. Blocks aldosterone receptors in the collecting tubule.
C. Inhibits carbonic anhydrase in the proximal convoluted tubule.
D. Inhibits the Na/K/2Cl cotransporter in the thick ascending limb.

Explanation: ### Explanation The drug described exhibits the classic profile of a **Thiazide diuretic**. **1. Why Option A is Correct:** Thiazides block the **Na+/Cl- cotransporter** in the **distal convoluted tubule (DCT)**. * **Urine Volume:** Increased due to inhibition of Na+ reabsorption. * **Urinary Ca2+:** Decreased (Hypocalciuria). Thiazides enhance Ca2+ reabsorption in the DCT, making them useful in preventing calcium oxalate stones. * **Body pH:** Increases (Metabolic Alkalosis). Increased Na+ delivery to the collecting duct promotes H+ and K+ secretion. * **Serum K+:** Decreased (Hypokalemia). Increased flow and Na+ delivery to the late distal tubule/collecting duct stimulate K+ excretion. **2. Why the Other Options are Incorrect:** * **Option B (Aldosterone Antagonists):** These are "potassium-sparing." They would **increase** serum K+ and **decrease** body pH (causing metabolic acidosis), which contradicts the question. * **Option C (Carbonic Anhydrase Inhibitors):** These cause **metabolic acidosis** (decreased pH) due to bicarbonate loss in the urine, whereas the drug in the question increases pH. * **Option D (Loop Diuretics):** While they cause hypokalemia and alkalosis, they **increase** urinary Ca2+ ("Loops lose calcium"). The drug in the question decreases urinary Ca2+. **3. NEET-PG High-Yield Pearls:** * **Thiazide Mnemonic:** "Thiazides treat Stones (hypercalciuria) but cause Bones (hypercalcemia)." * **Metabolic Profile:** Thiazides cause **"Hyper-GLUC"** (Hyperglycemia, Hyperlipidemia, Hyperuricemia, and Hypercalcemia). * **Drug of Choice:** Thiazides are often preferred for hypertension in patients with concomitant osteoporosis due to their calcium-sparing effect.

Question 90: On which part of the nephron do loop diuretics act?

A. Descending limb
B. Thick ascending limb (Correct Answer)
C. Cortical segment
D. Collecting duct

Explanation: **Explanation:** **Mechanism of Action (The Correct Answer):** Loop diuretics (e.g., Furosemide, Torsemide, Bumetanide) primarily act on the **Thick Ascending Limb (TAL)** of the Loop of Henle [1, 2]. They work by inhibiting the **Na⁺-K⁺-2Cl⁻ symporter (NKCC2)** on the luminal membrane [1, 2]. By blocking this transporter, they prevent the reabsorption of sodium, potassium, and chloride, leading to potent natriuresis and diuresis [1]. Because the TAL is responsible for reabsorbing approximately 25% of filtered sodium, these are the most efficacious diuretics ("High-ceiling diuretics") [2]. **Analysis of Incorrect Options:** * **A. Descending limb:** This segment is highly permeable to water but impermeable to solutes. No major diuretics act here. * **C. Cortical segment:** This usually refers to the Distal Convoluted Tubule (DCT), which is the site of action for **Thiazide diuretics** (inhibiting the Na⁺-Cl⁻ symporter). * **D. Collecting duct:** This is the site of action for **Potassium-sparing diuretics** (e.g., Spironolactone, Amiloride) and ADH antagonists (Vaptans). **High-Yield Clinical Pearls for NEET-PG:** * **Abolition of Corticomedullary Gradient:** By inhibiting solute reabsorption in the TAL, loop diuretics interfere with the kidney's ability to concentrate urine. * **Calcium Excretion:** Unlike Thiazides (which cause hypercalcemia), loop diuretics cause **hypocalcemia** ("Loops lose Calcium"). They are used in the emergency management of hypercalcemia. * **Ototoxicity:** This is a unique side effect of loop diuretics (especially Ethacrynic acid) due to the presence of the NKCC transporter in the stria vascularis of the inner ear. * **Drug of Choice:** Furosemide is the drug of choice for acute pulmonary edema due to its rapid action and additional venodilatory effect.

Question 91: Which of the following is a potassium sparing drug?

A. Indapamide
B. Frusemide
C. Spironolactone (Correct Answer)
D. Mannitol

Explanation: ### Explanation **Correct Answer: C. Spironolactone** **Mechanism of Action:** Spironolactone is a **Potassium-Sparing Diuretic**. It acts as a competitive antagonist to **Aldosterone** at the Mineralocorticoid Receptors (MR) in the late distal tubule and collecting duct. By blocking aldosterone, it inhibits the synthesis of Na+/K+ ATPase pumps and ENaC (Epithelial Sodium Channels). This results in the excretion of sodium and water while **retaining potassium and hydrogen ions**, making it effective in preventing hypokalemia. **Analysis of Incorrect Options:** * **A. Indapamide:** This is a **Thiazide-like diuretic**. It acts on the distal convoluted tubule (DCT) by inhibiting the Na+-Cl- symporter. Like all thiazides, it causes potassium loss (hypokalemia). * **B. Frusemide (Furosemide):** This is a potent **Loop diuretic**. It inhibits the Na+-K+-2Cl- cotransporter in the Thick Ascending Limb of the Loop of Henle. It causes significant potassium excretion and is a common cause of hypokalemia. * **C. Mannitol:** This is an **Osmotic diuretic**. It works by increasing the osmolarity of glomerular filtrate, mainly in the Proximal Convoluted Tubule and Descending limb of Henle, primarily used to reduce intracranial or intraocular pressure. **High-Yield Clinical Pearls for NEET-PG:** 1. **Classification:** Potassium-sparing diuretics are divided into **Aldosterone Antagonists** (Spironolactone, Eplerenone) and **Direct ENaC Blockers** (Amiloride, Triamterene). 2. **Side Effects:** Spironolactone can cause **gynecomastia** and impotence in men due to its non-specific anti-androgenic effects. Eplerenone is more selective and lacks these side effects. 3. **Clinical Use:** Spironolactone is the drug of choice for **Ascites in Cirrhosis** and is used to improve survival in **Congestive Heart Failure (NYHA Class III/IV)**. 4. **Contraindication:** Avoid in patients with chronic kidney disease (CKD) or those on ACE inhibitors/ARBs due to the high risk of **life-threatening hyperkalemia**.

Question 92: Mannitol when given intravenously causes which of the following changes?

A. Decrease in blood viscosity (Correct Answer)
B. Increase in blood viscosity
C. Increase in GFR
D. Increase in ICT

Explanation: **Explanation:** Mannitol is an osmotic diuretic that remains confined to the extracellular compartment. When administered intravenously, it creates an osmotic gradient that draws water from the intracellular space into the vascular compartment. **1. Why Option A is Correct:** The rapid shift of water from cells into the bloodstream leads to **hemodilution**. This expansion of plasma volume decreases the hematocrit and reduces the overall **blood viscosity**. This reduction in viscosity is clinically significant as it improves microcirculatory blood flow, particularly in the brain, which is one of the mechanisms by which mannitol reduces intracranial pressure (ICP). **2. Why the other options are incorrect:** * **Option B:** Mannitol decreases viscosity via hemodilution; it does not increase it. * **Option C:** While mannitol can increase renal blood flow, it does not consistently increase the **Glomerular Filtration Rate (GFR)**. In fact, its primary site of action is the Loop of Henle and the proximal tubule, where it limits water reabsorption. * **Option D:** Mannitol is used to **decrease** Intracranial Tension (ICT) and Intraocular Pressure (IOP) by drawing fluid out of the brain parenchyma and vitreous humor into the blood. It does not increase ICT. **High-Yield NEET-PG Pearls:** * **Mechanism:** Osmotic effect in the proximal tubule and descending limb of the Loop of Henle. * **Contraindications:** Acute Pulmonary Edema and Congestive Heart Failure (due to the initial rapid expansion of extracellular fluid volume) and Anuria. * **Clinical Uses:** Cerebral edema (to lower ICT), acute congestive glaucoma (to lower IOP), and prevention of cisplatin-induced nephrotoxicity. * **Side Effect:** Acute expansion of ECF can lead to "dialysis disequilibrium" or pulmonary congestion.

Question 93: Acetazolamide is administered to a glaucoma patient. Given that this drug inhibits carbonic anhydrase in the renal proximal tubule, which of the following substances will be excreted at a lower rate?

A. Na+
B. H2O
C. HCO3-
D. NH4+ (Correct Answer)

Explanation: **Explanation:** **Mechanism of Action & The Correct Answer (NH4+):** Acetazolamide is a Carbonic Anhydrase (CA) inhibitor. In the proximal convoluted tubule (PCT), CA is essential for the reabsorption of bicarbonate ($HCO_3^-$) and the secretion of Hydrogen ions ($H^+$). By inhibiting CA, the drug reduces the availability of $H^+$ ions in the tubular lumen. Ammonia ($NH_3$) is produced by tubular cells and diffuses into the lumen, where it normally combines with secreted $H^+$ to form Ammonium ($NH_4^+$). This process, known as **"Ammonia Trapping,"** renders the molecule non-diffusible, ensuring its excretion. Since Acetazolamide decreases $H^+$ secretion, $NH_3$ cannot be converted to $NH_4^+$. Consequently, $NH_4^+$ formation decreases, and $NH_3$ diffuses back into the systemic circulation. Therefore, the **excretion rate of $NH_4^+$ decreases.** **Why Other Options are Incorrect:** * **A & B (Na+ and H2O):** Inhibition of CA prevents $NaHCO_3$ reabsorption. This leads to increased luminal osmolarity, causing **Natriuresis** (increased $Na^+$ excretion) and **Diuresis** (increased $H_2O$ excretion). * **C (HCO3-):** The primary effect of Acetazolamide is the inhibition of $HCO_3^-$ reabsorption, leading to significant **Bicarbonaturia** (increased $HCO_3^-$ excretion) and subsequent hyperchloremic metabolic acidosis. **High-Yield NEET-PG Pearls:** * **Clinical Uses:** Glaucoma (decreases aqueous humor), Mountain Sickness (induces metabolic acidosis to stimulate respiration), and Urinary Alkalinization (to excrete acidic drugs like uric acid). * **Side Effects:** Hypokalemia, Metabolic Acidosis, and **Hyperammonemia** (contraindicated in Liver Cirrhosis as it can precipitate hepatic encephalopathy due to decreased $NH_4^+$ excretion). * **Site of Action:** Proximal Convoluted Tubule (PCT).

Question 94: Glycerol is an?

A. Osmotic diuretic (Correct Answer)
B. Purgative
C. Antidiabetic
D. Antiemetic

Explanation: Glycerol is a low-molecular-weight, pharmacologically inert substance that acts as an Osmotic Diuretic [1]. 1. Why Option A is Correct: Glycerol increases the osmolarity of the plasma and tubular fluid [1]. When administered, it remains in the extracellular compartment and draws water out of the cells (including the brain and eyes) into the bloodstream via osmosis. In the kidneys, it is filtered by the glomerulus but poorly reabsorbed, creating an osmotic gradient that limits water reabsorption in the proximal tubule and descending limb of the Loop of Henle, thereby increasing urine output [1]. 2. Why Other Options are Incorrect: Purgative: While some alcohols (like sorbitol) have laxative effects, glycerol is primarily used for its osmotic properties in systemic circulation or as a suppository for local lubrication, not as a standard oral purgative. Antidiabetic: Glycerol is actually a precursor for gluconeogenesis; it can potentially increase blood glucose levels, making it contraindicated or used with caution in diabetic patients. Antiemetic: Glycerol has no action on the chemoreceptor trigger zone (CTZ) or the vomiting center. High-Yield Clinical Pearls for NEET-PG: Primary Uses: Glycerol is used orally to acutely reduce Intraocular Pressure (IOP) in glaucoma and Intracranial Pressure (ICP) in cerebral edema. Comparison with Mannitol: Unlike Mannitol (which must be given IV), Glycerol is effective orally [1]. However, it provides significant calories (4.3 kcal/g), which can lead to hyperglycemia. Side Effects: Watch for nausea, headache, and dehydration. Other Osmotic Diuretics: Mannitol (prototype), Isosorbide, and Urea.

Question 95: A 68-year-old woman presents for a routine check-up with occasional ankle swelling. Her serum potassium is 3.5 mEq/L. Which of the following diuretics would be most appropriate for this patient, considering the need to avoid unnecessary potassium losses?

A. Furosemide
B. Hydrochlorothiazide
C. Spironolactone
D. Amiloride (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Amiloride** **1. Why Amiloride is the Correct Choice:** The patient has a serum potassium level of 3.5 mEq/L, which is at the lower limit of normal (3.5–5.0 mEq/L). To manage her edema without causing further hypokalemia, a **Potassium-Sparing Diuretic** is indicated. Amiloride works by directly blocking the **Epithelial Sodium Channels (ENaC)** in the late distal tubule and collecting duct. By preventing sodium reabsorption at this site, it reduces the negative luminal potential, thereby inhibiting the secretion of potassium into the urine. Unlike other diuretics, it preserves serum potassium levels. **2. Why the Other Options are Incorrect:** * **A. Furosemide:** A loop diuretic that inhibits the Na⁺-K⁺-2Cl⁻ symporter in the thick ascending limb. It causes significant potassium loss (hypokalemia) due to increased sodium delivery to the distal tubule and activation of the RAAS. * **B. Hydrochlorothiazide:** A thiazide diuretic that inhibits the Na⁺-Cl⁻ symporter in the distal convoluted tubule. Like loop diuretics, it is "potassium-wasting" and would likely push this patient into clinical hypokalemia. * **C. Spironolactone:** While also potassium-sparing, it is an **Aldosterone Antagonist**. It has a slow onset of action (taking days to work) and carries side effects like gynecomastia due to its non-specific binding to androgen receptors. Amiloride is often preferred when a direct ENaC blockade is sufficient. **3. NEET-PG High-Yield Pearls:** * **Liddle’s Syndrome:** Amiloride is the drug of choice for this rare genetic condition (overactive ENaC channels). * **Lithium-Induced Diabetes Insipidus:** Amiloride is the treatment of choice as it blocks lithium entry through ENaC in the collecting ducts. * **Site of Action:** Remember that potassium-sparing diuretics are the only class that acts on the **Collecting Duct**. * **Side Effect:** The most serious complication of this class is **hyperkalemia**, especially if used with ACE inhibitors or in patients with renal impairment.

Question 96: Which of the following is an adverse effect of thiazide diuretics?

A. Hyperkalemic metabolic acidosis
B. Hypolipidemia
C. Hypouricemia
D. Erectile dysfunction (Correct Answer)

Explanation: **Explanation:** Thiazide diuretics (e.g., Hydrochlorothiazide, Chlorthalidone) are a cornerstone of hypertension management, but they are associated with several metabolic and systemic side effects. **Why Erectile Dysfunction is Correct:** Erectile dysfunction (ED) is a well-documented, though often under-reported, adverse effect of thiazide diuretics. The exact mechanism is multifactorial; it is thought to be caused by a decrease in total peripheral resistance and a reduction in zinc levels (which are necessary for testosterone production), as well as direct effects on vascular smooth muscle. In clinical trials, thiazides are more frequently associated with ED compared to ACE inhibitors or Calcium Channel Blockers. **Analysis of Incorrect Options:** * **A. Hyperkalemic metabolic acidosis:** Thiazides cause **Hypokalemic metabolic alkalosis**. They increase sodium delivery to the distal tubule, promoting K+ and H+ secretion into the urine. * **B. Hypolipidemia:** Thiazides actually cause **Hyperlipidemia**. They can lead to a transient increase in total cholesterol, LDL, and triglycerides. * **C. Hypouricemia:** Thiazides cause **Hyperuricemia**. They compete with uric acid for the organic acid secretory secretory pump in the proximal tubule, leading to uric acid retention, which can precipitate gout. **NEET-PG High-Yield Pearls:** * **The "Hyper" Rule:** Thiazides cause **Hyper**glycemia, **Hyper**lipidemia, **Hyper**uricemia, and **Hyper**calcemia (useful in preventing calcium stones). * **The "Hypo" Rule:** They cause **Hypo**kalemia, **Hypo**natremia, and **Hypo**magnesemia. * **Chlorthalidone** is currently preferred over Hydrochlorothiazide due to its longer half-life and better evidence in reducing cardiovascular events.

Question 97: Which of the following is NOT caused by thiazide diuretics?

A. Hypercalcemia
B. Hypomagnesemia
C. Hyperkalemia (Correct Answer)
D. Hyperuricemia

Explanation: Thiazide diuretics (e.g., Hydrochlorothiazide, Chlorthalidone) act on the **Distal Convoluted Tubule (DCT)** by inhibiting the $Na^+/Cl^-$ symporter. **Why Hyperkalemia is the Correct Answer:** Thiazides cause **Hypokalemia**, not hyperkalemia. By inhibiting sodium reabsorption in the DCT, they increase the delivery of $Na^+$ to the collecting ducts. The aldosterone-sensitive principal cells then reabsorb this $Na^+$ in exchange for $K^+$ and $H^+$ ions, leading to increased urinary excretion of potassium. This results in hypokalemic metabolic alkalosis. **Analysis of Incorrect Options:** * **Hypercalcemia (A):** Thiazides increase calcium reabsorption in the DCT (via the $Na^+/Ca^{2+}$ exchanger). This makes them useful in treating idiopathic hypercalciuria and calcium stones. * **Hypomagnesemia (B):** Long-term use of thiazides leads to increased magnesium excretion, though the exact mechanism is less clear than with loop diuretics. * **Hyperuricemia (D):** Thiazides compete with uric acid for the organic acid secretory secretory system in the proximal tubule, leading to decreased uric acid excretion. This can precipitate acute gouty arthritis. **NEET-PG High-Yield Pearls:** * **Mnemonic for Thiazide Side Effects:** "Hyper **GLUC**" — Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia, and Hyper**C**alcemia. * **Drug of Choice:** Chlorthalidone is often preferred over Hydrochlorothiazide due to its longer half-life and better evidence in reducing CV events. * **Paradoxical Use:** Thiazides are used to treat **Nephrogenic Diabetes Insipidus** because they cause mild volume depletion, which triggers compensatory salt and water reabsorption in the proximal tubule.

Question 98: Which of the following inhibits the Na+-K+-2Cl- cotransporter?

A. Mannitol
B. Carbonic anhydrase inhibitor
C. Thiazide
D. Loop diuretic (Correct Answer)

Explanation: **Explanation:** **Correct Option: D (Loop Diuretics)** Loop diuretics (e.g., Furosemide, Torsemide, Bumetanide) exert their primary effect on the **Thick Ascending Limb (TAL)** of the Loop of Henle [4]. They act by inhibiting the **Na+-K+-2Cl- symporter (NKCC2)** on the apical membrane [1]. By blocking this transporter, they prevent the reabsorption of sodium, potassium, and chloride, leading to potent natriuresis [5]. Because the TAL is responsible for reabsorbing ~25% of filtered sodium, these are the most efficacious diuretics ("High-ceiling diuretics"). **Incorrect Options:** * **A. Mannitol:** This is an **Osmotic Diuretic**. It works primarily in the Proximal Convoluted Tubule (PCT) and the Descending Limb of the Loop of Henle by increasing the osmolarity of the tubular fluid, thereby retaining water in the lumen [3]. * **B. Carbonic Anhydrase Inhibitors (e.g., Acetazolamide):** These act in the **PCT** by inhibiting the enzyme carbonic anhydrase, which prevents the reabsorption of sodium bicarbonate ($NaHCO_3$) [2]. * **C. Thiazides:** These act on the **Distal Convoluted Tubule (DCT)** by inhibiting the **Na+-Cl- symporter**. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Loop diuretics act on the TAL; Thiazides act on the DCT. * **Calcium Dynamics:** Loop diuretics **increase** urinary calcium excretion ("Loops Lose Calcium"), making them useful in treating hypercalcemia [5]. Conversely, Thiazides **decrease** urinary calcium (useful in idiopathic hypercalciuria/stones). * **Ototoxicity:** This is a unique side effect of loop diuretics (especially Ethacrynic acid) due to the presence of NKCC transporters in the inner ear. * **Drug of Choice:** Loop diuretics are the preferred agents for acute pulmonary edema and congestive heart failure.

Question 99: What is the most potent diuretic among the following?

A. Bumetanide (Correct Answer)
B. Furosemide
C. Torsemide
D. Ethacrynic acid

Explanation: ### Explanation **Correct Answer: A. Bumetanide** **Why Bumetanide is the correct answer:** Bumetanide is a loop diuretic that acts on the **Na⁺-K⁺-2Cl⁻ symporter** in the thick ascending limb of the Henle's loop [2]. In terms of **potency** (the dose required to achieve a specific effect), Bumetanide is the most potent loop diuretic available [1]. It is approximately **40 times more potent** than Furosemide. For clinical context, 1 mg of Bumetanide is roughly equivalent to 40 mg of Furosemide [1]. **Analysis of Incorrect Options:** * **B. Furosemide:** While it is the most commonly used "prototype" loop diuretic, it is significantly less potent than Bumetanide and Torsemide [1]. It also has variable oral bioavailability (40–70%). * **C. Torsemide:** This is more potent than Furosemide (10–20 mg of Torsemide equals 40 mg of Furosemide) and has a longer duration of action, but it remains less potent than Bumetanide [1]. * **D. Ethacrynic Acid:** This is a non-sulfonamide loop diuretic [2]. It is the **least potent** among the options and carries a higher risk of **ototoxicity**. It is primarily reserved for patients with sulfonamide allergies. **High-Yield NEET-PG Pearls:** 1. **Potency Hierarchy:** Bumetanide > Torsemide > Furosemide > Ethacrynic acid [1]. 2. **Efficacy:** Despite differences in potency, all loop diuretics have similar **maximal efficacy** (ceiling effect). 3. **Drug of Choice:** Loop diuretics are the drugs of choice for acute pulmonary edema and symptomatic heart failure. 4. **Metabolic Side Effects:** They typically cause hypokalemic metabolic alkalosis, hyperuricemia, and hypocalcemia ("Loops Lose Calcium") [3]. 5. **Ototoxicity:** Ethacrynic acid is the most ototoxic; Bumetanide is generally considered the least ototoxic.

Question 100: Acetazolamide acts at which part of the nephron?

A. Proximal Convoluted Tubule (PCT) (Correct Answer)
B. Distal Convoluted Tubule (DCT)
C. Ascending loop of Henle
D. Descending loop of Henle

Explanation: **Explanation:** **Acetazolamide** is a potent **Carbonic Anhydrase (CA) inhibitor** [2]. Its primary site of action is the **Proximal Convoluted Tubule (PCT)** [4]. In the PCT, carbonic anhydrase (specifically the CA-IV isoenzyme on the brush border and CA-II in the cytoplasm) is responsible for the reabsorption of sodium bicarbonate ($NaHCO_3$) [3]. By inhibiting this enzyme, acetazolamide prevents the dehydration of carbonic acid and the subsequent reabsorption of bicarbonate, leading to alkaline diuresis and a mild diuretic effect [2]. **Analysis of Incorrect Options:** * **Distal Convoluted Tubule (DCT):** This is the site of action for **Thiazide diuretics**, which inhibit the $Na^+/Cl^-$ symporter. * **Ascending loop of Henle:** Specifically the Thick Ascending Limb (TAL), this is the site of action for **Loop diuretics** (e.g., Furosemide), which inhibit the $Na^+/K^+/2Cl^-$ cotransporter. * **Descending loop of Henle:** This segment is highly permeable to water but impermeable to solutes; it is primarily influenced by **Osmotic diuretics** like Mannitol [1]. **Clinical Pearls for NEET-PG:** * **Therapeutic Uses:** Glaucoma (decreases aqueous humor production), Acute Mountain Sickness (counteracts respiratory alkalosis), and Urinary Alkalinization (to excrete acidic drugs like uric acid or cystine). * **Adverse Effects:** Hyperchloremic metabolic acidosis, hypokalemia, and paresthesia. * **Contraindications:** Avoid in patients with hepatic cirrhosis, as it can decrease ammonia excretion, potentially precipitating hepatic encephalopathy.

Question 101: What is the mechanism of action of furosemide as a diuretic?

A. Inhibition of Na-K-Cl ion symporter (Correct Answer)
B. Aldosterone antagonism
C. Inhibition of Na-Cl symporter in distal tubules
D. Carbonic anhydrase inhibition

Explanation: **Explanation:** **1. Why Option A is Correct:** Furosemide is a potent **Loop Diuretic**. Its primary mechanism of action is the reversible inhibition of the **Naⁱ-Kⁱ-2Cl⁻ symporter (NKCC2)** [2] located in the luminal membrane of the **Thick Ascending Limb (TAL)** of the Loop of Henle [4]. By blocking this transporter, it prevents the reabsorption of these electrolytes, leading to a significant increase in the excretion of sodium, chloride, and water [2]. Because the TAL is responsible for reabsorbing ~25% of filtered sodium, loop diuretics are the most efficacious diuretics ("High-ceiling diuretics") [3]. **2. Why Other Options are Incorrect:** * **Option B (Aldosterone antagonism):** This describes **Spironolactone** and Eplerenone. These are potassium-sparing diuretics that act on the mineralocorticoid receptors in the collecting ducts. * **Option C (Inhibition of Na-Cl symporter):** This is the mechanism of **Thiazide diuretics** (e.g., Hydrochlorothiazide), which act specifically on the **Distal Convoluted Tubule (DCT)** [3]. * **Option D (Carbonic anhydrase inhibition):** This describes **Acetazolamide**, which acts primarily in the **Proximal Convoluted Tubule (PCT)** [5]. **3. High-Yield Clinical Pearls for NEET-PG:** * **Electrolyte Changes:** Furosemide causes **Hypokalemia**, **Hypomagnesemia**, and notably **Hypocalcemia** (unlike Thiazides, which cause hypercalcemia) [4]. "Loop loses calcium." * **Drug of Choice:** It is the treatment of choice for **Acute Pulmonary Edema** due to its rapid onset and additional vasodilator effect. * **Adverse Effects:** Watch for **Ototoxicity** (especially when combined with aminoglycosides), Hyperuricemia (can precipitate Gout), and Sulfa-allergy cross-reactivity [1]. * **Site of Action:** Always remember—Loop diuretics act on the **Thick Ascending Limb** [2].

Question 102: Acetazolamide side effects include all except:

A. Hypokalemia
B. Drowsiness
C. Diarrhea (Correct Answer)
D. Paresthesia

Explanation: **Explanation:** Acetazolamide is a **Carbonic Anhydrase Inhibitor** that acts primarily at the proximal convoluted tubule (PCT). It inhibits the enzyme carbonic anhydrase, leading to the excretion of sodium, potassium, and bicarbonate. **Why "Diarrhea" is the correct answer:** Diarrhea is not a recognized side effect of Acetazolamide. In fact, the most common gastrointestinal side effect associated with its use is **nausea or anorexia**, but it does not typically cause increased bowel motility or diarrhea. **Analysis of Incorrect Options:** * **Hypokalemia (Option A):** By increasing the delivery of sodium and water to the distal tubule, Acetazolamide promotes potassium secretion into the urine. This is a classic side effect of most diuretics (except potassium-sparing ones). * **Drowsiness (Option B):** Acetazolamide can cause Central Nervous System (CNS) depression, leading to sedation, fatigue, and drowsiness, especially in patients with hepatic impairment. * **Paresthesia (Option C):** This is a very common and high-yield side effect. Patients often report "pins and needles" sensations in the extremities and face due to the metabolic acidosis and electrolyte shifts induced by the drug. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolic Acidosis:** Acetazolamide causes **Hyperchloremic Metabolic Acidosis** (due to bicarbonate loss). * **Therapeutic Uses:** Glaucoma (decreases aqueous humor), Altitude Sickness (prophylaxis), and Urinary Alkalization (to excrete acidic drugs like aspirin). * **Contraindication:** Avoid in patients with **Liver Cirrhosis**, as it decreases ammonia excretion, potentially precipitating hepatic coma. * **Renal Stones:** It can cause calcium phosphate stones because calcium is less soluble in alkaline urine.

Question 103: Indomethacin reduces the diuretic action of furosemide by which mechanism?

A. Preventing prostaglandin-mediated hemodynamic actions (Correct Answer)
B. Blockade of furosemide action in the loop of Henle
C. Enhancing water reabsorption in the distal tubule
D. Increasing aldosterone secretion

Explanation: ### Explanation **Mechanism of Action (The Correct Answer)** Furosemide, a high-ceiling loop diuretic, acts not only by inhibiting the $Na^+-K^+-2Cl^-$ symporter but also by stimulating the synthesis of **renal prostaglandins** (specifically $PGE_2$ and $PGI_2$). These prostaglandins cause renal vasodilation, increasing renal blood flow and redistributing it to the cortex. This hemodynamic effect is crucial for the full expression of its diuretic action. **Indomethacin**, a non-selective NSAID, inhibits the enzyme **Cyclooxygenase (COX)**, thereby blocking prostaglandin synthesis. By preventing prostaglandin-mediated vasodilation, Indomethacin blunts the hemodynamic component of furosemide's action, leading to a reduced diuretic response. **Analysis of Incorrect Options** * **Option B:** Indomethacin does not compete for the binding site on the $Na^+-K^+-2Cl^-$ transporter in the Thick Ascending Limb; its interference is biochemical/hemodynamic, not a direct blockade of the transporter. * **Option C:** While NSAIDs can cause water retention, they do so by potentiating ADH action or reducing medullary blood flow, not by a direct enhancement of distal tubule reabsorption in the context of furosemide interaction. * **Option D:** NSAIDs actually tend to *decrease* renin and aldosterone secretion (hyporeninemic hypoaldosteronism), which would theoretically increase sodium excretion, not decrease it. **High-Yield Clinical Pearls for NEET-PG** * **Drug Interaction:** Always avoid prescribing NSAIDs (like Indomethacin or Ibuprofen) to patients on loop diuretics for heart failure or hypertension, as it can lead to fluid retention and exacerbation of symptoms. * **Bartter’s Syndrome:** This condition mimics chronic loop diuretic use. Interestingly, Indomethacin is used as a treatment for Bartter’s syndrome because it inhibits the excess prostaglandin production seen in these patients. * **Vascular Effect:** Furosemide’s rapid effect in pulmonary edema is due to its prostaglandin-mediated **venodilation**, which occurs even before the onset of diuresis. This effect is also abolished by NSAIDs.

Question 104: Which of the following potassium-sparing diuretics alters cardiac mortality?

A. Spironolactone (Correct Answer)
B. Amiloride
C. Triamterene
D. Eplerenone

Explanation: **Explanation:** **1. Why Spironolactone is Correct:** Spironolactone is a competitive **Aldosterone Receptor Antagonist (MRA)**. In chronic heart failure, aldosterone levels are chronically elevated, leading to pathological cardiac remodeling and myocardial fibrosis. Spironolactone inhibits these effects, thereby reducing cardiac stiffness and arrhythmias. The landmark **RALES trial** demonstrated that adding spironolactone to standard therapy significantly reduces morbidity and mortality in patients with severe Heart Failure with Reduced Ejection Fraction (HFrEF). **2. Why the Other Options are Incorrect:** * **Amiloride & Triamterene (Options B & C):** These are **epithelial sodium channel (ENaC) blockers** acting directly on the late distal tubule and collecting duct. Unlike MRAs, they do not antagonize the systemic effects of aldosterone on the heart. They are primarily used to prevent hypokalemia induced by other diuretics and have no proven mortality benefit in heart failure. * **Eplerenone (Option D):** While Eplerenone is also an MRA and *does* reduce mortality (proven in the **EMPHASIS-HF** trial), it is a more selective antagonist with fewer side effects (like gynecomastia). However, in the context of standard NEET-PG questions, **Spironolactone** is the classic, first-line answer as it was the first to demonstrate this benefit and remains the prototype drug for this category. **3. High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** Spironolactone causes **gynecomastia** and impotence due to its non-selective binding to androgen and progesterone receptors. Eplerenone is the preferred alternative if these occur. * **Contraindication:** Both are contraindicated in patients with **hyperkalemia** or significant renal impairment (Serum Creatinine >2.5 mg/dL). * **Site of Action:** They act on the **Collecting Duct** (the "late" part of the nephron). * **Other Mortality-Reducing Drugs in HF:** ACE inhibitors, ARBs, Beta-blockers, and SGLT2 inhibitors.

Question 105: Which of the following agents does NOT impair auto-regulation of renal blood flow?

A. NSAIDs
B. ACE inhibitors
C. Angiotensin-II-receptor blockers
D. Thiazide diuretics (Correct Answer)

Explanation: **Explanation:** Renal blood flow (RBF) and Glomerular Filtration Rate (GFR) are maintained through **autoregulation**, primarily via the balance between the afferent arteriole (dilated by Prostaglandins) and the efferent arteriole (constricted by Angiotensin II). **Why Thiazide Diuretics are the correct answer:** Thiazides act on the Distal Convoluted Tubule (DCT) by inhibiting the Na+/Cl- symporter. Unlike drugs that act directly on the renal vasculature or the renin-angiotensin-aldosterone system (RAAS), thiazides **do not interfere with the intrinsic myogenic or tubuloglomerular feedback mechanisms** that regulate renal hemodynamics. While they may cause a mild decrease in GFR due to volume depletion, they do not "impair" the autoregulatory capacity of the kidney. **Why the other options are incorrect:** * **NSAIDs:** These inhibit prostaglandin synthesis. Prostaglandins are essential for maintaining **afferent arteriolar vasodilation**. By causing afferent vasoconstriction, NSAIDs impair the kidney's ability to maintain GFR, especially in states of low effective circulating volume. * **ACE Inhibitors & ARBs:** These agents prevent the action of Angiotensin II, which is responsible for **efferent arteriolar vasoconstriction**. By causing efferent vasodilation, they drop the intraglomerular pressure and disrupt the autoregulatory response required to maintain GFR when renal perfusion pressure is low. **High-Yield Clinical Pearls for NEET-PG:** * **Triple Whammy:** The concurrent use of **NSAIDs, ACEIs/ARBs, and Diuretics** significantly increases the risk of Acute Kidney Injury (AKI) by simultaneously attacking all points of renal autoregulation. * **Loop Diuretics:** Unlike Thiazides, Loop diuretics can actually *increase* RBF by stimulating prostaglandin release, but they also disrupt tubuloglomerular feedback. * **Drug of Choice:** Thiazides are the first-line antihypertensives in the elderly and Black populations, but should be used with caution in patients with GFR <30 ml/min (where they lose efficacy).

Question 106: What is the diuretic of choice for rapid relief of congestive symptoms in a patient with congestive heart failure?

A. Hydrochlorothiazide
B. Furosemide (Correct Answer)
C. Metolazone
D. Amiloride

Explanation: **Furosemide** is the diuretic of choice for the rapid relief of congestive symptoms (such as pulmonary edema or peripheral edema) in patients with Congestive Heart Failure (CHF) [1]. **Why Furosemide is the Correct Answer:**Furosemide is a **Loop Diuretic** that acts by inhibiting the $Na^+-K^+-2Cl^-$ symporter in the Thick Ascending Limb (TAL) of the Loop of Henle [2]. It is preferred in acute CHF for two primary reasons:1. **High Efficacy:** Known as "high-ceiling" diuretics, loop diuretics have the highest natriuretic capacity, capable of excreting up to 25% of filtered sodium [2].2. **Rapid Action:** When given intravenously, it produces rapid venodilation (via prostaglandin release) even before the diuretic effect begins, which immediately reduces cardiac preload and relieves pulmonary congestion.**Why Other Options are Incorrect:** * **A. Hydrochlorothiazide:** Thiazides are "low-ceiling" diuretics. They are less potent than loop diuretics and are generally used for long-term management of hypertension rather than acute relief of CHF symptoms [1, 2].* **C. Metolazone:** While a potent thiazide-like diuretic, it is typically used as an "add-on" to loop diuretics in cases of diuretic resistance rather than as a first-line monotherapy for rapid relief.* **D. Amiloride:** This is a potassium-sparing diuretic with very weak natriuretic activity. It is used primarily to counteract hypokalemia caused by other diuretics [1].**High-Yield Clinical Pearls for NEET-PG:** * **DOC for Acute Pulmonary Edema:** IV Furosemide.* **Ototoxicity:** A key side effect of loop diuretics, especially when used with aminoglycosides.* **Metabolic Profile:** Loop diuretics cause **Hypokalemic Metabolic Alkalosis**, Hypomagnesemia, and Hyperuricemia (can precipitate Gout) [2].* **Calcium Handling:** Loop diuretics "Lose" calcium (used in hypercalcemia), whereas Thiazides "Thrive" on calcium (cause hypercalcemia; used in idiopathic hypercalciuria).

Question 107: Tolvaptan is used in which of the following conditions?

A. Hyponatremia (Correct Answer)
B. Hypernatremia
C. Nephrogenic diabetes insipidus
D. Decreased water clearance

Explanation: **Explanation:** **Tolvaptan** is a selective, competitive **Vasopressin V2-receptor antagonist**. It works by blocking the action of Antidiuretic Hormone (ADH) at the collecting ducts of the kidney. **1. Why Hyponatremia is correct:** Tolvaptan is classified as an **"Aquaretic."** By blocking V2 receptors, it prevents the insertion of aquaporin-2 channels, leading to the excretion of free water without significant loss of electrolytes (solute-free water clearance). This increases serum sodium levels, making it a first-line treatment for **euvolemic and hypervolemic hyponatremia**, such as that seen in **SIADH**, heart failure, or cirrhosis. **2. Why the other options are incorrect:** * **Hypernatremia:** Tolvaptan increases serum sodium by removing water; using it in hypernatremia would dangerously worsen the condition. * **Nephrogenic Diabetes Insipidus (NDI):** In NDI, the kidney is already resistant to ADH. Tolvaptan (an ADH antagonist) would have no therapeutic effect. NDI is typically managed with Thiazides or Amiloride. * **Decreased water clearance:** This is a *symptom* of SIADH, not a condition treated by Tolvaptan. Tolvaptan actually **increases** free water clearance (free water diuresis). **Clinical Pearls for NEET-PG:** * **Route:** Tolvaptan is administered **orally**, whereas Conivaptan (V1a/V2 antagonist) is given IV. * **Black Box Warning:** Avoid rapid correction of hyponatremia (risk of **Osmotic Demyelination Syndrome**) and limit use to 30 days due to potential **hepatotoxicity**. * **Other Indications:** It is also FDA-approved to slow kidney function decline in **Autosomal Dominant Polycystic Kidney Disease (ADPKD)**.

Question 108: What is the drug of choice in lithium-induced diabetes insipidus?

A. Amiloride (Correct Answer)
B. Vasopressin
C. Thiazide diuretics
D. Diclofenac

Explanation: ### Explanation **Correct Option: A. Amiloride** Lithium-induced Nephrogenic Diabetes Insipidus (NDI) occurs because lithium enters the principal cells of the collecting duct through **ENaC (Epithelial Sodium Channels)**. Once inside, lithium inhibits glycogen synthase kinase-3β, interfering with the action of ADH (Vasopressin) and reducing aquaporin-2 expression. **Amiloride** is the drug of choice because it blocks these ENaC channels, preventing lithium from entering the cells and thereby restoring the kidney's concentrating ability. **Why other options are incorrect:** * **B. Vasopressin:** In NDI, the kidneys are resistant to ADH. Therefore, administering exogenous vasopressin will not improve urine concentration. * **C. Thiazide diuretics:** While thiazides are used to treat other forms of NDI (by causing mild volume depletion and increasing proximal water reabsorption), they are not the specific treatment for lithium-induced cases and can actually increase lithium toxicity by decreasing its clearance. * **D. Diclofenac:** NSAIDs can be used in NDI to decrease GFR and inhibit prostaglandins (which antagonize ADH), but they are secondary treatments and carry risks of renal impairment. **High-Yield Clinical Pearls for NEET-PG:** * **Lithium Toxicity:** Thiazides, ACE inhibitors, and NSAIDs (except Aspirin) increase lithium levels and can lead to toxicity. * **Amiloride vs. Triamterene:** Both are K+-sparing diuretics (ENaC blockers), but Amiloride is specifically preferred for lithium-induced NDI. * **DOC for Central DI:** Desmopressin (dDAVP). * **DOC for General NDI:** Thiazides (e.g., Hydrochlorothiazide).

Question 109: Which of the following metabolic abnormalities is seen with long-term use of spironolactone?

A. Metabolic acidosis (Correct Answer)
B. Metabolic alkalosis
C. Hyperkalemia
D. None of the above

Explanation: **Explanation:** Spironolactone is a potassium-sparing diuretic that acts as a competitive antagonist of the mineralocorticoid receptor in the late distal tubule and collecting duct. **Why Metabolic Acidosis is Correct:** Aldosterone normally promotes the reabsorption of sodium ($Na^+$) in exchange for the secretion of potassium ($K^+$) and hydrogen ions ($H^+$) via the $H^+$-ATPase pump in the intercalated cells. By inhibiting aldosterone, spironolactone reduces the secretion of $H^+$ into the tubular lumen. This retention of hydrogen ions in the blood leads to **Hyperchloremic Metabolic Acidosis** (specifically a Normal Anion Gap Metabolic Acidosis). **Analysis of Incorrect Options:** * **B. Metabolic Alkalosis:** This is typically seen with "Loop" and "Thiazide" diuretics. These drugs increase sodium delivery to the distal tubule, stimulating $H^+$ secretion and causing contraction alkalosis. * **C. Hyperkalemia:** While spironolactone **does** cause hyperkalemia (by inhibiting $K^+$ secretion), the question specifically asks for the **metabolic** (acid-base) abnormality. Hyperkalemia is an electrolyte abnormality, not a metabolic one. In the context of acid-base balance, hyperkalemia and metabolic acidosis often coexist. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** Spironolactone causes **"High K and Low pH"** (Hyperkalemia and Acidosis). * **Side Effects:** Beyond metabolic changes, it causes **gynecomastia** and impotence in men due to its non-specific anti-androgenic effects (Eplerenone is a more selective alternative). * **Drug of Choice:** It is the DOC for edema in **Cirrhosis** and for treating **Primary Hyperaldosteronism (Conn’s Syndrome)**. * **Mortality Benefit:** It is proven to reduce mortality in patients with Chronic Heart Failure (NYHA Class II-IV).

Question 110: Spironolactone is most useful in?

A. Cardiac hypertrophy
B. Cirrhotic ascites (Correct Answer)
C. Exudative pleural effusion
D. Renal artery stenosis

Explanation: **Explanation:** **Spironolactone** is a potassium-sparing diuretic that acts as a competitive antagonist to the **Aldosterone receptor** (Mineralocorticoid receptor) in the distal convoluted tubule and collecting duct. **Why Cirrhotic Ascites is the correct answer:** In patients with liver cirrhosis, there is significant activation of the Renin-Angiotensin-Aldosterone System (RAAS) due to peripheral vasodilation and decreased effective arterial blood volume. This leads to **Secondary Hyperaldosteronism**, causing massive sodium and water retention. Spironolactone is the **drug of choice** for cirrhotic ascites because it directly counteracts the high levels of circulating aldosterone, promoting natriuresis while preserving potassium. **Analysis of Incorrect Options:** * **Cardiac Hypertrophy:** While Spironolactone (and Eplerenone) reduces cardiac remodeling and mortality in chronic heart failure (RALES trial), it is used as an adjunct. It is not the "most useful" or primary indication compared to its definitive role in managing the pathophysiology of ascites. * **Exudative Pleural Effusion:** This is typically caused by inflammation or malignancy. Diuretics are used for *transudative* effusions (like those in heart failure); they have no role in treating the underlying cause of exudative fluid. * **Renal Artery Stenosis:** This condition causes high renin levels. However, using Spironolactone or ACE inhibitors in bilateral renal artery stenosis can lead to a dangerous drop in GFR and acute kidney injury. **NEET-PG High-Yield Pearls:** * **Drug of Choice:** Spironolactone is the DOC for **Cirrhotic Ascites** and **Conn’s Syndrome** (Primary Hyperaldosteronism). * **Mechanism:** Inhibits the expression of ENaC (Epithelial Sodium Channels) and Na+/K+ ATPase. * **Side Effects:** The most characteristic side effect is **Gynecomastia** (due to non-specific binding to androgen and progesterone receptors). Eplerenone is a more selective alternative without this side effect. * **Metabolite:** **Canrenone** is the active metabolite of Spironolactone.

Question 111: Which of the following statements about furosemide is true?

A. It is administered only by the intravenous route.
B. It causes mild diuresis.
C. It is used in the management of pulmonary edema. (Correct Answer)
D. It acts on the proximal convoluted tubule (PCT).

Explanation: ### Explanation **Correct Answer: C. It is used in the management of pulmonary edema.** **Mechanism and Rationale:** Furosemide is a potent **Loop Diuretic** that inhibits the **Na⁺-K⁺-2Cl⁻ symporter** in the Thick Ascending Limb (TAL) of the Loop of Henle. It is the drug of choice for acute pulmonary edema because of two distinct actions: 1. **Hemodynamic effect:** When given intravenously, it causes rapid **venodilation** (mediated by prostaglandins), which reduces venous return (preload) even before the diuretic effect begins. 2. **Diuretic effect:** It promotes the excretion of sodium and water, reducing the overall fluid overload. --- ### Why other options are incorrect: * **Option A:** Furosemide has good oral bioavailability (~60%) and is commonly used in tablet form for chronic heart failure and hypertension. It is administered both **orally and intravenously**. * **Option B:** It is a **"High-ceiling" diuretic**, meaning it causes massive, brisk diuresis. It is the most efficacious class of diuretics, not "mild." * **Option D:** It acts on the **Thick Ascending Limb (TAL)** of the Loop of Henle, not the PCT. Acetazolamide is an example of a drug acting on the PCT. --- ### NEET-PG High-Yield Pearls: * **Side Effects (OH DANG!):** **O**totoxicity (especially with aminoglycosides), **H**ypokalemia, **D**ehydration, **A**llergy (Sulfa drug), **N**ephritis (Interstitial), **G**out (Hyperuricemia). * **Electrolyte Changes:** It causes **Hypomagnesemia** and **Hypocalcemia** (Loop diuretics "lose" calcium, whereas Thiazides "thrive" on/retain calcium). * **Drug Interaction:** NSAIDs can reduce the diuretic efficacy of furosemide by inhibiting prostaglandin synthesis.

Question 112: Spironolactone is most effective for which type of edema?

A. Cirrhotic edema (Correct Answer)
B. Cardiac edema
C. Idiopathic edema
D. Nutritional edema

Explanation: **Explanation:** **1. Why Cirrhotic Edema is Correct:** Spironolactone is the **drug of choice** for edema associated with liver cirrhosis. In cirrhosis, there is decreased hepatic clearance of aldosterone and activation of the Renin-Angiotensin-Aldosterone System (RAAS) due to splanchnic vasodilation. This leads to **secondary hyperaldosteronism**, causing significant sodium and water retention. As a competitive antagonist of the Mineralocorticoid Receptor (MR), spironolactone directly counteracts this excess aldosterone, making it more effective here than in other types of edema. **2. Why Other Options are Incorrect:** * **Cardiac Edema:** While spironolactone is used in Heart Failure (HF) to reduce mortality and remodeling (RALES trial), the primary diuretics for acute symptomatic relief of cardiac edema are **Loop diuretics** (e.g., Furosemide) due to their high efficacy and rapid onset. * **Idiopathic Edema:** This is typically managed with weight reduction, salt restriction, or occasionally low-dose thiazides. Spironolactone is not the primary treatment. * **Nutritional Edema:** This is primarily due to hypoproteinemia (low oncotic pressure). Treatment focuses on protein supplementation and addressing the underlying deficiency rather than specific hormonal antagonism. **3. Clinical Pearls for NEET-PG:** * **Mechanism:** Competitive antagonist of aldosterone at the late distal tubule and collecting duct. * **Side Effects:** The most high-yield side effect is **Gynecomastia** (due to non-specific binding to androgen receptors). Eplerenone is a more selective alternative that avoids this. * **Electrolyte Shift:** Always monitor for **Hyperkalemia**, especially if the patient is also on ACE inhibitors. * **Paradoxical Use:** It is also used in **Conn’s Syndrome** (Primary hyperaldosteronism) and Polycystic Ovary Syndrome (PCOS) for its anti-androgenic effects.

Question 113: Mannitol is not useful for which of the following conditions?

A. Glaucoma
B. Raised intracranial tension
C. Impending renal failure
D. Pulmonary edema (Correct Answer)

Explanation: **Explanation:** **Mannitol** is a prototype osmotic diuretic. It works by increasing the osmolarity of the plasma and tubular fluid, drawing water out of the intracellular and interstitial compartments into the vascular space. **Why it is NOT used in Pulmonary Edema (Option D):** Mannitol initially causes a rapid expansion of extracellular fluid (ECF) volume as it pulls water from cells into the bloodstream. In patients with cardiac insufficiency or pulmonary congestion, this sudden increase in preload can worsen **pulmonary edema** and potentially precipitate acute heart failure. Therefore, pulmonary edema is a strict **contraindication** for mannitol. **Analysis of Incorrect Options:** * **A. Glaucoma:** Mannitol increases plasma osmolarity, creating an osmotic gradient that draws aqueous humor from the eye into the systemic circulation, thereby acutely reducing intraocular pressure. * **B. Raised Intracranial Tension (ICT):** This is the most common clinical use. Mannitol draws fluid out of the brain parenchyma into the vascular space, effectively reducing cerebral edema. * **C. Impending Renal Failure:** In conditions like shock or hemolysis, mannitol maintains urine flow by preventing water reabsorption in the proximal tubule and Loop of Henle, helping to "flush" out toxins and prevent tubular necrosis. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Primarily the Thin Descending Limb of the Loop of Henle (and Proximal Convoluted Tubule). * **Route:** Must be given **IV only** (not absorbed orally; causes osmotic diarrhea if ingested). * **Contraindications:** Acute pulmonary edema, severe congestive heart failure, and established anuria (chronic renal failure). * **Side Effect:** Headache is common due to the stretching of dural vessels.

Question 114: What is the primary site of action for vasopressin antagonists in the kidney?

A. Medullary collecting duct (Correct Answer)
B. Cortical collecting duct
C. Proximal convoluted tubule
D. Distal convoluted tubule

Explanation: **Vasopressin antagonists** (also known as **Vaptans**, e.g., Tolvaptan, Conivaptan) act by blocking the V2 receptors in the kidney [3]. 1. **Why Medullary Collecting Duct is Correct:** The V2 receptors are primarily located on the basolateral membrane of the principal cells in the **medullary collecting duct**. When vasopressin (ADH) binds to these receptors, it triggers the insertion of **Aquaporin-2 (AQP2)** water channels into the apical membrane [2]. By antagonizing these receptors, Vaptans prevent water reabsorption, leading to **aquaresis** (excretion of free water without affecting electrolytes) [1]. While V2 receptors exist in the cortical segment, the density and the final concentration of urine are most significantly governed in the medullary portion. 2. **Why Other Options are Incorrect:** * **Cortical Collecting Duct:** While some V2 receptors are present here, the medullary portion is the primary site for the final concentration of urine and the major site of action for Vaptans. * **Proximal Convoluted Tubule (PCT):** This is the site for Carbonic Anhydrase inhibitors (Acetazolamide). Water reabsorption here is passive and independent of ADH. * **Distal Convoluted Tubule (DCT):** This is the site of action for Thiazide diuretics, which inhibit the Na+-Cl- symporter. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Vaptans cause "Aquaresis" (solute-free water excretion), unlike conventional diuretics which cause "Natriuresis." * **Indications:** SIADH (Drug of choice), Euvolemic or Hypervolemic hyponatremia, and Autosomal Dominant Polycystic Kidney Disease (ADPKD). * **Route:** **Tolvaptan** is oral (V2 selective); **Conivaptan** is intravenous (V1a + V2 non-selective). * **Caution:** Rapid correction of hyponatremia with Vaptans can lead to **Osmotic Demyelination Syndrome** (Central Pontine Myelinolysis).

Question 115: Which of the following is NOT caused by thiazide diuretics?

A. Hyperuricemia
B. Ototoxicity (Correct Answer)
C. Hypercalcemia
D. Hypokalemia

Explanation: Thiazide diuretics (e.g., Hydrochlorothiazide, Chlorthalidone) act on the distal convoluted tubule (DCT) by inhibiting the **Na⁺-Cl⁻ symporter**. **Why Ototoxicity is the Correct Answer:** Ototoxicity is a classic side effect of **Loop diuretics** (like Furosemide and Ethacrynic acid), not Thiazides. Loop diuretics inhibit the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb of Henle; a similar transporter exists in the stria vascularis of the inner ear. Disruption of this transporter leads to electrolyte imbalances in the endolymph, causing tinnitus or hearing loss. Thiazides do not affect this mechanism. **Explanation of Incorrect Options:** * **Hyperuricemia:** Thiazides compete with uric acid for the organic acid secretory pump in the proximal tubule. This leads to decreased uric acid excretion, potentially precipitating gout. * **Hypercalcemia:** Unlike Loop diuretics (which cause hypocalcemia), Thiazides **increase** calcium reabsorption in the DCT. This occurs because the inhibition of Na⁺ entry increases the activity of the Na⁺/Ca²⁺ exchanger on the basolateral membrane. * **Hypokalemia:** By increasing sodium delivery to the late distal tubule and collecting duct, Thiazides stimulate the exchange of Na⁺ for K⁺ (mediated by aldosterone), leading to potassium depletion. **High-Yield NEET-PG Pearls:** * **Mnemonic for Thiazide side effects:** "Hyper **GLUC**" — Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia, Hyper**C**alcemia. * **Clinical Use:** Because they cause hypercalcemia, Thiazides are the diuretic of choice for hypertensive patients with **osteoporosis** or **recurrent calcium oxalate stones** (as they reduce urinary calcium). * **Chlorthalidone** is often preferred over Hydrochlorothiazide due to its longer half-life and superior evidence in reducing cardiovascular events.

Question 116: Which of the following adverse effects is NOT typically produced by thiazide diuretics?

A. Hyperglycemia
B. Hyperkalemia (Correct Answer)
C. Hypokalemia
D. Hyperlipidemia

Explanation: **Explanation:** Thiazide diuretics (e.g., Hydrochlorothiazide, Chlorthalidone) act on the **Distal Convoluted Tubule (DCT)** by inhibiting the $Na^+/Cl^-$ symporter. The correct answer is **Hyperkalemia** because Thiazides characteristically cause **Hypokalemia**, not hyperkalemia. **1. Why Hyperkalemia is the correct answer (The Mechanism):** Thiazides increase sodium delivery to the late distal tubule and collecting duct. To reabsorb this excess sodium, the body activates the $Na^+/K^+$ exchange mechanism (driven by Aldosterone), leading to increased secretion of Potassium ($K^+$) into the urine. This results in **Hypokalemia**. Hyperkalemia is typically associated with Potassium-sparing diuretics (e.g., Spironolactone) or ACE inhibitors. **2. Analysis of Incorrect Options:** * **Hyperglycemia:** Thiazides inhibit insulin release from the pancreas (due to low $K^+$ levels) and decrease peripheral glucose utilization, leading to elevated blood sugar. * **Hypokalemia:** As explained above, this is a hallmark side effect due to increased $K^+$ excretion in the distal nephron. * **Hyperlipidemia:** Thiazides can cause a transient increase in serum LDL cholesterol and triglycerides. **Clinical Pearls for NEET-PG:** * **The "HYPER" Mnemonic:** Thiazides cause **Hyper**glycemia, **Hyper**lipidemia, **Hyper**uricemia (can precipitate Gout), and **Hyper**calcemia (useful in preventing calcium stones). * **The "HYPO" Mnemonic:** They cause **Hypo**kalemia, **Hypo**magnesemia, and **Hypo**natremia. * **Drug of Choice:** Chlorthalidone is often preferred over Hydrochlorothiazide due to its longer half-life and better evidence in reducing cardiovascular events.

Question 117: Which diuretic is commonly used in the management of essential hypertension?

A. Hydrochlorothiazide (Correct Answer)
B. Amiloride
C. Furosemide
D. Acetazolamide

Explanation: **Explanation:** **Hydrochlorothiazide (Option A)** is the correct answer because **Thiazide diuretics** are the first-line diuretic agents for the management of essential hypertension. Their antihypertensive effect occurs in two phases: initially, they reduce blood pressure by decreasing blood volume and cardiac output; long-term, they act as direct vasodilators by reducing intracellular sodium in vascular smooth muscle, which decreases peripheral vascular resistance. **Why other options are incorrect:** * **Amiloride (Option B):** This is a potassium-sparing diuretic. It has weak antihypertensive efficacy when used alone and is primarily used in combination with Thiazides to prevent hypokalemia. * **Furosemide (Option C):** A loop diuretic with a short duration of action (4–6 hours). While potent, it is less effective than Thiazides for essential hypertension unless the patient has concomitant chronic kidney disease (CrCl <30 ml/min) or congestive heart failure. * **Acetazolamide (Option D):** A carbonic anhydrase inhibitor used mainly for glaucoma, altitude sickness, and urinary alkalinization. It is not used for hypertension due to its weak diuretic effect and risk of metabolic acidosis. **High-Yield Clinical Pearls for NEET-PG:** 1. **Chlorthalidone** is often preferred over Hydrochlorothiazide in recent guidelines due to its longer half-life and superior evidence in reducing cardiovascular events. 2. **Metabolic Side Effects of Thiazides:** Remember the "4 Hypers and 2 Hypos": **Hyper**glycemia, **Hyper**lipidemia, **Hyper**uricemia, **Hyper**calcemia; **Hypo**kalemia and **Hypo**natremia. 3. Thiazides are ineffective if the GFR is less than 30 ml/min (except **Metolazone**).

Question 118: All of the following are true regarding diuretic-associated hypokalemia, EXCEPT:

A. Loop diuretics cause more hypokalemia than thiazide diuretics. (Correct Answer)
B. Increased distal tubular sodium delivery and distal tubular flow rate result in hypokalemia.
C. Secondary hyperaldosteronism also plays a role.
D. Thiazides cause hypocalciuria.

Explanation: ### Explanation **1. Why Option A is the Correct Answer (The False Statement):** Contrary to common belief, **Thiazide diuretics cause more clinically significant hypokalemia than Loop diuretics.** While Loop diuretics are more potent "natriuretics" (excreting more sodium), they have a shorter duration of action. Thiazides have a longer half-life, leading to a sustained increase in sodium delivery to the distal tubule over a longer period. This prolonged exposure results in a greater cumulative loss of potassium. **2. Analysis of Other Options:** * **Option B (Correct Mechanism):** Diuretics inhibit sodium reabsorption upstream (Loop of Henle or Distal Tubule). This increases **distal sodium delivery**. When more sodium reaches the collecting duct, it is reabsorbed via ENaC channels in exchange for potassium secretion (mediated by ROMK channels), leading to hypokalemia. * **Option C (Correct Mechanism):** Diuretics cause volume depletion, which activates the **Renin-Angiotensin-Aldosterone System (RAAS)**. Secondary hyperaldosteronism further stimulates the principal cells to reabsorb sodium and excrete potassium and hydrogen ions. * **Option D (True Statement):** Thiazides increase calcium reabsorption in the distal convoluted tubule, leading to **hypocalciuria**. This makes them useful in preventing calcium oxalate kidney stones. In contrast, Loop diuretics cause hypercalciuria ("Loops lose calcium"). **3. High-Yield Clinical Pearls for NEET-PG:** * **Metabolic Profile:** Both Thiazides and Loops cause **Hypokalemic Metabolic Alkalosis**. * **Calcium Rule:** Thiazides = Hypercalcemia/Hypocalciuria; Loops = Hypocalcemia/Hypercalciuria. * **Drug of Choice:** Thiazides are preferred for hypertension; Loops are preferred for edematous states (CHF, Cirrhosis). * **Digoxin Toxicity:** Diuretic-induced hypokalemia is a major risk factor for precipitating digoxin toxicity.

Question 119: Which of the following medications can be used to treat hypercalciuria?

A. Torsemide
B. Acetazolamide
C. Frusemide
D. Indapamide (Correct Answer)

Explanation: ### Explanation The correct answer is **Indapamide (Option D)**. **Why Indapamide is correct:** Indapamide is a **thiazide-like diuretic** [1]. Thiazides and thiazide-like diuretics (e.g., Chlorthalidone, Metolazone) act on the Distal Convoluted Tubule (DCT) by inhibiting the $Na^+/Cl^-$ symporter [1], [2]. This action leads to a decrease in intracellular sodium, which enhances the activity of the $Na^+/Ca^{2+}$ exchanger on the basolateral membrane. Consequently, more calcium is reabsorbed from the tubular fluid into the blood [1], [2]. By **decreasing urinary calcium excretion (hypocalciuria)**, these drugs are the treatment of choice for idiopathic hypercalciuria and the prevention of calcium oxalate renal stones [1], [2]. **Why other options are incorrect:** * **Torsemide & Frusemide (Options A & C):** These are **Loop Diuretics**. They inhibit the $Na^+/K^+/2Cl^-$ cotransporter in the Thick Ascending Limb (TAL). This abolishes the lumen-positive potential required for the paracellular reabsorption of divalent cations. Therefore, loop diuretics **increase calcium excretion** ("Loops Lose Calcium") [1] and are used to treat hypercalcemia, not hypercalciuria. * **Acetazolamide (Option B):** This is a Carbonic Anhydrase inhibitor. It acts on the Proximal Convoluted Tubule and increases the excretion of bicarbonate, which can lead to alkaline urine. This actually **increases the risk of calcium phosphate stone formation** and is not used for hypercalciuria [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** **L**oops **L**ose calcium; **T**hiazides **T**ake (retain) calcium. * **Paradoxical use:** Thiazides are used in **Nephrogenic Diabetes Insipidus** to reduce polyuria. * **Metabolic side effects of Thiazides:** Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia, and Hyper**C**alcemia (Mnemonic: **GLUC**) [1]. * Indapamide is often preferred in hypertensive patients with renal impairment as it is primarily excreted via the biliary route [1].

Question 120: Which of the following is a potassium-sparing diuretic?

A. Furosemide
B. Spironolactone (Correct Answer)
C. Thiazide
D. None of the above

Explanation: **Explanation:** **Correct Answer: B. Spironolactone** **Mechanism of Action:** Spironolactone is a competitive antagonist of the **Mineralocorticoid Receptor (Aldosterone receptor)** located in the late distal tubule and collecting duct. Normally, aldosterone promotes the reabsorption of Na⁺ and the secretion of K⁺ and H⁺. By blocking this receptor, spironolactone inhibits Na⁺-K⁺ exchange, leading to sodium excretion (natriuresis) while retaining potassium in the blood. Hence, it is classified as a **Potassium-Sparing Diuretic**. **Why other options are incorrect:** * **A. Furosemide:** This is a **Loop Diuretic** that inhibits the Na⁺-K⁺-2Cl⁻ symporter in the Thick Ascending Limb of Henle. It causes significant potassium loss (hypokalemia) because the increased sodium delivery to the distal tubule stimulates K⁺ secretion. * **C. Thiazide:** These act on the Distal Convoluted Tubule (DCT) by inhibiting the Na⁺-Cl⁻ symporter. Like loop diuretics, they increase sodium delivery to the late distal segments, leading to compensatory K⁺ excretion and **hypokalemia**. **High-Yield NEET-PG Pearls:** 1. **Classification:** Potassium-sparing diuretics are divided into **Aldosterone Antagonists** (Spironolactone, Eplerenone) and **Direct ENaC Blockers** (Amiloride, Triamterene). 2. **Clinical Use:** Spironolactone is the drug of choice for **Primary Hyperaldosteronism (Conn’s Syndrome)** and edema associated with **Liver Cirrhosis**. 3. **Side Effects:** A classic side effect of Spironolactone is **Gynecomastia** (due to its non-specific anti-androgenic activity). Eplerenone is a more selective alternative with fewer endocrine side effects. 4. **Contraindication:** These drugs should be avoided in patients with **Hyperkalemia** or chronic kidney disease (CKD) to prevent life-threatening arrhythmias.

Question 121: Which is the most potent loop diuretic?

A. Furosemide
B. Bumetanide (Correct Answer)
C. Torsemide
D. Ethacrynic acid

Explanation: **Explanation:** **Bumetanide** is the correct answer because it is the most potent loop diuretic currently available in clinical practice. Potency in pharmacology refers to the amount of drug (dose) required to produce a specific effect. Bumetanide is approximately **40 times more potent** than Furosemide; typically, 1 mg of Bumetanide achieves the same diuresis as 40 mg of Furosemide. It also possesses superior and more predictable oral bioavailability (80-100%). **Analysis of Incorrect Options:** * **Furosemide (A):** While it is the most commonly used loop diuretic, it is significantly less potent than Bumetanide. Its oral absorption is erratic (10-90%), making it less predictable in patients with gut edema (e.g., CHF). * **Torsemide (C):** It is more potent than Furosemide (ratio 1:2) and has a longer half-life, but it remains less potent than Bumetanide. It is often preferred for chronic heart failure due to its anti-aldosterone properties. * **Ethacrynic Acid (D):** This is the least potent loop diuretic listed. It is a non-sulfonamide derivative, making it the drug of choice only for patients with a true sulfonamide allergy. It carries the highest risk of **ototoxicity**. **High-Yield NEET-PG Pearls:** 1. **Mechanism of Action:** Loop diuretics inhibit the **Na+-K+-2Cl- symporter** in the Thick Ascending Limb (TAL) of the Loop of Henle. 2. **Site of Action:** They are also called "High-ceiling diuretics" because they act on the segment with the highest reabsorptive capacity. 3. **Metabolic Side Effects:** Remember the mnemonic **"Hypo-everything"** (Hypokalemia, Hyponatremia, Hypomagnesemia, Hypocalcemia) EXCEPT for **Hyperuricemia** and **Hyperglycemia**. 4. **Drug of Choice:** Loop diuretics are the first-line treatment for **Acute Pulmonary Edema**.

Question 122: Regarding furosemide, which of the following statements is true?

A. Given by parenteral route only
B. Used in pulmonary edema (Correct Answer)
C. Acts at the proximal convoluted tubule (PCT)
D. Causes hypercalcemia

Explanation: **Explanation:** **Furosemide** is a high-ceiling loop diuretic that acts by inhibiting the **Na⁺-K⁺-2Cl⁻ symporter** in the **Thick Ascending Limb (TAL)** of the Loop of Henle. **Why Option B is Correct:** Furosemide is the drug of choice for **acute pulmonary edema**. Its efficacy is twofold: 1. **Hemodynamic effect:** When given IV, it causes rapid venodilation (mediated by prostaglandins), which decreases venous return (preload) and relieves pulmonary congestion even before the diuresis begins. 2. **Diuretic effect:** It promotes intense diuresis, reducing the total circulating blood volume. **Analysis of Incorrect Options:** * **Option A:** Furosemide has good oral bioavailability (~60%) and is available in both **oral and parenteral** (IV/IM) formulations. * **Option C:** It acts on the **TAL**, not the PCT. Diuretics acting on the PCT include Acetazolamide and Osmotic diuretics (Mannitol). * **Option D:** Loop diuretics cause **hypocalcemia** ("Loops lose calcium"). They abolish the lumen-positive potential in the TAL, preventing the paracellular reabsorption of Ca²⁺ and Mg²⁺. (Note: Thiazides cause hypercalcemia). **High-Yield Clinical Pearls for NEET-PG:** * **Adverse Effects:** Hypokalemic metabolic alkalosis, Ototoxicity (especially when combined with aminoglycosides), Hyperuricemia, and Hypomagnesemia. * **Drug Interactions:** NSAIDs can reduce the diuretic efficacy of furosemide by inhibiting prostaglandin synthesis. * **Mnemonic:** "OH DANG" (Ototoxicity, Hypokalemia, Dehydration, Allergy/Alkalosis, Nephrotoxicity, Gout).

Question 123: Which drug causes hypercalcemia?

A. Bumetanide
B. Spironolactone
C. Thiazide (Correct Answer)
D. Furosemide

Explanation: **Explanation:** **Thiazide diuretics** (e.g., Hydrochlorothiazide, Chlorthalidone) are the correct answer because they promote the renal reabsorption of calcium [1]. They act on the **Distal Convoluted Tubule (DCT)** by inhibiting the $Na^+/Cl^-$ symporter [2]. This decrease in intracellular sodium enhances the activity of the $Na^+/Ca^{2+}$ exchanger on the basolateral membrane, which in turn drives more calcium reabsorption from the tubular lumen into the blood. Consequently, Thiazides cause **hypercalcemia** and **hypocalciuria** [1], [2]. **Analysis of Incorrect Options:** * **Bumetanide & Furosemide (Options A & D):** These are **Loop diuretics** that inhibit the $Na^+/K^+/2Cl^-$ cotransporter in the Thick Ascending Limb of Henle. This action abolishes the lumen-positive potential required for the paracellular reabsorption of divalent cations. Therefore, Loop diuretics cause **hypocalcemia** (calcium excretion). *Mnemonic: "Loops Lose Calcium." * **Spironolactone (Option B):** This is a **Potassium-sparing diuretic** (Aldosterone antagonist). While it significantly affects potassium and hydrogen ion excretion, it has no clinically significant effect on serum calcium levels. **NEET-PG High-Yield Pearls:** * **Clinical Utility:** Because Thiazides decrease urinary calcium, they are the drug of choice for patients with **idiopathic hypercalciuria** and recurrent **calcium oxalate stones**. * **Bone Health:** Thiazides are preferred for hypertensive patients with **osteoporosis** as they help preserve bone mineral density. * **Metabolic Side Effects:** Thiazides are associated with the "4 Hypers and 2 Hypos": **Hyper**uricemia, **Hyper**glycemia, **Hyper**lipidemia, **Hyper**calcemia; **Hypo**kalemia, and **Hypo**natremia [1].

Question 124: All of the following statements about amiloride are true EXCEPT:

A. It antagonizes the action of aldosterone. (Correct Answer)
B. It is the drug of choice for the treatment of lithium-induced diabetes insipidus.
C. It decreases calcium loss in the urine.
D. It is more potent than triamterene.

Explanation: **Explanation:** Amiloride is a **Potassium-Sparing Diuretic** that belongs to the class of **Renal Epithelial Sodium Channel (ENaC) blockers**. **1. Why Option A is the correct answer (The False Statement):** Amiloride does **not** antagonize the action of aldosterone. Instead, it acts independently of aldosterone by directly blocking the ENaC channels in the late distal tubule and collecting duct. In contrast, drugs like Spironolactone and Eplerenone are the ones that competitively antagonize the Mineralocorticoid (Aldosterone) Receptor. **2. Analysis of Incorrect Options (True Statements):** * **Option B:** Amiloride is the **drug of choice for Lithium-induced Nephrogenic Diabetes Insipidus**. Lithium enters the collecting duct cells through ENaC channels; amiloride blocks these channels, preventing lithium from accumulating and interfering with ADH action. * **Option C:** Like thiazides, amiloride **decreases urinary calcium excretion** (hypocalciuric effect), which can be beneficial in patients with calcium-containing kidney stones. * **Option D:** Amiloride is significantly **more potent** than Triamterene (the other ENaC blocker), requiring a much lower dose (5 mg vs. 50-100 mg) to achieve the same effect. **NEET-PG High-Yield Pearls:** * **Mechanism:** Direct ENaC blockade $\rightarrow$ decreased Na+ reabsorption $\rightarrow$ decreased K+ and H+ secretion (hence "potassium-sparing"). * **Liddle’s Syndrome:** Amiloride is the treatment of choice for this rare genetic condition characterized by overactive ENaC channels. * **Side Effect:** The most serious adverse effect is **Hyperkalemia**, especially when used with ACE inhibitors or in patients with renal impairment.

Question 125: Canrenone is a metabolite of which drug?

A. Ampicillin
B. Spironolactone (Correct Answer)
C. Furosemide
D. Acetazolamide

Explanation: **Explanation:** **Correct Answer: B. Spironolactone** Spironolactone is a synthetic steroid that acts as a competitive antagonist of the mineralocorticoid receptor (Aldosterone antagonist) [1]. It is a **prodrug** that undergoes extensive first-pass metabolism in the liver. Its primary active metabolite is **Canrenone**, which accounts for a significant portion of its long-lasting antimalarials activity [2]. Canrenone has a much longer half-life (approx. 16.5 hours) compared to parent spironolactone (approx. 1.5 hours), contributing to the drug's prolonged clinical effect [2]. **Why other options are incorrect:** * **A. Ampicillin:** An aminopenicillin antibiotic. It is excreted mostly unchanged in the urine; it does not produce canrenone. * **C. Furosemide:** A loop diuretic acting on the Na⁺-K⁺-2Cl⁻ symporter in the thick ascending limb. It is primarily excreted unchanged and does not have steroid-based metabolites. * **D. Acetazolamide:** A carbonic anhydrase inhibitor acting on the proximal convoluted tubule. It is excreted unchanged by the kidneys. **High-Yield Clinical Pearls for NEET-PG:** * **Potassium-Sparing:** Spironolactone and Eplerenone are the only diuretics that can cause **hyperkalemia** [1]. * **Side Effects:** Due to its non-specific binding to androgen and progesterone receptors, spironolactone can cause **gynecomastia**, impotence, and menstrual irregularities [1]. **Eplerenone** is a more selective alternative with fewer endocrine side effects [1]. * **Clinical Use:** It is the drug of choice for **primary hyperaldosteronism (Conn’s Syndrome)** and is used to improve survival in **Congestive Heart Failure (NYHA Class II-IV)** and to manage ascites in **liver cirrhosis**.

Question 126: What is the mechanism of action of acetazolamide?

A. Inhibition of aldosterone
B. Stimulation of aldosterone
C. Inhibition of carbonic anhydrase (Correct Answer)
D. Stimulation of carbonic anhydrase

Explanation: **Explanation:** **Mechanism of Action:** Acetazolamide is a potent inhibitor of the enzyme **carbonic anhydrase (CA)**, primarily located in the **proximal convoluted tubule (PCT)** of the nephron. Under normal conditions, CA facilitates the conversion of $H_2CO_3$ into $H_2O$ and $CO_2$ in the lumen, and the reverse reaction inside the cell. By inhibiting this enzyme, acetazolamide prevents the reabsorption of sodium bicarbonate ($NaHCO_3$). This leads to increased urinary excretion of bicarbonate, sodium, and water, resulting in alkaline urine and a mild diuretic effect. **Analysis of Options:** * **Option A & B (Aldosterone):** Aldosterone acts on the distal tubule and collecting ducts to increase sodium reabsorption and potassium excretion. Drugs that inhibit aldosterone are known as Potassium-Sparing Diuretics (e.g., Spironolactone). Acetazolamide has no direct effect on aldosterone receptors. * **Option D (Stimulation of CA):** Stimulating carbonic anhydrase would theoretically increase bicarbonate reabsorption, which is the opposite of the desired diuretic effect. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Uses:** Glaucoma (decreases aqueous humor production), Acute Mountain Sickness (induces metabolic acidosis to stimulate respiration), and Urinary Alkalinization (to excrete acidic drugs like aspirin). * **Side Effects:** Hyperchloremic metabolic acidosis, hypokalemia, and sulfonamide-like hypersensitivity reactions. * **Contraindication:** It should be avoided in patients with hepatic cirrhosis as it decreases ammonia excretion, potentially precipitating hepatic encephalopathy.

Question 127: Which group of diuretics does not require access to the tubular lumen to induce diuresis?

A. Carbonic anhydrase inhibitor
B. Na-Cl symporter inhibitor
C. Mineralocorticoid antagonist (Correct Answer)
D. Na-K-2Cl symporter inhibitor

Explanation: ### Explanation **Correct Option: C. Mineralocorticoid antagonist** **Mechanism of Action:** Most diuretics act from the **luminal side** of the nephron. However, Mineralocorticoid Antagonists (e.g., Spironolactone, Eplerenone) are unique because they are **lipid-soluble steroids**. They do not need to be secreted into the tubular lumen; instead, they cross the basolateral membrane from the bloodstream to reach the cytoplasm of the principal cells in the late distal tubule and collecting duct. Once inside, they bind to and inhibit the **intracellular Mineralocorticoid Receptor (MR)**, preventing the expression of ENaC (epithelial sodium channels) and Na+/K+ ATPase. **Why Incorrect Options are Wrong:** * **A. Carbonic anhydrase inhibitors (Acetazolamide):** These must be filtered or secreted into the proximal convoluted tubule to inhibit the membrane-bound carbonic anhydrase enzyme on the luminal brush border. * **B. Na-Cl symporter inhibitors (Thiazides):** These act on the Distal Convoluted Tubule (DCT). They are organic acids that are secreted into the lumen via the organic acid transport system to inhibit the NCC transporter from the luminal side. * **D. Na-K-2Cl symporter inhibitors (Loop diuretics):** Drugs like Furosemide are highly protein-bound and are not filtered at the glomerulus. They must be actively secreted into the tubular lumen by the proximal tubule to reach the Thick Ascending Limb (TAL) and inhibit the NKCC2 transporter. **NEET-PG High-Yield Pearls:** 1. **Site of Action:** Spironolactone is the only diuretic that acts on the **cytosolic receptor** rather than a membrane protein. 2. **Pharmacokinetics:** Because they act via gene transcription and protein synthesis, mineralocorticoid antagonists have a **slow onset of action** (several days). 3. **Clinical Use:** Spironolactone is the drug of choice for edema in **liver cirrhosis** (due to secondary hyperaldosteronism) and is proven to reduce mortality in **Congestive Heart Failure (CHF)**.

Question 128: Potassium supplementation is often necessary for patients taking which of the following drugs?

A. Spironolactone
B. Triamterene
C. Furosemide (Correct Answer)
D. Amiloride

Explanation: **Explanation:** **Correct Option: C. Furosemide** Furosemide is a potent **Loop Diuretic** that acts by inhibiting the **Na⁺-K⁺-2Cl⁻ cotransporter** in the Thick Ascending Limb (TAL) of the Loop of Henle. By preventing sodium reabsorption, it increases the delivery of Na⁺ to the distal nephron. This triggers the renin-angiotensin-aldosterone system (RAAS), leading to increased Na⁺-K⁺ exchange in the collecting ducts. Consequently, there is significant urinary excretion of potassium (**Hypokalemia**). To prevent cardiac arrhythmias and muscle weakness, patients on long-term loop diuretics often require exogenous potassium supplementation. **Why other options are incorrect:** * **A, B, and D (Spironolactone, Triamterene, Amiloride):** These are all **Potassium-Sparing Diuretics**. Spironolactone is an aldosterone antagonist, while Triamterene and Amiloride block the Epithelial Sodium Channels (ENaC). These drugs prevent K⁺ secretion into the urine. Therefore, they carry a risk of **Hyperkalemia**, and potassium supplementation is strictly contraindicated as it could lead to fatal potassium levels. **High-Yield Clinical Pearls for NEET-PG:** * **Loop Diuretics (Furosemide):** Cause "Hypo-everything" (Hypokalemia, Hypomagnesemia, Hypocalcemia) except for Hyperuricemia and Hyperglycemia. * **Thiazides:** Also cause hypokalemia but, unlike loop diuretics, they cause **Hypercalcemia** (useful in patients with osteoporosis or calcium stones). * **Drug of Choice:** Furosemide is the DOC for acute pulmonary edema; Spironolactone is the DOC for edema in hepatic cirrhosis and Conn’s syndrome.

Question 129: Which of the following diuretics can lead to hyperglycemia and hyperlipidemia?

A. Carbonic anhydrase inhibitors
B. Loop diuretics
C. Thiazide diuretics (Correct Answer)
D. Vasopressin antagonists

Explanation: **Explanation:** **Thiazide diuretics** (e.g., Hydrochlorothiazide, Chlorthalidone) are well-known for causing metabolic side effects, specifically **hyperglycemia** and **hyperlipidemia**. 1. **Hyperglycemia:** Thiazides inhibit insulin release from the pancreas (due to hypokalemia-induced closure of ATP-sensitive K+ channels) and decrease peripheral glucose utilization, leading to impaired glucose tolerance. 2. **Hyperlipidemia:** They cause a transient increase in serum total cholesterol, LDL, and triglycerides, likely due to altered lipid metabolism and insulin resistance. **Analysis of Incorrect Options:** * **Carbonic Anhydrase Inhibitors (e.g., Acetazolamide):** These primarily cause metabolic acidosis and hypokalemia. They are not typically associated with significant glucose or lipid elevations. * **Loop Diuretics (e.g., Furosemide):** While they can cause mild hyperglycemia (also via hypokalemia), the effect is significantly less pronounced than with Thiazides. Their hallmark side effects are ototoxicity and profound hypocalcemia. * **Vasopressin Antagonists (e.g., Tolvaptan):** These are "aquaretics" used in SIADH. Their main side effect is thirst, dry mouth, and potential hepatotoxicity (with Tolvaptan). **High-Yield Clinical Pearls for NEET-PG:** * **The "Hyper" Rule for Thiazides:** They cause **Hyper**glycemia, **Hyper**lipidemia, **Hyper**uricemia (can precipitate Gout), and **Hyper**calcemia (useful in nephrolithiasis). * **The "Hypo" Rule for Thiazides:** They cause **Hypo**kalemia, **Hypo**natremia, and **Hypo**magnesemia. * **Drug of Choice:** Thiazides are the preferred diuretics for hypertension in patients with osteoporosis because they decrease urinary calcium excretion.

Question 130: What is true about Acetazolamide?

A. Decreased GFR (Correct Answer)
B. Action similar to sulphonamide
C. It decreases Na, K, and Glucose excretion
D. It causes metabolic alkalosis

Explanation: **Explanation:** **Acetazolamide** is a potent Carbonic Anhydrase (CA) inhibitor that acts primarily at the Proximal Convoluted Tubule (PCT). **Why Option A is Correct:** Acetazolamide causes a **decrease in Glomerular Filtration Rate (GFR)** through a mechanism known as **Tubuloglomerular Feedback (TGF)**. By inhibiting CA, it prevents the reabsorption of NaHCO₃, leading to an increased delivery of solutes (sodium and chloride) to the Macula Densa in the distal tubule. The Macula Densa senses this high solute load and triggers afferent arteriolar vasoconstriction, thereby reducing the GFR. **Analysis of Incorrect Options:** * **Option B:** While Acetazolamide is chemically a **sulfonamide derivative**, its *action* is not similar to sulfonamide antibiotics (which inhibit dihydropteroate synthase). It is used for its enzyme-inhibiting properties, not antimicrobial ones. * **Option C:** It **increases** the excretion of Sodium (Na⁺), Potassium (K⁺), and Bicarbonate (HCO₃⁻). It does not significantly affect glucose excretion. * **Option D:** By causing significant loss of bicarbonate in the urine (bicarbonaturia), it leads to **Hyperchloremic Metabolic Acidosis**, not alkalosis. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Indications:** Glaucoma (decreases aqueous humor production), Acute Mountain Sickness (counteracts respiratory alkalosis), and Urinary Alkalinization (to excrete acidic drugs like uric acid or aspirin). * **Side Effects:** Hypokalemia, Paresthesia, Renal stones (due to calcium phosphate precipitation in alkaline urine), and Sulfonamide hypersensitivity. * **Contraindication:** Hepatic Cirrhosis (it decreases ammonia excretion, potentially precipitating hepatic encephalopathy).

Question 131: Thiazide diuretics do not produce which of the following adverse effects?

A. Hypoglycemia (Correct Answer)
B. Hyponatremia
C. Hypokalemia
D. Hyperuricemia

Explanation: **Explanation:** Thiazide diuretics are known for causing a variety of metabolic disturbances, but **Hypoglycemia** is not one of them. In fact, Thiazides are notorious for causing **Hyperglycemia**. **1. Why Hypoglycemia is the correct answer:** Thiazides impair glucose tolerance by inhibiting insulin release from the pancreas (partially due to hypokalemia, which hyperpolarizes beta cells) and decreasing peripheral glucose utilization. Therefore, they cause an *increase* in blood sugar levels, making "hypoglycemia" the incorrect clinical effect. **2. Analysis of Incorrect Options:** * **Hyponatremia (B):** Thiazides inhibit the $Na^+/Cl^-$ symporter in the distal convoluted tubule. They increase sodium excretion while the body’s ability to dilute urine is impaired, frequently leading to low serum sodium. * **Hypokalemia (C):** Increased sodium delivery to the collecting ducts stimulates the exchange of $Na^+$ for $K^+$, leading to significant potassium loss in the urine. * **Hyperuricemia (D):** Thiazides compete with uric acid for the organic acid secretory secretory pathway in the proximal tubule. This leads to uric acid retention, which can precipitate acute gouty arthritis. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Thiazide side effects:** **"Hyper GLUC"** – **G**lycemia, **L**ipidemia (Hyperlipidemia), **U**ricemia, and **C**alcemia (Hypercalcemia). * **Calcium Sparing:** Unlike Loop diuretics ("Loops Lose Calcium"), Thiazides *increase* calcium reabsorption and are used clinically to prevent calcium-containing renal stones. * **Drug of Choice:** Thiazides are often the first-line treatment for essential hypertension in patients without co-morbidities.

Question 132: A 68-year-old woman presents with symptoms and signs of congestive heart failure. Which of the following is a contraindication to the use of furosemide?

A. Hypoalbuminemia
B. Oliguria
C. Acidosis
D. A history of rash with trimethoprim-sulfamethoxazole (Correct Answer)

Explanation: ### Explanation **Correct Option: D. A history of rash with trimethoprim-sulfamethoxazole** The correct answer is based on the concept of **cross-reactivity among sulfonamide-derived drugs**. Furosemide is a sulfonamide derivative. Trimethoprim-sulfamethoxazole (Bactrim/Septra) contains sulfamethoxazole, a sulfonamide antibiotic. Patients who have experienced an allergic reaction (like a rash, urticaria, or Stevens-Johnson Syndrome) to sulfonamide antibiotics may exhibit cross-reactivity with non-antibiotic sulfonamides, including loop diuretics (furosemide, bumetanide), thiazides, and sulfonylureas. While the clinical risk of cross-reactivity is sometimes debated, for the purpose of exams like NEET-PG, a known sulfonamide allergy is a classic contraindication for furosemide. **Why other options are incorrect:** * **A. Hypoalbuminemia:** Furosemide is highly protein-bound (to albumin). In hypoalbuminemia, the delivery of furosemide to the proximal tubule is reduced, leading to "diuretic resistance." It is not a contraindication; rather, it may necessitate higher doses or co-administration with albumin. * **B. Oliguria:** Furosemide is frequently used to treat oliguria in the setting of acute kidney injury or fluid overload to "convert" oliguric renal failure to non-oliguric failure. It is only contraindicated in **anuria** (complete absence of urine production). * **C. Acidosis:** Furosemide actually tends to cause **contraction alkalosis** (hypokalemic metabolic alkalosis). It is not contraindicated in acidosis; in fact, it does not worsen the acidotic state directly. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits the **Na+/K+/2Cl- symporter** in the Thick Ascending Limb (TAL) of the Loop of Henle. * **Drug of Choice:** Furosemide is the DOC for **acute pulmonary edema** due to its rapid action and venodilatory properties. * **Side Effects Mnemonic (OH DANG!):** **O**totoxicity, **H**ypokalemia, **D**ehydration, **A**llergy (Sulfa), **N**ephritis (Interstitial), **G**out (Hyperuricemia). * **Ethacrynic Acid:** The only loop diuretic that is **not** a sulfonamide; it is the alternative for patients with sulfa allergies but carries a higher risk of ototoxicity.

Question 133: Hypokalemia is seen with which of the following?

A. Frusemide
B. Cortisol
C. Amiloride
D. Addison's disease (Correct Answer)

Explanation: ### Explanation The question asks to identify the condition or drug associated with **Hypokalemia** (low serum potassium). #### **1. Why the Correct Answer is Right (Addison’s Disease)** Wait, there appears to be a **discrepancy in the provided key**. In clinical medicine, **Addison’s disease** (Primary Adrenocortical Insufficiency) is characterized by a deficiency of aldosterone. Since aldosterone normally promotes $K^+$ excretion, its absence leads to **Hyperkalemia**, not hypokalemia. However, if we analyze the options based on standard pharmacological principles: * **Frusemide (Option A)** and **Cortisol (Option B)** both cause **Hypokalemia**. * **Amiloride (Option C)** and **Addison’s disease (Option D)** cause **Hyperkalemia**. *Note: If the question intended to ask for "Hyperkalemia," then Addison's Disease and Amiloride would be correct. If the question asks for "Hypokalemia," then Frusemide and Cortisol are the correct answers.* #### **2. Analysis of Options** * **A. Frusemide:** A loop diuretic that inhibits the $Na^+-K^+-2Cl^-$ symporter. It increases distal sodium delivery, leading to increased $K^+$ secretion and **Hypokalemia**. * **B. Cortisol:** Has mineralocorticoid activity. It acts on the distal tubule to reabsorb $Na^+$ and excrete $K^+$, leading to **Hypokalemia** (as seen in Cushing’s syndrome). * **C. Amiloride:** A potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the collecting duct. It prevents $K^+$ secretion, leading to **Hyperkalemia**. * **D. Addison’s Disease:** Results in hypoaldosteronism. Lack of aldosterone prevents $K^+$ excretion, classically causing **Hyperkalemia**, hyponatremia, and metabolic acidosis. #### **3. High-Yield Clinical Pearls for NEET-PG** * **Diuretics causing Hypokalemia:** Loop diuretics (Frusemide) and Thiazides. * **Diuretics causing Hyperkalemia:** Spironolactone, Eplerenone, Amiloride, and Triamterene. * **Endocrine causes of Hypokalemia:** Conn’s Syndrome (Primary Hyperaldosteronism), Cushing’s Syndrome. * **Endocrine causes of Hyperkalemia:** Addison’s Disease, Type IV Renal Tubular Acidosis.

Question 134: Which diuretic is the drug of choice in patients with pulmonary edema?

A. Furosemide (Correct Answer)
B. Thiazide
C. Spironolactone
D. Amiloride

Explanation: ### Explanation **Furosemide** is the drug of choice for the emergency management of acute pulmonary edema. Its efficacy is attributed to two distinct mechanisms: 1. **Immediate Venodilation:** Before the diuretic effect begins, intravenous furosemide increases venous capacitance (via prostaglandin-mediated venodilation). This rapidly reduces venous return (preload), relieving pulmonary congestion within minutes. 2. **Potent Diuresis:** As a "High-Ceiling" Loop Diuretic, it inhibits the **Na⁺-K⁺-2Cl⁻ symporter** in the Thick Ascending Limb of Henle. This results in a rapid, massive excretion of salt and water, further reducing circulating blood volume. **Why the other options are incorrect:** * **Thiazides (e.g., Hydrochlorothiazide):** These are "low-ceiling" diuretics acting on the distal convoluted tubule. They have a slower onset, are less potent, and lack the immediate venodilatory effect required for acute pulmonary emergencies. * **Spironolactone:** This is a potassium-sparing diuretic (Aldosterone antagonist). It is used for long-term remodeling in chronic heart failure but is far too slow and weak for acute pulmonary edema. * **Amiloride:** This is a sodium channel blocker (K⁺-sparing) acting on the collecting duct. Like spironolactone, its diuretic potency is insufficient for emergency fluid mobilization. **High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** In pulmonary edema, furosemide must be given **Intravenously (IV)** for rapid action. * **Ototoxicity:** Furosemide can cause dose-dependent hearing loss, especially when combined with aminoglycosides. * **Metabolic Profile:** Loop diuretics cause "Low" levels of almost everything (**Hypokalemia, Hypomagnesemia, Hyponatremia, Hypocalcemia**) but "High" levels of **Uric acid (Hyperuricemia)** and **Glucose (Hyperglycemia)**. * **Sulfa Allergy:** Most loop diuretics (except Ethacrynic acid) are sulfonamide derivatives.

Question 135: Vasopressin antagonists act on which part of the nephron?

A. Proximal convoluted tubule
B. Distal convoluted tubule
C. Cortical collecting tubule
D. Medullary collecting duct (Correct Answer)

Explanation: **Explanation:** Vasopressin (Antidiuretic Hormone/ADH) antagonists, also known as **Vaptans** (e.g., Tolvaptan, Conivaptan), exert their primary diuretic effect by blocking **V2 receptors**. These receptors are located on the basolateral membrane of the principal cells in the **medullary collecting duct**. **Mechanism of Action:** Under normal physiological conditions, ADH binds to V2 receptors, triggering the insertion of **Aquaporin-2 (AQP2)** water channels into the apical membrane. This allows for free water reabsorption. By antagonizing these receptors, Vaptans prevent water reabsorption, leading to **aquaresis** (excretion of solute-free water) without significant loss of electrolytes like sodium or potassium. **Analysis of Options:** * **A. Proximal Convoluted Tubule:** This is the site of action for Carbonic Anhydrase inhibitors (Acetazolamide) and SGLT2 inhibitors. * **B. Distal Convoluted Tubule:** This is the site of action for Thiazide diuretics, which inhibit the Na+-Cl- symporter. * **C. Cortical Collecting Tubule:** While some V2 receptors exist here, the **medullary** portion of the collecting duct has the highest density of these receptors and is the critical site for establishing the final urine concentration. Potassium-sparing diuretics (Amiloride, Spironolactone) act primarily in the cortical segment. **NEET-PG High-Yield Pearls:** * **Indications:** Vaptans are the treatment of choice for **SIADH** and are used in hypervolemic hyponatremia (e.g., CHF, Cirrhosis). * **Tolvaptan:** Oral, selective V2 antagonist. * **Conivaptan:** IV, non-selective (blocks both V1a and V2 receptors). * **Side Effect:** Rapid correction of hyponatremia with Vaptans carries a risk of **Osmotic Demyelination Syndrome (Central Pontine Myelinolysis).**

Question 136: All of the following diuretics inhibit Na+-K+-2Cl- symporter, EXCEPT:

A. Furosemide
B. Metolazone (Correct Answer)
C. Ethacrynic acid
D. Mersalyl

Explanation: **Explanation:** The question tests your ability to distinguish between different classes of diuretics based on their site and mechanism of action. **1. Why Metolazone is the correct answer:** Metolazone is a **Thiazide-like diuretic**. Unlike loop diuretics, it acts on the **Distal Convoluted Tubule (DCT)** by inhibiting the **Na+-Cl- symporter**. It does not act on the Na+-K+-2Cl- (NKCC2) symporter. * *Clinical Pearl:* Metolazone is unique because it remains effective even in patients with a low Glomerular Filtration Rate (GFR <30 mL/min), where other thiazides typically fail. **2. Why the other options are incorrect:** Options A, C, and D are all **Loop Diuretics**, which exert their primary effect by inhibiting the **Na+-K+-2Cl- symporter** in the Thick Ascending Limb (TAL) of the Loop of Henle. * **Furosemide:** A prototype high-ceiling sulfonamide loop diuretic. * **Ethacrynic acid:** A phenoxyacetic acid derivative. It is the only non-sulfonamide loop diuretic, making it the drug of choice for patients with sulfa allergies. * **Mersalyl:** An older organomercurial diuretic that also inhibits the NKCC2 symporter, though it is rarely used today due to toxicity. **High-Yield Facts for NEET-PG:** * **Site of Action:** Loop diuretics act on the TAL (NKCC2); Thiazides act on the DCT (NCC). * **Calcium Handling:** Loop diuretics cause **hypocalcemia** ("Loops lose calcium"), whereas Thiazides cause **hypercalcemia** (useful in nephrolithiasis). * **Ototoxicity:** Ethacrynic acid has the highest risk of ototoxicity among loop diuretics. * **Sequential Nephron Blockade:** Combining Metolazone with a Loop diuretic (e.g., Furosemide) creates a synergistic effect used in refractory edema.

Question 137: On which part of the nephron do loop diuretics act?

A. Descending limb of the loop of Henle
B. Thick ascending limb of the loop of Henle (Correct Answer)
C. Cortical segment of the distal convoluted tubule
D. Collecting duct

Explanation: **Explanation:** **Correct Option: B. Thick ascending limb (TAL) of the loop of Henle** Loop diuretics (e.g., Furosemide, Torsemide, Bumetanide) exert their primary effect by inhibiting the **Na⁺-K⁺-2Cl⁻ (NKCC2) symporter** located in the luminal membrane of the **thick ascending limb**. This segment is responsible for reabsorbing approximately 25% of filtered sodium. By blocking this transporter, loop diuretics significantly increase the excretion of Na⁺, Cl⁻, and water, making them the most potent diuretics ("High-ceiling diuretics"). **Analysis of Incorrect Options:** * **A. Descending limb of the loop of Henle:** This segment is highly permeable to water but impermeable to solutes. No major diuretic class acts here; however, osmotic diuretics (like Mannitol) primarily exert their effect in the proximal tubule and descending limb by retaining water in the lumen. * **C. Cortical segment of the distal convoluted tubule:** This is the site of action for **Thiazide diuretics**, which inhibit the Na⁺-Cl⁻ symporter. * **D. Collecting duct:** This is the site of action for **Potassium-sparing diuretics** (e.g., Spironolactone, Amiloride) and Antidiuretic Hormone (ADH) antagonists (Vaptans). **High-Yield Clinical Pearls for NEET-PG:** 1. **Mechanism of Hypocalcemia:** By inhibiting NKCC2, loop diuretics abolish the lumen-positive potential usually created by K⁺ back-leak. This inhibits the paracellular reabsorption of **Ca²⁺ and Mg²⁺**, leading to increased excretion. (*Mnemonic: Loop Loses Calcium*). 2. **Drug of Choice:** Furosemide is the drug of choice for acute pulmonary edema and congestive heart failure. 3. **Ototoxicity:** Loop diuretics can cause dose-dependent hearing loss (Ethacrynic acid is the most ototoxic). 4. **Sulfa Allergy:** Most loop diuretics are sulfonamide derivatives (except Ethacrynic acid).

Question 138: Which diuretic agent is most useful in the treatment of recurrent calcium stones?

A. Mannitol
B. Furosemide
C. Spironolactone
D. Hydrochlorothiazide (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Hydrochlorothiazide** **Mechanism and Rationale:** Thiazide diuretics (like Hydrochlorothiazide) are the drugs of choice for preventing recurrent calcium oxalate stones. Their effectiveness lies in their ability to **decrease urinary calcium excretion (hypocalciuria)**. Thiazides inhibit the $Na^+/Cl^-$ symporter in the Distal Convoluted Tubule (DCT). This reduction in intracellular sodium enhances the activity of the $Na^+/Ca^{2+}$ exchanger on the basolateral membrane, which in turn creates a gradient that promotes **increased reabsorption of calcium** from the tubular lumen into the blood. By lowering the concentration of calcium in the urine, the likelihood of stone precipitation is significantly reduced. **Why the other options are incorrect:** * **A. Mannitol:** An osmotic diuretic used primarily to reduce intracranial or intraocular pressure. It does not specifically target calcium handling and can cause electrolyte imbalances. * **B. Furosemide:** A loop diuretic that **increases** urinary calcium excretion ("Loops Lose Calcium"). It is used to treat hypercalcemia but would worsen the risk of calcium stone formation. * **C. Spironolactone:** A potassium-sparing diuretic (aldosterone antagonist). While it prevents potassium loss, it has no significant effect on renal calcium reabsorption. **NEET-PG High-Yield Pearls:** * **Mnemonic:** **L**oops **L**ose calcium; **T**hiazides **T**ake it up (reabsorb). * **Paradoxical Use:** Thiazides are also used in **Nephrogenic Diabetes Insipidus** to reduce polyuria by inducing mild volume depletion and increasing proximal water reabsorption. * **Metabolic Side Effects of Thiazides:** Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia, and Hyper**C**alcemia (Mnemonic: **GLUC**).

Question 139: All of the following about loop diuretics are true EXCEPT:

A. Ethacrynic acid is the most ototoxic loop diuretic.
B. They release prostaglandins and lead to vasodilation.
C. Loop diuretics lead to hypokalemia and metabolic alkalosis.
D. Furosemide is the most potent loop diuretic. (Correct Answer)

Explanation: **Explanation:** **1. Why Option D is the correct (False) statement:** While Furosemide is the most commonly used loop diuretic, it is **not** the most potent. In the context of loop diuretics, potency refers to the dose required to achieve a specific effect. **Bumetanide** is the most potent loop diuretic (approximately 40 times more potent than Furosemide), followed by Torsemide. Furosemide actually has the lowest potency among the commonly used sulfonamide loop diuretics. **2. Analysis of other options:** * **Option A:** **Ethacrynic acid** is a non-sulfonamide loop diuretic. It is associated with the highest incidence of **ototoxicity** (tinnitus and deafness) compared to others and is generally reserved for patients with sulfonamide allergies. * **Option B:** Loop diuretics stimulate the intrarenal synthesis of **prostaglandins (PGE2)**. This leads to renal and systemic vasodilation, which is why IV Furosemide provides rapid symptomatic relief in acute pulmonary edema even before the diuresis begins. * **Option C:** By inhibiting the Na⁺-K⁺-2Cl⁻ symporter in the Thick Ascending Limb (TAL), more Na⁺ reaches the distal tubule. This promotes K⁺ and H⁺ secretion, leading to **hypokalemia** and **metabolic alkalosis** (contraction alkalosis). **NEET-PG High-Yield Pearls:** * **Mechanism:** Inhibits Na⁺-K⁺-2Cl⁻ cotransporter in the TAL of the Loop of Henle. * **Electrolyte Profile:** Causes "Hypo-everything" (Hypokalemia, Hypomagnesemia, Hypocalcemia, Hyponatremia) **EXCEPT** Hyperuricemia and Hyperglycemia. * **Drug of Choice:** Furosemide is the DOC for acute pulmonary edema and edema associated with CHF, cirrhosis, and renal failure. * **Torsemide:** Has a longer half-life and better oral bioavailability than Furosemide.

Question 140: Glycerol is classified as which of the following?

A. Osmotic diuretic (Correct Answer)
B. Purgative
C. Antidiabetic
D. Antiemetic

Explanation: **Explanation:** **Glycerol** is a low-molecular-weight, pharmacologically inert substance that acts as an **Osmotic Diuretic**. When administered (usually orally), it increases the osmolality of the plasma and tubular fluid. This creates an osmotic gradient that draws water out of the intracellular and interstitial compartments into the vascular space and prevents water reabsorption in the proximal convoluted tubule and descending limb of Henle's loop. **Why the other options are incorrect:** * **Purgative:** While some osmotic agents like Lactulose or Magnesium salts are used as purgatives, Glycerol's primary systemic classification in pharmacology is an osmotic agent. (Note: Glycerin suppositories can be used for constipation, but it is not its primary systemic classification). * **Antidiabetic:** Glycerol is actually a precursor for gluconeogenesis; it does not lower blood glucose. * **Antiemetic:** Glycerol has no action on the chemoreceptor trigger zone (CTZ) or the vomiting center. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Use:** Glycerol is most commonly used to rapidly reduce **intraocular pressure (IOP)** in acute glaucoma and **intracranial pressure (ICP)** in cerebral edema. * **Route:** Unlike Mannitol (which must be given IV), Glycerol is **effective orally**. * **Metabolism:** Unlike Mannitol, Glycerol is metabolized in the body and provides approximately **4.3 kcal/g**, which can lead to hyperglycemia. * **Caution:** Use with extreme caution in **Diabetic patients** (due to hyperglycemia) and **Congestive Heart Failure (CHF)** patients (due to rapid expansion of extracellular fluid volume).

Question 141: Glucose transport and reabsorption in the kidneys is inhibited by which of the following?

A. Tetrodotoxin
B. GLUT
C. SGLT
D. Phlorhizin (Correct Answer)

Explanation: **Explanation:** The correct answer is **Phlorhizin**. **1. Why Phlorhizin is correct:** Glucose reabsorption in the kidney occurs primarily in the proximal convoluted tubule (PCT) via **SGLT2** (90%) and **SGLT1** (10%) transporters [1]. **Phlorhizin** is a naturally occurring glucoside (found in the bark of fruit trees) that acts as a **non-selective, competitive inhibitor of both SGLT1 and SGLT2**. By blocking these transporters, it prevents the reabsorption of filtered glucose, leading to glycosuria and a reduction in blood glucose levels. While not used clinically due to poor absorption and GI side effects, it served as the prototype for the modern "Gliflozin" class (e.g., Dapagliflozin) [2]. **2. Why other options are incorrect:** * **Tetrodotoxin:** A potent neurotoxin found in pufferfish. It acts by blocking **voltage-gated sodium channels**, inhibiting action potentials in nerve and muscle cells. It has no effect on glucose transport. * **GLUT:** These are a family of **uniporters** (facilitated diffusion) responsible for moving glucose across cell membranes (e.g., GLUT2 on the basolateral membrane of the PCT). They are the *mediators* of transport, not inhibitors. * **SGLT:** Sodium-Glucose Linked Transporters are the **targets** for inhibition. SGLT proteins facilitate the active transport of glucose; they do not inhibit it. **3. High-Yield NEET-PG Clinical Pearls:** * **SGLT2 Inhibitors (Gliflozins):** These are the clinical descendants of phlorhizin. They are now first-line agents for Type 2 Diabetes, especially in patients with **Heart Failure (HFrEF)** and **Chronic Kidney Disease (CKD)** due to their cardio-protective and reno-protective effects [2]. * **Location:** SGLT2 is located in the **S1 segment** of the PCT, while SGLT1 is in the **S3 segment**. * **Side Effects:** The most common side effect of SGLT2 inhibitors is **genital mycotic infections** (candidiasis) due to increased glucose in the urine.

Question 142: In the proximal convoluted tubule (PCT), sodium reabsorption is prevented by which class of drugs?

A. Ethacrynic acid
B. Acetazolamide
C. Osmotic diuretics (Correct Answer)
D. Triamterene

Explanation: ### Explanation **Correct Answer: C. Osmotic diuretics** **Mechanism of Action:** Osmotic diuretics (e.g., **Mannitol**) are pharmacologically inert substances that are freely filtered at the glomerulus but undergo minimal reabsorption. Their primary site of action is the **Proximal Convoluted Tubule (PCT)** and the descending limb of the Loop of Henle. By increasing the osmotic pressure of the tubular fluid, they counteract the osmotic force of sodium, thereby **preventing the passive reabsorption of water and sodium**. This leads to an increase in urine volume (diuresis) and sodium excretion (natriuresis). **Analysis of Incorrect Options:** * **A. Ethacrynic acid:** This is a **Loop diuretic**. It acts on the **Thick Ascending Limb (TAL)** of the Loop of Henle by inhibiting the $Na^+-K^+-2Cl^-$ symporter. * **B. Acetazolamide:** While it acts on the PCT, its primary mechanism is the inhibition of **Carbonic Anhydrase**. This prevents the reabsorption of **Bicarbonate ($HCO_3^-$)** rather than primarily targeting sodium reabsorption directly. * **D. Triamterene:** This is a **Potassium-sparing diuretic**. It acts on the **Late Distal Tubule and Collecting Duct** by blocking the Epithelial Sodium Channels (ENaC). **High-Yield Clinical Pearls for NEET-PG:** * **Mannitol** must be administered **intravenously**; it is not absorbed orally. * **Therapeutic Uses:** Reduction of intracranial pressure (cerebral edema) and intraocular pressure (acute glaucoma). * **Contraindications:** It is strictly contraindicated in **Acute Pulmonary Edema** and **Congestive Heart Failure** because it initially expands the extracellular fluid volume before diuresis occurs. * **Side Effect:** Can cause "Dialysis Disequilibrium Syndrome" if cleared too rapidly.

Question 143: Which of the following is a potassium-sparing diuretic?

A. Furosemide
B. Spironolactone (Correct Answer)
C. Mannitol
D. Acetazolamide

Explanation: ### Explanation **Correct Answer: B. Spironolactone** **Mechanism of Action:** Spironolactone is a **Potassium-Sparing Diuretic** that acts as a competitive antagonist of the **Aldosterone receptor (Mineralocorticoid receptor)** in the late distal tubule and collecting duct. Normally, aldosterone promotes the reabsorption of sodium ($Na^+$) and the excretion of potassium ($K^+$) and hydrogen ions ($H^+$). By blocking this receptor, spironolactone inhibits $Na^+$ reabsorption and prevents $K^+$ secretion, leading to its "potassium-sparing" effect. **Analysis of Incorrect Options:** * **A. Furosemide:** A potent **Loop Diuretic** that inhibits the $Na^+-K^+-2Cl^-$ symporter in the Thick Ascending Limb of Henle. It causes significant potassium loss (hypokalemia). * **C. Mannitol:** An **Osmotic Diuretic** that works by increasing the osmolarity of tubular fluid, primarily in the Proximal Convoluted Tubule (PCT) and Descending Limb of Henle. * **D. Acetazolamide:** A **Carbonic Anhydrase Inhibitor** acting on the PCT. It increases bicarbonate excretion and can also lead to hypokalemia. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** Spironolactone can cause **hyperkalemia** and, due to its non-specific binding to androgen receptors, **gynecomastia** and impotence in men. * **Eplerenone:** A more selective aldosterone antagonist with fewer anti-androgenic side effects (less gynecomastia). * **Clinical Use:** Spironolactone is the drug of choice for **primary hyperaldosteronism (Conn’s Syndrome)** and is used to improve survival in **Congestive Heart Failure (NYHA Class II-IV)**. * **Other K+-Sparing Diuretics:** Amiloride and Triamterene (these block ENaC channels directly rather than the aldosterone receptor).

Question 144: Which of the following adverse effects is NOT caused by thiazide diuretics?

A. Hypercalcemia
B. Hypomagnesemia
C. Hypernatremia (Correct Answer)
D. Hyperuricemia

Explanation: Thiazide diuretics (e.g., Hydrochlorothiazide, Chlorthalidone) act on the **Distal Convoluted Tubule (DCT)** by inhibiting the **Na⁺-Cl⁻ symporter**. ### Why Hypernatremia is the Correct Answer Thiazides inhibit the reabsorption of Sodium (Na⁺) and Chloride (Cl⁻) in the DCT, leading to increased excretion of these ions in the urine. This loss of sodium typically results in **Hyponatremia**, not hypernatremia. In fact, thiazides are one of the most common drug-related causes of hyponatremia in clinical practice. ### Explanation of Incorrect Options (Adverse Effects of Thiazides) * **Hypercalcemia (A):** Thiazides increase Ca²⁺ reabsorption in the DCT (via the Na⁺/Ca²⁺ exchanger on the basolateral membrane). This makes them useful in treating idiopathic hypercalciuria and calcium stones. * **Hypomagnesemia (B):** Long-term use of thiazides leads to increased renal excretion of Magnesium, though the exact mechanism is less defined than that of loop diuretics. * **Hyperuricemia (D):** Thiazides compete with uric acid for the organic acid secretory secretory system in the proximal tubule, leading to decreased uric acid excretion. This can precipitate acute gouty arthritis. ### NEET-PG High-Yield Pearls: "The Hypo-Hyper Rule" To remember Thiazide side effects, think of **4 Hypos** and **4 Hypers**: * **HYPO:** Hyponatremia, Hypokalemia, Hypomagnesemia, Hypochloremic alkalosis. * **HYPER:** Hypercalcemia, Hyperuricemia, Hyperglycemia (due to decreased insulin release), Hyperlipidemia (increased LDL/Cholesterol). **Key Distinction:** Loop diuretics cause **Hypocalcemia** ("Loops lose calcium"), whereas Thiazides cause **Hypercalcemia**.

Question 145: Which diuretic can be considered appropriate for combining with ACE inhibitors?

A. Spironolactone
B. Eplerenone
C. Hydrochlorothiazide (Correct Answer)
D. Amiloride

Explanation: **Explanation:** The combination of **Hydrochlorothiazide (HCTZ)** and ACE inhibitors (ACEIs) is a standard, synergistic therapeutic strategy in managing hypertension and heart failure. **Why Hydrochlorothiazide is correct:** 1. **Synergistic BP Lowering:** Thiazides cause sodium depletion, which activates the Renin-Angiotensin-Aldosterone System (RAAS). ACE inhibitors block this compensatory RAAS activation, leading to a more profound drop in blood pressure. 2. **Potassium Homeostasis:** This is the most critical clinical reason. ACE inhibitors cause **potassium retention** (hyperkalemia) by inhibiting aldosterone. Thiazides are **potassium-wasting** diuretics. When used together, they counteract each other's effects on serum potassium, maintaining electrolyte balance. **Why the other options are incorrect:** * **Spironolactone & Eplerenone (Options A & B):** These are Potassium-Sparing Diuretics (Mineralocorticoid Receptor Antagonists). Combining them with ACEIs significantly increases the risk of **severe, life-threatening hyperkalemia**, as both drug classes promote potassium retention. * **Amiloride (Option D):** This is an epithelial sodium channel (ENaC) blocker, also classified as a potassium-sparing diuretic. Like Spironolactone, it carries a high risk of hyperkalemia when combined with ACEIs. **High-Yield Clinical Pearls for NEET-PG:** * **First-Dose Hypotension:** ACEIs can cause a sharp drop in BP if the patient is already volume-depleted by diuretics. It is often advised to stop the diuretic for 24–48 hours before starting an ACEI. * **Metabolic Neutrality:** ACEIs can mitigate the hyperglycemia and hyperuricemia sometimes induced by high-dose Thiazides. * **Preferred Combination:** Fixed-dose combinations of ACEIs/ARBs with HCTZ are among the most commonly prescribed antihypertensives worldwide.

Question 146: What is a known side effect of Triamterene?

A. Hypokalemia
B. Muscle cramps (Correct Answer)
C. Decrease in urea level
D. Improved glucose tolerance

Explanation: **Explanation:** **Triamterene** is a potassium-sparing diuretic that acts by directly blocking the epithelial sodium channels (ENaC) in the late distal tubule and collecting duct. Unlike Spironolactone, its action is independent of aldosterone. **Why Muscle Cramps?** The most characteristic and frequently reported side effect of Triamterene is **muscle cramps**. This occurs due to the rapid electrolyte shifts and the specific way it handles cations. Additionally, Triamterene is poorly soluble and can precipitate in the urine, leading to **crystalluria** or the formation of kidney stones (triamterene nephrolithiasis). **Analysis of Incorrect Options:** * **A. Hypokalemia:** As a potassium-sparing diuretic, Triamterene causes **hyperkalemia**, not hypokalemia. This is its most dangerous potential side effect, especially if used with ACE inhibitors. * **C. Decrease in urea level:** Diuretics generally cause a mild increase in Blood Urea Nitrogen (BUN) due to decreased effective circulating volume and reduced renal perfusion (pre-renal azotemia). * **D. Improved glucose tolerance:** Most diuretics, particularly thiazides, tend to *impair* glucose tolerance. While potassium-sparing diuretics have a neutral effect compared to thiazides, they do not "improve" glucose tolerance. **NEET-PG High-Yield Pearls:** 1. **Mechanism:** Direct ENaC inhibitor (along with Amiloride). 2. **Liddle’s Syndrome:** Amiloride/Triamterene are the drugs of choice for this condition (pseudohyperaldosteronism). 3. **Photosensitivity:** Triamterene is known to cause photosensitivity reactions. 4. **Megalo-blastic Anemia:** It is a weak folic acid antagonist; use with caution in patients with cirrhosis or pregnancy as it may precipitate megaloblastic changes.

Question 147: Mannitol produces diuresis by which mechanism?

A. Osmotic effect (Correct Answer)
B. Inhibition of Na-K-2Cl cotransporter
C. Inhibition of Na-K ATPase
D. Inhibition of aquaporin channels

Explanation: ### Explanation **Correct Option: A. Osmotic effect** Mannitol is a pharmacologically inert, non-metabolizable sugar that acts as an **osmotic diuretic**. It is freely filtered at the glomerulus but is not reabsorbed by the renal tubules. Its presence in the tubular lumen creates an osmotic gradient that "holds" water, preventing its reabsorption. This occurs primarily in the **Proximal Convoluted Tubule (PCT)** and the **Descending Limb of the Loop of Henle**, which are highly permeable to water. By increasing the osmolarity of the tubular fluid, it forces the excretion of water along with some sodium. **Why the other options are incorrect:** * **B. Inhibition of Na-K-2Cl cotransporter:** This is the mechanism of **Loop Diuretics** (e.g., Furosemide, Torsemide) acting on the Thick Ascending Limb of the Loop of Henle. * **C. Inhibition of Na-K ATPase:** This is the mechanism of **Cardiac Glycosides** (e.g., Digoxin). While it affects sodium transport, it is not the mechanism for diuresis in clinical practice. * **D. Inhibition of aquaporin channels:** This describes the action of **Vaptans** (e.g., Tolvaptan), which are vasopressin receptor antagonists used to treat hyponatremia. **High-Yield Clinical Pearls for NEET-PG:** * **Route:** Must be given **IV only** (poorly absorbed orally; causes osmotic diarrhea if swallowed). * **Indications:** Primarily used to reduce **Increased Intracranial Pressure (ICP)** in cerebral edema and **Intraocular Pressure (IOP)** in acute glaucoma. * **Contraindications:** Acute Pulmonary Edema and Congestive Heart Failure (due to initial expansion of extracellular fluid volume) and Chronic Renal Failure (Anuria). * **Side Effect:** Can cause initial "expansion hypervolemia" followed by dehydration and hypernatremia.

Question 148: Which diuretic is used in the treatment of hypercalcemia?

A. Furosemide (Correct Answer)
B. Spironolactone
C. Hydrochlorothiazide
D. Mannitol

Explanation: **Explanation:** **1. Why Furosemide is Correct:** Furosemide is a **Loop Diuretic** that acts by inhibiting the $Na^+/K^+/2Cl^-$ symporter in the Thick Ascending Limb (TAL) of the Loop of Henle. Under normal conditions, the reabsorption of these ions creates a positive lumen potential that drives the paracellular reabsorption of divalent cations like **Calcium ($Ca^{2+}$)** and Magnesium ($Mg^{2+}$). By inhibiting this transporter, Furosemide abolishes the electrical gradient, leading to increased urinary excretion of calcium (**calciuria**). Therefore, it is used in the emergency management of symptomatic hypercalcemia, typically administered alongside aggressive intravenous saline hydration to prevent volume depletion. **2. Why Other Options are Incorrect:** * **Spironolactone:** A Potassium-sparing diuretic (Aldosterone antagonist) that acts on the collecting duct. It does not significantly affect calcium excretion. * **Hydrochlorothiazide:** Thiazides actually **increase** renal calcium reabsorption (hypocalciuric effect). They are used to treat hypercalciuria and calcium stones, but they would worsen hypercalcemia. * **Mannitol:** An osmotic diuretic used primarily to reduce intracranial or intraocular pressure; it is not a standard treatment for electrolyte imbalances like hypercalcemia. **3. NEET-PG High-Yield Pearls:** * **Mnemonic:** "**L**oops **L**ose Calcium; **T**hiazides **T**ake-in Calcium." * **Drug of Choice:** While Furosemide is used for acute hypercalcemia, the long-term drugs of choice for malignancy-associated hypercalcemia are **Bisphosphonates** (e.g., Zoledronic acid). * **Side Effects of Furosemide:** Hypokalemia, Ototoxicity, Hyperuricemia, and Hypomagnesemia.

Question 149: Which diuretic causes gynecomastia?

A. Lubiprostone
B. Spironolactone (Correct Answer)
C. Cimetidine
D. Chlorthalidone

Explanation: **Explanation:** **Spironolactone** is a potassium-sparing diuretic that acts as a competitive antagonist at the mineralocorticoid (aldosterone) receptor. The development of **gynecomastia** (and other side effects like decreased libido or menstrual irregularities) is due to its lack of receptor specificity. It acts as a non-specific antagonist at **androgen receptors** and increases the peripheral conversion of testosterone to estradiol. This hormonal imbalance leads to the enlargement of male breast tissue. **Analysis of Options:** * **Lubiprostone (A):** This is not a diuretic; it is a chloride channel activator used in the treatment of chronic idiopathic constipation and IBS-C. * **Cimetidine (C):** While Cimetidine is a well-known cause of gynecomastia (via H2 receptor blockade and anti-androgenic effects), it is an **H2-receptor antagonist** used for peptic ulcers, not a diuretic. The question specifically asks for a diuretic. * **Chlorthalidone (D):** This is a thiazide-like diuretic. Its primary side effects include hypokalemia, hyperuricemia, and hyperglycemia, but it does not typically cause gynecomastia. **NEET-PG High-Yield Pearls:** * **Eplerenone** is a selective aldosterone antagonist. It has a much lower affinity for androgen and progesterone receptors, making it the preferred alternative if a patient develops gynecomastia on Spironolactone. * **Mnemonic for Gynecomastia (DISCO):** **D**igoxin, **I**soniazid, **S**pironolactone, **C**imetidine, **O**estrogens/Ketoconazole. * Spironolactone is the drug of choice for **ascites in liver cirrhosis** and is used to reduce mortality in **Congestive Heart Failure (NYHA Class III/IV)**.

Question 150: Which of the following drugs is used in the management of nephrogenic diabetes insipidus?

A. Mannitol
B. Spironolactone
C. Thiazides (Correct Answer)
D. Demeclocycline

Explanation: ### Explanation **Correct Answer: C. Thiazides** **Mechanism in Nephrogenic Diabetes Insipidus (NDI):** It may seem paradoxical to use a diuretic to treat polyuria, but Thiazides are the mainstay for NDI. They inhibit the $Na^+/Cl^-$ symporter in the distal convoluted tubule, leading to mild volume depletion. This causes a compensatory increase in the reabsorption of sodium and water in the **proximal tubule**. Consequently, less fluid reaches the distal parts of the nephron, reducing the total urine volume excreted. **Analysis of Incorrect Options:** * **A. Mannitol:** An osmotic diuretic used primarily to reduce intracranial or intraocular pressure. It would worsen polyuria in DI. * **B. Spironolactone:** A potassium-sparing diuretic (aldosterone antagonist) used in cirrhosis, heart failure, and Conn’s syndrome. It has no role in treating DI. * **D. Demeclocycline:** A tetracycline derivative that actually **causes** nephrogenic DI by inhibiting ADH action in the collecting duct. It is used to treat SIADH (Syndrome of Inappropriate Antidiuretic Hormone). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** For Central DI, the DOC is **Desmopressin (dDAVP)**. For Nephrogenic DI, the DOC is **Thiazides** (often Amiloride if caused by Lithium). * **Lithium-Induced NDI:** **Amiloride** is specifically preferred because it blocks the ENaC channels through which Lithium enters the collecting duct cells. * **Prostaglandin Inhibitors:** NSAIDs (like Indomethacin) can also be used in NDI as they reduce renal blood flow and inhibit the antagonistic effect of prostaglandins on ADH. * **Side Effects of Thiazides:** Remember the "Hypo" triad: Hypokalemia, Hyponatremia, and Hypomagnesemia; and the "Hyper" triad: Hypercalcemia, Hyperuricemia, and Hyperglycemia.

Question 151: Which thiazide diuretic can be used when the Glomerular Filtration Rate (GFR) is less than 30 ml/min?

A. Metolazone (Correct Answer)
B. Benzthiazide
C. Chlorthalidone
D. Hydroflumethiazide

Explanation: ### **Explanation** **1. Why Metolazone is Correct:** The fundamental rule of thiazide diuretics is that they lose their efficacy when the **Glomerular Filtration Rate (GFR) falls below 30 ml/min**. This is because they must be secreted into the tubular lumen to act on the Na⁺-Cl⁻ symporter in the distal convoluted tubule; in renal failure, this delivery is impaired. **Metolazone** (and to some extent Indapamide) is the notable exception to this rule. It remains potent and effective even in patients with advanced renal insufficiency (GFR < 30 ml/min). It is frequently used in clinical practice to treat refractory edema in patients with Chronic Kidney Disease (CKD) or in combination with loop diuretics to achieve "sequential nephron blockade." **2. Why the Other Options are Incorrect:** * **Benzthiazide, Chlorthalidone, and Hydroflumethiazide:** These are classic thiazide/thiazide-like diuretics. While Chlorthalidone is highly potent and has a long half-life, all three drugs generally fail to produce significant diuresis once the GFR drops below 30 ml/min. Using them in severe renal failure is typically ineffective for fluid management. **3. NEET-PG High-Yield Pearls:** * **Sequential Nephron Blockade:** Combining Metolazone (acting on the Distal Tubule) with a Loop Diuretic (acting on the Thick Ascending Limb) is a high-yield strategy for treating "diuretic resistance." * **Indapamide:** Another thiazide-like diuretic that can be used in renal failure; it is also the thiazide of choice for hypertensive patients with diabetes as it is "metabolically neutral." * **Side Effects:** Remember the "Hyper-Hypo" rule for thiazides: They cause **Hyper**glycemia, **Hyper**uricemia, **Hyper**calcemia, and **Hypo**kalemia, **Hypo**natremia, **Hypo**magnesemia. * **Site of Action:** Thiazides inhibit the Na⁺-Cl⁻ symporter in the **early Distal Convoluted Tubule (DCT)**.

Question 152: Which of the following is NOT a potassium-sparing diuretic?

A. Spironolactone
B. Triamterene
C. Amiloride
D. Ethacrynic acid (Correct Answer)

Explanation: ### Explanation The correct answer is **D. Ethacrynic acid**. **1. Why Ethacrynic acid is the correct answer:** Ethacrynic acid is a **Loop Diuretic**, not a potassium-sparing one. It works by inhibiting the **Na⁺/K⁺/2Cl⁻ symporter** in the Thick Ascending Limb (TAL) of the Loop of Henle. Because it causes a massive delivery of sodium to the distal tubule, it increases potassium secretion into the urine, leading to **hypokalemia** (low potassium). It is chemically unique among loop diuretics because it is a phenoxyacetic acid derivative and **not a sulfonamide**, making it the drug of choice for patients with sulfa allergies. **2. Why the other options are incorrect:** * **A. Spironolactone:** This is a competitive **Aldosterone Antagonist** (Mineralocorticoid receptor antagonist). By blocking aldosterone in the collecting duct, it prevents the reabsorption of Na⁺ and the secretion of K⁺, thus "sparing" potassium. * **B. Triamterene & C. Amiloride:** These are **Direct ENaC (Epithelial Sodium Channel) Blockers**. They act on the late distal tubule and collecting duct to block sodium entry independently of aldosterone. By decreasing the negative intraluminal potential, they reduce the driving force for potassium secretion. **3. High-Yield Clinical Pearls for NEET-PG:** * **Ototoxicity:** Ethacrynic acid is the **most ototoxic** loop diuretic; it is more likely to cause permanent hearing loss compared to Furosemide. * **Liddle’s Syndrome:** Amiloride is the treatment of choice for this rare genetic condition. * **Spironolactone Side Effects:** Can cause **gynecomastia** and impotence due to its non-specific binding to androgen and progesterone receptors. **Eplerenone** is a more specific alternative with fewer hormonal side effects. * **Potassium-sparing diuretics** are often combined with Thiazides or Loop diuretics to counteract drug-induced hypokalemia.

Question 153: All of the following diuretics act from the luminal side of the renal tubules except?

A. Loop diuretics
B. ENaC blockers
C. Aldosterone antagonists (Correct Answer)
D. Mannitol

Explanation: ### Explanation The correct answer is **Aldosterone antagonists** (e.g., Spironolactone, Eplerenone). **1. Why Aldosterone Antagonists are the exception:** Most diuretics must be present in the tubular fluid (the lumen) to exert their effect. However, Aldosterone antagonists are **highly lipid-soluble** drugs that act from the **basolateral (blood) side**. They cross the cell membrane to bind with intracellular mineralocorticoid receptors in the cytoplasm of the collecting duct cells [1], [2]. This prevents the translocation of the receptor complex into the nucleus, thereby inhibiting the synthesis of Aldosterone-Induced Proteins (AIPs) [1]. **2. Why the other options are incorrect:** * **Loop Diuretics (e.g., Furosemide):** These act from the **luminal side** by inhibiting the $Na^+-K^+-2Cl^-$ (NKCC2) cotransporter in the Thick Ascending Limb. They reach the lumen via active secretion through organic anion transporters (OATs) in the proximal tubule. * **ENaC Blockers (e.g., Amiloride, Triamterene):** These act directly on the **luminal side** of the principal cells in the collecting duct to block the Epithelial Sodium Channels (ENaC). * **Mannitol:** As an osmotic diuretic, it remains in the **tubular lumen**, creating an osmotic gradient that prevents water reabsorption [3]. **3. NEET-PG Clinical Pearls:** * **Site of Action:** Aldosterone antagonists are the only diuretics that do not require access to the tubular lumen to function [1]. * **Potassium Sparing:** Both ENaC blockers and Aldosterone antagonists are "Potassium-Sparing Diuretics," but their mechanisms differ (Direct channel blockade vs. Receptor antagonism) [1]. * **Clinical Use:** Spironolactone is the drug of choice for edema in **liver cirrhosis** (secondary hyperaldosteronism) and is proven to reduce mortality in **Congestive Heart Failure (CHF)**. * **Side Effect:** Gynecomastia is a common side effect of Spironolactone due to its non-specific binding to androgen receptors; Eplerenone is more selective and avoids this.

Question 154: Tolvaptan is approved for use in which of the following conditions?

A. Hypernatremia
B. Hyperkalemia
C. Hypercalcemia
D. Hyponatremia (Correct Answer)

Explanation: **Explanation:** **Tolvaptan** is a selective, oral **V2-receptor antagonist** (Vaptan). It works by blocking the action of Antidiuretic Hormone (ADH/Vasopressin) at the V2 receptors in the collecting ducts of the kidney. This leads to **aquaresis**—the excretion of free water without significant loss of electrolytes like sodium or potassium. **Why Hyponatremia is Correct:** By promoting free water clearance, Tolvaptan increases the concentration of serum sodium. It is specifically FDA-approved for the treatment of **euvolemic and hypervolemic hyponatremia**, such as that seen in **SIADH** (Syndrome of Inappropriate ADH secretion), Cirrhosis, or Heart Failure. **Why Other Options are Incorrect:** * **A. Hypernatremia:** Tolvaptan increases serum sodium levels; using it in hypernatremia would dangerously worsen the condition. * **B. Hyperkalemia:** Tolvaptan does not significantly affect potassium excretion. Hyperkalemia is typically managed with Loop diuretics, insulin/dextrose, or potassium binders. * **C. Hypercalcemia:** Loop diuretics (like Furosemide) are used to treat hypercalcemia by increasing calcium excretion. Tolvaptan has no role in calcium homeostasis. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Selective V2 antagonist (Aquaretic). * **Other Indications:** Also approved to slow the progression of **Autosomal Dominant Polycystic Kidney Disease (ADPKD)**. * **Contraindication:** Should not be used for more than 30 days due to the risk of **hepatotoxicity**. * **Caution:** Rapid correction of hyponatremia must be avoided to prevent **Osmotic Demyelination Syndrome (Central Pontine Myelinolysis)**. * **Conivaptan** is a related drug but differs as it is a non-selective (V1a and V2) antagonist and is administered intravenously.

Question 155: NSAIDs attenuate the action of which of the following diuretics?

A. Carbonic anhydrase inhibitors
B. Loop diuretics (Correct Answer)
C. Thiazide diuretics
D. Spironolactone

Explanation: **Explanation:** The correct answer is **Loop diuretics (Option B)**. **Mechanism of Interaction:** Loop diuretics (e.g., Furosemide) exert their effect not only by inhibiting the $Na^+-K^+-2Cl^-$ symporter in the Thick Ascending Limb but also by stimulating the synthesis of **renal prostaglandins** (especially $PGE_2$). These prostaglandins cause renal vasodilation, increasing renal blood flow and enhancing the delivery of the drug to its site of action. **NSAIDs** inhibit the enzyme Cyclooxygenase (COX), thereby blocking prostaglandin synthesis [2]. This results in afferent arteriolar vasoconstriction, reduced renal perfusion, and a significant blunting of the natriuretic and diuretic efficacy of loop diuretics [1]. Additionally, NSAIDs can interfere with the organic anion transport (OAT) mechanism required for loop diuretics to reach the tubular lumen [1]. **Analysis of Incorrect Options:** * **A. Carbonic Anhydrase Inhibitors:** Their primary action is in the proximal convoluted tubule via inhibition of $HCO_3^-$ reabsorption [3]; their effect is not significantly dependent on prostaglandin-mediated vasodilation. * **C. Thiazide Diuretics:** While NSAIDs can slightly reduce the effect of Thiazides [1], the clinical interaction is far more pronounced and classically associated with Loop diuretics in the context of acute heart failure or edema management [2]. * **D. Spironolactone:** This is a potassium-sparing diuretic (aldosterone antagonist). While NSAIDs increase the risk of **hyperkalemia** when used with Spironolactone, they do not directly attenuate its primary mechanism of action in the same way they do with Loop diuretics. **High-Yield Clinical Pearls for NEET-PG:** * **Prostaglandins & The Kidney:** Prostaglandins "keep the afferent arteriole open." NSAIDs "close" it. * **Triple Whammy:** Avoid the combination of **ACE inhibitors/ARBs + Diuretics + NSAIDs**, as this triad significantly increases the risk of Acute Kidney Injury (AKI). * **Furosemide Fact:** Furosemide also has a potent venodilatory effect (useful in acute pulmonary edema) which is also mediated by prostaglandins and can be inhibited by NSAIDs.

Question 156: Acetazolamide can be used in all the following conditions except:

A. Epilepsy
B. Acute mountain sickness
C. Cirrhosis (Correct Answer)
D. Glaucoma

Explanation: **Explanation:** **Acetazolamide** is a Carbonic Anhydrase (CA) inhibitor that acts primarily on the proximal convoluted tubule. **Why Cirrhosis is the Correct Answer (Contraindication):** In patients with cirrhosis, the liver cannot efficiently convert ammonia ($NH_3$) into urea. Acetazolamide alkalinizes the urine by increasing bicarbonate excretion. In an alkaline urinary environment, ammonium ions ($NH_4^+$) are converted back into lipid-soluble ammonia ($NH_3$), which is reabsorbed into the systemic circulation. This elevation in blood ammonia levels can cross the blood-brain barrier, precipitating or worsening **Hepatic Encephalopathy**. Therefore, it is strictly contraindicated in liver cirrhosis. **Why other options are incorrect (Indications):** * **Epilepsy:** Acetazolamide creates a mild metabolic acidosis in the CNS, which increases the seizure threshold. It is used as an adjuvant in absence and tonic-clonic seizures. * **Acute Mountain Sickness:** It counteracts respiratory alkalosis by increasing bicarbonate excretion, thereby lowering blood pH. This stimulates the respiratory center to increase ventilation and improves oxygenation. * **Glaucoma:** By inhibiting CA in the ciliary body, it reduces the formation of aqueous humor, thereby lowering intraocular pressure. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Proximal Convoluted Tubule (PCT). * **Side Effects:** Hyperchloremic metabolic acidosis, hypokalemia, paresthesia, and renal stones (due to calcium phosphate precipitation in alkaline urine). * **Other Uses:** Idiopathic Intracranial Hypertension (Pseudotumor cerebri) and urinary alkalinization (to excrete acidic drugs like uric acid or cystine). * **Sulfa-Allergy:** As a sulfonamide derivative, it may cause cross-reactivity in sensitive patients.

Question 157: Which of the following diuretics acts at the nephron's distal tubule?

A. Ethacrynic acid
B. Furosemide
C. Hydrochlorothiazide (Correct Answer)
D. Mannitol

Explanation: **Explanation:** The correct answer is **Hydrochlorothiazide (C)**. **Mechanism and Site of Action:** Hydrochlorothiazide belongs to the **Thiazide** class of diuretics. These agents act specifically on the **early distal convoluted tubule (DCT)** [1]. They work by inhibiting the **Na⁺-Cl⁻ symporter** on the luminal membrane [2]. By blocking this transporter, they increase the excretion of sodium and chloride, followed by water. Because the DCT is responsible for only about 5–10% of sodium reabsorption, thiazides are considered "medium-efficacy" diuretics [4]. **Analysis of Incorrect Options:** * **A & B (Ethacrynic acid and Furosemide):** These are **Loop Diuretics**. They act on the **thick ascending limb (TAL) of the Loop of Henle** by inhibiting the Na⁺-K⁺-2Cl⁻ cotransporter [2]. They are "high-ceiling" diuretics used for acute pulmonary edema and refractory hypertension. * **D (Mannitol):** This is an **Osmotic Diuretic**. Its primary site of action is the **Proximal Convoluted Tubule (PCT)** and the descending limb of the Loop of Henle [3]. It works by increasing the osmolarity of the tubular fluid, preventing water reabsorption. **NEET-PG High-Yield Pearls:** * **Calcium Paradox:** Unlike Loop diuretics (which cause hypocalcemia), Thiazides **decrease urinary calcium excretion** (hypercalcemia) [1]. This makes them the drug of choice for hypertension in patients with **osteoporosis** or recurrent **calcium oxalate stones**. * **Metabolic Side Effects:** Remember the "4 Hypers and 2 Hypos": **Hyper**uricemia (gout), **Hyper**glycemia, **Hyper**lipidemia, **Hyper**calcemia; and **Hypo**kalemia, **Hypo**natremia [1]. * **Sulfa Allergy:** Most thiazides and loop diuretics (except Ethacrynic acid) are sulfonamide derivatives [2].

Question 158: Which of the following drugs does not require its presence in the tubular lumen for diuretic action?

A. Chlorthalidone
B. Acetazolamide
C. Mannitol
D. Eplerenone (Correct Answer)

Explanation: ### Explanation The correct answer is **D. Eplerenone**. #### 1. Why Eplerenone is Correct Most diuretics function by inhibiting transporters or enzymes located on the **luminal (apical) membrane** of the renal tubule. To reach these targets, they must be filtered or secreted into the tubular fluid. **Eplerenone** (and Spironolactone) are **Mineralocorticoid Receptor Antagonists (MRAs)**. Their target receptors are located in the **cytosol** of the principal cells in the late distal tubule and collecting duct. These drugs reach their target by diffusing directly from the **peritubular capillaries (blood side)** across the basolateral membrane into the cell. Therefore, their presence in the tubular lumen is not required for their pharmacological action. #### 2. Why Other Options are Incorrect * **Chlorthalidone (Thiazide-like):** Must be secreted into the lumen via the organic acid secretory pathway to inhibit the Na⁺/Cl⁻ symporter on the luminal membrane of the distal convoluted tubule. * **Acetazolamide (Carbonic Anhydrase Inhibitor):** Acts primarily on luminal carbonic anhydrase (Type IV) in the proximal convoluted tubule; it requires luminal presence to function. * **Mannitol (Osmotic Diuretic):** Works by increasing the osmolarity of the **tubular fluid**, thereby retaining water in the lumen. It must be filtered into the lumen to exert its effect. #### 3. NEET-PG High-Yield Pearls * **Site of Action:** MRAs are the only diuretics that do not act from the luminal side. * **Clinical Advantage:** Because they don't rely on tubular secretion, MRAs remain effective even in states of reduced renal perfusion where organic acid transporters are compromised. * **Side Effects:** Eplerenone is more selective than Spironolactone, causing significantly fewer endocrine side effects like gynecomastia or impotence. * **Key Contraindication:** Avoid in patients with hyperkalemia (K⁺ > 5.5 mEq/L) or severe renal impairment.

Question 159: All of the following are true about loop diuretics except:

A. They are called "high ceiling" diuretics.
B. They act on the Na+, K+, 2Cl- symporter.
C. They can cause hyperuricemia.
D. Loop diuretics lead to hypercalcemia and hypomagnesemia. (Correct Answer)

Explanation: **Explanation:** The correct answer is **D** because loop diuretics (e.g., Furosemide) actually cause **hypocalcemia**, not hypercalcemia. **1. Why Option D is the correct (false) statement:** Loop diuretics inhibit the **Na⁺-K⁺-2Cl⁻ symporter** in the Thick Ascending Limb (TAL) of the Loop of Henle. Normally, the "back-leak" of potassium into the lumen creates a positive luminal potential that drives the paracellular reabsorption of divalent cations like **Calcium (Ca²⁺)** and **Magnesium (Mg²⁺)**. By blocking this transporter, loop diuretics abolish this electrical gradient, leading to increased urinary excretion of both Calcium and Magnesium. Thus, they cause **hypocalcemia** and **hypomagnesemia**. **2. Why other options are incorrect (true statements):** * **Option A:** They are "high ceiling" diuretics because they have a very high maximal efficacy; as the dose increases, the diuretic effect continues to rise significantly compared to other classes. * **Option B:** Their primary mechanism of action is the reversible inhibition of the **NKCC2** (Na⁺-K⁺-2Cl⁻) symporter in the TAL. * **Option C:** They cause **hyperuricemia** by competing with uric acid for the organic acid secretory pump in the proximal tubule and by increasing proximal reabsorption due to volume depletion. **NEET-PG High-Yield Pearls:** * **Mnemonic for Calcium:** **L**oops **L**ose Calcium (Hypocalcemia); **T**hiazides **T**ake Calcium (Hypercalcemia). * **Drug of Choice:** Furosemide is the drug of choice for **Acute Pulmonary Edema**. * **Ototoxicity:** Loop diuretics (especially Ethacrynic acid) can cause dose-dependent hearing loss. * **Metabolic Effect:** They typically cause **Hypokalemic Metabolic Alkalosis**.

Question 160: Hypercalcemia is caused by all of the following except:

A. Thyrotoxicosis
B. Vitamin D intoxication
C. Sarcoidosis
D. Furosemide (Correct Answer)

Explanation: ### Explanation The correct answer is **D. Furosemide**. **1. Why Furosemide is the Correct Answer:** Furosemide is a **Loop Diuretic** that inhibits the $Na^+-K^+-2Cl^-$ symporter in the Thick Ascending Limb (TAL) of the Henle’s loop. This inhibition abolishes the positive transepithelial potential usually generated by the back-diffusion of potassium. Without this positive charge, the paracellular reabsorption of divalent cations ($Ca^{2+}$ and $Mg^{2+}$) is blocked, leading to increased urinary calcium excretion (**Hypercalciuria**). Consequently, Furosemide causes **hypocalcemia**, not hypercalcemia, and is clinically used in the emergency management of severe hypercalcemia. **2. Analysis of Incorrect Options:** * **Thyrotoxicosis:** Excess thyroid hormone increases bone turnover by stimulating osteoclastic activity, leading to the release of calcium into the bloodstream. * **Vitamin D Intoxication:** Vitamin D increases calcium absorption from the GI tract and enhances bone resorption, directly causing hypercalcemia. * **Sarcoidosis:** This granulomatous disease involves macrophages that contain 1-alpha-hydroxylase, which converts Vitamin D into its active form ($1,25-(OH)_2D_3$), leading to hypercalcemia. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** *"Loop Loses Calcium, Thiazide Takes Calcium."* * **Thiazides:** Unlike loops, Thiazides cause **hypercalcemia** (by increasing proximal tubule reabsorption and distal tubular $Ca^{2+}$ exchange). They are used to treat idiopathic hypercalciuria/renal stones. * **Loop Diuretics:** Cause **Hypomagnesemia** and **Hypocalcemia**. Furosemide is the drug of choice for acute hypercalcemia (given with saline to prevent volume depletion). * **Milk-Alkali Syndrome:** Another classic cause of hypercalcemia due to excessive intake of calcium carbonate antacids.

Question 161: Which drug is a vasopressin V2 receptor selective agonist?

A. Lypressin
B. Desmopressin (Correct Answer)
C. Terlipressin
D. None of the above

Explanation: **Explanation:** The correct answer is **Desmopressin**. **1. Why Desmopressin is correct:** Vasopressin (ADH) acts on two primary receptors: **V1** (located on vascular smooth muscle, causing vasoconstriction) and **V2** (located in the renal collecting ducts, causing water reabsorption via aquaporin-2 channels). **Desmopressin (dDAVP)** is a synthetic analogue of vasopressin designed to be a **selective V2 receptor agonist**. It has negligible V1 activity, meaning it provides potent antidiuretic effects without causing significant hypertension or vasoconstriction. It also has a longer duration of action than natural vasopressin. **2. Why the other options are incorrect:** * **Lypressin:** This is a synthetic version of lysine-vasopressin. While it acts on both V1 and V2 receptors, it is not selective for V2 and is rarely used in modern practice due to its short half-life. * **Terlipressin:** This is a prodrug of lysine-vasopressin that is highly **V1-selective**. Because it causes potent vasoconstriction, it is the drug of choice for managing bleeding esophageal varices and hepatorenal syndrome, rather than for its antidiuretic effects. **3. NEET-PG High-Yield Pearls:** * **Clinical Uses of Desmopressin:** Central Diabetes Insipidus (drug of choice), Nocturnal Enuresis, von Willebrand Disease (Type 1), and Hemophilia A (it increases levels of Factor VIII and vWF). * **Route of Administration:** Desmopressin is commonly administered intranasally, orally, or parenterally. * **Adverse Effect:** The most serious side effect of Desmopressin is **dilutional hyponatremia**, which can lead to seizures. * **V3 Receptors:** These are located in the anterior pituitary and mediate the release of ACTH.

Question 162: Which of the following diuretics is contraindicated in the presence of cardiac failure?

A. Mannitol (Correct Answer)
B. Spironolactone
C. Furosemide
D. Hydrochlorothiazide

Explanation: ### Explanation **Correct Option: A. Mannitol** Mannitol is an **osmotic diuretic**. When administered intravenously, it remains in the extracellular fluid (ECF) and creates a high osmotic pressure. This causes a rapid shift of water from the intracellular compartment into the vascular space. In patients with pre-existing **congestive heart failure (CHF)**, this sudden increase in intravascular volume (acute volume expansion) can overload the heart, leading to **acute pulmonary edema**. Therefore, it is strictly contraindicated in patients with cardiac failure or pulmonary congestion. **Why the other options are incorrect:** * **B. Spironolactone:** This is a potassium-sparing diuretic (aldosterone antagonist). It is actually **indicated** in chronic heart failure (NYHA Class II-IV) as it reduces cardiac remodeling and decreases mortality (as proven in the RALES trial). * **C. Furosemide:** This is a loop diuretic and the **drug of choice** for acute pulmonary edema secondary to heart failure. It rapidly reduces preload through both venodilation and potent diuresis. * **D. Hydrochlorothiazide:** Thiazide diuretics are commonly used to manage fluid overload in mild heart failure and are first-line agents for hypertension. **Clinical Pearls for NEET-PG:** * **Indications for Mannitol:** Increased intracranial pressure (cerebral edema) and increased intraocular pressure (acute glaucoma). * **Test-taking Tip:** If a question asks for a diuretic that *causes* pulmonary edema, think Mannitol. If it asks for the drug to *treat* pulmonary edema, think Furosemide. * **Contraindications for Mannitol:** Active intracranial bleeding (except during craniotomy), severe dehydration, and established renal failure (anuria).

Question 163: Which one of the following is an aldosterone antagonist?

A. Spironolactone (Correct Answer)
B. Amiloride
C. Triamterene
D. Acetazolamide

Explanation: **Explanation:** The correct answer is **Spironolactone**. **1. Why Spironolactone is correct:** Spironolactone is a **competitive aldosterone antagonist**. It acts on the mineralocorticoid receptors in the late distal tubule and collecting duct. By blocking these receptors, it prevents the synthesis of aldosterone-induced proteins (AIPs), leading to decreased sodium reabsorption and decreased potassium secretion. It is classified as a **Potassium-Sparing Diuretic**. **2. Why the other options are incorrect:** * **Amiloride & Triamterene:** While these are also potassium-sparing diuretics, they are **not** aldosterone antagonists. Instead, they act as **direct ENaC (Epithelial Sodium Channel) blockers** in the luminal membrane of the collecting duct. They work independently of aldosterone levels. * **Acetazolamide:** This is a **Carbonic Anhydrase inhibitor** that acts primarily on the proximal convoluted tubule (PCT). It is used for glaucoma and altitude sickness, not for its aldosterone-modulating effects. **3. NEET-PG High-Yield Clinical Pearls:** * **Side Effects:** Spironolactone can cause **gynecomastia** and impotence in men because it also blocks androgen receptors. **Eplerenone** is a more selective aldosterone antagonist with fewer anti-androgenic side effects. * **Clinical Use:** Spironolactone is the drug of choice for **Primary Hyperaldosteronism (Conn’s Syndrome)** and is proven to reduce mortality in **Congestive Heart Failure (NYHA Class II-IV)**. * **Contraindication:** All potassium-sparing diuretics are contraindicated in patients with **hyperkalemia** or chronic renal failure.

Question 164: Brinzolamide is a

A. Highly specific irreversible and noncompetitive carbonic anhydrase inhibitor
B. Highly specific irreversible and competitive carbonic anhydrase inhibitor.
C. Highly specific reversible and competitive carbonic anhydrase inhibitor
D. Highly specific reversible and non-competitive carbonic anhydrase inhibitor. (Correct Answer)

Explanation: **Explanation:** **Brinzolamide** is a second-generation topical carbonic anhydrase inhibitor (CAI) primarily used to reduce intraocular pressure in open-angle glaucoma and ocular hypertension. **1. Why Option D is Correct:** Carbonic anhydrase inhibitors, including Brinzolamide and Acetazolamide, function by binding to the active site of the enzyme **Carbonic Anhydrase II (CA-II)**. * **Highly Specific:** Brinzolamide has a high affinity specifically for the CA-II isoenzyme found in the ciliary body. * **Reversible:** The binding is non-covalent, meaning the drug eventually dissociates from the enzyme. * **Non-competitive:** Unlike classical competitive inhibitors that compete with the substrate ($CO_2$), CAIs bind to the enzyme in a manner that prevents the catalytic process regardless of substrate concentration, effectively acting as non-competitive inhibitors in a clinical kinetic context. **2. Why Other Options are Incorrect:** * **Options A & B (Irreversible):** Irreversible inhibition involves covalent bonding (like Organophosphates). Brinzolamide binds non-covalently; its effects wear off as the drug is cleared, making it reversible. * **Option C (Competitive):** While some texts simplify CAIs, they are pharmacologically classified as non-competitive inhibitors because they bind to the enzyme-substrate complex or the enzyme itself in a way that cannot be overcome by simply increasing the concentration of $CO_2$. **3. NEET-PG High-Yield Pearls:** * **Topical vs. Systemic:** Brinzolamide and Dorzolamide are **topical** CAIs, preferred over oral Acetazolamide for glaucoma to minimize systemic side effects like metabolic acidosis and paresthesia. * **Side Effects:** The most common side effect of Brinzolamide is **blurred vision** and a **bitter taste** (dysgeusia) due to drainage into the nasolacrimal duct. * **Mechanism in Eye:** It decreases the formation of aqueous humor by reducing $HCO_3^-$ production in the ciliary body.

Question 165: Brinzolamide is a

A. Highly specific irreversible and noncompetitive carbonic anhydrase inhibitor
B. Highly specific irreversible and competitive carbonic anhydrase inhibitor.
C. Highly specific reversible and competitive carbonic anhydrase inhibitor
D. Highly specific reversible and non-competitive carbonic anhydrase inhibitor. (Correct Answer)

Explanation: **Explanation:** **Brinzolamide** is a topical carbonic anhydrase inhibitor (CAI) primarily used to reduce intraocular pressure in open-angle glaucoma and ocular hypertension. **1. Why Option D is correct:** Carbonic anhydrase inhibitors like Brinzolamide and Dorzolamide work by binding to the **CA-II isoenzyme** in the ciliary processes of the eye. * **Highly Specific:** It has a high affinity for the CA-II isoform, which is the most active form involved in aqueous humor production. * **Reversible:** The binding is not permanent; the drug eventually dissociates from the enzyme. * **Non-competitive:** Brinzolamide binds to a site on the enzyme that is distinct from the substrate-binding site (the active site where $CO_2$ and $H_2O$ react). Therefore, it inhibits the enzyme regardless of the substrate concentration. **2. Why other options are incorrect:** * **Options A & B (Irreversible):** Most clinically used diuretics and CAIs bind reversibly. Irreversible binding would lead to prolonged enzyme inactivation until new enzymes are synthesized, which is not the pharmacokinetic profile of Brinzolamide. * **Option C (Competitive):** Competitive inhibitors compete with the substrate for the active site. Brinzolamide’s mechanism involves non-competitive inhibition, ensuring potent suppression of aqueous humor formation even when substrate levels vary. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits CA-II $\rightarrow$ Decreased $HCO_3^-$ production $\rightarrow$ Decreased aqueous humor secretion $\rightarrow$ Lower Intraocular Pressure (IOP). * **Advantage over Dorzolamide:** Brinzolamide is a suspension with a physiological pH, making it **less irritating** (less stinging/burning) than Dorzolamide. * **Systemic CAIs:** Acetazolamide is the prototype oral CAI, often used for altitude sickness and glaucoma, but carries a risk of metabolic acidosis and hypokalemia. * **Side Effect:** A common side effect of topical CAIs is a **bitter taste** (dysgeusia) due to the drug draining through the nasolacrimal duct.

Question 166: All of the following are true regarding diuretics except?

A. Spironolactone is a potassium sparing drug.
B. Mannitol is an osmotic diuretic.
C. Thiazides act by inhibiting sodium-chloride co-transporter. (Correct Answer)
D. Acetazolamide inhibits carbonic anhydrase enzyme.

Explanation: **Explanation** This question requires identifying the incorrect statement regarding the mechanism of action of various diuretics. However, based on pharmacological principles, **all four statements provided are actually correct.** In the context of NEET-PG, if this question appeared as written, it would be considered a "disputed" or "bonus" question. 1. **Why Option C is technically correct (but listed as the answer):** Thiazide diuretics (e.g., Hydrochlorothiazide) act specifically on the **Distal Convoluted Tubule (DCT)** by inhibiting the **$Na^+-Cl^-$ symporter** (co-transporter). This increases the excretion of sodium and chloride. If this was intended as the "incorrect" answer, it may be due to a typographical error in the question stem or options. 2. **Analysis of other options:** * **Option A:** **Spironolactone** is indeed a potassium-sparing diuretic. It acts as an **Aldosterone antagonist** in the collecting duct, preventing sodium reabsorption and potassium secretion. * **Option B:** **Mannitol** is a classic **osmotic diuretic**. It works by increasing the osmolarity of tubular fluid, primarily in the Proximal Convoluted Tubule and the Descending Loop of Henle, preventing water reabsorption. * **Option D:** **Acetazolamide** is a **Carbonic Anhydrase inhibitor**. It acts in the PCT to prevent $NaHCO_3$ reabsorption, leading to alkaline diuresis. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Carbonic Anhydrase Inhibitors (PCT); Loop Diuretics (Thick Ascending Limb); Thiazides (DCT); K-Sparing (Collecting Duct). * **Loop Diuretics (Furosemide):** Inhibit $Na^+-K^+-2Cl^-$ co-transporter; cause hypokalemia and **hypocalcemia**. * **Thiazides:** Can cause hypokalemia but lead to **hypercalcemia** (useful in post-menopausal osteoporosis). * **Drug of Choice:** Acetazolamide is the DOC for Glaucoma and Mountain Sickness; Spironolactone is the DOC for Cirrhotic Ascites.

Question 167: A 52-year-old male presents with a chief complaint of a substantial increase in breast size over the past few months. Three months ago, he was diagnosed with hypertension and placed on antihypertensive medication. Which of the following medications was most likely prescribed?

A. Captopril
B. Furosemide
C. Hydrochlorothiazide
D. Spironolactone (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Spironolactone** **Mechanism & Rationale:** The clinical presentation describes **gynecomastia** (enlargement of male breast tissue), a well-known side effect of **Spironolactone**. Spironolactone is a potassium-sparing diuretic that acts as a competitive antagonist at the mineralocorticoid receptor. However, it lacks specificity and also acts as an **anti-androgen**. It causes gynecomastia through three primary mechanisms: 1. Displacing dihydrotestosterone (DHT) from androgen receptors. 2. Increasing the peripheral conversion of testosterone to estradiol. 3. Increasing the metabolic clearance of testosterone. **Analysis of Incorrect Options:** * **A. Captopril:** An ACE inhibitor. While it can cause a dry cough or angioedema, it is not typically associated with gynecomastia. * **B. Furosemide:** A loop diuretic used for edema and heart failure. Its primary side effects include ototoxicity, hypokalemia, and hyperuricemia, but not endocrine disturbances like gynecomastia. * **C. Hydrochlorothiazide:** A thiazide diuretic. Common side effects include hyperglycemia, hyperlipidemia, and hyperuricemia. While it can occasionally cause erectile dysfunction, it does not cause breast enlargement. **High-Yield Clinical Pearls for NEET-PG:** * **Eplerenone** is a selective aldosterone antagonist that does *not* cause gynecomastia, making it the preferred alternative if this side effect occurs. * **Mnemonic for drugs causing Gynecomastia (DISCO):** **D**igoxin, **I**soniazid, **S**pironolactone, **C**imetidine, **O**estrogens/Ketoconazole. * Spironolactone is the drug of choice for **Primary Hyperaldosteronism (Conn’s Syndrome)** and is used to improve survival in Congestive Heart Failure (NYHA Class II-IV).

Question 168: What is a known adverse effect of Triamterene?

A. Improved glucose tolerance
B. Muscle cramps (Correct Answer)
C. Decrease in urea level
D. Hypokalemia

Explanation: **Explanation:** **Triamterene** is a potassium-sparing diuretic that acts by directly blocking the epithelial sodium channels (ENaC) in the late distal tubule and collecting duct [1], [2]. Unlike spironolactone, its action is independent of aldosterone. **Why Muscle Cramps?** Muscle cramps are a frequently reported side effect of Triamterene. This occurs due to the rapid alteration in electrolyte balance and the contraction of extracellular fluid volume. While it spares potassium, the net loss of sodium and water can lead to localized electrolyte imbalances in muscle tissue, triggering involuntary contractions. **Analysis of Incorrect Options:** * **A. Improved glucose tolerance:** Diuretics, particularly thiazides, are known to *worsen* glucose tolerance (hyperglycemia). Triamterene does not improve it; in some cases, it may impair it. * **C. Decrease in urea level:** Diuretics can cause a decrease in effective circulating volume, leading to pre-renal azotemia, which actually **increases** blood urea nitrogen (BUN) levels. * **D. Hypokalemia:** As a potassium-sparing diuretic, Triamterene causes **hyperkalemia**, not hypokalemia [1]. This is its most dangerous potential side effect, especially when used with ACE inhibitors [1]. **High-Yield Facts for NEET-PG:** 1. **Triamterene & Kidney Stones:** A unique side effect of Triamterene is that it is poorly soluble and can precipitate in the urine, leading to **crystalluria and kidney stones** (triamterene casts). 2. **Mechanism:** It is a "renal epithelial sodium channel blocker," similar to Amiloride [2]. 3. **Liddle’s Syndrome:** While Amiloride is the drug of choice, this class is used to treat Liddle’s syndrome (pseudo-hyperaldosteronism).

Question 169: A group of people are travelling to the mountains, and a girl starts complaining of mountain sickness. What is the drug of choice?

A. Thiazide
B. Acetazolamide (Correct Answer)
C. Promethazine
D. Dimenhydrinate

Explanation: ***Acetazolamide*** - This drug is the agent of choice for prophylaxis and treatment of **Acute Mountain Sickness (AMS)** due to its ability to accelerate **acclimatization**. - It functions as a **carbonic anhydrase inhibitor**, inducing a mild metabolic acidosis that stimulates the respiratory center, thereby increasing ventilation and improving blood oxygen saturation. *Promethazine* - This is an **antihistamine** (H1 blocker) often used for its potent **antiemetic** (nausea) and sedative effects. - While it may relieve nausea symptoms associated with AMS, it does not address the underlying physiological disturbances or enhance **acclimatization**. *Dimenhydrinate* - This medication is also an **antihistamine** typically employed to treat and prevent **motion sickness** and vertigo. - It lacks the crucial physiological mechanism (carbonic anhydrase inhibition) required to improve breathing efficiency and accelerate the body's response to **hypoxia**. *Thiazide* - This category of drugs, such as hydrochlorothiazide, are **diuretics** primarily used for hypertension and edema. - They do not possess the necessary respiratory stimulation properties of **Acetazolamide** and are therefore ineffective in treating or preventing mountain sickness.

Question 170: A patient having hypertension is on thiazides and is complaining of fatigue and hypokalemia. Which of the following drugs can prevent potassium loss?

A. Acetazolamide
B. Indapamide
C. Furosemide
D. Amiloride (Correct Answer)

Explanation: ***Amiloride***- Amiloride is a **potassium-sparing diuretic** that acts by blocking the **Epithelial Sodium Channel (ENaC)** in the collecting duct. [5]- By inhibiting Na+ reabsorption here, it decreases the electrical gradient that drives **potassium secretion**, effectively counteracting the hypokalemic effect of thiazides. [2]*Furosemide*- Furosemide is a **loop diuretic** that inhibits the Na-K-2Cl cotransporter in the thick ascending limb.- It is notorious for causing significant urinary **potassium loss** and would worsen the patient's **hypokalemia** and fatigue. [5]*Acetazolamide*- Acetazolamide is a **carbonic anhydrase inhibitor** that increases the delivery of Na+ and bicarbonate (HCO3-) to the collecting duct. [4]- The increased delivery of these ions promotes the secretion and loss of **potassium** in the urine, thus failing to prevent hypokalemia. [4]*Indapamide*- Indapamide is a **thiazide-like diuretic** that, similar to thiazides, inhibits the NaCl cotransporter in the distal convoluted tubule. [1]- Like other thiazides, Indapamide is a **potassium-wasting diuretic** and would exacerbate the existing **hypokalemia**. [3]

Question 171: A 35-year-old male experiences headache, nausea, and shortness of breath while trekking. The physician prescribes a drug to alleviate his symptoms. The drug administered primarily acts on which part of the nephron?

A. Loop of Henle
B. Collecting duct (CD)
C. Proximal convoluted tubule (PCT) (Correct Answer)
D. Distal convoluted tubule (DCT)

Explanation: ***Proximal convoluted tubule (PCT)***- The clinical presentation (headache, nausea, shortness of breath while trekking) is consistent with **Acute Mountain Sickness (AMS)**, which is typically prevented or treated with **Acetazolamide**.- **Acetazolamide** is a **carbonic anhydrase inhibitor** that acts primarily in the PCT, reducing bicarbonate reabsorption and inducing metabolic acidosis, which stimulates ventilation to counteract altitude-induced respiratory alkalosis.*Loop of Henle*- This segment is the primary site for **Loop Diuretics** (e.g., **Furosemide**), which inhibit the **Na+-K+-2Cl- cotransporter** in the thick ascending limb.- Loop diuretics promote powerful diuresis but are not the standard pharmacological choice for treating or preventing the symptoms of AMS.*Distal convoluted tubule (DCT)*- The DCT is the target site for **Thiazide Diuretics** (e.g., **Hydrochlorothiazide**), which block the **Na+-Cl- cotransporter**.- Thiazides primarily manage hypertension and edema and lack the necessary mechanism (carbonic anhydrase inhibition) to directly increase ventilation required for AMS treatment.*Collecting duct (CD)*- The collecting duct is where **Potassium-sparing diuretics** and **Aldosterone antagonists** (e.g., **Spironolactone**) exert their effects by controlling final sodium and potassium balance.- While these drugs can influence fluid balance, their primary actions are far removed from the need to induce metabolic acidosis to stimulate central respiratory drives in high-altitude illness.

Question 172: Which of the following diuretics primarily acts on the part labeled 'D' in the given diagram of a nephron?

A. Acetazolamide
B. Mannitol
C. Hydrochlorothiazide (Correct Answer)
D. Furosemide

Explanation: ***Hydrochlorothiazide*** - The part labeled 'D' in the diagram is the **Distal Convoluted Tubule (DCT)**. **Thiazide diuretics**, such as hydrochlorothiazide, primarily act on this segment of the nephron. - They work by inhibiting the **Na+/Cl- cotransporter** in the DCT, which reduces the reabsorption of sodium and chloride from the tubular fluid, leading to increased water excretion. *Furosemide* - Furosemide is a **loop diuretic** that acts on the **thick ascending limb of the Loop of Henle** (part of B), not the DCT. - It is a more potent diuretic than thiazides because it inhibits the **Na+-K+-2Cl- cotransporter**, which is responsible for reabsorbing a significant portion of filtered sodium. *Acetazolamide* - Acetazolamide is a **carbonic anhydrase inhibitor** that primarily acts on the **Proximal Convoluted Tubule (PCT)** (labeled 'A'). - Its mechanism involves reducing the reabsorption of **bicarbonate (HCO3-)**, which leads to a mild diuretic effect and can cause metabolic acidosis. *Mannitol* - Mannitol is an **osmotic diuretic** that acts mainly in the **Proximal Convoluted Tubule (PCT)** and the **descending limb of the Loop of Henle**. - It is a pharmacologically inert substance that increases the **osmolarity** of the tubular fluid, thereby preventing water reabsorption.

Question 173: A 50-year-old woman was prescribed a diuretic by a doctor to manage hypertension. Which of the following diuretics acts on site 'A' as marked in the given image?

A. Acetazolamide
B. Mannitol
C. Hydrochlorothiazide (Correct Answer)
D. Furosemide

Explanation: ***Hydrochlorothiazide*** - Hydrochlorothiazide is a **thiazide diuretic** that acts on the **Distal Convoluted Tubule (DCT)**, which is indicated by the letter 'A' in the provided diagram. - It works by inhibiting the **Na+/Cl- cotransporter** in the early DCT, leading to increased excretion of sodium and water, which helps lower blood pressure. *Furosemide* - Furosemide is a potent **loop diuretic** that acts on the **thick ascending limb of the loop of Henle** (labeled as 'G'). - It inhibits the **Na+/K+/2Cl- cotransporter**, causing a significant increase in sodium and water excretion, making it more powerful than thiazides. *Acetazolamide* - Acetazolamide is a **carbonic anhydrase inhibitor**, and its primary site of action is the **Proximal Convoluted Tubule (PCT)** (labeled as 'D'). - It is a weak diuretic and is more commonly used for glaucoma, metabolic alkalosis, or altitude sickness rather than as a primary agent for hypertension. *Mannitol* - Mannitol is an **osmotic diuretic** that exerts its effect primarily in the **Proximal Convoluted Tubule (PCT)** and the **descending limb of the loop of Henle**. - It is administered intravenously and is used to reduce intracranial or intraocular pressure, not for the chronic management of hypertension.

Question 174: A patient on hydrochlorothiazide develops renal stones. What explains this adverse effect?

A. Decreased urinary citrate (Correct Answer)
B. Increased urinary citrate
C. Decrease urinary calcium
D. Increase urinary calcium

Explanation: ***Decreased urinary citrate*** - **Hydrochlorothiazide** (HCTZ) can cause hypokalemia associated with **metabolic alkalosis** - Metabolic alkalosis leads to **decreased urinary citrate** excretion (hypocitraturia) - **Citrate is a key inhibitor** of calcium oxalate and calcium phosphate stone formation by complexing with urinary calcium - Hypocitraturia theoretically increases stone formation risk by reducing this protective effect - **Clinical Note:** Despite this mechanism, thiazides are actually used to **prevent** recurrent calcium stones due to their dominant effect of reducing urinary calcium excretion *Increased urinary calcium* - This would promote stone formation, but thiazides actually **decrease** urinary calcium excretion (hypocalciuria) - The calcium-lowering effect is why thiazides are used therapeutically for **preventing** calcium nephrolithiasis - In this question, the mechanism relates to altered citrate, not calcium excretion *Decreased urinary calcium* - Thiazides do decrease urinary calcium, which is **protective** against stones, not causative - This is the primary beneficial effect that makes thiazides useful in preventing recurrent calcium nephrolithiasis - The stone formation in the question stem relates to the **citrate** mechanism, not calcium *Increased urinary citrate* - Increased citrate would be **protective** against stone formation by binding urinary calcium - Thiazides cause the opposite effect: **hypocitraturia** (decreased citrate) due to associated metabolic alkalosis - Higher urinary citrate is actually a therapeutic goal in stone prevention

Question 175: By what primary mechanism does hydrochlorothiazide help prevent the formation of calcium stones?

A. It directly dissolves existing calcium stones by altering urinary pH and increasing their solubility.
B. It increases the urinary excretion of citrate, which acts as a chelating agent.
C. It increases calcium reabsorption in the distal convoluted tubule, leading to a decrease in urinary calcium excretion. (Correct Answer)
D. It increases the filtration of calcium at the glomerulus, thereby reducing serum calcium levels.

Explanation: ***It increases calcium reabsorption in the distal convoluted tubule, leading to a decrease in urinary calcium excretion.*** - By inhibiting the **sodium-chloride cotransporter (NCC)** in the **distal convoluted tubule (DCT)**, thiazides indirectly enhance calcium reabsorption via the basolateral Na+/Ca2+ exchanger. - This pharmacological effect causes **hypocalciuria**, which reduces the supersaturation of calcium oxalate/phosphate in the urine, thereby preventing stone formation. *It increases the urinary excretion of citrate, which acts as a chelating agent.* - While citrate is a powerful inhibitor of stones, thiazides are **not** primarily known to substantially increase urinary citrate excretion. - Other measures, such as oral **potassium citrate**, are used specifically to increase urinary citrate levels in stone formers. *It increases the filtration of calcium at the glomerulus, thereby reducing serum calcium levels.* - Thiazides actually tend to cause a slight **increase** in serum calcium (due to enhanced reabsorption in the DCT and bone effects), a condition known as thiazide-induced hypercalcemia. - Their mechanism of stone prevention is focused on reducing **urinary** calcium, not primarily filtering more calcium. *It directly dissolves existing calcium stones by altering urinary pH and increasing their solubility.* - Thiazides are primarily **preventative** medications for stone formation; they do not have a role in directly dissolving existing calcium stones. - The dissolution of some stones (like uric acid stones) is usually achieved by urinary alkalinization (e.g., using **potassium citrate**), which is not the main action of HCTZ.

Question 176: A patient is started on hydrochlorothiazide for hypertension and later develops renal stones. Which metabolic effect of hydrochlorothiazide is most likely responsible?

A. Hypocitraturia
B. Hypocalciuria
C. Hypomagnesemia
D. Hyperuricemia (Correct Answer)

Explanation: ***Hyperuricemia*** * Hydrochlorothiazide causes **hyperuricemia** by competing with uric acid for secretion in the proximal tubule, leading to decreased uric acid excretion. * Elevated serum uric acid levels increase the risk of **uric acid stone formation**, which is a well-recognized adverse effect of thiazide diuretics. * This is why thiazides can precipitate gout attacks and increase uric acid stone risk. *Hypocalciuria* * HCTZ causes **decreased urinary calcium excretion** (hypocalciuria) by enhancing calcium reabsorption in the DCT. * This effect is **stone-PROTECTIVE**, not causative - thiazides are actually used therapeutically to prevent recurrent calcium stones. * This would NOT explain stone formation in this patient. *Hypomagnesemia* * While HCTZ can cause magnesium loss, hypomagnesemia is not a primary mechanism for stone formation with thiazide use. * Magnesium is actually a stone inhibitor, so low levels could theoretically contribute, but this is not the main mechanism. *Hypocitraturia* * HCTZ does not typically cause significant citrate wasting or hypocitraturia. * Hypocitraturia is more characteristic of **carbonic anhydrase inhibitors** and chronic metabolic acidosis, not thiazide diuretics.

Question 177: The image shows drug 'X' blocking a channel in the renal tubule. Which of the following drugs is 'X'?

A. Eplerenone
B. Canrenone
C. Indapamide
D. Amiloride (Correct Answer)

Explanation: ***Amiloride*** - The image shows drug 'X' inhibiting the **epithelial sodium channel (ENaC)** in the kidney tubule. **Amiloride** is a potassium-sparing diuretic that directly blocks ENaC. - By blocking ENaC, amiloride reduces sodium reabsorption and thereby reduces potassium excretion, making it a **potassium-sparing diuretic**. *Eplerenone* - **Eplerenone** is a selective aldosterone receptor antagonist. It blocks the action of aldosterone, not directly the ENaC. - While it has a similar overall effect of potassium-sparing, its mechanism is upstream of the ENaC receptor itself, by preventing aldosterone from increasing ENaC expression. *Canrenone* - **Canrenone** is an active metabolite of spironolactone, which is also an aldosterone receptor antagonist. - Like eplerenone, it works by blocking aldosterone receptors, preventing aldosterone from increasing ENaC activity, rather than directly blocking the channel itself. *Indapamide* - **Indapamide** is a thiazide-like diuretic that acts on the distal convoluted tubule. - It inhibits the **Na+/Cl- symporter**, which is different from the ENaC shown in the image, affecting a different part of the nephron and mechanism of action.

Question 178: A 42-year old man with history of alcohol dependency presents with progressive abdominal distension. Abdominal examination reveals a shifting dullness. Which one of the following is the most appropriate drug to relieve this abdominal distension?

A. Lactulose
B. Spironolactone (Correct Answer)
C. Propranolol
D. Octreotide

Explanation: **Spironolactone** - **Spironolactone** is an **aldosterone antagonist**, which is the **first-line diuretic** used in the management of **ascites** due to **cirrhosis**, often developing secondary to alcohol dependency. - It works by blocking aldosterone receptors in the **renal collecting duct**, leading to increased sodium and water excretion while conserving potassium, effectively reducing fluid accumulation. *Lactulose* - **Lactulose** is a non-absorbable disaccharide primarily used to treat and prevent **hepatic encephalopathy** by reducing ammonia levels. - It does not directly relieve abdominal distension caused by ascites, and its use is unrelated to fluid overload. *Propranolol* - **Propranolol** is a **non-selective beta-blocker** used to reduce **portal pressure** and prevent **variceal bleeding** in patients with cirrhosis. - While it addresses a complication of chronic liver disease, it does not directly manage or relieve ascites. *Octreotide* - **Octreotide** is a **somatostatin analog** used to treat complications like **acute variceal bleeding** or **hepatic encephalopathy** by reducing splanchnic blood inflow. - It is not indicated for the management of ascites or relief of abdominal distension caused by fluid accumulation.

Question 179: A 66-year-old male presents to the outpatient cardiology clinic for evaluation of suspected primary hypertension. His blood pressure is elevated to 169/96 mm Hg, and his heart rate is 85/min. Physical examination reveals an overweight male with regular heart and lung sounds. Following repeated elevated blood pressure measurements, the diagnosis is made and the patient is started on hydrochlorothiazide. Of the following options, which is a side effect that one could experience from thiazide-like diuretics?

A. Hyperuricemia (Correct Answer)
B. Hyperkalemia
C. Hypocalcemia
D. Hypernatremia
E. Hypoglycemia

Explanation: ***Hyperuricemia*** - Thiazide diuretics inhibit the secretion of **uric acid** in the renal tubules. [1] - This can lead to increased serum uric acid levels, potentially exacerbating or precipitating **gout**. [1] *Hyperkalemia* - Thiazide diuretics work by inhibiting the Na+/Cl- cotransporter in the **distal convoluted tubule**, which leads to increased sodium delivery to the collecting duct. [1] - This promotes the excretion of potassium, resulting in **hypokalemia**, not hyperkalemia. *Hypocalcemia* - Thiazide diuretics decrease the excretion of **calcium** by increasing its reabsorption in the distal convoluted tubule. [1], [2] - This effect leads to **hypercalcemia**, not hypocalcemia, and can be beneficial in patients with osteoporosis. [2] *Hypernatremia* - Thiazide diuretics increase the excretion of **sodium** along with water. - This effect tends to cause **hyponatremia**, not hypernatremia, due to increased urinary sodium loss and water retention relative to sodium. [2]

Question 180: Which of the following is a carbonic anhydrase inhibitor?

A. Hydrochlorothiazide
B. Mannitol
C. Furosemide
D. Acetazolamide (Correct Answer)

Explanation: ***Acetazolamide*** - Acetazolamide is a classic example of a **carbonic anhydrase inhibitor**, primarily used as a diuretic and for managing **glaucoma** and **altitude sickness**. - It works by inhibiting the enzyme **carbonic anhydrase** in the **proximal renal tubule**, reducing bicarbonate reabsorption and thus promoting diuresis. *Hydrochlorothiazide* - Hydrochlorothiazide is a **thiazide diuretic** that acts on the **distal convoluted tubule** to inhibit the reabsorption of sodium and chloride. - It is not a carbonic anhydrase inhibitor. *Mannitol* - Mannitol is an **osmotic diuretic** that works in the **proximal tubule** and **descending limb of Henle's loop** by creating an osmotic gradient. - It is not a carbonic anhydrase inhibitor and functions by drawing water into the renal tubule, leading to increased urine output. *Furosemide* - Furosemide is a **loop diuretic** that acts on the **thick ascending limb of the loop of Henle** by inhibiting the Na+-K+-2Cl- cotransporter. - It is one of the most potent diuretics but does not inhibit carbonic anhydrase.

Question 181: Hydrochlorothiazide works by inhibiting

A. Na+ Cl pump in late DCT
B. Na+ K+ 2Cl pump in descending limb of loop of Henle
C. Na+ K+ 2Cl pump in ascending limb of loop of Henle
D. Na+ Cl pump in early DCT (Correct Answer)

Explanation: ***Na+ Cl pump in early DCT*** - **Hydrochlorothiazide** is a **thiazide diuretic** that acts primarily on the **early distal convoluted tubule (DCT)**. - It inhibits the **sodium-chloride cotransporter (NCC)**, leading to increased excretion of sodium, chloride, and water. *Na+ Cl pump in late DCT* - The **late DCT** and collecting duct are primarily involved in fine-tuning sodium reabsorption, influenced by **aldosterone**, not the primary site of action for thiazides. - The **epithelial sodium channel (ENaC)** and Na+/K+-ATPase are more prominent here. *Na+ K+ 2Cl pump in descending limb of loop of Henle* - The **descending limb of the loop of Henle** is primarily permeable to water, with no active ion pumps like **Na+ K+ 2Cl pump**. - Its main function is to concentrate the urine by allowing water to move out. *Na+ K+ 2Cl pump in ascending limb of loop of Henle* - **Furosemide** and other **loop diuretics** act on the **Na+ K+ 2Cl cotransporter (NKCC2)** in the **thick ascending limb of the loop of Henle**, not hydrochlorothiazide. - Inhibition here prevents significant reabsorption of sodium, potassium, and chloride, leading to potent diuresis.

Question 182: Which one of the following is not a clinical use of spironolactone?

A. Pulmonary edema (Correct Answer)
B. Congestive heart failure
C. Hypertension
D. To counteract hypokalemia due to thiazide diuretics

Explanation: ***Pulmonary edema*** - While spironolactone is a **diuretic**, its onset of action is relatively slow (days to weeks), making it unsuitable for the acute management of **pulmonary edema**, which requires rapid fluid removal. - For acute pulmonary edema, fast-acting loop diuretics like **furosemide** are preferred due to their potent and rapid diuresis. *Congestive heart failure* - Spironolactone is a **potassium-sparing diuretic** and an **aldosterone antagonist**, which improves outcomes in **congestive heart failure** by reducing fluid retention, myocardial fibrosis, and sympathetic activation. - It specifically helps in preventing **cardiac remodeling** and has been shown to reduce mortality in patients with heart failure. *Hypertension* - Spironolactone is used as an **adjunctive treatment for hypertension**, particularly in cases of **resistant hypertension** or when there is evidence of primary hyperaldosteronism. - It helps lower **blood pressure** by blocking aldosterone's effects, leading to increased sodium and water excretion. *To counteract hypokalemia due to thiazide diuretics* - As a **potassium-sparing diuretic**, spironolactone directly counteracts the **hypokalemia** (low potassium) that can be induced by other diuretics, such as **thiazide diuretics** and **loop diuretics**. - Its mechanism involves blocking **aldosterone receptors** in the collecting duct, reducing potassium secretion and sodium reabsorption.

Question 183: Which of the following diuretics is contraindicated in Hepatic coma?

A. Bumetanide
B. Furosemide
C. Acetazolamide (Correct Answer)
D. Spironolactone

Explanation: ***Acetazolamide*** - **Acetazolamide** inhibits carbonic anhydrase, leading to increased bicarbonate excretion and metabolic acidosis. In patients with **hepatic coma**, this can worsen the condition by impairing the liver's ability to convert ammonia to urea, leading to increased levels of **ionized ammonia** that can cross the blood-brain barrier. - The resulting **metabolic acidosis** can also interfere with the kidney's response to ammonia, further exacerbating the **hepatic encephalopathy**. *Bumetanide* - **Bumetanide** is a loop diuretic that acts on the **thick ascending limb of the loop of Henle** to inhibit sodium, potassium, and chloride reabsorption. - It does not directly exacerbate **hepatic encephalopathy** through metabolic acidosis in the same way as acetazolamide. *Furosemide* - **Furosemide** is a loop diuretic similar to bumetanide, acting on the **thick ascending limb** to promote diuresis. - While aggressive diuresis with furosemide in critical patients can sometimes lead to **volume depletion** and electrolyte imbalances that may indirectly affect liver function, it does not directly worsen **hepatic coma** by altering systemic acid-base balance and ammonia detoxification like acetazolamide. *Spironolactone* - **Spironolactone** is an **aldosterone antagonist** and a potassium-sparing diuretic, commonly used in liver cirrhosis with ascites. - It does not directly cause **metabolic acidosis** or increase ionized ammonia levels; in fact, by improving fluid balance, it can sometimes help manage complications of liver disease.

Question 184: What is the effect of thiazide diuretics on urinary calcium excretion?

A. Increase excretion
B. Decrease excretion (Correct Answer)
C. No effect
D. Variable effect

Explanation: ***Decrease excretion*** - Thiazide diuretics work by inhibiting the **sodium-chloride cotransporter (NCC)** in the **distal convoluted tubule** of the nephron. - This action leads to increased reabsorption of calcium in the distal tubule via **enhanced activity of the apical calcium channels (TRPV5)** and **basolateral Na+/Ca2+ exchanger (NCX1)**, thereby **decreasing urinary calcium excretion**. - This effect is clinically utilized in patients with **recurrent calcium kidney stones** and **hypercalciuria**. *Increase excretion* - Loop diuretics, like furosemide, block the **Na-K-2Cl cotransporter (NKCC2)** in the thick ascending limb of the loop of Henle, which is associated with **increased calcium excretion**. - Thiazide diuretics have the opposite effect on calcium handling compared to loop diuretics. *No effect* - This is incorrect because thiazide diuretics have a **well-documented and clinically significant effect** on calcium excretion. - The calcium-retaining effect is **consistent and predictable**, not absent. *Variable effect* - The effect of thiazides on calcium is **not variable** but rather **consistent and dose-dependent** in decreasing urinary calcium excretion. - This is a **primary pharmacological action**, not a variable or secondary effect.

Question 185: The Loop diuretic acts at

A. Ascending loop (Correct Answer)
B. PCT
C. DCT
D. Descending loop

Explanation: ***Ascending loop*** - Loop diuretics, such as **furosemide**, inhibit the **Na-K-2Cl cotransporter** in the **thick ascending limb of the loop of Henle**. - This action prevents the reabsorption of sodium, potassium, and chloride, leading to increased excretion of water. *PCT* - The **proximal convoluted tubule (PCT)** is primarily involved in the reabsorption of most filtered solutes like glucose, amino acids, and bicarbonate. - While carbonic anhydrase inhibitors act here, loop diuretics do not exert their main effect in the PCT. *DCT* - The **distal convoluted tubule (DCT)** is where thiazide diuretics primarily act by inhibiting the **Na-Cl cotransporter**. - Loop diuretics have no significant effect on electrolyte handling in the DCT. *Descending loop* - The **descending loop of Henle** is mainly permeable to **water** and impermeable to solutes. - Its function is to concentrate the urine, but it is not a primary site of action for loop diuretics.

Question 186: Side effects of oral carbonic anhydrase inhibitors include?

A. Paresthesia (Correct Answer)
B. Hyperkalemia
C. Insomnia
D. Weight gain

Explanation: ***Paresthesia*** - **Paresthesia** (tingling sensation, especially in fingers, toes, and perioral region) is one of the **most common side effects** of carbonic anhydrase inhibitors like acetazolamide - Occurs due to **systemic metabolic acidosis** and altered neuronal excitability from pH shifts and electrolyte changes - This symptom is so common that patients should be counseled about it before starting therapy *Hyperkalemia* - Carbonic anhydrase inhibitors cause **hypokalemia (potassium wasting)**, NOT hyperkalemia - Mechanism: Increased sodium delivery to distal tubule → increased Na-K exchange → urinary potassium loss - Although metabolic acidosis can shift potassium out of cells, the **diuretic effect predominates**, leading to net potassium loss *Insomnia* - **Not a recognized side effect** of carbonic anhydrase inhibitors - Patients may actually experience **fatigue or drowsiness** rather than insomnia - No direct pharmacological mechanism links carbonic anhydrase inhibition to sleep disturbances *Weight gain* - Carbonic anhydrase inhibitors have a **diuretic effect** causing fluid and sodium loss - Patients typically experience **weight loss or stable weight**, not weight gain - Weight gain is associated with fluid-retaining medications, which is the opposite effect of diuretics

Question 187: Loop and thiazide diuretics commonly cause clinically significant loss of:

A. Sodium
B. Calcium
C. Potassium (Correct Answer)
D. Iron

Explanation: ***Potassium*** - Loop diuretics (e.g., furosemide) and thiazide diuretics (e.g., hydrochlorothiazide) inhibit sodium reabsorption in the renal tubules, leading to **increased urinary potassium excretion**. - This results in **hypokalemia**, a clinically significant side effect that requires monitoring and often necessitates **potassium supplementation** or the addition of **potassium-sparing diuretics** (e.g., spironolactone, amiloride). - Hypokalemia can cause muscle weakness, cardiac arrhythmias, and increased digitalis toxicity. *Sodium* - While diuretics do increase sodium excretion (their primary therapeutic mechanism), the question focuses on **clinically significant electrolyte loss** that requires intervention. - Sodium loss is the intended therapeutic effect for volume reduction, not typically considered a problematic "side effect." *Calcium* - **Loop diuretics** increase calcium excretion (useful in hypercalcemia treatment). - **Thiazide diuretics** actually decrease calcium excretion (can increase serum calcium, useful in osteoporosis). - The effects are variable depending on diuretic class. *Iron* - Diuretics do not directly affect iron excretion or absorption. - Iron balance is regulated primarily through intestinal absorption, not renal excretion.

Question 188: Furosemide acts to inhibit Na+ reabsorption in which of the following locations?

A. Collecting duct
B. Distal convoluted tubule
C. Descending limb of the loop of Henle
D. Ascending limb of the loop of Henle (Correct Answer)

Explanation: ***Ascending limb of the loop of Henle*** - **Furosemide** is a **loop diuretic** that primarily acts on the thick ascending limb of the loop of Henle. - It inhibits the **Na+-K+-2Cl- cotransporter (NKCC2)**, thereby preventing the reabsorption of these ions and increasing their excretion. *Collecting duct* - The collecting duct is primarily targeted by **potassium-sparing diuretics** (e.g., amiloride, spironolactone), which act on different channels and receptors. - **Sodium reabsorption** here is regulated by aldosterone and involves the epithelial sodium channel (ENaC). *Distal convoluted tubule* - This segment is the primary site of action for **thiazide diuretics**, which inhibit the **Na+-Cl- cotransporter**. - While some reabsorption occurs here, it is not the main site of action for furosemide. *Descending limb of the loop of Henle* - The descending limb is highly permeable to **water** but relatively impermeable to solutes. - There is no significant active sodium reabsorption in this segment that would be inhibited by furosemide.

Question 189: Following are the side effects of thiazides except-

A. Hypocalcemia (Correct Answer)
B. Hepatic coma
C. Hypokalemia
D. Impotence

Explanation: ***Hypocalcemia*** - Thiazide diuretics are known to cause **hypercalcemia** (increased calcium levels) rather than hypocalcemia. - They enhance calcium reabsorption in the **distal convoluted tubule**, leading to elevated serum calcium. *Hepatic coma* - Thiazides can exacerbate **hepatic encephalopathy** in patients with liver cirrhosis due to their potassium-wasting effects and potential for metabolic alkalosis. - This can precipitate or worsen hepatic coma, especially in susceptible individuals. *Hypokalemia* - Thiazide diuretics inhibit the reabsorption of sodium and chloride in the **distal convoluted tubule**, leading to increased delivery of sodium to the collecting ducts. - This promotes **potassium excretion** via the aldosterone-sensitive Na+/K+ exchanger, resulting in hypokalemia. *Impotence* - **Erectile dysfunction** is a recognized, albeit less common, side effect of thiazide diuretics. - The exact mechanism is not fully understood but may involve effects on blood flow or neuronal pathways.

Question 190: Gout can be precipitated by -

A. Digitalis
B. Calcium channel blockers
C. Thiazide diuretics (Correct Answer)
D. Omeprazole

Explanation: ***Thiazide diuretics*** - **Thiazide diuretics** reduce the renal excretion of **uric acid**, leading to increased serum uric acid levels (hyperuricemia). - This elevation in uric acid can lead to the formation of **uric acid crystals** in joints, precipitating a gout attack. *Digitalis* - **Digitalis** (digoxin) is a cardiac glycoside used for heart failure and arrhythmias; it does not directly affect uric acid metabolism. - Its primary mechanism involves inhibiting the **Na+/K+-ATPase pump**, increasing intracellular calcium, and enhancing myocardial contractility. *Calcium channel blockers* - **Calcium channel blockers** primarily act by blocking calcium influx into vascular smooth muscle and cardiac cells. - They are generally considered **neutral** or even slightly beneficial for uric acid levels; some, like amlodipine, have shown potential to lower uric acid slightly. *Omeprazole* - **Omeprazole** is a proton pump inhibitor (PPI) that reduces stomach acid production. - It does not have a direct mechanism that would significantly impact **uric acid metabolism** or precipitate gout.

Question 191: Which of the following is not caused by furosemide?

A. Hyponatremia
B. Hyperuricemia
C. Hypokalemia
D. Hypercalcemia (Correct Answer)

Explanation: ***Hypercalcemia*** - Furosemide, a **loop diuretic**, inhibits the reabsorption of calcium in the thick ascending limb of the loop of Henle, leading to increased urinary calcium excretion and thus **hypocalcemia**. - Its mechanism of action directly contrasts with conditions that cause elevated calcium levels. *Hyponatremia* - Furosemide inhibits the reabsorption of sodium and chloride in the loop of Henle, leading to increased excretion of these electrolytes and **free water**. - This can result in a state of **sodium depletion** and dilutional hyponatremia. *Hyperuricemia* - Furosemide competes with uric acid for secretion into the renal tubule. - This competition leads to **decreased renal excretion of uric acid**, which can result in elevated blood uric acid levels. *Hypokalemia* - Furosemide increases the delivery of sodium to the collecting ducts, which enhances the activity of the sodium-potassium ATPase pump and potassium secretion. - This leads to increased excretion of potassium in the urine and can cause **low serum potassium levels**.

Question 192: All of the following drugs are known to worsen hyperkalemia except

A. Furosemide (Correct Answer)
B. ACE inhibitors
C. Amiloride
D. Spironolactone

Explanation: ***Furosemide*** - **Furosemide** is a loop diuretic that acts on the **thick ascending limb of the loop of Henle**, inhibiting the reabsorption of sodium, chloride, and potassium. - This action leads to increased excretion of potassium in the urine, thus **preventing hyperkalemia** and often causing hypokalemia. *ACE inhibitors* - **ACE inhibitors** block the production of angiotensin II, leading to decreased aldosterone secretion. - Reduced aldosterone levels decrease potassium excretion in the renal tubules, which can **worsen hyperkalemia**. *Amiloride* - **Amiloride** is a potassium-sparing diuretic that blocks sodium channels in the collecting duct. - This action reduces potassium secretion, making it a drug that can **worsen hyperkalemia**. *Spironolactone* - **Spironolactone** is an aldosterone antagonist that also acts as a potassium-sparing diuretic. - By blocking aldosterone's effects, it **decreases potassium excretion** in the renal tubules and can therefore worsen hyperkalemia.

Question 193: In the presence of renal failure, which of the following should not be given?

A. Bumetanide
B. Furosemide
C. Spironolactone (Correct Answer)
D. None of the options

Explanation: ***Spironolactone*** - **Spironolactone** is an **aldosterone antagonist**, a **potassium-sparing diuretic**, which can cause **hyperkalemia**, especially in patients with **renal impairment** where potassium excretion is already compromised - Due to the risk of severe **hyperkalemia**, which can lead to life-threatening **cardiac arrhythmias**, spironolactone is **contraindicated** or used with extreme caution in **renal failure** - In renal failure, the kidneys cannot adequately excrete potassium, and adding a potassium-sparing diuretic significantly increases the risk of dangerous hyperkalemia *Bumetanide* - **Bumetanide** is a **loop diuretic** that primarily acts on the **ascending limb of the loop of Henle** to inhibit sodium and chloride reabsorption - While its efficacy may be reduced in severe renal failure, it is still commonly used at higher doses and can be effective in managing fluid overload in these patients - Loop diuretics remain the mainstay of diuretic therapy in renal failure, unlike potassium-sparing diuretics *Furosemide* - **Furosemide** is another **loop diuretic** that is often used in patients with **renal failure** to promote diuresis and manage fluid overload - Even with impaired kidney function, it can still exert its diuretic effect, although higher doses may be required - It does not cause significant potassium retention and is safe to use in renal failure *None of the options* - This option is incorrect because **spironolactone** is specifically contraindicated in patients with **renal failure** due to the high risk of **hyperkalemia**

Question 194: All of the following adverse effects can be caused by loop diuretics except :

A. Hypomagnesemia
B. Hyperglycemia
C. Hypercalcemia (Correct Answer)
D. Hyperuricemia

Explanation: ***Hypercalcemia*** - Loop diuretics inhibit the reabsorption of calcium in the thick ascending limb of the loop of Henle, leading to **increased calcium excretion** and thus **hypocalcemia**, not hypercalcemia [2]. - This property makes them useful in treating conditions like hypercalcemia, but it means they do not cause hypercalcemia themselves. *Hypomagnesemia* - Loop diuretics inhibit magnesium reabsorption in the thick ascending limb, leading to **increased urinary magnesium excretion** and potential **hypomagnesemia** [1], [2]. - This electrolyte imbalance can contribute to cardiac arrhythmias and muscle weakness [2]. *Hyperglycemia* - Loop diuretics, particularly in high doses, can decrease **insulin secretion** and increase **insulin resistance**, leading to **hyperglycemia**. - This effect is generally mild but can be significant in patients with **diabetes mellitus**. *Hyperuricemia* - Loop diuretics compete with uric acid for secretion into the renal tubules, leading to **reduced uric acid excretion** and elevated serum uric acid levels, also known as **hyperuricemia** [1]. - This can precipitate or exacerbate **gout attacks** in susceptible individuals [1].

Question 195: Thiazide diuretics cause all except:

A. Decreased uric acid excretion
B. Hyperkalemia
C. Hyperglycemia
D. Increased calcium excretion (Correct Answer)

Explanation: ***Increased calcium excretion*** - Thiazide diuretics are known to **decrease urinary calcium excretion**, leading to an increase in serum calcium levels. - This property makes them useful in the treatment of **calcium nephrolithiasis** and **osteoporosis**. *Decreased uric acid excretion* - Thiazide diuretics compete with uric acid for secretion in the **proximal tubule**, leading to decreased uric acid excretion and potential **hyperuricemia**. - This can precipitate or exacerbate **gout**. *Hyperkalemia* - Thiazide diuretics cause **hypokalemia**, NOT hyperkalemia, by increasing potassium excretion in the **distal convoluted tubule**. - Thiazides block Na-Cl cotransporter, leading to increased sodium delivery to collecting duct where **sodium-potassium exchange** occurs, causing potassium loss. *Hyperglycemia* - Thiazide diuretics can cause **hyperglycemia** by impairing insulin secretion from the pancreas and increasing insulin resistance in peripheral tissues. - This effect is more prominent in patients with **pre-existing diabetes** or impaired glucose tolerance.

Question 196: Which potassium-sparing diuretic alters cardiac morphology and is associated with anti-androgenic side effects?

A. Amiloride
B. Triamterene
C. Spironolactone (Correct Answer)
D. Eplerenone

Explanation: ***Spironolactone*** - **Spironolactone** is a **non-selective aldosterone antagonist** that blocks mineralocorticoid receptors - It has significant **anti-androgenic effects** due to binding to androgen receptors, causing gynecomastia, decreased libido, and menstrual irregularities - Aldosterone promotes **cardiac remodeling** (hypertrophy and fibrosis) in heart failure; spironolactone's antagonistic action **reverses or prevents** these detrimental changes, thus altering cardiac morphology favorably - Used in **heart failure with reduced ejection fraction** (HFrEF) to improve outcomes and reduce mortality *Amiloride* - **Amiloride** is a direct epithelial sodium channel (ENaC) blocker - Its primary action is to inhibit sodium reabsorption in the collecting tubule - While it helps in treating hypertension and heart failure through its diuretic effect, it does **not directly alter cardiac morphology** like aldosterone antagonists - No anti-androgenic effects *Triamterene* - **Triamterene** is another direct ENaC blocker, similar in mechanism to amiloride - Promotes sodium excretion and potassium retention, often combined with loop or thiazide diuretics - Does **not have direct effects on aldosterone-mediated cardiac remodeling** - No anti-androgenic effects *Eplerenone* - **Eplerenone** is a **selective aldosterone receptor antagonist**, similar to spironolactone in altering cardiac morphology - However, it is **more selective** for mineralocorticoid receptors and has **minimal anti-androgenic effects** - This selectivity reduces hormonal side effects like gynecomastia - Also used in heart failure and post-MI, but the question specifically asks about the drug associated with anti-androgenic effects

Question 197: Chronic thiazide therapy causes persistent hypercalcemia which is due to:

A. Fanconi's syndrome
B. Hypervitaminosis D
C. Renal tubular acidosis
D. Increased distal tubular calcium reabsorption (Correct Answer)

Explanation: ***Increased distal tubular calcium reabsorption*** - Thiazide diuretics work by inhibiting the **sodium-chloride cotransporter** in the **distal convoluted tubule**, leading to increased sodium and water excretion. - This inhibition also leads to enhanced **calcium reabsorption** in the distal tubule by increasing the electrochemical gradient and affecting transmembrane calcium channels, resulting in **hypercalcemia**. *Fanconi's syndrome* - This is a generalized dysfunction of the **proximal renal tubules**, leading to the excretion of amino acids, glucose, phosphate, and bicarbonate in the urine. - It typically causes **hypophosphatemia** and **renal osteodystrophy**, not primary hypercalcemia. *Hypervitaminosis D* - This condition results from excessive intake of **vitamin D**, leading to increased intestinal calcium absorption and bone resorption, causing hypercalcemia. - It is not directly caused by chronic thiazide therapy. *Renal tubular acidosis* - This is a group of disorders characterized by a defect in renal acid excretion or bicarbonate reabsorption, leading to **metabolic acidosis**. - While it can be associated with various electrolyte disturbances, it does not directly cause persistent hypercalcemia.

Question 198: Amiloride can cause hyperkalemia due to its action on:

A. Electrogenic K+ channels
B. Electrogenic Na+ channels (Correct Answer)
C. Non-electrogenic Na+-Cl- symporter
D. H+-K+ ATPase

Explanation: ***Correct: Electrogenic Na+ channels*** - Amiloride is a **potassium-sparing diuretic** that blocks the **epithelial sodium channels (ENaC)** in the apical membrane of the collecting duct cells. - By blocking **ENaC**, amiloride reduces the reabsorption of sodium, which in turn diminishes the negative potential in the tubular lumen, thereby reducing the driving force for **potassium secretion** and leading to hyperkalemia. *Incorrect: Electrogenic K+ channels* - While potassium channels are involved in potassium balance, amiloride's primary action is not directly on these channels. - Its effects on potassium are secondary to its impact on sodium reabsorption and the resulting electrochemical gradient. *Incorrect: Non-electrogenic Na+-Cl- symporter* - The **Na+-Cl- symporter (NCC)** is located in the distal convoluted tubule and is the target of **thiazide diuretics**, not amiloride. - Blocking NCC leads to increased delivery of sodium and water to the collecting duct, but does not directly cause hyperkalemia. *Incorrect: H+-K+ ATPase* - The **H+-K+ ATPase** in the collecting duct is involved in potassium reabsorption and hydrogen ion secretion. - Amiloride does not directly inhibit this pump; instead, it affects potassium handling by altering the electrical gradient associated with sodium reabsorption.

Question 199: Regarding furosemide, which statement is true?

A. Acute pulmonary edema is an indication (Correct Answer)
B. Primarily administered via the oral route
C. Causes diuresis by acting on the distal tubule
D. Acts on the collecting duct

Explanation: ***Acute pulmonary edema is an indication*** - **Furosemide** is a potent diuretic frequently used to treat **acute pulmonary edema** due to its rapid onset of action and significant diuretic effect. - It helps reduce systemic and pulmonary congestion by promoting the excretion of excess fluid. *Primarily administered via the oral route* - While furosemide can be administered orally, in acute and severe conditions like **pulmonary edema**, it is often given **intravenously** for a faster and more potent effect. - Oral administration is more common for chronic management of fluid retention, but not the primary route for acute, life-threatening situations where rapid action is needed. *Causes diuresis by acting on the distal tubule* - Furosemide is a **loop diuretic** that primarily acts on the **thick ascending limb of the loop of Henle**, not the distal tubule. - It inhibits the **Na+-K+-2Cl- cotransporter** in this segment, leading to significant diuresis. *Acts on the collecting duct* - Diuretics that act on the **collecting duct** primarily include **potassium-sparing diuretics** like spironolactone and amiloride, which work differently from furosemide. - Furosemide's main site of action is earlier in the nephron, at the **loop of Henle**.

Question 200: Site of action of furosemide is:-

A. PCT
B. Descending limb
C. DCT
D. Thick ascending limb of loop of Henle (Correct Answer)

Explanation: ***Thick ascending limb of loop of Henle*** - Furosemide is a **loop diuretic** that acts on the **Na+-K+-2Cl- cotransporter** in the apical membrane of cells in the thick ascending limb. - By inhibiting this cotransporter, furosemide prevents the reabsorption of these ions, leading to increased excretion of water and electrolytes. *PCT* - The **proximal convoluted tubule (PCT)** is the primary site of reabsorption for many solutes, including glucose, amino acids, and bicarbonate. - Carbonic anhydrase inhibitors and SGLT2 inhibitors primarily act here, but not loop diuretics like furosemide. *Descending limb* - The **descending limb of the loop of Henle** is highly permeable to water but impermeable to solutes, allowing for passive water reabsorption as the filtrate moves into the hypertonic medulla. - No major diuretic classes primarily target this segment. *DCT* - The **distal convoluted tubule (DCT)** is responsible for fine-tuning electrolyte reabsorption, particularly sodium and chloride. - **Thiazide diuretics** act on the Na+-Cl- cotransporter in the DCT.

Question 201: What is the expected change in electrolyte excretion within the first 24 hours of administering a thiazide diuretic for hypertension?

A. Sodium excretion increases, Potassium excretion increases, Calcium excretion decreases (Correct Answer)
B. Sodium excretion increases, Potassium excretion increases, Calcium excretion increases
C. Sodium excretion increases, Potassium excretion decreases, Calcium excretion decreases
D. Sodium excretion increases, Potassium excretion decreases, Calcium excretion increases

Explanation: **Sodium excretion increases, Potassium excretion increases, Calcium excretion decreases** - Thiazide diuretics primarily act on the **distal convoluted tubule** to inhibit the **Na+-Cl− cotransporter** [2], leading to increased sodium and water excretion. - The increased sodium load arriving at the collecting duct promotes **potassium secretion** due to increased activity of the Na+/K+ ATPase and enhanced electrochemical gradient [3], while **calcium reabsorption** is paradoxically increased [1]. *Sodium excretion increases, Potassium excretion increases, Calcium excretion increases* - While **sodium and potassium excretion increase** with thiazide use, **calcium excretion actually decreases** [2]. - Thiazides are known to reduce **urinary calcium excretion**, making them useful in treating nephrolithiasis due to hypercalciuria [1]. *Sodium excretion increases, Potassium excretion decreases, Calcium excretion decreases* - Thiazides cause **increased potassium excretion**, leading to **hypokalemia**, not decreased potassium excretion [4]. - The initial increase in sodium and fluid delivery to the collecting duct stimulates the **renin-angiotensin-aldosterone system**, contributing to potassium loss. *Sodium excretion increases, Potassium decreases, Calcium excretion increases* - This option incorrectly states that **potassium excretion decreases** and **calcium excretion increases**. - Thiazides are associated with **hypokalemia** and a **reduction in urinary calcium excretion** [1].

Question 202: Thiazides and loop diuretics both have opposite action on which of the following ions ?

A. Potassium
B. Sodium
C. Chloride
D. Calcium (Correct Answer)

Explanation: ***Calcium*** - Thiazide diuretics **increase calcium reabsorption** in the distal convoluted tubule, leading to decreased urinary calcium excretion. - Loop diuretics **decrease calcium reabsorption** in the thick ascending limb of the loop of Henle, resulting in increased urinary calcium excretion. *Potassium* - Both thiazide and loop diuretics can cause **hypokalemia** by increasing potassium excretion in the urine. - This is due to increased sodium delivery to the collecting duct, which stimulates potassium secretion. *Sodium* - Both thiazide and loop diuretics inhibit sodium reabsorption at different sites in the nephron, leading to **increased urinary sodium excretion** (natriuresis). - This is their primary mechanism of action for diuresis. *Chloride* - Both thiazide and loop diuretics inhibit **chloride reabsorption** as they block specific sodium-chloride cotransporters. - Thiazides inhibit the Na-Cl cotransporter in the DCT, while loop diuretics inhibit the Na-K-2Cl cotransporter in the thick ascending limb.

Question 203: Furosemide causes all except -

A. Hypokalemia
B. Ototoxicity
C. Hypercalcemia (Correct Answer)
D. Hyperuricemia

Explanation: ***Hypercalcemia*** - Furosemide, a **loop diuretic**, inhibits the reabsorption of calcium in the thick ascending limb of the loop of Henle, leading to increased urinary calcium excretion and thus **hypocalcemia**, not hypercalcemia. - This effect makes loop diuretics useful in managing **hypercalcemia** by promoting calcium excretion. *Hypokalemia* - Furosemide inhibits the Na-K-2Cl cotransporter, leading to increased delivery of sodium to the collecting duct, which enhances potassium secretion and can cause **hypokalemia**. - Monitoring serum potassium levels and potassium supplementation are often necessary during furosemide therapy. *Ototoxicity* - Furosemide can cause **ototoxicity**, particularly with rapid intravenous administration or in patients with renal impairment. - This adverse effect typically manifests as **tinnitus** or **hearing loss**, which can be transient or permanent. *Hyperuricemia* - Furosemide competes with uric acid for secretion in the proximal tubule, leading to decreased uric acid excretion and subsequently **hyperuricemia**. - This can precipitate or exacerbate **gout attacks** in susceptible individuals.

Question 204: A drug that can be used for producing alkalinization of urine is?

A. Spironolactone
B. Furosemide
C. Hydrochlorothiazide
D. Acetazolamide (Correct Answer)

Explanation: ***Acetazolamide*** - This drug is a **carbonic anhydrase inhibitor** that works in the **proximal tubule** of the kidney to decrease bicarbonate reabsorption. - By inhibiting **carbonic anhydrase**, it increases the excretion of **bicarbonate**, leading to an **alkaline urine** and mild systemic acidosis. *Spironolactone* - This is a **potassium-sparing diuretic** that acts as an **aldosterone antagonist** in the collecting duct. - It increases sodium excretion and potassium retention, but does not primarily cause **urine alkalinization**. *Furosemide* - This is a **loop diuretic** that acts on the **thick ascending limb of the loop of Henle** to inhibit the Na-K-2Cl cotransporter. - While it can increase urine output, it primarily increases the excretion of sodium, potassium, and chloride, and typically causes a **mild metabolic alkalosis** in the blood, but does not directly alkalinize the urine. *Hydrochlorothiazide* - This is a **thiazide diuretic** that acts in the **distal convoluted tubule** to inhibit the Na-Cl cotransporter. - It promotes the excretion of sodium and chloride, and can cause **hypokalemia** and metabolic alkalosis, but does not primarily induce **urine alkalinization**.

Question 205: Free water clearance is decreased by?

A. Furosemide
B. Vinblastine
C. Vincristine
D. Chlorpropamide (Correct Answer)

Explanation: ***Chlorpropamide*** - **Chlorpropamide** is a sulfonylurea oral hypoglycemic agent that is a **classic and well-documented cause of SIADH (Syndrome of Inappropriate Antidiuretic Hormone)**. - **SIADH** leads to increased ADH secretion, causing increased water reabsorption in the collecting ducts and thus **decreased free water clearance**. - Among the options listed, chlorpropamide is the **prototypical drug** associated with drug-induced SIADH in pharmacology teaching. *Furosemide* - **Furosemide** is a loop diuretic that inhibits the reabsorption of sodium and chloride in the **loop of Henle**. - This disrupts the medullary concentration gradient and leads to increased excretion of water and electrolytes, thereby **increasing free water clearance**. *Vinblastine* - **Vinblastine** is a vinca alkaloid chemotherapeutic agent primarily used in cancer treatment. - It does not significantly affect renal water handling or ADH secretion and does **not typically cause SIADH**. *Vincristine* - **Vincristine** is another vinca alkaloid chemotherapy drug that **can also cause SIADH** and decrease free water clearance. - However, in the context of standard pharmacology teaching and board examinations, **chlorpropamide** is the more classical example emphasized for drug-induced SIADH and decreased free water clearance. - Vincristine is primarily known for its **neurotoxicity** as a major side effect.

Question 206: Which of the following is NOT known as adverse drug reaction of furosemide?

A. Hyperkalemia (Correct Answer)
B. Hypomagnesemia
C. Hyperuricemia
D. Acidosis

Explanation: ***Hyperkalemia*** - Furosemide is a **loop diuretic** that primarily acts on the **thick ascending limb of the loop of Henle**, inhibiting the Na-K-2Cl cotransporter. - This action leads to increased excretion of potassium in the distal tubule, therefore, **hypokalemia** is a common adverse effect, not hyperkalemia. - **Hyperkalemia is NOT an adverse effect of furosemide** - it causes the opposite effect (hypokalemia). *Hypomagnesemia* - Furosemide inhibits magnesium reabsorption in the **loop of Henle**, leading to increased urinary excretion of magnesium. - This can result in clinically significant **hypomagnesemia**, especially with long-term use. - This IS a well-recognized adverse effect. *Hyperuricemia* - Furosemide competes with uric acid for secretion into the renal tubule at the **proximal tubule**. - This competition reduces uric acid excretion, causing an increase in serum **uric acid levels** and potentially precipitating **gout attacks**. - This IS a well-recognized adverse effect. *Acidosis* - Furosemide characteristically causes **metabolic alkalosis** (not acidosis) due to: - Contraction alkalosis from volume depletion - Enhanced H+ secretion in the distal tubule - Loss of Cl- in urine - **Metabolic acidosis is NOT a typical adverse effect** of furosemide. - While severe volume depletion theoretically could contribute to lactic acidosis, this is not a recognized or standard adverse drug reaction of furosemide.

Question 207: One of the following diuretics does not require its presence in the tubular lumen for its pharmacological effects

A. Aldosterone antagonists (Correct Answer)
B. Loop diuretics
C. Carbonic anhydrase inhibitors
D. Thiazide diuretics

Explanation: ***Aldosterone antagonists*** - These diuretics act from the **basolateral side** of the renal tubular cells, binding to **cytoplasmic mineralocorticoid receptors**. - Their action is independent of their concentration within the **tubular lumen**, as they modulate gene transcription rather than directly blocking ion channels from the luminal side. *Loop diuretics* - These agents, such as **furosemide**, must reach the **tubular lumen** via **active secretion** in the proximal tubule to exert their effect. - They inhibit the **Na+-K+-2Cl− cotransporter (NKCC2)** on the luminal membrane in the thick ascending limb of the loop of Henle. *Carbonic anhydrase inhibitors* - Drugs like **acetazolamide** primarily act within the **tubular lumen** and in the cytoplasm of proximal tubule cells. - They inhibit **carbonic anhydrase**, reducing bicarbonate reabsorption and thus requiring luminal presence for part of their effect. *Thiazide diuretics* - Similar to loop diuretics, thiazides must be **secreted into the tubular lumen** by the organic acid transporter in the proximal tubule. - They then inhibit the **Na+-Cl− cotransporter (NCC)** on the luminal membrane of the distal convoluted tubule.

Question 208: What is the mechanism of action of thiazides?

A. Carbonic anhydrase inhibitor
B. Na+Cl- co-transporter inhibitor (Correct Answer)
C. Osmotic diuresis
D. Na+K+ co-transporter inhibitor

Explanation: **Na+Cl- co-transporter inhibitor** - Thiazide diuretics primarily act by inhibiting the **Na+Cl- cotransporter** (also known as the **NCC cotransporter**) in the **distal convoluted tubule** of the nephron. - This inhibition reduces the reabsorption of **sodium chloride**, leading to increased excretion of sodium, chloride, and water. *Carbonic anhydrase inhibitor* - **Carbonic anhydrase inhibitors** like acetazolamide primarily act in the **proximal convoluted tubule**. - They inhibit carbonic anhydrase, reducing bicarbonate reabsorption and leading to increased excretion of bicarbonate, sodium, and potassium, as well as a subsequent diuresis. *Osmotic diuresis* - **Osmotic diuretics** (e.g., mannitol) are filtered by the glomeruli but poorly reabsorbed, creating an **osmotic gradient** in the renal tubule. - This osmotic effect prevents water reabsorption, leading to increased urinary flow and excretion of solutes. *Na+K+ co-transporter inhibitor* - This refers to the **Na+K+2Cl- cotransporter** (NKCC2) which is inhibited by **loop diuretics** in the **thick ascending limb of the loop of Henle**. - Inhibition of this cotransporter leads to significant diuresis due to the large amount of sodium reabsorbed in this segment.

Question 209: Long-term use of which diuretic agent can result in gynaecomastia?

A. Amiloride
B. Acetazolamide
C. Spironolactone (Correct Answer)
D. Triamterene

Explanation: ***Spironolactone*** - **Spironolactone** is an **aldosterone antagonist** with a chemical structure similar to steroid hormones, enabling it to also act as a weak **androgen receptor antagonist** and **progesterone receptor partial agonist**. - This anti-androgenic and progestogenic activity can lead to **gynaecomastia** (breast enlargement in males), **breast tenderness**, and menstrual irregularities as dose-dependent side effects. *Amiloride* - **Amiloride** is a **potassium-sparing diuretic** that directly blocks epithelial sodium channels (ENaC) in the collecting duct. - It does not interfere with hormone receptors and is **not associated with gynaecomastia**. *Acetazolamide* - **Acetazolamide** is a **carbonic anhydrase inhibitor** that primarily acts in the proximal tubule. - Its mechanism of action does not involve modulation of steroid hormones, and it is **not known to cause gynaecomastia**. *Triamterene* - **Triamterene** is another **potassium-sparing diuretic** that, like amiloride, directly blocks ENaC channels. - It lacks significant hormonal effects and is **not associated with gynaecomastia**.

Question 210: Which diuretic causes impaired glucose tolerance?

A. Thiazide (Correct Answer)
B. Acetazolamide
C. Triamterene
D. Amiloride

Explanation: ***Thiazide*** - **Thiazide diuretics** can cause **impaired glucose tolerance** or even exacerbate existing diabetes due to several mechanisms, including **hypokalemia**, which impairs insulin secretion. - They may also reduce **peripheral glucose utilization** and increase hepatic glucose production. - This is a well-known adverse effect that requires monitoring in diabetic patients. *Acetazolamide* - **Acetazolamide** is a **carbonic anhydrase inhibitor** primarily used for glaucoma, altitude sickness, and metabolic alkalosis. - It does not typically cause **impaired glucose tolerance** as a significant side effect. *Triamterene* - **Triamterene** is a **potassium-sparing diuretic** that acts by blocking sodium channels in the collecting duct. - It is not commonly associated with **impaired glucose tolerance**. *Amiloride* - **Amiloride** is another **potassium-sparing diuretic** with a mechanism similar to triamterene. - It is not known to cause **impaired glucose tolerance** as a side effect.

Question 211: Thiazide diuretics act on:

A. Loop of Henle
B. PCT mainly
C. DCT mainly (Correct Answer)
D. All parts of tubule

Explanation: ***DCT mainly*** - Thiazide diuretics primarily act on the **distal convoluted tubule (DCT)** [2, 3]. - They inhibit the **sodium-chloride cotransporter (NCC)** in the luminal membrane of the DCT cells, blocking the reabsorption of Na+ and Cl- [1, 2, 3].*Loop of henle* - The loop of Henle is the site of action for **loop diuretics**, which inhibit the Na-K-2Cl cotransporter. - While it's an important part of the nephron for fluid balance, it's not the primary target for thiazide diuretics.*PCT mainly* - The **proximal convoluted tubule (PCT)** is where the majority of solute and water reabsorption occurs. - **Carbonic anhydrase inhibitors** (e.g., acetazolamide) primarily act in the PCT, not thiazides.*All part of tubule* - No single class of diuretic acts on **all parts of the renal tubule**. - Each class has a specific site of action to allow for selective modulation of electrolyte and water balance.

Question 212: The site of action of the loop diuretic furosemide is:

A. Distal convoluted tubule
B. Descending limb of loop of Henle
C. Proximal convoluted tubule
D. Thick ascending limb of loop of Henle (Correct Answer)

Explanation: ***Thick ascending limb of loop of Henle*** - Furosemide, a **loop diuretic**, acts by inhibiting the **Na+-K+-2Cl- cotransporter (NKCC2)** in the luminal membrane of the epithelial cells in the thick ascending limb. - This inhibition prevents the reabsorption of these ions, leading to increased excretion of **sodium**, **potassium**, **chloride**, and water. *Distal convoluted tubule* - This is the primary site of action for **thiazide diuretics**, which inhibit the **Na+-Cl- cotransporter**. - While some water reabsorption occurs here, it is not the main target for loop diuretics like furosemide. *Descending limb of loop of Henle* - This segment is primarily permeable to **water** due to aquaporins but impermeable to solutes, allowing for passive water reabsorption. - No significant transport mechanisms are directly targeted by furosemide here. *Proximal convoluted tubule* - The proximal tubule is where the majority of filtered **sodium**, **water**, and other solutes are reabsorbed. - **Carbonic anhydrase inhibitors** (e.g., acetazolamide) primarily act here.

Question 213: Thiazides cause -

A. Respiratory alkalosis
B. Metabolic alkalosis (Correct Answer)
C. Metabolic acidosis
D. Respiratory acidosis

Explanation: ***Metabolic alkalosis*** - Thiazide diuretics cause increased excretion of **potassium** and **hydrogen ions** in the urine, leading to **hypokalemia** and an increase in serum bicarbonate [1]. - This increased bicarbonate reabsorption by the kidneys, coupled with an increase in extracellular fluid volume contraction, results in **metabolic alkalosis** [1]. *Respiratory alkalosis* - This condition is characterized by a decrease in **arterial carbon dioxide (PaCO2)** due to **hyperventilation**, which is not directly caused by thiazide diuretics. - While electrolyte imbalances can indirectly affect respiration, thiazides primarily influence metabolic acid-base balance. *Metabolic acidosis* - This occurs due to a decrease in **serum bicarbonate** or an increase in acid, which is the opposite effect of thiazide diuretics. - Thiazides, by promoting hydrogen ion excretion, would tend to prevent rather than cause metabolic acidosis. *Respiratory acidosis* - Characterized by an increase in **arterial carbon dioxide (PaCO2)** due to **hypoventilation**, which is not a direct effect of thiazide diuretics. - Thiazide use does not typically lead to impaired ventilation.

Question 214: Potassium sparing diuretics act on:

A. Carbonic anhydrase
B. Aldosterone receptor (Correct Answer)
C. Na+ K+ pump
D. Na+ Cl- symporter

Explanation: ***Aldosterone receptor*** - **Potassium-sparing diuretics** include two main classes: **aldosterone antagonists** (spironolactone, eplerenone) and **ENaC blockers** (amiloride, triamterene). - **Aldosterone antagonists** like **spironolactone** and **eplerenone** act as **aldosterone receptor antagonists**, blocking the effects of aldosterone in the **collecting duct**. - By blocking aldosterone, these diuretics prevent the reabsorption of **sodium** and the secretion of **potassium** and **hydrogen ions**, leading to increased sodium excretion and potassium retention. - Note: Amiloride and triamterene work by directly blocking **epithelial sodium channels (ENaC)** rather than aldosterone receptors, but achieve the same net effect of potassium retention. *Carbonic anhydrase* - **Carbonic anhydrase inhibitors** (like acetazolamide) primarily act in the **proximal convoluted tubule** to inhibit the enzyme **carbonic anhydrase**. - This action reduces **bicarbonate reabsorption** and consequently impairs sodium reabsorption, leading to diuresis. - These are not potassium-sparing; they actually cause potassium loss. *Na+ K+ pump* - The **Na+/K+-ATPase pump** is located in the **basolateral membrane** of tubular cells and is responsible for maintaining the electrochemical gradients for sodium and potassium, driving reabsorption. - While other diuretics indirectly affect the activity of this pump, it is not the **primary direct target** of potassium-sparing diuretics. *Na+ Cl- symporter* - The **Na+/Cl- symporter** is the primary target of **thiazide diuretics**, located in the **distal convoluted tubule**. - Inhibition of this symporter reduces the reabsorption of sodium and chloride, leading to increased excretion of these ions. - Thiazides cause potassium loss, not potassium retention.

Question 215: Thiazide diuretics can be used for the treatment of all of these conditions EXCEPT :

A. Hypertension
B. Hyperlipidemia (Correct Answer)
C. Congestive Heart Failure
D. Idiopathic hypercalciuria with nephrocalcinosis

Explanation: ***Hyperlipidemia***- Thiazide diuretics are **not used to treat hyperlipidemia** and can sometimes have a mild **adverse effect of causing dyslipidemia** (increased LDL cholesterol and triglycerides).- Their mechanism of action primarily involves diuresis and vasodilation, not directly affecting lipid metabolism.*Hypertension*- Thiazide diuretics are **first-line agents** for the treatment of hypertension, especially for uncomplicated cases [3].- They reduce blood pressure by increasing sodium and water excretion, leading to a decrease in **extracellular fluid volume** and peripheral vascular resistance [2].*Congestive Heart Failure*- Thiazide diuretics are effective in managing **fluid overload** and **edema** associated with congestive heart failure [2].- While loop diuretics are often preferred for severe heart failure due to their greater diuretic potency, thiazides can be beneficial in milder cases or as adjuncts.*Idiopathic hypercalciuria with nephrocalcinosis*- Thiazide diuretics are used to treat **idiopathic hypercalciuria** because they promote **calcium reabsorption** in the renal tubules, thereby reducing urinary calcium excretion [1].- This property helps prevent the formation of calcium-containing kidney stones and can be beneficial in patients with **nephrocalcinosis**.

Question 216: Mechanism of action of thiazides is by -

A. Inhibiting Na+K+2Cl- in ascending limb of loop of henle
B. Inhibiting Na+/Cl- symporter in DCT (Correct Answer)
C. Inhibiting Na+/Cl- symporter in PCT
D. Inhibiting Na+K+2Cl- in descending limb of loop of henle

Explanation: **Inhibiting Na+/Cl- symporter in DCT** - Thiazide diuretics primarily act on the **distal convoluted tubule (DCT)** of the nephron [2]. - They inhibit the **Na+/Cl- symporter** (NCC channel) on the apical membrane, preventing reabsorption of sodium and chloride ions [1], [2]. *Inhibiting Na+K+2CI- in descending limb of loop of henle* - The descending limb of the loop of Henle is permeable to water but largely impermeable to solutes; there is no significant Na+K+2Cl- symporter activity here. - This mechanism describes the action of loop diuretics, but they act on the **ascending** limb, not the descending limb. *Inhibiting Na+K+2Cl- in ascending limb of loop of henle* - This mechanism describes the action of **loop diuretics** (e.g., furosemide, bumetanide) [3]. - Loop diuretics inhibit the **Na+K+2Cl- cotransporter (NKCC2)** in the thick ascending limb of the loop of Henle, leading to significant diuresis [3]. *Inhibiting Na+/Cl- symporter in PCT* - The **proximal convoluted tubule (PCT)** is primarily responsible for reabsorbing most of the filtered sodium, chloride, bicarbonate, and other solutes. - While sodium is reabsorbed in the PCT, it's mainly through Na+/H+ exchangers and other mechanisms, not a specific Na+/Cl- symporter that is targeted by thiazides [2].

Question 217: Which of the following is NOT an effect of Mannitol?

A. Increases blood osmolality
B. Increases GFR
C. Decreases ICP
D. Increases blood viscosity (Correct Answer)

Explanation: ***Increases blood viscosity*** - Mannitol is an **osmotic diuretic** that works by increasing the osmolality of the blood plasma, which draws water from the interstitial fluid and intracellular compartments into the intravascular space. - This process leads to **hemodilution**, which would decrease blood viscosity rather than increase it. *Increases blood osmolality* - Mannitol, as an **osmotic diuretic**, directly works by increasing the osmolality of the plasma. - This elevated plasma osmolality creates an osmotic gradient that pulls water from cells and interstitial spaces into the blood. *Increases GFR* - By increasing plasma volume through the movement of fluid from the interstitial space, mannitol can lead to **increased renal blood flow** and, consequently, an elevated GFR. - The increased fluid volume delivered to the kidneys also contributes to its diuretic effect. *Decreases ICP* - Mannitol is frequently used to reduce **intracranial pressure** (ICP) because it draws water out of the brain parenchyma into the blood vessels due to its osmotic effect. - This reduction in brain volume lessens the pressure within the skull.

Question 218: All of the following diuretics increase K+ excretion EXCEPT:

A. Acetazolamide
B. Triamterene (Correct Answer)
C. Thiazide
D. Furosemide

Explanation: ***Triamterene*** - **Triamterene** is a **potassium-sparing diuretic** that blocks epithelial sodium channels (ENaC) in the collecting duct, thereby reducing sodium reabsorption and potassium secretion. - Unlike most other diuretics, it causes **decreased K+ excretion** and can lead to hyperkalemia. *Acetazolamide* - **Acetazolamide** is a **carbonic anhydrase inhibitor** that acts in the proximal tubule, inhibiting bicarbonate reabsorption. - This leads to increased delivery of sodium and bicarbonate to the collecting duct, which enhances **potassium secretion** and increases K+ excretion. *Thiazide* - **Thiazide diuretics** (e.g., hydrochlorothiazide) act by inhibiting the Na+/Cl- cotransporter in the **distal convoluted tubule**. - This increases the delivery of sodium to the collecting duct, which stimulates the exchange of sodium for **potassium**, leading to increased K+ excretion and hypokalemia. *Furosemide* - **Furosemide** is a **loop diuretic** that inhibits the Na+/K+/2Cl- cotransporter in the **thick ascending limb of the loop of Henle**. - This prevents the reabsorption of these ions, leading to increased delivery of sodium to the collecting duct, which promotes **potassium secretion** and increased K+ excretion.

Question 219: All of the following are potassium sparing diuretic EXCEPT:

A. Indapamide (Correct Answer)
B. Triamterene
C. Amiloride
D. Spironolactone

Explanation: ***Indapamide*** - **Indapamide** is a **thiazide-like diuretic**, acting primarily on the distal convoluted tubule to inhibit sodium and chloride reabsorption, thus promoting their excretion along with water. - Unlike potassium-sparing diuretics, it can cause **potassium wasting (hypokalemia)** due to increased delivery of sodium to the collecting duct, where it is exchanged for potassium. *Triamterene* - **Triamterene** is a **potassium-sparing diuretic** that directly inhibits epithelial sodium channels (ENaC) in the collecting tubule, reducing sodium reabsorption and potassium secretion. - This mechanism helps to conserve potassium, preventing hypokalemia often associated with other diuretic classes. *Amiloride* - **Amiloride** is another **potassium-sparing diuretic** that, like triamterene, blocks epithelial sodium channels (ENaC) in the late distal tubule and collecting duct. - By inhibiting sodium reabsorption in this segment, it reduces the electrochemical gradient for potassium secretion, leading to potassium retention. *Spironolactone* - **Spironolactone** is an **aldosterone antagonist**, making it a potassium-sparing diuretic that competitively blocks aldosterone receptors in the collecting duct. - This blockage prevents aldosterone from promoting sodium reabsorption and potassium secretion, resulting in increased sodium excretion and **potassium retention**.

Question 220: Which of the following thiazides can be used in severe renal failure?

A. Chlorthiazide
B. Metolazone (Correct Answer)
C. Bendroflumethiazide
D. Trichloromethazide

Explanation: **Metolazone** - **Metolazone** is an exception among thiazides, as it retains its efficacy even in cases of **severe renal impairment** (creatinine clearance below 30 mL/min). - Its ability to act at more distal sites in the nephron and its different pharmacokinetic profile contribute to its effectiveness in reduced renal function. *Chlorthiazide* - This is a **thiazide diuretic** that loses significant efficacy when the **glomerular filtration rate (GFR)** falls below 30 mL/min. - It is generally not recommended for use in patients with **severe renal failure** due to diminished diuretic response. *Bendroflumethiazide* - Similar to most other **thiazide diuretics**, **bendroflumethiazide's** effectiveness is greatly reduced in **renal insufficiency**. - Its use is limited when the **creatinine clearance** drops below 30 mL/min, rendering it ineffective for diuresis in severe renal failure. *Trichloromethazide* - **Trichloromethazide** is another **thiazide diuretic** that shares the common characteristic of losing its diuretic effect in the presence of **significant renal impairment**. - It is not a suitable choice for managing fluid retention in patients with **severe renal failure**.

Question 221: Potassium-sparing diuretics act at the level of

A. Carbonic anhydrase
B. Aldosterone receptor (Correct Answer)
C. NaCl symporter
D. Na-K pump

Explanation: ***Aldosterone receptor*** - **Potassium-sparing diuretics** include two main classes: 1. **Aldosterone receptor antagonists** (e.g., **spironolactone**, **eplerenone**) that act on **aldosterone receptors** in the collecting tubules 2. **ENaC blockers** (e.g., **amiloride**, **triamterene**) that directly block **epithelial sodium channels (ENaC)** in the collecting duct - Both mechanisms reduce **sodium reabsorption** and **potassium secretion** in the **collecting tubule**, leading to retained potassium. - The aldosterone receptor is the most commonly tested site for this drug class. *Carbonic anhydrase* - **Carbonic anhydrase inhibitors** (e.g., **acetazolamide**) act primarily in the **proximal convoluted tubule**. - They inhibit **bicarbonate reabsorption**, leading to diuresis and metabolic acidosis, and are not considered potassium-sparing. *NaCl symporter* - **Thiazide diuretics** act on the **NaCl symporter (NCC)** in the **distal convoluted tubule**. - They inhibit sodium and chloride reabsorption but do not spare potassium; chronic use can lead to **hypokalemia**. *Na-K pump* - The **Na-K pump** (Na+/K+-ATPase) is found in many cells and maintains ion gradients, but it is not the primary target of potassium-sparing diuretics. - While involved in renal transport, diuretics targeting this pump have different primary mechanisms and therapeutic uses.

Question 222: Which of the following statements accurately compares the potency of amiloride and triamterene?

A. Amiloride is more potent than triamterene
B. Both drugs have equal potency
C. Potency cannot be compared between these drugs
D. Triamterene is more potent than amiloride (Correct Answer)

Explanation: ***Triamterene is more potent than amiloride*** - **Triamterene** is generally considered to be **more potent** than amiloride, with approximately **10-fold greater potency** on a weight basis. - This higher potency is reflected in the **lower effective dosing** of triamterene (50-100 mg/day) compared to amiloride (5-10 mg/day), though the starting doses appear different due to available formulations. - Both are **potassium-sparing diuretics** that block epithelial sodium channels (ENaC) in the collecting duct, but triamterene requires a smaller dose to achieve equivalent diuretic effects. *Amiloride is more potent than triamterene* - This statement is incorrect; **amiloride** is typically considered **less potent** than triamterene on a milligram-per-milligram basis. - The standard therapeutic doses reflect this difference in potency, with amiloride requiring relatively higher doses for comparable effects. *Both drugs have equal potency* - This statement is incorrect as there are well-documented differences in the **potency** of these two **potassium-sparing diuretics**. - While both work through the same mechanism (blocking ENaC channels in the collecting tubule), their individual pharmacological profiles result in different dose-response relationships. *Potency cannot be compared between these drugs* - This statement is incorrect; the **potency** of drugs within the same class and mechanism of action, such as these two potassium-sparing diuretics, **can and should be compared**. - Clinical and pharmacological studies routinely assess and compare the relative potencies of similar therapeutic agents to guide appropriate dosing.

Question 223: Which one of the following drugs causes increased concentration of Na+ & Cl- in urine with normal bicarbonate?

A. Furosemide
B. Ethacrynic acid (Correct Answer)
C. Bumetanide
D. Acetazolamide

Explanation: ***Ethacrynic acid*** - Ethacrynic acid is a **loop diuretic** that inhibits the Na+-K+-2Cl- cotransporter in the **thick ascending limb of the loop of Henle**. - It causes increased urinary excretion of **Na+ and Cl-** while maintaining **normal bicarbonate levels** (does not affect carbonic anhydrase). - **Key distinguishing feature**: Ethacrynic acid is a **phenoxyacetic acid derivative** (NOT a sulfonamide), making it useful in patients with **sulfonamide allergies**. - Note: All loop diuretics share the property of increasing Na+ and Cl- excretion with normal bicarbonate. *Furosemide* - Furosemide is a **sulfonamide-derived loop diuretic** with the same mechanism as ethacrynic acid (inhibits Na+-K+-2Cl- cotransporter). - It also increases Na+ and Cl- excretion with normal bicarbonate levels. - While pharmacologically equivalent to ethacrynic acid for this effect, it is structurally different (sulfonamide derivative). *Bumetanide* - Bumetanide is another **sulfonamide-derived loop diuretic** with identical mechanism to furosemide and ethacrynic acid. - It produces the same electrolyte effects: increased Na+ and Cl- excretion with normal bicarbonate. - Structurally, it is a sulfonamide derivative like furosemide. *Acetazolamide* - Acetazolamide is a **carbonic anhydrase inhibitor** acting in the **proximal tubule**. - It increases excretion of **bicarbonate** (causing metabolic acidosis), along with Na+ and K+. - This would result in **elevated bicarbonate in urine**, NOT normal bicarbonate, making it incorrect.

Question 224: Which of the following diuretics can lead to erectile dysfunction?

A. Thiazide diuretics (Correct Answer)
B. Carbonic anhydrase inhibitor
C. Loop diuretics
D. Mannitol

Explanation: ***Thiazide diuretics*** - **Thiazide diuretics** can cause **erectile dysfunction**, possibly due to effects on vascular function and **reduced blood flow** to the penis. - This adverse effect is a known concern and can impact patient adherence to **antihypertensive therapy**. *Carbonic anhydrase inhibitor* - **Carbonic anhydrase inhibitors** like acetazolamide are primarily used for glaucoma, altitude sickness, and metabolic alkalosis, and do not typically cause **erectile dysfunction**. - Their primary side effects relate to **metabolic acidosis** and electrolyte imbalances, not sexual function. *Loop diuretics* - **Loop diuretics** like furosemide are potent diuretics used in conditions like heart failure and edema; **erectile dysfunction** is not a common or significant side effect. - Their main adverse effects include **hypokalemia**, ototoxicity, and hypovolemia. *Mannitol* - **Mannitol** is an osmotic diuretic used to reduce intracranial and intraocular pressure. - It is administered intravenously and its side effects primarily involve **fluid and electrolyte disturbances**, not **erectile dysfunction**.

Question 225: Which of the following potassium sparing diuretics cause renal stones?

A. Triamterene (Correct Answer)
B. Amiloride
C. Eplerenone
D. Spironolactone

Explanation: ***Triamterene*** - **Triamterene** is known particularly for its propensity to form **renal stones**, especially when combined with indomethacin or in patients with underlying kidney disease. - The drug itself is poorly soluble and can precipitate in the urine, forming stones or crystal aggregates. *Amiloride* - **Amiloride** is a potassium-sparing diuretic that inhibits sodium channels in the distal nephron, but it is **not associated with renal stone formation**. - Its mechanism of action does not involve precipitation in the urinary tract. *Eplerenone* - **Eplerenone** is a selective aldosterone receptor antagonist that prevents potassium excretion, but it has **not been linked to renal stone development**. - It works by blocking aldosterone's effects on the mineralocorticoid receptor, without crystal formation issues. *Spironolactone* - **Spironolactone** is a non-selective aldosterone antagonist, similar to eplerenone, and is **not recognized as a cause of renal stones**. - It competes with aldosterone for receptor binding in the collecting duct, leading to potassium sparing and sodium excretion.

Question 226: Carbonic anhydrase inhibitors are:

A. Competitive and reversible inhibitors (Correct Answer)
B. Noncompetitive and reversible inhibitors
C. Competitive and irreversible inhibitors
D. Noncompetitive and irreversible inhibitors

Explanation: ***Competitive and reversible inhibitors*** - Carbonic anhydrase inhibitors like **acetazolamide** bind to the zinc ion at the **active site** of the enzyme, making them competitive inhibitors. - They compete with the natural substrate (CO₂ and H₂O) for binding to the enzyme. - Their binding is **reversible**, meaning the inhibitor-enzyme complex can dissociate, and their effects can be overcome by increasing substrate concentration. - This is the **correct mechanism** of action for drugs like acetazolamide, methazolamide, and dorzolamide. *Competitive and irreversible inhibitors* - While carbonic anhydrase inhibitors are **competitive**, they are NOT irreversible. - Irreversible inhibitors form **covalent bonds** or cause permanent enzyme modification, which is not the case here. *Noncompetitive and irreversible inhibitors* - Carbonic anhydrase inhibitors do NOT bind to allosteric sites (noncompetitive mechanism). - They directly bind to the **active site zinc ion**, making them competitive, not noncompetitive. - They are also reversible, not irreversible. *Noncompetitive and reversible inhibitors* - This is incorrect because these drugs are **competitive inhibitors** that bind to the active site. - Noncompetitive inhibitors would bind at a site other than the active site, which does not describe carbonic anhydrase inhibitors.

Question 227: Tolvaptan is used for:-

A. SIADH (Correct Answer)
B. Von Willebrand disease
C. Central DI
D. Catecholamine resistant Shock

Explanation: ***SIADH*** - **Tolvaptan** is a **vasopressin V2 receptor antagonist** that promotes water excretion without affecting sodium, making it ideal for treating **euvolemic and hypervolemic hyponatremia** associated with SIADH. - In **syndrome of inappropriate antidiuretic hormone secretion (SIADH)**, there is excessive **ADH** leading to water retention and dilutional hyponatremia; tolvaptan effectively counters this by blocking vasopressin's action. *Von Willebrand disease* - This is a **bleeding disorder** caused by a deficiency or dysfunction of **von Willebrand factor**, treated with **desmopressin** or factor replacement, not tolvaptan. - Tolvaptan has no role in coagulation pathways or the management of bleeding disorders. *Central DI* - **Central diabetes insipidus (DI)** results from reduced **ADH production** by the hypothalamus or posterior pituitary, leading to excessive water loss. - It is treated with **desmopressin** (synthetic ADH) to replace the deficient hormone, which is the opposite effect of tolvaptan. *Catecholamine resistant Shock* - **Catecholamine-resistant shock** is characterized by persistent hypotension despite high doses of **vasopressors**. - Treatment often involves agents like **vasopressin** (not tolvaptan) or corticosteroids to improve vascular tone, as tolvaptan would worsen the hypotension by promoting diuresis.

Question 228: Mannitol is used in the management of:-

A. Acute renal failure
B. Pulmonary edema
C. Congestive cardiac failure
D. Acute angle-closure glaucoma (Correct Answer)

Explanation: ***Acute angle-closure glaucoma*** - **Mannitol** is an osmotic diuretic [1] used to rapidly reduce **intraocular pressure** in conditions like acute angle-closure glaucoma [2]. - It works by creating an **osmotic gradient** that draws fluid from the vitreous humor into the bloodstream [2]. - This is a well-established **emergency indication** for mannitol [2]. *Acute renal failure* - While mannitol may be used in **prevention** of acute kidney injury (e.g., in rhabdomyolysis, cardiovascular surgery) [2], its use in established acute renal failure is generally **contraindicated** if the patient is **anuric**, as it can exacerbate fluid overload [2]. - It is **not a primary management** for acute renal failure among the given options. *Pulmonary edema* - **Mannitol** is generally **contraindicated** in pulmonary edema because its initial effect is to increase **intravascular volume** [2], which can worsen fluid accumulation in the lungs. - Loop diuretics like **furosemide** are preferred for their rapid onset and profound diuretic effect in pulmonary edema. *Congestive cardiac failure* - **Mannitol** is typically **contraindicated** in congestive cardiac failure as it can cause a **transient increase in plasma volume**, potentially worsening cardiac workload and leading to decompensation [2]. - Diuretics commonly used in heart failure, such as **loop diuretics** (e.g., furosemide) or **thiazide diuretics**, are preferred to reduce fluid overload.

Question 229: Assertion: Thiazide diuretics can cause hypercalcemia. Reason: Thiazides reduce urinary calcium excretion by acting on the distal convoluted tubule.

A. Both Assertion and Reason are true, but Reason is NOT the correct explanation of Assertion
B. Both Assertion and Reason are true, and Reason is the correct explanation of Assertion (Correct Answer)
C. Assertion is true, but Reason is false
D. Assertion is false, but Reason is true

Explanation: ***Both Assertion and Reason are true, and Reason is the correct explanation of Assertion*** - Thiazide diuretics cause **hypercalcemia** by enhancing calcium reabsorption in the distal convoluted tubule (DCT) - By increasing Ca²⁺ reabsorption, thiazides **reduce urinary calcium excretion**, leading to elevated serum calcium levels - The mechanism described in the Reason directly explains why the Assertion occurs - Clinical relevance: This effect is beneficial in preventing **calcium-containing kidney stones** but can be problematic in patients with **hypercalcemia** or **hyperparathyroidism** *Both Assertion and Reason are true, but Reason is NOT the correct explanation of Assertion* - Incorrect because the Reason (reduced urinary Ca²⁺ excretion at DCT) **is the direct mechanism** causing hypercalcemia - The two statements are causally linked, making this option wrong *Assertion is true, but Reason is false* - Incorrect because both statements are factually correct - Thiazides do reduce urinary calcium excretion via DCT action *Assertion is false, but Reason is true* - Incorrect because the Assertion is true - Thiazides are well-known to cause hypercalcemia, especially with chronic use

Question 230: A 45-year-old man with chronic liver disease presents with ascites and severe edema. Which diuretic combination is most suitable to manage his condition?

A. Acetazolamide and Mannitol
B. Spironolactone and Furosemide (Correct Answer)
C. Metolazone and Torsemide
D. Hydrochlorothiazide and Amiloride

Explanation: ***Spironolactone and Furosemide*** - **Spironolactone**, an **aldosterone antagonist**, is crucial because **secondary hyperaldosteronism** often contributes to sodium and water retention in patients with chronic liver disease and ascites. - **Furosemide**, a **loop diuretic**, provides potent diuresis by inhibiting sodium reabsorption in the **thick ascending limb of the loop of Henle**, effectively reducing fluid overload. *Acetazolamide and Mannitol* - **Acetazolamide**, a **carbonic anhydrase inhibitor**, has a relatively weak diuretic effect and is not typically used for significant ascites due to chronic liver disease. - **Mannitol**, an **osmotic diuretic**, is primarily used for cerebral edema or acute renal failure, not for chronic fluid retention in liver disease, as it can worsen volume status. *Metolazone and Torsemide* - **Metolazone**, a **thiazide-like diuretic**, can be effective in combination with loop diuretics for refractory edema but is not the first-line combination for initial management of ascites in chronic liver disease. - **Torsemide** is a loop diuretic, similar to furosemide, but typically not combined with metolazone as a primary strategy without prior trials of spironolactone and a loop diuretic. *Hydrochlorothiazide and Amiloride* - **Hydrochlorothiazide**, a **thiazide diuretic**, is less potent than loop diuretics and generally less effective in patients with advanced liver disease and significant ascites. - **Amiloride**, a **potassium-sparing diuretic**, is weaker than spironolactone and does not block aldosterone, making it less effective in combating the pathophysiology of ascites in liver disease.

Question 231: Which diuretic acts on the loop of Henle?

A. Amiloride
B. Thiazides
C. Spironolactone
D. Furosemide (Correct Answer)

Explanation: ***Furosemide*** - Furosemide is a **loop diuretic** that primarily acts on the **thick ascending limb of the loop of Henle**. - It inhibits the **Na+-K+-2Cl− cotransporter** (NKCC2), leading to increased excretion of sodium, potassium, and chloride. *Amiloride* - Amiloride is a **potassium-sparing diuretic** that acts on the **collecting duct**. - It inhibits the **epithelial sodium channel (ENaC)**, decreasing sodium reabsorption and potassium secretion. *Thiazides* - Thiazide diuretics (e.g., hydrochlorothiazide) act on the **distal convoluted tubule**. - They inhibit the **Na+-Cl− cotransporter**, reducing sodium reabsorption in this segment. *Spironolactone* - Spironolactone is an **aldosterone antagonist** that acts on the **collecting duct**. - It competitively inhibits aldosterone receptors, leading to decreased sodium reabsorption and increased potassium retention.

Question 232: What is the primary effect of acetazolamide when used at high altitudes?

A. Elevate pH
B. Decrease ventilation
C. Reduce HCO3- (Correct Answer)
D. Increase CO2

Explanation: ***Reduce HCO3-*** - Acetazolamide is a **carbonic anhydrase inhibitor**, which primarily acts on the kidneys to block **bicarbonate reabsorption**. - By reducing **bicarbonate levels (HCO3-)**, it induces a **metabolic acidosis**, which in turn stimulates **respiratory drive** and increases ventilation, thereby counteracting the effects of altitude sickness. *Elevate pH* - Acetazolamide causes a **metabolic acidosis**, leading to a *decrease* in blood pH, not an elevation. - The reduced pH is the stimulus for **increased ventilation**, which helps to normalize blood gases at altitude. *Decrease ventilation* - The **metabolic acidosis** induced by acetazolamide actually *stimulates* peripheral chemoreceptors, leading to an *increase* in ventilation. - Increased ventilation helps to **excrete CO2**, thereby improving oxygenation at high altitudes. *Increase CO2* - Increased ventilation (due to the **metabolic acidosis** induced by acetazolamide) leads to a *decrease* in partial pressure of **carbon dioxide (PCO2)**, not an increase. - This reduction in **PCO2** helps to improve the body's acid-base balance and oxygenation.

Question 233: A 70-year-old man with chronic heart failure is currently on optimal medical therapy with an ACE inhibitor, beta-blocker, and loop diuretic, but is experiencing worsening symptoms. Which diuretic should be added to his regimen to provide additional benefit?

A. Furosemide
B. Hydrochlorothiazide
C. Mannitol
D. Spironolactone (Correct Answer)

Explanation: ***Spironolactone*** - As an **aldosterone antagonist**, spironolactone is particularly indicated for **HFrEF (Heart Failure with reduced Ejection Fraction)** based on landmark trials like **RALES** and **EMPHASIS-HF**, providing additional diuretic effects and mortality benefit. - It's typically used as **add-on therapy** in patients already on **ACE inhibitors/ARBs** and **beta-blockers**, offering **cardioprotective benefits** by reducing myocardial fibrosis and improving ventricular remodeling. *Furosemide* - Furosemide is a **loop diuretic** often used as **first-line therapy** in heart failure for rapid symptom relief, but the question implies a patient already on a regimen needing *additional* relief. - While it can be **titrated upward**, adding another class of diuretic like an aldosterone antagonist provides **synergistic effects** and addresses different pathophysiological mechanisms. *Hydrochlorothiazide* - Hydrochlorothiazide is a **thiazide diuretic** typically used for **hypertension** or mild edema, which has **limited efficacy** in advanced heart failure due to reduced renal perfusion. - Its diuretic effect is generally **weaker than loop diuretics** and not usually the preferred add-on for worsening symptoms in chronic heart failure. *Mannitol* - Mannitol is an **osmotic diuretic** primarily used to reduce **intracranial** or **intraocular pressure**, not for chronic heart failure management. - It can **acutely increase intravascular volume**, which might worsen heart failure symptoms in patients with compromised cardiac function.

Question 234: Which type of diuretic is commonly prescribed for patients with heart failure to reduce fluid accumulation and manage blood pressure?

A. Thiazide
B. Loop (Correct Answer)
C. Osmotic
D. Carbonic anhydrase inhibitor

Explanation: ***Loop (Correct)*** - **Loop diuretics** are highly effective in removing significant amounts of fluid, making them ideal for managing **fluid overload** and **pulmonary congestion** in heart failure patients. - They work in the **loop of Henle** to inhibit Na+/K+/2Cl- co-transporters, leading to increased excretion of water, sodium, potassium, and chloride. - **First-line therapy** for acute decompensated heart failure and chronic heart failure with volume overload. *Thiazide (Incorrect)* - **Thiazide diuretics** are generally less potent than loop diuretics in inducing diuresis and are typically used for **mild to moderate hypertension** or edema. - Their primary site of action is the **distal convoluted tubule**, where they inhibit the Na+/Cl- co-transporter. - Not preferred in severe heart failure due to reduced efficacy in patients with decreased renal function. *Osmotic (Incorrect)* - **Osmotic diuretics**, such as mannitol, are primarily used to reduce **intracranial pressure** or **intraocular pressure** and are not routinely used for chronic fluid management in heart failure. - They exert their effect by creating an osmotic gradient in the renal tubules, drawing water into the lumen. *Carbonic anhydrase inhibitor (Incorrect)* - **Carbonic anhydrase inhibitors**, like acetazolamide, are mainly used for conditions such as **glaucoma**, **altitude sickness**, and to treat **metabolic alkalosis**. - They act in the **proximal convoluted tubule** to inhibit carbonic anhydrase, reducing bicarbonate reabsorption and leading to a mild diuretic effect. - Not used for heart failure management due to weak diuretic effect.

Question 235: A 72-year-old male with chronic kidney disease has elevated serum potassium levels. Which drug is likely contributing to his hyperkalemia?

A. Furosemide
B. Hydrochlorothiazide
C. Spironolactone (Correct Answer)
D. Amlodipine

Explanation: **Spironolactone** - **Spironolactone** is a **potassium-sparing diuretic** [1, 2] that blocks aldosterone's effects [1], leading to **sodium excretion** and **potassium retention** [1]. - In patients with **chronic kidney disease (CKD)**, the kidneys' ability to excrete potassium is impaired, making them highly susceptible to **hyperkalemia** when taking spironolactone. *Furosemide* - **Furosemide** is a **loop diuretic** that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle. - This action leads to increased excretion of **sodium**, **potassium**, and chloride, making it more likely to cause **hypokalemia** rather than hyperkalemia. *Hydrochlorothiazide* - **Hydrochlorothiazide** is a **thiazide diuretic** that inhibits the Na-Cl cotransporter in the distal convoluted tubule. - It increases the excretion of **sodium** and **chloride**, and can lead to **potassium wasting**, typically causing **hypokalemia**. *Amlodipine* - **Amlodipine** is a **calcium channel blocker** used for hypertension and angina. - It primarily affects vascular smooth muscle and **does not directly influence potassium balance** or renal potassium handling.

Question 236: Which of the following drugs is used in SIADH?

A. Desmopressin
B. Von Willebrand factor
C. Tolvaptan (Correct Answer)
D. Terlipressin

Explanation: ***Tolvaptan*** - **Tolvaptan** is an **oral vasopressin V2-receptor antagonist** that promotes water excretion without affecting sodium, making it effective for **hyponatremia** associated with SIADH [1]. - It works by blocking the action of **antidiuretic hormone (ADH)** at the renal collecting ducts, increasing free water clearance and thus raising serum sodium levels [1].*Desmopressin* - **Desmopressin** is a synthetic analog of **ADH (vasopressin)**, which acts as a V2 receptor agonist [2]. - It is used to **increase water reabsorption** and is therefore contraindicated in SIADH, where ADH levels are already inappropriately high [1].*Von Willebrand factor* - **Von Willebrand factor** is a protein primarily involved in **hemostasis** and is used to treat **Von Willebrand disease** and **hemophilia A**. - It has no role in the management of SIADH, which is a disorder of water balance.*Terlipressin* - **Terlipressin** is a vasopressin analog that acts as a **V1 receptor agonist**, primarily causing splanchnic vasoconstriction. - It is used to treat **esophageal variceal bleeding** and **hepatorenal syndrome**, but it is not indicated for SIADH.

Question 237: Gitelman's syndrome resembles the effects of which of the following drugs?

A. Thiazide diuretics (Correct Answer)
B. Loop diuretics (Furosemide)
C. Potassium-sparing diuretics (Spironolactone)
D. Carbonic anhydrase inhibitors (Acetazolamide)

Explanation: ***Thiazide diuretics*** - **Gitelman's syndrome** is a genetic disorder characterized by impaired function of the **thiazide-sensitive Na-Cl cotransporter (NCC)** in the distal convoluted tubule, functionally mimicking the effect of thiazide diuretics. - Both Gitelman's syndrome and thiazide diuretics cause **hypokalemia**, **hypomagnesemia**, **metabolic alkalosis**, and **hypocalciuria** due to impaired NCC function and secondary hyperaldosteronism. *Loop diuretics (Furosemide)* - Loop diuretics act on the **Na-K-2Cl cotransporter (NKCC2)** in the thick ascending limb of the loop of Henle, a more proximal site than the NCC. - While they also cause electrolyte abnormalities like hypokalemia, they typically lead to **hypercalciuria** rather than hypocalciuria, which is characteristic of Gitelman's syndrome. - Loop diuretic toxicity resembles **Bartter's syndrome**, not Gitelman's. *Potassium-sparing diuretics (Spironolactone)* - Spironolactone is an **aldosterone antagonist** that acts on the collecting duct, reducing sodium reabsorption and potassium secretion. - This drug primarily leads to **hyperkalemia**, which is the opposite of the hypokalemia seen in Gitelman's syndrome. *Carbonic anhydrase inhibitors (Acetazolamide)* - Acetazolamide inhibits carbonic anhydrase in the **proximal tubule**, reducing bicarbonate reabsorption. - This leads to **metabolic acidosis** with hypokalemia, which contrasts sharply with the **metabolic alkalosis** characteristic of Gitelman's syndrome.

Question 238: What is the most clinically significant electrolyte disturbance caused by loop diuretics?

A. Hypokalemia (Correct Answer)
B. Dehydration
C. Hyperkalemia
D. Fluid retention

Explanation: ***Hypokalemia*** - Loop diuretics inhibit the **Na-K-2Cl cotransporter** in the **thick ascending limb** of the loop of Henle, increasing sodium delivery to the collecting duct. - This increased sodium delivery promotes potassium secretion by the principal cells in the collecting duct, leading to significant **potassium loss** in the urine and **hypokalemia**. - Hypokalemia is the **most clinically significant electrolyte disturbance** with loop diuretics, potentially causing cardiac arrhythmias, muscle weakness, and requiring routine monitoring and supplementation. - **Clinical relevance:** May necessitate potassium supplementation or concurrent use of potassium-sparing diuretics. *Dehydration* - While loop diuretics can cause volume depletion and dehydration due to increased diuresis, the question specifically asks about **electrolyte disturbances**. - Dehydration represents fluid volume loss rather than a specific electrolyte abnormality. *Hyperkalemia* - Loop diuretics cause **potassium loss**, not potassium retention. - Hyperkalemia would be expected with **potassium-sparing diuretics** (spironolactone, amiloride), not loop diuretics. - This is the **opposite** of the actual electrolyte effect. *Fluid retention* - Loop diuretics are prescribed specifically to **reduce fluid retention** (edema) by promoting diuresis. - Fluid retention is the therapeutic **indication** for loop diuretics, not a side effect. - This would represent therapeutic failure rather than an adverse effect.

Question 239: Mannitol is most commonly used for which of the following conditions?

A. Impending renal failure
B. Glaucoma
C. Raised intracranial tension (ICT) (Correct Answer)
D. Pulmonary edema

Explanation: ***Raised intracranial tension (ICT)*** - **Mannitol** is an osmotic diuretic that creates an osmotic gradient, drawing water from the **brain parenchyma** into the vascular space, thereby reducing brain volume and **intracranial pressure**. - It is particularly effective in acute settings for managing **cerebral edema** associated with trauma, stroke, or tumors. *Glaucoma* - While mannitol can reduce **intraocular pressure** in acute glaucoma, it is not the most common or first-line treatment. - Other medications like topical beta-blockers, alpha-agonists, and prostaglandin analogs are typically preferred for long-term management and acute relief. *Impending renal failure* - **Mannitol** can induce osmosis of fluid, which could increase urine output. However, it is **contraindicated** in established **renal failure** due to the risk of exacerbating fluid overload and electrolyte imbalances. - Its use in impending renal failure is limited and typically reserved for specific situations like preventing acute kidney injury during cardiac surgery, and it is not a primary treatment. *Pulmonary edema* - **Mannitol** can increase **intravascular volume** as it draws fluid from interstitial spaces, which can worsen **pulmonary edema**, especially in patients with heart failure. - Diuretics like furosemide (loop diuretics) are the preferred treatment for pulmonary edema.

Question 240: How do thiazides cause hypercalcemia?

A. Decreased calcium excretion (Correct Answer)
B. Increased parathyroid hormone secretion
C. Decreased calcitonin secretion
D. Increased calcium absorption

Explanation: ***Decreased calcium excretion*** - Thiazides inhibit the **Na-Cl co-transporter** in the **distal convoluted tubule**, leading to increased reabsorption of calcium [1], [2]. - This increased reabsorption of calcium is mediated by a low intracellular sodium concentration, which enhances the activity of the **Na+/Ca2+ exchanger** on the basolateral membrane [1]. *Increased parathyroid hormone secretion* - Thiazides **do not directly stimulate** parathyroid hormone (PTH) secretion; instead, they *decrease* calcium excretion, which would typically *lower* PTH levels through negative feedback. - Elevated PTH would lead to increased bone resorption and kidney calcium reabsorption, but this is not the **primary mechanism** for thiazide-induced hypercalcemia [2]. *Decreased calcitonin secretion* - **Calcitonin** is a hormone that *lowers* blood calcium levels, and its decrease would theoretically contribute to hypercalcemia. - However, thiazides have **no direct effect** on calcitonin secretion, making this an unlikely primary mechanism. *Increased calcium absorption* - While increased calcium absorption from the gut can contribute to hypercalcemia, thiazides do **not directly increase intestinal calcium absorption**. - Their primary action for influencing calcium levels is within the **kidney**, specifically on reabsorption, not absorption from the GI tract [1], [2].

Question 241: Which of the following is not a side effect of thiazide diuretics?

A. Hypokalemia
B. Impotence
C. Hypocalcemia (Correct Answer)
D. Hepatic coma

Explanation: ***Hypocalcemia*** - Thiazide diuretics are known to cause **hypercalcemia** (increased calcium levels) by enhancing calcium reabsorption in the distal convoluted tubule. - Therefore, hypocalcemia is not a direct side effect of thiazide diuretics. *Hypokalemia* - Thiazide diuretics inhibit the Na+/Cl- cotransporter in the **distal convoluted tubule**, leading to increased sodium delivery to the collecting duct. - This increased sodium delivery promotes potassium secretion and can result in **hypokalemia**. *Hepatic coma* - Thiazide diuretics can exacerbate or precipitate **hepatic encephalopathy** and coma in patients with pre-existing liver disease. - This is primarily due to diuretic-induced **hypokalemia** and metabolic alkalosis, which increase renal ammonia production. *Impotence* - Thiazide diuretics, particularly at higher doses, have been associated with various sexual side effects, including **erectile dysfunction (impotence)** in men. - While the exact mechanism is not fully understood, it is a recognized adverse effect.

Question 242: Which diuretic is most likely to cause hyponatremia by impairing free water excretion?

A. Loop diuretics
B. Acetazolamide
C. Amiloride
D. Thiazide diuretics (Correct Answer)

Explanation: ***Thiazide diuretics*** - **Thiazide diuretics** inhibit the **Na-Cl cotransporter in the distal convoluted tubule (DCT)**, impairing the kidney's ability to dilute urine and excrete free water - This impaired urinary dilution leads to **water retention relative to sodium**, resulting in **dilutional hyponatremia** - **Most common in elderly patients**, those on low-salt diets, or with pre-existing volume depletion - **Mechanism**: By blocking sodium reabsorption in the DCT (a key site for urinary dilution), thiazides prevent the generation of free water, leading to hyponatremia when water intake continues *Loop diuretics* - **Loop diuretics** inhibit the **Na-K-2Cl cotransporter in the thick ascending limb of Henle**, causing significant diuresis - They impair the medullary concentration gradient, **enhancing free water excretion** - **Less likely to cause hyponatremia** compared to thiazides because they promote rather than impair free water clearance - When hyponatremia occurs with loop diuretics, it's usually due to concurrent SIADH or excessive free water intake *Acetazolamide* - **Acetazolamide** is a **carbonic anhydrase inhibitor** acting primarily on the **proximal tubule** - Causes **bicarbonate and sodium excretion**, leading to mild diuresis - Main side effect is **metabolic acidosis** (type 2 RTA) - **Does not significantly impair free water excretion**, making hyponatremia uncommon *Amiloride* - **Amiloride** is a **potassium-sparing diuretic** that blocks **epithelial sodium channels (ENaC) in the collecting duct** - Weak diuretic effect, primarily used to prevent potassium loss - **Does not impair urinary dilution mechanisms**, so hyponatremia is rare - Main concern is **hyperkalemia**, especially with ACE inhibitors or in renal insufficiency

Question 243: Which diuretic is known to cause the maximum potassium loss?

A. Spironolactone
B. Furosemide (Correct Answer)
C. Thiazide diuretics
D. Acetazolamide

Explanation: ***Furosemide*** - Furosemide is a **loop diuretic** that inhibits the Na-K-2Cl cotransporter in the **thick ascending limb of the loop of Henle**, leading to significant excretion of sodium, chloride, potassium, and water. - Its potent diuresis and impact on potassium reabsorption result in a **high risk of hypokalemia**. *Thiazide* - Thiazide diuretics inhibit the **Na-Cl cotransporter** in the **distal convoluted tubule**, causing moderate sodium and water excretion, and some potassium loss. - While they can cause hypokalemia, their effect on potassium excretion is generally **less pronounced than loop diuretics**. *Acetazolamide* - Acetazolamide is a **carbonic anhydrase inhibitor** that acts primarily in the **proximal tubule**, inhibiting bicarbonate reabsorption and leading to increased excretion of bicarbonate, sodium, potassium, and water. - The potassium loss is due to increased delivery of sodium to the collecting duct, leading to enhanced potassium secretion, but it is typically **less severe than with loop diuretics**. *Spironolactone* - Spironolactone is a **potassium-sparing diuretic** that acts as an **aldosterone antagonist** in the collecting duct, inhibiting sodium reabsorption and potassium secretion. - Instead of causing potassium loss, spironolactone actually **conserves potassium** and can lead to hyperkalemia.

Question 244: Which diuretic inhibits the Na+-K+-2Cl- symporter in the thick ascending limb of the loop of Henle?

A. Thiazides
B. Furosemide (Correct Answer)
C. Amiloride
D. Acetazolamide

Explanation: ***Furosemide*** - Furosemide is a **loop diuretic** that acts by inhibiting the **Na+-K+-2Cl- symporter** (NKCC2) in the luminal membrane of the epithelial cells in the thick ascending limb of the **loop of Henle** [1], [2]. - This inhibition prevents the reabsorption of sodium, potassium, and chloride ions, leading to increased excretion of these ions and water [1]. *Thiazides* - Thiazide diuretics, such as **hydrochlorothiazide**, primarily act on the **distal convoluted tubule** [4]. - They inhibit the **Na+-Cl- cotransporter**, not the Na+-K+-2Cl- symporter [4]. *Acetazolamide* - Acetazolamide is a **carbonic anhydrase inhibitor** that primarily acts in the **proximal convoluted tubule** [3]. - It inhibits the reabsorption of bicarbonate, leading to increased excretion of bicarbonate, sodium, and water [3]. *Amiloride* - Amiloride is a **potassium-sparing diuretic** that acts on the **collecting duct**. - It inhibits the **epithelial sodium channel (ENaC)**, leading to reduced sodium reabsorption and potassium secretion.

Question 245: Thiazides act on which part of the nephron?

A. Proximal Convoluted Tubule
B. Descending limb of loop of Henle
C. Glomerulus
D. Distal Convoluted Tubule (Correct Answer)

Explanation: ***Distal Convoluted Tubule*** - **Thiazide diuretics** specifically inhibit the **sodium-chloride cotransporter (NCC)** in the apical membrane of cells in the distal convoluted tubule. - This inhibition leads to decreased reabsorption of sodium and chloride, resulting in increased excretion of water, sodium, and chloride. *Proximal Convoluted Tubule* - The proximal convoluted tubule is the primary site for reabsorption of the majority of filtered substances, including sodium, bicarbonate, glucose, and amino acids. - While some diuretics like **acetazolamide** (a carbonic anhydrase inhibitor) act here, thiazides do not. *Glomerulus* - The **glomerulus** is primarily responsible for the **filtration** of blood, forming the initial filtrate. - It is not a site for diuretic action as it does not participate in active reabsorption or secretion of electrolytes. *Descending limb of loop of Henle* - The descending limb is highly permeable to **water** but impermeable to solutes, leading to water reabsorption due to the hyperosmotic medulla. - Diuretics typically do not act on this segment to inhibit solute transport, though osmotic diuretics can affect water movement here.

Question 246: Side effects of thiazide diuretics include all of the following except?

A. Hypokalemia
B. Erectile dysfunction
C. Hyponatremia
D. Hypocalcemia (Correct Answer)

Explanation: ***Hypocalcemia*** - Thiazide diuretics are known to cause **hypercalcemia** (increased calcium reabsorption), NOT hypocalcemia, due to their action on the distal convoluted tubule. - This property makes them useful in treating conditions like **idiopathic hypercalciuria** and **calcium-containing kidney stones**. - The mechanism involves enhanced passive calcium reabsorption in the proximal tubule and active reabsorption in the distal tubule. *Hyponatremia* - Thiazide diuretics impair the kidney's ability to dilute urine and reabsorb sodium in the distal tubule, leading to **increased sodium excretion** and potential hyponatremia. - This effect is more pronounced in **elderly patients** and those with increased free water intake. - Hyponatremia is one of the most common electrolyte disturbances with thiazides. *Hypokalemia* - Thiazides increase the delivery of sodium and water to the collecting duct, leading to increased activity of the **renin-angiotensin-aldosterone system** and enhanced potassium secretion. - This results in **potassium wasting** and hypokalemia, which may require potassium supplementation or combination with potassium-sparing diuretics. *Erectile dysfunction* - Thiazide diuretics can cause **erectile dysfunction** through mechanisms including effects on vascular smooth muscle, reduced blood flow, and possible hormonal effects. - This is a common side effect reported in male patients using these medications for hypertension and may affect compliance.

Question 247: Which diuretic exhibits paradoxical antidiuretic activity in diabetes insipidus?

A. Thiazide diuretics (Correct Answer)
B. Aldosterone antagonists (Spironolactone)
C. Loop diuretics (Furosemide)
D. Potassium-sparing diuretics (Triamterene)

Explanation: ***Thiazide diuretics*** - Thiazides cause a modest **volume depletion**, leading to increased proximal tubular reabsorption of water and solutes [1]. - They also lower the **glomerular filtration rate**, further reducing the amount of fluid delivered to the collecting ducts, thus paradoxically reducing urine output in diabetes insipidus [2]. - This effect is particularly useful in **nephrogenic diabetes insipidus**, where the kidneys cannot respond to ADH [2]. *Potassium-sparing diuretics (Triamterene)* - Triamterene is a **potassium-sparing diuretic** that blocks epithelial sodium channels in the late distal tubule and collecting duct. - It increases sodium and water excretion, which would worsen, not improve, the polyuria of diabetes insipidus. *Aldosterone antagonists (Spironolactone)* - Spironolactone is a **mineralocorticoid receptor antagonist** that increases sodium and water excretion while conserving potassium in the collecting duct. - Its primary action is to counteract aldosterone, and it does not exhibit the paradoxical antidiuretic effect seen with thiazides in diabetes insipidus. *Loop diuretics (Furosemide)* - Loop diuretics like furosemide act on the **thick ascending limb of the loop of Henle** to inhibit sodium, potassium, and chloride reabsorption. - They cause significant diuresis and would **exacerbate the polyuria** in patients with diabetes insipidus, rather than improving it.

Question 248: Which medication is commonly used in heart failure that also has aldosterone antagonistic properties?

A. Carvedilol
B. Spironolactone (Correct Answer)
C. Abiraterone
D. Sacubitril/Valsartan

Explanation: ***Spironolactone*** - **Spironolactone** is a **potassium-sparing diuretic** that acts as a **competitive antagonist of aldosterone** receptors, primarily in the collecting ducts of the kidneys. - This action leads to increased excretion of sodium and water, and retention of potassium, which is beneficial in **heart failure** by reducing fluid overload and mitigating the detrimental effects of aldosterone on cardiac remodeling. *Carvedilol* - **Carvedilol** is a **beta-blocker** with additional **alpha-1 blocking** properties, commonly used in heart failure to reduce heart rate, blood pressure, and myocardial oxygen demand. - It does not possess significant aldosterone antagonistic properties. *Sacubitril/Valsartan* - **Sacubitril/Valsartan** is an **angiotensin receptor-neprilysin inhibitor (ARNI)**. Valsartan is an **angiotensin receptor blocker (ARB)**, and sacubitril inhibits neprilysin, an enzyme that degrades natriuretic peptides. - While it modulates the **renin-angiotensin-aldosterone system (RAAS)** and is highly effective in heart failure, it does not directly antagonize aldosterone receptors. *Abiraterone* - **Abiraterone** is an **androgen-biosynthesis inhibitor** used in the treatment of **prostate cancer**. - Its primary mechanism involves inhibiting **CYP17**, an enzyme critical for androgen production, and it has no role in the management of heart failure or aldosterone antagonism.

Question 249: Which of the following is an aldosterone antagonist?

A. Furosemide
B. Eplerenone (Correct Answer)
C. Fenoldopam
D. Deoxycorticosterone

Explanation: ***Eplerenone*** - **Eplerenone** acts as a **selective aldosterone antagonist**, blocking aldosterone receptors in epithelial tissues and various non-epithelial tissues. - Due to its selectivity, it causes fewer **endocrine side effects** (like gynecomastia or impotence) compared to spironolactone. *Fenoldopam* - **Fenoldopam** is a **dopamine D1-receptor agonist** that causes peripheral vasodilation and increased renal blood flow, primarily used for severe hypertension. - It does not directly interact with the **aldosterone pathway** and is not an aldosterone antagonist. *Furosemide* - **Furosemide** is a **loop diuretic** that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, leading to increased excretion of water, sodium, potassium, and chloride. - It does not directly block aldosterone's action but rather affects electrolyte reabsorption higher up in the nephron. *Deoxycorticosterone* - **Deoxycorticosterone (DOC)** is a **mineralocorticoid** hormone, a precursor to aldosterone, and functions as an agonist at the mineralocorticoid receptor. - It actually mimics the effects of aldosterone, promoting sodium and water retention, and is therefore not an aldosterone antagonist.

Question 250: How does amiloride differ from spironolactone in its mechanism of action?

A. It is effective in conditions with normal or low aldosterone levels.
B. It typically does not cause hypokalemia.
C. It has a different mechanism of action that does not involve aldosterone receptor blockade.
D. It acts primarily on the luminal side of the collecting duct cells. (Correct Answer)

Explanation: ***It acts primarily on the luminal side of the collecting duct cells.*** - **Amiloride** is a direct **epithelial sodium channel (ENaC) inhibitor** in the luminal membrane of the collecting duct, preventing sodium reabsorption and subsequent potassium excretion. - This mechanism is **aldosterone-independent**, distinguishing it from spironolactone, which antagonizes the aldosterone receptor. *It is effective in conditions with normal or low aldosterone levels.* - While amiloride is effective in these conditions, this statement does not directly describe its **mechanism of action** in differentiating it from spironolactone; both can be used. - The effectiveness of amiloride in normal or low aldosterone levels is a consequence of its **direct ENaC inhibition**, which is independent of aldosterone signaling. *It typically does not cause hypokalemia.* - This statement describes a **consequence** of amiloride's action (potassium-sparing effect) rather than its distinct mechanism compared to spironolactone. - Both amiloride and spironolactone are **potassium-sparing diuretics** and thus typically do not cause hypokalemia. *It has a different mechanism of action that does not involve aldosterone receptor blockade.* - This statement is true but is less precise about the specific **cellular location and target** of amiloride's action. - It broadly describes the difference but doesn't explain **how** amiloride directly intervenes in sodium transport at the cellular level.

Question 251: The longest-acting loop diuretic is:

A. Torsemide (Correct Answer)
B. Bumetanide
C. Ethacrynic acid
D. Furosemide

Explanation: ***Torsemide*** - **Torsemide** has a longer half-life (3.5 hours) compared to other loop diuretics, leading to a more sustained diuretic effect. - Its prolonged action contributes to its classification as the **longest-acting loop diuretic**, making it suitable for less frequent dosing. *Bumetanide* - **Bumetanide** has a rapid onset and short duration of action, with a half-life of about 1 to 1.5 hours. - While it is a potent loop diuretic, its duration of action is significantly shorter than that of torsemide. *Ethacrynic acid* - **Ethacrynic acid** has a duration of action of approximately 6-8 hours and a half-life of 2-4 hours. - Although it is unique as a non-sulfonamide loop diuretic, its duration of action is not the longest among this class. *Furosemide* - **Furosemide** typically has a half-life of about 1.5 to 2 hours, resulting in a relatively short duration of action (6-8 hours). - It is frequently administered multiple times a day due to its short-acting nature.

Question 252: Which of the following is not associated with thiazide diuretics?

A. Hypercalciuria (Correct Answer)
B. Hyponatremia
C. Hypokalemia
D. Hyperuricemia

Explanation: ***Hypercalciuria*** - Thiazide diuretics are known to **decrease urinary calcium excretion** (hypocalciuria), not increase it (hypercalciuria). - This effect makes them useful in preventing **recurrent calcium kidney stones**. *Hyponatremia* - Thiazides can cause **hyponatremia** by increasing the reabsorption of water (via ADH) and impairing salt reabsorption in the distal tubule, leading to reduced free water clearance. - This side effect is a common concern, especially in elderly patients. *Hypokalemia* - Thiazide diuretics inhibit sodium and chloride reabsorption in the distal convoluted tubule, leading to increased delivery of sodium to the collecting duct. - This increased sodium delivery, coupled with increased aldosterone secretion, promotes **potassium secretion** and can result in **hypokalemia**. *Hyperuricemia* - Thiazide diuretics compete with uric acid for secretion in the **proximal tubule**, leading to reduced uric acid excretion. - This can elevate **serum uric acid levels** and potentially precipitate gout attacks.

Question 253: Which of the following statements about furosemide is TRUE?

A. It causes minimal diuresis.
B. It can only be administered intravenously.
C. It is used in the treatment of pulmonary edema. (Correct Answer)
D. It primarily acts on the distal convoluted tubule.

Explanation: ***It is used in the treatment of pulmonary edema.*** - **Furosemide** is a potent **loop diuretic** that rapidly reduces **fluid overload**, making it highly effective in managing acute **pulmonary edema**. - Its ability to induce significant diuresis helps decrease systemic and pulmonary venous congestion, thereby improving respiratory function. *It can only be administered intravenously.* - While it can be administered **intravenously** for rapid effect, **furosemide** is also commonly available and effective when given **orally** [1]. - Oral administration is preferred for chronic management and outpatient settings. *It causes minimal diuresis.* - **Furosemide** is known as a **high-ceiling loop diuretic** because it produces a significant and rapid diuresis, not minimal [2]. - It works by inhibiting the **sodium-potassium-2 chloride cotransporter** [3] in the **thick ascending limb of the loop of Henle**, leading to substantial fluid and electrolyte excretion. *It primarily acts on the distal convoluted tubule.* - **Furosemide** primarily acts on the **thick ascending limb of the loop of Henle**, not the distal convoluted tubule [2]. - Diuretics that primarily act on the distal convoluted tubule are **thiazide diuretics**, such as hydrochlorothiazide [2].

Question 254: Potassium secretion is decreased by action on the late distal tubule by which agent?

A. Spironolactone (Correct Answer)
B. Thiazide
C. Furosemide
D. Acetazolamide

Explanation: ***Spironolactone*** - Spironolactone is a **potassium-sparing diuretic** that acts as an **aldosterone antagonist** in the **late distal tubule and collecting ducts**. - By blocking aldosterone receptors, it **decreases sodium reabsorption** and **inhibits potassium secretion**. - This is the only option that specifically acts on the late distal tubule to decrease potassium secretion. *Thiazide* - Thiazide diuretics act on the **early distal convoluted tubule (DCT)**, not the late distal tubule, to inhibit the Na+/Cl− cotransporter. - This typically leads to **increased potassium secretion** indirectly, as increased sodium delivery to the collecting duct drives potassium excretion. *Furosemide* - Furosemide is a **loop diuretic** that acts on the **thick ascending limb of the loop of Henle**, inhibiting the Na+/K+/2Cl− cotransporter. - Its action results in a significant increase in **potassium excretion** due to increased sodium delivery to the collecting duct. *Acetazolamide* - Acetazolamide is a **carbonic anhydrase inhibitor** that primarily acts on the **proximal convoluted tubule**. - It causes increased excretion of bicarbonate, sodium, and potassium, thus **increasing potassium secretion**, not decreasing it.

Question 255: Loop diuretics act on:

A. PCT
B. DCT
C. Thick ascending limb of loop of Henle (Correct Answer)
D. Collecting duct

Explanation: ***Thick ascending limb of loop of Henle*** - Loop diuretics, such as **furosemide** and **bumetanide**, exert their action primarily on the **Na+-K+-2Cl- cotransporter (NKCC2)** located in the apical membrane of cells in the **thick ascending limb of the loop of Henle**. - By inhibiting this cotransporter, they prevent the reabsorption of **sodium, potassium, and chloride ions**, leading to increased excretion of water and electrolytes. *PCT* - The **proximal convoluted tubule (PCT)** is the primary site for reabsorption of most filtered substances including sodium, glucose, and amino acids. - While some diuretics like **acetazolamide (carbonic anhydrase inhibitors)** act on the PCT, loop diuretics do not. *DCT* - The **distal convoluted tubule (DCT)** is responsible for fine-tuning electrolyte reabsorption, particularly calcium, and sodium through the **Na+-Cl- cotransporter**. - **Thiazide diuretics** act on the DCT, but loop diuretics work upstream in the loop of Henle. *Collecting duct* - The **collecting duct** is the final site for urine concentration and regulation of water and urea reabsorption, influenced by **ADH (vasopressin)**. - **Potassium-sparing diuretics** like spironolactone and amiloride act on the collecting duct, but this is not the target for loop diuretics.

Question 256: A 50-year-old man has a history of frequent episodes of renal colic with high calcium renal stones. The most useful diuretic in the treatment of recurrent calcium stones is:

A. Furosemide
B. Hydrochlorothiazide (Correct Answer)
C. Acetazolamide
D. Spironolactone

Explanation: ***Hydrochlorothiazide*** - **Thiazide diuretics** reduce urinary calcium excretion by increasing calcium reabsorption in the distal convoluted tubule. - This mechanism makes them effective in preventing the recurrence of **calcium oxalate** and **calcium phosphate kidney stones**. *Furosemide* - **Loop diuretics** like furosemide increase urinary calcium excretion, which would *aggravate* rather than prevent calcium stone formation. - This effect is due to inhibiting sodium-potassium-chloride reabsorption in the **loop of Henle**, thereby reducing calcium reabsorption. *Spironolactone* - **Spironolactone** is a potassium-sparing diuretic that acts as an aldosterone antagonist, primarily affecting sodium and potassium balance. - It does not significantly impact urinary calcium excretion, and therefore, it is **not indicated** for the prevention of calcium renal stones. *Acetazolamide* - **Acetazolamide** is a carbonic anhydrase inhibitor that increases bicarbonate excretion and causes a metabolic acidosis. - It increases urinary pH and can potentially *promote* the formation of calcium phosphate stones in susceptible individuals.

Question 257: Which of the following statements about the PRIMARY mechanism of action of acetazolamide is correct?

A. It causes metabolic alkalosis
B. It decreases potassium excretion
C. Has structural resemblance to penicillins
D. Reversible inhibitor of carbonic anhydrase (Correct Answer)

Explanation: ***Reversible inhibitor of carbonic anhydrase*** - Acetazolamide is a **carbonic anhydrase inhibitor** that primarily acts by reducing the reabsorption of bicarbonate in the proximal tubule of the kidney. - This inhibition leads to increased urinary excretion of **bicarbonate, sodium, and water**, ultimately reducing intraocular pressure, intracranial pressure, and systemic fluid retention. *It decreases potassium excretion* - Acetazolamide actually **increases potassium excretion** indirectly by increasing the delivery of sodium and bicarbonate to the collecting duct, which enhances potassium secretion. - This can lead to **hypokalemia** with prolonged use. *It causes metabolic alkalosis* - Acetazolamide causes **metabolic acidosis**, not alkalosis, because it inhibits the reabsorption of bicarbonate in the renal tubules, leading to increased bicarbonate excretion and a decrease in serum bicarbonate levels. - This effect makes it useful in treating metabolic alkalosis, but it does not cause it. *Has structural resemblance to penicillins* - Acetazolamide is a **sulfonamide derivative** and does not have a structural resemblance to penicillins. - Its mechanism of action is completely distinct from that of antibiotics in the penicillin class.

Question 258: Select the diuretic that is most effective in acute angle-closure glaucoma.

A. Furosemide
B. Amiloride
C. Indapamide
D. Mannitol (Correct Answer)

Explanation: ***Mannitol*** - **Mannitol** is an osmotic diuretic that creates an osmotic gradient, drawing fluid from the eye into the bloodstream, thereby **rapidly reducing intraocular pressure (IOP)**. - Its quick onset of action and potent IOP-lowering effect make it the **drug of choice for acute angle-closure glaucoma** when rapid pressure reduction is critical. *Furosemide* - **Furosemide** is a loop diuretic that primarily acts on the renal tubules to increase urine output, with **minimal direct effect on intraocular pressure**. - While it can lower systemic blood pressure, its efficacy in **rapidly reducing elevated IOP in acute glaucoma is limited** compared to osmotic agents. *Amiloride* - **Amiloride** is a potassium-sparing diuretic that works in the collecting ducts of the kidneys and is primarily used for **hypertension and heart failure**, often in combination with other diuretics. - It does not have a significant or rapid effect on **intraocular pressure**, making it ineffective for acute angle-closure glaucoma. *Indapamide* - **Indapamide** is a thiazide-like diuretic that acts on the distal convoluted tubule and is primarily used for the treatment of **hypertension and edema**. - It has a slower onset of action and **does not effectively reduce intraocular pressure** in acute settings, making it unsuitable for acute angle-closure glaucoma.

Practice by Chapter

Carbonic Anhydrase Inhibitors

Practice Questions

Loop Diuretics

Practice Questions

Thiazide and Thiazide-Like Diuretics

Practice Questions

Potassium-Sparing Diuretics

Practice Questions

Carbonic Anhydrase Inhibitors

Practice Questions

Osmotic Diuretics

Practice Questions

Combination Diuretic Therapy

Practice Questions

Diuretics in Heart Failure

Practice Questions

Diuretics in Hypertension

Practice Questions

Diuretics in Renal Disorders

Practice Questions

Adverse Effects and Drug Interactions

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Diuretics — MCQs

Diuretics — MCQs

On this page